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He knew now, he said to Kunth, what he wanted to concern himself with: Life. 
He couldn't give his approval, said Kunth. One had more tasks on earth than mere 
existence. Life in and of itself did not supply the content for existence.  
That wasn´t what he´d meant, he replied. He wanted to investigate Life, to 
understand its strange grip on the world. He wanted to uncover its tricks! 
 
Measuring the World by Daniel Kehlmann 
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Scope of the thesis 
All living cells, from bacteria to the cells of a multicellular organism, are covered 
with glycans, chains of sugar molecules that are linked to one another. Glycans 
show a tremendous diversity, because they can be composed of many different 
types of sugars and they vary enormously in length and structure. Many glycans 
have in common that they are capped with a particular type of sugar − sialic acid. 
Located at the outer end of cell surface glycans, sialic acids effectively participate 
in numerous physiological processes at the molecular and cellular level for 
instance in cell-cell or cell-extracellular matrix interactions. In the immune system, 
sialic acids can mediate leukocyte trafficking, prevent complement activation on 
sialylated host cells, and regulate immune cell activation by interacting with the 
immunoinhibitory Siglec receptor family. Sialic acids are also involved in different 
pathologies including infection, autoimmunity and cancer. Especially in cancer, 
sialic acids contribute to multiple aspects of the disease. Cancer cells express 
aberrantly high levels of sialic acids on their cell surface that support cancer cell 
development, migration and metastasis. Moreover, cancer cell-derived sialic acids 
appear to contribute to the formation of an immunosuppressive tumor 
microenvironment which limits the immune system's natural capacity to detect and 
eradicate cancer cells. Overcoming the immunosuppressive tumor 
microenvironment is therefore a crucial step for the development of effective 
cancer immunotherapies. In the tumor microenvironment, sialic acids support 
immune inhibitory cell types (e.g. regulatory T cells an myeloid-derived suppressor 
cells) while dampening effector immune cells (NK cells, cytotoxic T cells). This 
process is not yet understood in great detail, but involves the interaction of cancer 
cell sialic acids with immunoinhibitory Siglecs on immune cells. Detailed studies on 
sialic acids and sialic acid-Siglec interactions in cancer and cancer immunology 
have been hampered by the limited number of glycotools available. 
 
In this thesis, the role of sialic acids and Siglecs is investigated in cancer and 
immunotherapy using chemically modified sialic acids. These so called sialic acid 
mimetics either block sialic acid expression on cells or alter sialic acid behavior and 
recognition by sialic acid binding receptors like the Siglecs that are abundantly 
present on immune cells in the immunosuppressive tumor microenvironment 
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Outline of the thesis 
 
Introduction 
This part introduces sialic acids and Siglecs and their role in the immune system 
and cancer. Furthermore, an introduction to sialic acid mimetics their development 
and therapeutic use is provided. Chapter 1 summarizes the molecular 
mechanisms and functional consequences of aberrant sialic acid expression in 
tumor cells. Approaches to target aberrant sialic acid expression in tumor cells are 
discussed, including the blockade of sialic acid expression using sialic acid 
mimetics. Chapter 2 introduces the Siglec family and the role of sialic acid-Siglec 
interactions in the immune system as well as various diseases including cancer. 
The chemical design and potential therapeutic applications of sialic acid mimetics 
to target sialic acid-Siglec interactions are explained. 
 
Part I Sialic acid mimetics to remodel the sialome 
Sialic acid mimetics are great tools to manipulate cell surface sialic acid 
expression, generally referred to as the ‘sialome’. In this part, two types of sialic 
acid mimetics are characterized; i) a sialic acid mimetic that blocks sialic acid 
expression and ii) sialic acid mimetics that can be employed to study binding to 
Siglecs. Chapter 3 describes a fluorinated sialic acid mimetic that blocks sialic acid 
expression in tumor cells and the consequences hereof on tumor cell adhesion and 
migration in vitro as well as tumor outgrowth in vivo. Chapter 4 reports on a group 
of reactive sialic acid mimetics that can be metabolically incorporated into cell 
surface sialoglycans. At the cell surface, the reactive sialic acids can be conjugated 
to fluorophores for sialic acid detection or small molecules that alter the binding to 
Siglecs. Chapter 5 further explores the use of this system to generate a library of 
cells with different binding properties to members of the Siglec family. The thereby 
modified cells can be used to mimic the interaction of surface sialic acids with a 
particular member of the Siglec family to study its function in immune cells. 
 
Part II Sialic acids and Siglecs as targets for cancer immunotherapy 
This part focuses on the role of sialic acids and Siglecs in tumor immunology and 
the application of the sialic acid-blocking mimetic in cancer immunotherapy. 
Chapter 6 describes the use of this sialic acid mimetic to prevent cancer cell 
metastasis. Targeted delivery of the sialic acid mimetic is achieved through 
incorporation into tumor-targeting nanoparticles that specifically block sialic acid 
expression in tumor cells. Chapter 7 ascertains sialic acid-Siglec interactions in the 
tumor microenvironment of glioma patients. Specifically, the expression of Siglecs 
on myeloid-derived suppressor cells and their sialic acid ligands on glioma cells 
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was investigated. Chapter 8 assesses the effect of the sialic acid-blocking mimetic 
on human monocyte-derived dendritic cell maturation, cytokine production and T 
cell activation capacity. Furthermore the effect of this mimetic on sialic acid-Siglec 
interactions on the dendritic cell surface is investigated. Chapter 9 reports on the 
use of the sialic acid-blocking mimetic in immunocombination therapy for cancer. 
The consequences of intratumoral injections on tumor growth and the tumor 
microenvironment are examined in mouse tumor models. In particular, the effects 
on tumor cell killing by CD8+ T cells after treatment with the sialic acid mimetic 
alone or in combination with CpG immune adjuvant are scrutinized. 
 
Summarizing discussion and prospective 
Chapter 10 summarizes the findings obtained in this thesis and places them in the 
context of the immunosuppressive tumor microenvironment and tumor immune 
evasion. Emerging concepts and future implications of the work described in this 
thesis are discussed with emphasis on the use of sialic acid mimetics for cancer 
immunotherapy. 
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Sialic Acids Sweeten a Tumor's Life  
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Abstract 
Over four decades ago, specific tumor characteristics were ascribed to the 
increased expression of sialic acid sugars on the surface of cancer cells, and this 
led to the definition of sialic acids as potential therapeutic targets. Recent 
advances in glycobiology and cancer research have defined the key processes 
underlying aberrant expression of sialic acids in cancer, and its consequences, 
more precisely. These consequences include effects on tumor growth, escape from 
apoptosis, metastases formation and resistance to therapy. Collectively, these 
novel insights provide further rationale for the design and development of 
therapeutic approaches that interfere with excessively high expression of sialic 
acids in cancer cells. Strategies to target aberrant sialylation in cancer, however, 
have evolved comparatively slowly. Here, we review recent findings that 
emphasize the detrimental effects of hypersialylation on multiple aspects of tumor 
growth and behavior. We also discuss novel therapeutic strategies.  
 
Introduction 
Tumor cells of various origins feature increased expression of sialic acid sugars on 
membrane glycoproteins and glycolipids and their secretion into the tumor 
microenvironment. Sialic acids are synthesized in and expressed by essentially 
every vertebrate cell, and are involved in multiple different physiologic processes. 
However, hypersialylation of tumor cells relative to their untransformed normal 
counter parts specifically benefits tumor cell growth and correlates with a poor 
prognosis for patients with cancer.1,2 Sialic acids comprise a family of more than 50 
carbohydrates that share a nine-carbon backbone (C1-9) to which specific 
chemical modifications are enzymatically attached inside the cell. The most 
common sialic acid derivate found in mammals is N-Acetylneuraminic acid 
(Neu5Ac) which bears an acetyl group on the fifth carbon atom (C5). In general, 
sialic acids terminate the outer end of glycans (sialoglycans), where they are 
enzymatically linked to other carbohydrates, such as the monosaccharide 
galactose, by glycosidic bonds. This enzymatic process is carried out by more than 
20 distinct Golgi-resident sialyltransferases (STs) that link sialic acids via their 
second carbon (C2), to the carbon atom at position C3 (ST3Gal I-VI), C6 (ST6Gal 
I,II and ST6GalNAc I-VI) or to C8 (ST8Sia I-VI) of carbohydrates, yielding α2,3-, 
α2,6- or α2,8-linked sialic acids, respectively.3 The latter enzymes are also involved 
in creating α2,8-linked polysialic acids. Together, the multifarious chemical 
substitutions, the different linkages to underlying sugars and their spatial and 
temporal organization result in a tremendous diversity of sialoglycans, termed the 
sialome by Ajit Varki.4 
1 
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Though we have just begun to understand the biology of the sialome and its 
implications in pathology, sialoglycans are known to regulate glycoprotein and 
glycolipid structure, stability, trafficking and function. Moreover, their prominent 
position on the cell membrane allows sialoglycans to effectively participate in cell-
cell and cell-extracellular matrix interactions, including adhesion, migration and 
immune recognition.3 There are receptor families that specifically recognize 
sialoglycans such as selectins or sialic acid-binding immunoglobulin-like lectins 
(Siglecs). Selectins are expressed on endothelial cells and leukocytes and enable 
extravasation of immune cells to sites of inflammation and, also allow 
hematogenous spread of cancer cells. Siglecs are expressed on most cells of the 
immune system and can transmit immunosuppressive signals upon binding to sialic 
acid ligands. Increased expression of Siglec ligands by tumor cells could thus 
contribute to tumor immune evasion.5-7 
In line with their vital role in many physiologic processes, several lines of evidence 
imply that aberrant expression of sialic acids confers major advantages to tumor 
cells, ranging from inhibition of apoptosis to resistance to cancer therapy. For these 
reasons, strategies to block aberrant sialylation on tumors may be highly beneficial, 
not only to directly limit tumor growth, but also to enhance the effect of cancer 
therapeutics. 
 
Mechanisms of Aberrant Sialylation in Cancer 
To date, three key mechanisms have been reported to cause aberrant sialylation in 
cancer cells. First, overexpression and/or altered activity of sialyltransferases 
results in increased sialylation of glycans and expression of specific tumor-
associated carbohydrate antigens (e.g. sLex/a, STn, GD2, GD3 or PSA).8,9 The 
proto-oncogenes Ras and c-Myc have been shown to control transcription of the 
sialyltransferases ST6Gal I and ST3Gal I, II, IV, respectively. This has been 
reported to result in increased α2,6-sialylation of β1 integrin (Ras) and high 
expression of sLex/a antigens (c-Myc), both facilitating tumor cell motility.10,11 In 
addition, low oxygen levels and high hormone levels have been found to 
upregulate expression of STs. Hypoxia eventually selects highly aggressive tumor 
cells and is associated with a poor prognosis in patients. Low oxygen levels were 
found to induce ST3Gal I expression and subsequently sLex/a antigen synthesis in 
colon cancer cells, eventually favoring binding to selectins and entry into the blood 
stream.12 Hatano and colleagues demonstrated that in hormone-sensitive prostate 
cancer cells androgens control transcription of ST3Gal II sialyltransferase by 
inducing promoter demethylation resulting in high GD1a expression, a 
sialoganglioside involved in tumor progression.13 Multiple other studies have 
1 
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reported overexpression of STs in tumor tissue indicating that sialyltransferase 
upregulation is a dominant mechanism underlying hypersialylation in cancer. 
The second mechanism was proposed by Almaraz and colleagues, who provided 
evidence that the metabolic flux through the sialic acid synthesis pathway is 
enhanced in cancer cells due to increased substrate availability or overexpression 
of genes involved in sialic acid biosynthesis. They demonstrated that sialylation of 
glycoproteins increased dramatically when enhancing the flux rate through the 
sialic acid pathway by the addition of sialic acid precursors to cancer cells in vitro.14 
Interestingly, mainly glycoproteins affiliated with extracellular matrix (ECM) 
interactions and cell migration were found to be hypersialylated, instead of gross 
upregulation of protein sialylation. Whether this is truly a tumor-specific 
phenomenon remains to be answered, but these data imply that metabolic 
changes in sialic acid biosynthesis in the tumor microenvironment can lead to 
hypersialylation of cancer cells, and therefore alter the expression of molecules 
involved in migration and metastasis. 
Increased tumor cell sialylation caused by differential expression of endogenous 
sialidases has been put forward as a third mechanism. Sialidases can 
enzymatically cleave sialic acids from glycans and thereby regulate shedding, 
plasticity and degradation of sialoglycans. At present, four human sialidases have 
been identified, located in the lysosome (NEU1, 4), cytosol (NEU2) or plasma 
membrane (NEU3). Expression of NEU1, 2 and 4 has been reported to be 
decreased in malignancies leading to accumulation of sialoglycans in cancer cells. 
Interestingly, NEU3 is found to be upregulated in some cancer cell types, but the 
functional consequences on sialylation are not yet understood.15 
 
Although the molecular mechanisms responsible for hypersialylation are starting to 
be unraveled, many questions remain, for instance how sialic acid and sialoglycan 
synthesis or hydrolysis rates relate to the function of individual glycoproteins and 
glycolipids in the cell membrane. Another unresolved issue is whether 
hypersialylation can have a causative role in tumorigenesis or is a bystander effect 
of malignant transformation. Overexpression of ST3Gal I in cancer cells has been 
reported to be sufficient to drive tumorigenesis in a mouse model for breast cancer, 
and Swindall and colleagues found indications that ST6Gal I upregulation is 
associated with cancer stem cell maintenance.16,17 These findings at least suggest 
that sialyltransferase overexpression may have a significant role in promoting 
tumorigenesis.  
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Sialic Acids and Apoptosis Evasion in Cancer  
Resisting cell death is one hallmark of cancer cells.18 Mutations or downregulation 
of molecules involved in the Fas receptor-Fas ligand (FasR-FasL) apoptotic 
pathway are well-known mechanisms exploited by cancer cells to escape 
apoptosis. Swindall and Bellis discovered a novel strategy whereby tumor cells 
escape from Fas mediated apoptosis: Hypersialylation of the Fas receptor was 
shown to disable apoptosis induction in cancer cells.19 They identified FasR, which 
serves as a substrate for ST6Gal I. Silencing expression of ST6Gal I in cancer cells 
enhanced Fas ligand-induced apoptosis, whereas overexpression of ST6Gal I 
hindered Fas-mediated apoptosis. Detailed analysis revealed that α2,6-sialylation 
of the FasR prevents the initiation of the death-inducing signaling complex (DISC) 
by hindering the binding of the Fas-associated adaptor molecule FADD to the FasR 
death domain. In addition, it was shown that α2,6-sialylation impaired 
internalization of the Fas receptor. Normally, internalization of FasR leads to further 
DISC complex formation and acts as a positive feedback loop for Fas-mediated 
apoptosis.20 Sialylation of FasR prevented this signal amplification loop and 
disrupted the downstream apoptotic signaling cascade allowing tumor cells to 
disable a major mechanism of apoptosis.  
Next to Fas-mediated apoptosis, hypersialylation has been reported to mediate 
resistance to anoikis, a cell death process triggered when cells detach from 
adjacent cells or the ECM.21 Amano and colleagues and Sanchez-Ruderisch and 
colleagues suggested an on/off switch model in which sialylation of the fibronectin 
receptor α5β1 integrin controls galectin-1-mediated anoikis.22,23 In this model, 
galectin-1 binds α5β1 integrin following detachment from fibronectin and triggers 
pro-apoptotic signals leading to caspase 8 activation and subsequent cell death. 
α2,6-hypersialylation of α5β1 integrin prevented its binding to galectin-1 and the 
subsequent induction of anoikis. These findings support the concept that α2,6-
linked sialic acids generally prevent binding of galectins to cell surface glycans and 
inhibit galectin signaling.24 Interestingly, in these studies a correlation was 
observed between the anoikis-inducing tumor suppressor p16INK4a and expression 
of genes involved in sialic acid synthesis. p16INK4a selectively upregulates 
expression of both α5β1 integrin and galectin-1 and reduces α2,6 sialylation by 
downregulation of two rate-limiting enzymes in sialic acid biosynthesis, UDP-
GlcNAc-2-epimerase/ManAc kinase (GNE) and sialic acid synthase (NANS).22,25 In 
line with these findings, GNE overexpression has been shown to counteract 
p16INK4a-induced anoikis, most likely via increasing the metabolic flux through the 
sialic acid pathway.22,26  
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Figure 1 Aberrant sialylation favors tumor growth and progression. 
Several factors (e.g. oncogenes, hormones or chemotherapy) increase the expression of 
sialyltransferases (STs) and downregulate the expression of sialidases (Neu) in cancer cells (red). As a 
result, sialoglycan synthesis in the Golgi system by sialyltransferases is enhanced and hydrolysis of 
sialoglycans by sialidases in the lysosome is reduced leading to accumulation of hypersialylated 
structures on the cell membrane. The aberrant high expression of sialoglycans impairs apoptotic 
signaling by the Fas receptor or integrins following detachment from the ECM (green); facilitates binding 
to the ECM or selectins allowing migration/tissue invasion and metastasis formation, respectively 
(orange); mediates resistance to chemo- and radiotherapy (blue). 
1 
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Sialic Acids and Cancer Progression and Metastasis 
Elevated expression of sialoglycans correlates with tumor aggressiveness and their 
capacity to metastasize and invade surrounding tissue, and therefore correlates 
with a poor prognosis for patients with cancer 27. Cell biologic aspects of high 
sialoglycan expression on cell adhesion and motility are well documented and have 
been extensively reviewed elsewhere.28 Much less is known about the molecular 
changes during tumor progression that lead to high expression of sialoglycans and 
a metastatic phenotype. Recent insights reveal that the changes that occur during 
epithelial-mesenchymal transition (EMT) are associated with altered expression of 
sialoglycans. EMT is essential for tumor progression and is a prerequisite for 
cancer cells to invade surrounding tissues and to metastasize. EGF-induced EMT 
in colon cancer cells resulted in high expression of the sialoglycans sialyl Lewis x 
(sLex) and sialyl Lewis a (sLea) due to increased expression of ST3Gal I, III, IV 11. 
SLex/a are both ligands for selectins expressed on endothelial cells that allow 
adherence to blood vessels, facilitate extravasation into surrounding tissue and 
trigger angiogenesis. Indeed, high sLex/a expression correlates with tumor 
aggressiveness and patient survival.29 In another comprehensive study, Maupin 
and colleagues analyzed gene expression in a model of TGF-β-induced EMT. Here 
EMT induction caused upregulation of the enzymes ST3Gal II, ST6GalNAc IV and 
ST8Sia IV, which are involved in the synthesis of the adhesion molecules GD1a 
and PSA.30 These studies indicate that the upregulation of sialyltransferases and 
subsequent expression of sialoglycans during EMT represent an important step 
underlying the migratory phenotype of metastasizing cancer cells.  
Further support for the importance of sialic acids in cancer metastasis comes from 
the scant information that is available about the contribution of sialidases to tumor 
migration and metastasis. Generally it is believed that downregulation of sialidases 
in cancer increases their metastatic ability. For example downregulation of the 
lysosomal sialidases NEU1 and NEU4 favors tumor metastasis through 
hypersialylation and enhanced signaling of the laminin receptor β4 integrin or 
reduced hydrolysis of sLex antigens, respectively.31,32 Additional work is necessary 
to understand the individual and combined contribution of STs and sialidases in 
cancer cell motility, tissue invasion and metastasis formation. 
 
Sialic Acids and Resistance to Cancer Therapy  
Tumor cell resistance to chemotherapeutics or radiotherapy forms a major barrier 
toward effective cancer therapy. Recently, several groups provided evidence that 
aberrant sialylation and especially overexpression of ST6Gal I contribute to therapy 
resistance in cancer. Schultz and colleagues reported that overexpression of 
ST6Gal I confers resistance to cisplatin, a platinum-based chemotherapeutic drug 
1 
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frequently used in the clinics. They showed that ST6Gal I knockout sensitizes 
cancer cells to cisplatin treatment, while overexpression confers resistance. 
Moreover, they demonstrated that ST6Gal I is highly expressed in cisplatin 
resistant cells compared to non-resistant cells.33 However the effects on α2,6-
sialylation of surface sialoglycans, for example, FasR, need to be determined. 
Lately, this group also indicated that expression of ST6Gal I regulates cancer stem 
cell resistance to chemotherapy with irinocetan.17 Importantly, the sialidase NEU3 
has recently been found to mediate resistance to the topoisomerase inhibitor 
etoposide, potentially by affecting surface expression of b1 integrins and increased 
FAK/AKT signaling.34 
Other than chemotherapy, Lee and colleagues reported that radiotherapy induces 
high ST6Gal I expression in both cancer cells and healthy tissue. Radiation of 
cancer cells increased α2,6-sialylation of b1 integrins and could be linked to 
increased cell adhesion and migration. As is the case with cisplatin resistance, 
ST6Gal I expression mediated resistance to radiation-induced cell death, but could 
be reversed upon knockout of ST6Gal I or expression of the plasma sialidase 
NEU2. Irradiation induced the expression of other sialyltransferases (ST3Gal I-IV, 
ST8Sia I) as well.35,36 However, their role in radiation resistance remains to be 
investigated. Together, the data available so far provide preliminary evidence that 
altered sialyltransferase and possibly sialidase expression, and hypersialylation of 
cancer cells can modulate the efficacy of anticancer drugs and confer resistance to 
chemo and radiation therapy. These intriguing findings imply that it may be highly 
rewarding to study the role of sialic acids in cancer therapy resistance further. 
 
Sialic Acids as Targets for Cancer Therapy 
In the late 1960s several groups reported that high expression of sialic acids on 
tumors favors tumor growth and therefore defined sialic acids as a potential 
therapeutic target for cancer. Consequently, bacterial sialidases that remove 
surface sialic acids were utilized for cancer therapy and sialidase-treated tumor 
cells were used to therapeutically vaccinate patients with cancer in clinical trials, 
although with limited success.37 For several decades, bacterial sialidases 
constituted the only robust approach to remove sialic acids from cells and are still 
widely used in research. However, the fact that tumor cells can rapidly replenish 
sialic acid expression on their cell surface following enzymatic removal severely 
limits the usage of sialidases for cancer therapy.38  
Today, advances in glycobiology and carbohydrate chemistry have boosted the 
development of novel strategies to target aberrant sialylation in cancer. Current 
strategies include specific or global inhibition of sialyltransferases and other 
enzymes involved in sialic acid biosynthesis (e.g. GNE), overexpression and 
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selective inhibition of sialidases, incorporation of unnatural (antigenic) sialic acid 
analogues into sialoglycans and delivery of drugs to tumors using sialic acid-
recognizing antibodies or newly developed phenylboronic acid-installed polymeric 
micelles.39-42 Experimentally, some approaches have already produced promising 
results in vitro or in tumor mouse models. Our group has recently evaluated the 
therapeutic potential of a novel sialyltransferase inhibitor, P-3Fax-Neu5Ac, that was 
developed by Rillahan and colleagues.43 P-3Fax-Neu5Ac is a fluorinated sialic acid 
analogue that globally inhibits sialyltransferases and prevents the de novo 
synthesis of sialoglycans with high potency. P-3Fax-Neu5Ac treatment is 
significantly more effective in prolonged reduction of surface expression of sialic 
acids on tumor cells when compared with bacterial sialidases. Moreover, in 
agreement with the proposed consequences of aberrant sialylation for tumor 
growth, we were able to demonstrate that blockage of sialylation with P-3Fax-
Neu5Ac strongly hinders tumor cell adhesion to ECM ligands and migration in vitro 
and tumor engraftment in a mouse model in vivo.38 Accordingly, Chen and 
colleagues reported that another ST inhibitor Lith-O-Asp attenuates spontaneous 
metastasis formation in a mouse breast cancer model.44 These examples 
compellingly suggest that the recent approaches to selectively block aberrant 
sialylation in cancer have the potential to counteract tumor growth and metastasis 
formation and should be further explored for anticancer therapy.  
 
Conclusions and Future Directions 
Sialic acids promote tumorigenesis and enhance tumor progression at multiple 
levels by facilitating escape from apoptosis, formation of metastasis and resistance 
to therapy. Selective approaches interfering with sialic acid expression would 
therefore affect multiple different key processes in cancer cells simultaneously and 
hold great promise for cancer treatment. For a long time, only a few compounds 
interfering with sialic acids were available and data from preclinical trials have been 
limited. Recently, novel sialyltransferase inhibitors have been developed that show 
specific and potent blockade of the aberrant sialylation of tumor cells. Moreover, 
the potential of this new class of inhibitors is emphasized by their ability to 
antagonize tumor growth and metastasis formation in mouse tumor models. These 
findings will not only stimulate further basic research into the mechanisms and 
consequences of aberrant sialylation in cancer, but should also boost further 
studies on the therapeutic window of opportunities to apply these inhibitors in 
(pre)clinical models for cancer therapy. It may turn out to be highly rewarding to 
evaluate the therapeutic potential of these inhibitors for clinical application, either 
as stand-alone treatment or in combination with other cancer treatment modalities.  
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Abstract 
Sialic acid sugars are vital regulators of the immune system through binding to 
immunosuppressive sialic acid-binding immunoglobulin-like lectin (Siglec) 
receptors on immune cells. Aberrant sialic acid-Siglec interactions are associated 
with an increasing number of pathologies including infection, autoimmunity and 
cancer. Therefore, the sialic acid-Siglec axis is an emerging target to prevent or 
affect the course of several diseases. Chemical modifications of the natural sialic 
acid ligands have led to sialic acid mimetics (SAMs) with improved binding affinity 
and selectivity towards Siglecs. Recent progress in glycobiotechnology allows the 
presentation of these SAMs on nanoparticles, polymers and living cells via 
bioorthogonal synthesis. These developments now enable the detailed study of the 
sialic acid-Siglec axis including its therapeutic potential as an immune modulator. 
 
The sialic acid-Siglec axis in health and disease 
Following nucleic acids, lipids and proteins, almost half of the ‘building blocks of 
life’ are glycans, sugar chains comprising various monosaccharides.1 Glycans 
cover the membrane of every living cell and display a staggering structural diversity 
(the glycome), greatly exceeding the diversity of the genome and proteome. One 
family of monosaccharides that stands out from other glycan components is the 
sialic acid family. Sialic acids literally stand out, because they are usually found at 
the terminal position of so-called sialoglycans.2,3 The sialic acid family comprises 
about 50 naturally occurring members sharing a nine-carbon backbone, that can 
be enzymatically modified inside the cell (Box 1). In the Golgi apparatus, a subset 
of the 20 known sialyltransferases attach sialic acids to underlying 
monosaccharides, such as galactose, via three different types of linkage (α2,3, 
α2,6, α2,8). Together, the diversity within the sialic acid family itself and the 
variable ‘linkability’ of sialic acids enable cells to synthesize and express a great 
variety of sialoglycans at the cell membrane, creating the sialome (Figure 1).4,5 
Sialic acids play important roles in many physiological processes (e.g., protein 
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folding, neural development, cell-cell interactions) as well as pathological 
processes (e.g., autoimmunity, cancer).6-9 Sialic acids exert their function in biology 
through multiple mechanisms as they are directly and indirectly involved in 
numerous events at both the molecular and cellular level.2,3 Several of the 
biological effects of sialic acids are mediated via their negative charge. More 
specific interactions occur with sialic acid-binding receptors such as selectins, 
factor H and Siglecs. While modifications of the sialic acid backbone appear to play 
a minor role in recognition by selectins and factor H, Siglecs feature distinct binding 
preferences for the sialic acid modifications (Box 1).10,11 Siglecs are expressed 
predominantly by immune cells and can be divided into two groups: the conserved 
Siglecs (Siglec-1, -2, -4 and -15) and the CD33-related Siglecs (Siglec-3, -5, -6, -7, 
-8, -9, -10, -11, -14 and -16).12 Siglec-12 lost sialic acid-binding capacity and 
Siglec-13 and Siglec-17 have been inactivated during human evolution and so they 
are not included in either of these groups.13,14  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Sialoglycan expression on the cell surface. 
Schematic representation of sialic acid-carrying glycans on the cell surface and structural representation 
of a sialic acid molecule with its nine-carbon backbone. 
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Box 1: Molecular basis of sialic acid-Siglec interactions. 
The sialic acid family consists of more than 50 naturally occurring, negatively charged 
carbohydrates sharing a common nine-carbon (C-1-9) neuraminic acid backbone that can 
be modified by intracellular enzymes at several positions (see Figure 1 in main text). The 
most common sialic acid variant found in humans is Neu5Ac (N-Acetylneuraminic acid), a 
sialic acid carrying an acetyl group at the C-5 position. Other prominent sialic acid family 
members are Neu5,9Ac2 (N-acetyl-9-O-acetylneuraminic acid), which next to the acetyl 
group on C-5 carries a second O-acetyl group on C-9, and Neu5Gc (N-glycolylneuraminic 
acid), with a glycolyl group at the C-5 position.2-4 These different sialic acids are linked to 
glycans via α2,3, α2,6 or α2,8 linkages generating a tremendous structural diversity of 
sialoglycans. The diversity of sialoglycans indicates an important role for these sugars in 
human physiology, yet many aspects in sialic acids biology remain elusive. Sialic acids can 
exert their function by interacting with sialic acid-binding receptors such as Siglecs. Siglecs 
have an extracellular N-terminal V-set domain that engages in extensive molecular 
interactions with sialic acids, followed by a varying number of C2-set immunoglobulin 
domains, a transmembrane domain and a cytoplasmic C terminus. The C terminus of most 
Siglecs contains an ITIM that is phosphorylated upon sialic acid binding and recruits SHP-
1/2 phosphatases that inhibit downstream activation pathways (see Figure 2 in main 
text).12,50 Siglec-14, -15, -16 are believed to have an activitory function by interacting with 
the adaptor protein DAP12.15 Siglecs show distinct binding preferences for different sialic 
acids and also the type of linkage and type of underlying sugar also affect recognition of 
sialic acids. Via a conserved arginine residue in the V-set domain, Siglecs form a salt bridge 
with the carboxylate group at the C-1 position of sialic acids. Further interactions occur 
between Siglecs and the hydroxyl group (C-4) of sialic acids and conserved hydrophobic 
tryptophan or tyrosine residues of Siglecs and the N-acetyl group (C-5) and the glycerol side 
chain (C-7 to C-9) of sialic acids. Responsible for the glycan-context specificity of Siglec 
binding is a highly variable loop region in the V-set domain.14,50 So far, little is known about 
the glycan-context dependency of Siglec binding to sialic acids. Ongoing efforts 
(http://www.functionalglycomics.org/static/index.shtml) now focus on answering crucial but 
challenging questions regarding the identity of the preferred natural sialoglycan ligands for 
different Siglecs.  
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Most Siglecs have an intracellular immunoreceptor tyrosine-based inhibition motif 
(ITIM) that can mediate inhibitory signals on binding to a sialic acid (Box 1, Figure 
2).14,15 Thereby, the sialic acid-Siglec axis, the total collection of interactions 
between sialic acids and Siglec receptors leading to Siglec signaling, can modulate 
cellular function. Although the biological functions of many Siglecs are largely 
unknown, Siglecs have emerged as important immunomodulatory receptors that 
alter immune cell function upon binding to sialic acids. This concept is further 
supported by recent studies showing that disturbances in the sialic acid-Siglec axis 
contribute to autoimmunity, infection, inflammation, aging and cancer.16-24 Notably, 
the expression and function of Siglecs is not limited to the immune system. For 
instance, Siglec-4/myelin-associated glycoprotein (MAG) is expressed on cells of 
the central and peripheral nervous system and is involved in axon maintenance 
and function.14 Table 1 summarizes the suggested biological functions of Siglecs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 The sialic acid-Siglec axis. 
a) Sialic acids interact with a Siglec on the same cell surface in cis resulting in ITIM phosphorylation and 
downstream inhibitory signaling through the recruitment of SHP-1/2 phosphatases. b) Trans sialic acid-
Siglec interactions between effector cell and a target cell lead to downstream inhibitory signaling. 
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Collectively, the increasing level of understanding of the role of Siglecs in health 
and disease together with recent advances in sialic acid chemistry have stimulated 
the development of SAMs with high binding affinities and their presentation as 
bioactive molecules to Siglecs. Here, we discuss recently developed 
glycoengineering approaches that now enable targeted manipulation of the sialic 
acid-Siglec axis and their potential use in clinical applications. 
 
Siglec Expression Suggested Biological Functions Refs 
Siglec-1 
CD169 
Sialoadhesin 
Macrophages Macrophage interaction with lymphocytes 
Internalization of sialylated pathogens 
 
14,78 
 
Siglec-2 
CD22 
B cells Negative regulation of B cell activation 
Induces B cell tolerance 
14,26 
Siglec-3 
CD33 
Myeloid cells, 
monocytes, 
microglia cells 
Regulates myeloid cell development and 
function 
Suppresses amyloid-β uptake by microglia 
cells in the brain 
14,38 
45 
Siglec-4 
MAG 
Schwann cells, 
oligodendrocytes 
Maintenance of myelinated axons 
Suppresses axonal regeneration after injury 
14,79 
Siglec-5 
CD170 
Monocytes, 
neutrophils 
Recognition and internalization of sialylated 
pathogens 
Inhibits immune cell activation 
14,35 
80 
Siglec-6 
CD327 
Trophoblasts,  
B cell subset 
Regulates trophoblast proliferation and 
invasiveness 
14,81 
Siglec-7 
CD328 
NK cells, 
monocytes, mast 
cells, basophils 
Attenuates NK cell activation and function 
Inhibits mast cells and basophils 
14,24 
74,82 
Siglec-8 
SAF2 
Mast cells, 
basophils, 
eosinophils 
Induces apoptosis in eosinophils 14,24 
72 
Siglec-9 
CD329 
NK cells, 
monocytes, 
macrophages, 
DCs, neutrophils 
Inhibits NK cell and neutrophil activation and 
function 
Immune modulation of myeloid cells 
14,20 
23,33 
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Siglec-10 
SLG2 
B cells, NK cells, 
monocytes, 
CD4+ T cells 
Dampens of immune activation and 
overreaction 
Suppresses of CD4+ T cells 
14,18 
30,83 
Siglec-11 Microglia cells, 
macrophages 
Inhibits microglia cell activation 14,84 
Siglec-14 Neutrophils, 
monocytes 
Triggers proinflammatory pathway in 
monocytes 
Recognition of sialylated pathogens 
14,35 
80 
Siglec-15 
CD33L3 
Osteoclasts, 
macrophages 
Regulates of osteoclast differentiation and 
bone resorption 
Immune modulation of macrophages 
14,37 
39,40 
Siglec-16 Macrophages Unknown 15 
 
Table 1 Human Siglec family members and suggested biological functions. 
 
Emergence of SAMs for the therapeutic targeting of the sialic acid-Siglec axis 
Sialic acid-Siglec interactions play a versatile role in human physiology as they 
mediate cell adhesion, cell signaling or uptake of sialylated pathogens. 
Consequently, abnormal sialic acid-Siglec interactions can contribute to the onset 
and development of diseases. In addition, by expressing sialic acids on their 
surface pathogens and cancer cells can interact with Siglecs on immune cells to 
escape immune recognition. Below, we discuss pathophysiological processes 
involving sialic acids and Siglecs that provide the rationale for the development of 
SAMs for therapeutic targeting of the sialic acid-Siglec axis. As most Siglecs are 
expressed on immune cells, we here focus on immune-related disorders. 
 
Autoimmunity, inflammatory diseases and graft-versus-host-disease (GVHD) 
Consistent with the broad expression of Siglecs on cells of the immune system, 
faulty synthesis or expression of sialic acids and altered expression or mutation of 
Siglecs contributes to the development of immune abnormalities.15 For instance, 
loss-of-function mutations in the human sialic acid acetylesterase (SIAE) gene, 
which lead to reduced expression of sialic acid ligands for Siglec-2 (CD22) and 
2 
Introduction 
34 
Siglec-10, have been associated with autoimmune diseases such as rheumatoid 
arthritis, type I diabetes and autoimmune polyglandular syndrome.16,25 Studies in 
mice and humans suggest that Siglec-2 and Siglec-10 (Siglec-G in mice) are 
immunosuppressive receptors that regulate B cell tolerance by counteracting B cell 
receptor signaling.26 Hence, reduced sialic acid ligand synthesis or Siglec-2 and 
Siglec-10/G deficiencies can result in uncontrolled B cell activation and systemic 
autoimmunity.27,28 In addition, by interacting with CD24, Siglec-10/G has been 
suggested to dampen immune activation in response to danger-associated 
molecular patterns (DAMPs) during tissue damage, thereby avoiding inflammation 
and possibly autoimmunity.18,29 In line with these findings, recent evidence by 
Toubai et al. implicates that Siglec-10/G-CD24 interactions limit the severity of 
GVHD.30 Whether the observed Siglec-10/G-CD24 interactions are sialic acid 
mediated remains to be proven. These studies suggest that SAMs with high 
binding affinities for these Siglecs could limit autoimmunity, inflammatory diseases, 
and GVHD. 
Pathogen and tumor immune evasion 
By expressing sialic acids on their surface, pathogens and cancer cells have been 
reported to interact with Siglecs on immune cells in trans, thereby escaping 
immune recognition.8,31,32 Group B Streptococcus expresses host sialic acids that 
bind to immunosuppressive Siglecs (Siglec-5 and -9) as molecular mimicry to avoid 
immune activation.33-35 In addition to their immunomodulatory role as targets of 
pathogenic sialic acids, Siglecs can also assist in the transmission of HIV-1. Siglec-
1 expressed by dendritic cells has been shown to act as entry site for sialylated 
HIV-1, facilitating virus trans-infection.36 SAMs competing with pathogenic sialic 
acids for Siglec binding could enhance the recognition of pathogens by the immune 
system or prevent Siglec-mediated transmission of HIV-1.  
Tumor cells express high levels of sialic acids and have been reported to utilize the 
immunosuppressive effect of the sialic acid-Siglec axis to avoid recognition and 
eradication by the immune system.8 For instance, tumor cells originating from 
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various tissues express high levels of sialic acid ligands for Siglec-7 and Siglec-9. 
Natural killer (NK) cells that are effective in recognition and eradication of tumor 
cells express Siglec-7 and -9; however, the interaction between tumor sialic acids 
and Siglec-7 and -9 on NK cells strongly attenuates their ability to kill tumor cells.23 
In another example, tumor sialoglycan interactions with Siglec-9 or Siglec-15 have 
been reported to render myeloid cells pro-tumorigenic, and non-small cell lung 
cancer patients carrying a Siglec-9 polymorphism that lowers binding to tumor 
sialic acids showed better initial tumor control.22,37 These data suggest that tumor 
sialic acids can attenuate immune responses by interacting with 
immunosuppressive Siglec receptors. Hence, sialic acid glycoengineering 
approaches that render the tumor glycocalyx nonreactive towards Siglecs or 
synthetic sialic acids that block binding of tumor sialic acids to Siglecs may 
enhance antitumor immunity. 
 
Aging and age-related disease 
Abnormalities in the sialic acid-Siglec axis have recently also been associated with 
neurodegeneration, Alzheimer’s disease, faulty bone resorption, and aging.21,38-40 
Genome-wide association studies have identified SNPs in the Siglec-3 (CD33) loci 
that protect against or correlate with a high risk for Alzheimer’s.41-43 Siglec-3 is 
present on microglia cells, macrophage-like cells, in the brain and its expression is 
elevated in individuals carrying the high risk Siglec-3 SNP and decreased in 
individuals with the low risk SNP. Alzheimer’s disease is characterized by the 
deposition of amyloid beta protein plaques in the brain. It is hypothesized that 
these plaques interfere with neuron communication leading to neurodegeneration. 
High Siglec-3 expression was found to be sufficient to promote amyloid beta 
protein and plaque accumulation, a phenotype associated with Alzheimer’s, 
whereas low Siglec-3 expression was associated with low amyloid beta protein 
accumulation levels in the brain.44,45 Although the underlying mechanism is 
unknown, the sialic acid-binding capacity of Siglec-3 was shown to be essential to 
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promote amyloid beta accumulation. These data imply that SAMs with high affinity 
for Siglec-3 could counteract plaque formation in the brain and Alzheimer’s disease 
development and progression. In summary, sialic acid-Siglec interactions have 
been associated with various diseases ranging from autoimmunity to 
neurodegeneration and cancer. Still, further research is needed to fully elucidate 
their precise role in health and disease and guide the development of SAMs to 
therapeutically target aberrant sialic acid-Siglec interactions in disease. 
 
SAMs as high affinity ligands for Siglecs 
Aberrant sialic acid-Siglec interactions are involved in a broad spectrum of 
diseases, hence strategies to tune the sialic acid-Siglec axis in pathophysiological 
processes could have great therapeutic potential.46,47 Twenty years ago, it was 
noticed that structural features of sialic acids are important for Siglec binding 
because naturally occurring modifications, such as 9-O-acetylation and C-5 
acetylation or glycolylation, showed differential binding to Siglec-2.48,49 These early 
findings were the starting point to further establish the contribution of the sialic acid 
substituents to Siglec binding using SAMs.  
Compared with natural sialosides, which have weak monovalent binding affinities 
for Siglecs (0.1-3 mM), SAMs can feature binding affinities in the nanomolar 
range.50,51 Therefore, SMAs can be used to target Siglecs and to functionally 
modulate Siglec-expressing cells. The sialic acid backbone can be chemically 
modified at various positions (Figure 3). The carboxylic acid is crucial for Siglec 
binding and hence is left unmodified, but all other positions ranging from the 
aglycone (C-2) to the rest of the backbone (C-3 – C-9) can potentially be modified 
to improve Siglec binding. Early examples of SAMs to target Siglecs carried a 
single modification, but recent examples contain up to four different modifications.51 
Most of the work on the development of SAMs has focused on Siglec-2 as target. 
Hence, we review the development of SAMs for Siglec-2 separately before 
discussing the development of SAMs for the other human Siglecs.  
 
2 
Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis 
37 
Figure 3 Development of sialic acid mimetics as high affinity ligands for Siglec-2. 
Center: Structure, substituents and affinity of natural Siglec-2 ligands. Surrounding: Development of 
sialic acid mimetics with high affinity for Siglec-2 over time. 
 
Development of high affinity SAMs for Siglec-2 
To the best of our knowledge, Kelm et al. were the first to report the use of SAMs 
to establish the contributions of the C-9, C-5 and C-2 positions to Siglec binding.52 
Most modifications of the C-5 and C-9 positions disrupted Siglec-2 binding, yet 
some modifications such as C-9-NH2 (9-NH2-Neu5AcαMe) and C-5-FAc 
(Neu5FAcαMe) improved Siglec-2 binding.52 The increased binding affinity was 
ascribed to hydrogen bonding and lipophilic interactions between the SAMs and 
Siglec-2.53,54 This observation inspired the rational design and synthesis of new 
unnatural Siglec-2 ligands carrying lipophilic groups to gain binding affinity.55-57 
Kelm et al. further noted that the C-9 position is flanked by a hydrophobic patch 
that could be exploited to increase binding affinity and possibly also selectivity for 
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Siglec-2. A small library of C-9-modified SAMs carrying a hydrophobic extension 
was synthesized and screened for binding to human Siglec-2.56 Modification of the 
C-9 position with a biphenyl (BPC-Neu5Ac) showed a 244-fold increase in binding 
affinity (4 µM) as well as much improved selectivity towards human Siglec-2 
compared with murine Siglec-2 and Siglec-1 (Figure 3). Minor modifications at the 
C-5 position and the incorporation of a natural aglycone at C-2 yielded a slight 
improvement of binding affinity (2.1 µM).58 The binding affinity towards Siglec-2 
could be further improved by hydroxylation of the C-9 biphenyl substituent and 
conversion of the amide linkage into an amine linked construct.59 Moreover, by 
replacing the α2,6-Gal linkage with a phenyl or biphenyl glycoside they developed 
SAMs for Siglec-2 with binding affinities in the high nanomolar range (100 nM).60,61  
At this stage it was clear that modification at various positions on the sialic acid 
backbone could improve binding affinity. Based on this, Mesch et al. hypothesized 
that adding multiple modifications to the C-2, C-5 and C-9 positions of sialic acid at 
the same time should lead to optimized Siglec-2 ligands 55,62. This approach led to 
a new SAM modified at C-2 with an o-nosyl group, at C-5 with an α2,3-
dichlorobenzyl group and a 4-(4-hydroxy)biphenyl group at C-9 that showed 
nanomolar affinity for Siglec-2 (60 nM). Subsequently, Kelm et al. reported the 
modification of the C-4 position in combination with C-9 modifications 63. Based on 
a homology model of Siglec-2 and other Siglecs and molecular modeling 
experiments they concluded that modifications at the C-4 position could lead to an 
increase in affinity. Modification at the C-4 position with an m-
nitrophenylcarboxamido group indeed led to a 15-fold increase in binding affinity. 
Further modification of the C-9 position by a BPC group led to an overall 9100-fold 
increase in binding affinity showing a synergistic effect of C-4 and C-9 
modifications. Saturation transfer-difference (STD) NMR showed that C-9 and C-4 
modified SAMs are likely to bind the same pocket as natural ligands and that the C-
9 and C-4 modifications interact with the binding pocket. Modification with a C-4 N-
tosyl group and a C-9 BPC group showed the best binding at 150 nm. Later that 
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year, Prescher et al. reported another study on C-4 and C-9 modifications and 
changes at the C-2 and C-3 positions. This led to the synthesis of SAMs containing 
three (C-2, -4, -9) or four (C-2, -3, -4, 9) modifications of the sialic acid molecule 
(Figure 3). Interestingly, the sialoside with four combined modifications showed a 
high binding affinity (6 nM) for Siglec 2, but a SAM with three modifications is so far 
the Siglec-2 ligand with the highest binding affinity (2 nM).51 
Together, these studies demonstrate that chemical modifications of the sialic acid 
backbone can dramatically increase the binding affinity to a Siglec. Compared with 
natural sialosides with affinities in the high micromolar range, SAMs with low 
nanomolar affinities are now available to target Siglec-2.  
 
Development of high affinity SAMs for the human Siglec family 
The development of Siglec-2 ligands with increasing potency has already allowed a 
better understanding of the role of Siglec-2 in health and disease.26 These studies 
have triggered the development of high-affinity SAMs for other members of the 
Siglec family to unravel their biological role and potential therapeutic value (vide 
supra). In general, the same approach to developing SAMs for Siglec-2 can be 
applied to obtain high affinity SAMs for other Siglecs. The SAMs with the highest 
affinity known to date for each of the Siglec receptors are shown in Table 2. 
Although effective, this approach is rather slow and therefore new high throughput 
approaches were developed. Rillahan et al. reported such an approach to map the 
effect of sialic acid modifications on a broader set of Siglecs.64 First, sialic acids 
carrying a C-9 azide or alkyne or a C-5 azide or alkyne were enzymatically linked 
to a lactose scaffold in either a α2,3 linkage or α2,6 linkage. The eight different 
constructs were then immobilized on a microarray slide and the azide or alkyne 
groups were modified by a small library of alkynes or azides, respectively, using 
copper(I)catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. Binding of 
several recombinant human Siglecs to the SAMs library was assessed. This ‘click 
and pick’ approach identified novel SAMs with high binding to Siglec-3, -5, -7, -9 
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and -10. It is important to note that while no IC50 values were determined the 
relative affinity towards different Siglecs and the crossreactivity was investigated. 
The comparison of different Siglecs indicated that the SAMs with the highest 
affinity are not necessarily the most selective. For example, the best SAM for 
Siglec-5 also displayed significant affinity for Siglec-9.64  
At present, the affinity of SAMs for most members of the human Siglec family is in 
the (low) micromolar range and for 6 of the 14 Siglec members no SAM has yet 
been described (Table 2). Future research is needed to improve the affinities of the 
known SAMs and de novo screening exploiting combinatorial sialic acid chemistry 
should allow the identification of SAMs for Siglecs with no high affinity ligand. 
 
Siglec High-affinity SAM IC50 [µM] Refs 
Siglec-1 
CD169 
Sialoadhesin  
0.38 85 
Siglec-2 
CD22 
 
0.002 51 
Siglec-3 
CD33 
 
11 86 
Siglec-4 
MAG 
 
0.25 87 
Siglec-5 
CD170 
 
NA 64 
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Siglec-6 
CD327 
NA --- --- 
Siglec-7 
CD328 
 
140 88 
Siglec-8 
SAF2 
NA --- --- 
Siglec-9 
CD329 
 
NA 64 
Siglec-10 
SLG2 
 
NA 64 
Siglec-11 NA --- --- 
Siglec-14 NA --- --- 
Siglec-15 
CD33L3 
NA --- --- 
Siglec-16 NA --- --- 
 
Table 2 Sialic acid mimetics with high affinity for the human Siglec family. 
Note: NA = not available; for these Siglecs no sialic acid mimetic has been reported. 
 
Multivalent presentation of high affinity SAMs to Siglecs 
Chemical modifications of the sialic acid backbone can dramatically increase 
binding affinities to Siglecs. Still, for these high affinity ligands to trigger Siglec 
signaling high-avidity binding and clustering of the receptors is required. In nature, 
multiple sialic acids are often presented on a glycoprotein or glycolipid enabling 
multivalent binding and clustering of Siglecs.57 At present, multivalent presentation 
of SAMs to Siglecs can be achieved via three different glycoengineering 
approaches (Figure 4). 
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SAM-decorated nanoparticles 
Sialosides can be crosslinked to various types of nanoparticle such as liposomes, 
gold nanoparticles or dendrimer-/poly(lactic-co-glycolic acid) (PLGA)-based 
nanoparticles, allowing their multivalent presentation. Recently, SAM-decorated 
nanoparticles for delivery of cargo to Siglec expressing cells have been developed 
(Figure 4a). The group of Paulson has generated BPC-Neu5Ac-coated liposomes 
loaded with the cytotoxic agent doxorubicin to target and kill Siglec-2 expressing B 
cell lymphoma cells in vivo.65 Moreover, liposomes decorated with SAMs specific 
for Siglec-1 or Siglec-7 enabled targeting of antigens to antigen-presenting cells to 
activate antigen-specific T cells.66,67 Besides their function in cargo delivery, SAM-
decorated nanoparticles can be applied to stimulate Siglec signaling.46 Paulson 
and coworkers reported that multivalent presentation of SAMs with high affinity for 
Siglec-2 on liposome nanoparticles triggered immunosuppressive signaling in B 
cells.68 The liposomes were crosslinked with antigens to target the B cell receptor 
and BPA-NeuGc or BPC-Neu5Ac to engage mouse or human Siglec-2. B cell 
receptor signaling was strongly inhibited by these liposomes leading to B cell 
apoptosis and antigen-specific tolerance induction. In a similar approach, 
liposomes decorated with 3′-BPA-NeuGc that target Siglec-G on mouse B cell 
subsets were able to inhibit B cell receptor signaling and induced tolerance towards 
selected antigens.69 The suppression of B cell receptor signaling was dependent 
on SHP-1 indicating that immune inhibitory signaling of Siglec-G was directly 
stimulated by the 3′-BPA-NeuGc liposomes. These so called Siglec-engaging 
tolerance-inducing antigenic liposomes (STALs) are attractive candidates to restore 
B cell tolerance in autoimmune patients.68 
In addition to liposomes, PLGA-based nanoparticles have also been decorated 
with α2,8-linked sialic acid. In this case, the nanoparticles were used for targeting 
of mouse Siglec-E and have anti-inflammatory effects in mice.70 PLGA-
nanoparticles binding to Siglec-E+ macrophages and neutrophils in mice limited 
their proinflammatory cytokine production in response to lipopolysaccharide (LPS) 
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avoiding severe systemic inflammation. The Siglec-E-engaging nanoparticles 
triggered immunosuppressive signaling via the recruitment of SHP-2 to the 
cytoplasmic tail of Siglec-E and resulted in enhanced production of the anti-
inflammatory cytokine interleukin (IL)-10. Interestingly, the same nanoparticles 
bound Siglec-7 and Siglec-9 on macrophages and showed anti-inflammatory 
effects in a human ex vivo lung perfusion model. In addition to liposome or PLGA-
based nanoparticles, SAMs can be crosslinked to any type of nanoparticle. For 
instance, gold core nanoparticles decorated with the sialoside GM3 were shown 
resemble the Siglec-1-mediated transmission of HIV-1.71 These early examples 
illustrate that different types of nanoparticle carriers allow multivalent presentation 
of high affinity Siglec ligands to immune cells or other Siglec-expressing cell types. 
These sialic acid mimetic nanoparticles possess strong immunomodulatory 
properties by triggering Siglec signaling and could be of high value to counteract 
autoimmunity or inflammation. 
  
Figure 4 Multivalent presentation of sialic acid mimetics for Siglec targeting. 
a) Nanoparticle carriers decorated with sialic acid mimetics for high affinity binding to Siglecs. b) 
Membrane-targeting glycopolymers crosslinked with sialic acid mimetics for Siglec binding on target 
cells. c) Incorporation of clickable sialic acids into cell surface sialoglycans and reaction with clickable 
azides to render the cell glycocalyx highly reactive to Siglecs.  
Membrane anchor
Siglec
Sialoglycan 
synthesis
Glycopolymer
Clickable 
azides
Clickable sialic acids
a) SAM-decorated nanoparticles b) SAM-decorated polymers c) On-cell SAM synthesis
Nanoparticle carrier
(PLGA, liposome, 
dendrimer, gold)
Effector cell
Target cell
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SAM-decorated polymers 
Similarly to nanoparticles, high-affinity Siglec ligands can be crosslinked to 
polymeric materials to create multivalency and trigger Siglec signaling. Duong et al. 
generated polyacrylamide conjugates with BPC-Neu5Gc to interact in trans with 
mouse Siglec-2 and Siglec-G on B cells. Engagement of sialoside polymers 
increased Siglec-2 phosphorylation and induced B cell tolerance towards a model 
antigen. Polyacrylamide polymers decorated with 6′-sulfo-sialyl LewisX were shown 
to bind selectively to Siglec-8 on human eosinophils in trans and induced 
apoptosis.72 Recently, polymers carrying naturally occurring sialosides (α2,3- or 
α2,6-SiaLAcNac, GD3 or Sialyl Lewisx) with a phospholipid tail that enabled their 
integration into the cell membrane were synthesized (Figure 4b).73,74 Cells loaded 
with specific sialoside polymers showed strongly enhanced binding to Siglec-7 and 
were largely protected against killing by Siglec-7+ NK cells. Further analysis 
showed that suppression of cytotoxic function of NK cells by these target cells 
coincided with Siglec-7 phosphorylation and subsequent SHP-1 recruitment. In an 
in vitro transplantation rejection model, the sialoside glycopolymers were even 
shown to protect human stem cells from NK cell cytotoxicity. Together, these data 
indicate that soluble or membrane-incorporated polymers can function as carriers 
to present SAMs to Siglecs on immune cells in cis or trans, thereby inducing their 
immunosuppressive signaling. 
 
On-cell synthesis of SAMs 
Sialic acids on surface glycoproteins and glycolipids serve as natural multivalent 
ligands for Siglecs in cis and trans. A glycoengineering approach has recently been 
developed to harness cell surface sialic acids for high affinity Siglec binding 
(Figure 4c).75 First, sialic acids carrying an alkyne on C-5 (Ac5NeuNPoc) were 
metabolically incorporated into the cell surface sialoglycans of human cells. Alkyne-
presenting surface sialic acids were then reacted with various azides that were 
shown to enhance binding to Siglec-7 on a sialoglycan array using CuAAC click 
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chemistry.76 The thereby altered human THP-1 or Jurkat cells showed high 
reactivity towards recombinant human Siglec-7. Interestingly, while recombinant 
Siglec-2 showed no binding to untreated cells, cells glycoengineered with a 3-
bromo-benzyl azide became highly reactive towards Siglec-2 whereas binding of 
Siglec-7 to these cells was only slightly increased and Siglec-4 binding remained 
unaltered. This glycoengineering approach allows the on-cell synthesis of SAMs 
with high affinity for Siglecs on living cells and their multivalent presentation on cell 
surface glycoproteins and glycolipids simultaneously. In addition, these data 
indicate that, depending on the azide used, different Siglecs can be targeted. 
Intriguingly, the development of in vivo bioorthogonal chemistry could allow the 
translation of this approach to living organisms.77 Here, cells or tissues could be 
reacted with high-affinity Siglec ligands to modulate the sialic acid-Siglec axis 
directly in vivo. 
 
Concluding Remarks and Future Perspectives 
Recent discoveries link aberrant sialic acid-Siglec interactions to a broad spectrum 
of pathologies and thus identify the sialic acid-Siglec axis as a potential therapeutic 
target. The precise biological roles of many sialic acid-Siglec interactions, however, 
remain elusive. The development of high affinity SAMs for individual Siglecs is 
crucial to further elucidate their biological function (see Outstanding Questions). 
SAMs for Siglec-2 are relatively advanced and their application on nanocarriers or 
glycopolymers has already been used to induce B cell tolerance and limit disease 
in animal models. Progress in sialic acid chemistry and high-throughput 
approaches for the synthesis and screening of chemically-modified sialic acids now 
allows more rapid targeting of other members of the Siglec family. The first 
promising high-affinity Siglec binding candidates have been defined that now 
require further optimization and testing for their ability to modulate Siglec signaling. 
For the future development of SAMs, their specificity for and crossreactivity with 
other Siglec family members as well as the glycan context should be taken into 
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consideration. It will be highly rewarding to further invest in strategies for the 
multivalent presentation of high affinity ligands, to increase specificity but also to 
enhance their biological potential in vitro and in vivo disease models. Intriguingly, 
recent progress in sialic acid glycoengineering raises the possibility of 
reprogramming the sialome on the surface of living cells and hence their binding to 
Siglecs. Collectively, these novel glycobiotechnological approaches will not only 
contribute to a better comprehension of the roles of sialic acids and their receptors 
in biology but also expose the full clinical potential of tuning the sialic acid-Siglec 
axis in disease processes.  
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Abstract 
Cancer cells decorate their surface with a dense layer of sialylated glycans by 
upregulating the expression of sialyltransferases and other glycogenes. Although 
sialic acids play a vital role in many biologic processes, hypersialylation in 
particular has been shown to contribute to cancer cell progression and metastasis. 
Accordingly, selective strategies to interfere with sialic acid synthesis might offer a 
powerful approach in cancer therapy. In the present study, we assessed the 
potential of a recently developed fluorinated sialic acid analogue (P-3Fax-Neu5Ac) 
to block the synthesis of sialoglycans in murine melanoma cells and the 
consequences on cell adhesion, migration and in vivo growth. The results showed 
that P-3Fax-Neu5Ac readily caused depletion of α2,3-/α2,6-linked sialic acids in 
B16F10 cells for several days. Long-term inhibition of sialylation for 28 days was 
feasible without affecting cell viability or proliferation. Moreover, P-3Fax-Neu5Ac 
proved to be a highly potent inhibitor of sialylation even at high concentrations of 
competing sialyltransferase substrates. P-3Fax-Neu5Ac-treated cancer cells 
exhibited impaired binding to poly-L-lysine, type I collagen and fibronectin and 
diminished migratory capacity. Finally, blocking sialylation of B16F10 tumor cells 
with this novel sialic acid analogue reduced their growth in vivo. These results 
indicate that P-3Fax-Neu5Ac is a powerful glycomimetic capable of inhibiting 
aberrant sialylation that can potentially be used for anticancer therapy. 
 
Introduction 
Overexpression of sialyltransferases and other glycogenes during malignant 
transformation and progression results in aberrant sialylation of cancer cells.1-3 The 
high expression of sialic acids can protect cancer cells from apoptosis, promote 
metastasis and has been suggested to confer resistance to therapy.4-8 Despite 
increasing amounts of evidence showing the involvement of sialyltransferases and 
aberrant sialylation in cancer progression, therapeutic strategies to reduce aberrant 
sialylation lag behind. So far sialidases or compounds that block enzymes in sialic 
acid synthesis have been tested with limited success. Enzymatic removal of sialic 
acids with bacterial sialidases only leads to short term depletion of cell surface 
sialic acids. Plant-derived or synthetic inhibitors of the sialic acid machinery are 
rare and show low efficacy.9 The rational design of sialic acid analogues that 
interfere with the cellular sialic acid synthesis machinery might form a more 
promising approach.10-12 Here sialyltransferases constitute an attractive target 
since they have been shown to underlie aberrant cancer sialylation. 
Sialyltransferases are expressed in the Golgi system where they incorporate sialic 
acid residues into assembling glycan trees of cell surface glycoproteins and 
lipids.13 Up to date, more than 20 different human and murine sialyltransferases 
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have been identified, each attaching sialic acids via distinct glycosidic linkages 
(e.g. α2,3 or α2,6) to various monosaccharide residues like galactose.13,14 Hence, 
upregulation of sialyltransferases results in the expression of highly sialylated 
structures including sialoglycoproteins, sialogangliosides or sialyl Lewis a or x 
(SLea/x) antigens. These sialylated structures are a hallmark of many cancer cells 
and have been shown to contribute to numerous processes in cancer growth.15-19 
For example, overexpression of ST6Gal-I and increased α2,6-sialylation of the Fas 
receptor mediates resistance to Fas-induced apoptosis.4 Hypersialylation (α2,6) of 
α1β1 integrin enhances binding to collagen type I and favors cancer cell 
migration.20 Pérez-Garay and colleagues reported that ST3Gal-III-overexpressing 
pancreatic adenocarcinoma cells formed metastatic lesions and drastically 
decreased survival in mice.21 
Recently, Rillahan and colleagues have described the synthesis of a global 
metabolic inhibitor of sialyltransferases, P-3Fax-Neu5Ac.22 P-3Fax-Neu5Ac has 
been shown to efficiently inhibit sialylation following uptake by human leukemia 
cells. Structurally, P-3Fax-Neu5Ac resembles N-acetylneuraminic acid (Neu5Ac), 
the most common sialic acid derivate and the endogenous substrate for Golgi-
resident sialyltransferases. During chemical synthesis, Neu5Ac is converted to a 
methyl ester and peracetylated (P-Neu5Ac) to enhance cellular uptake and 
subsequently an axial fluorine atom is incorporated at the C-3 carbon via the glycal 
to yield P-3Fax-Neu5Ac (Figure 1a). P-3Fax-Neu5Ac presumably enters the 
intracellular sialic acid synthesis pathway via a salvage pathway and is converted 
to CMP-P-3Fax-Neu5Ac.23 Only CMP-activated sialic acids can be recognized by 
the CMP-sialic acid transporter and undergo active transportation into the Golgi 
lumen where they serve as substrate for sialyltransferases.24,25 Rillahan and 
colleagues proposed that P-3Fax-Neu5Ac blocks sialylation globally via 2 
mechanisms. Initially, CMP-activated P-3Fax-Neu5Ac inhibits sialyltransferases 
directly and thereby prevents incorporation of natural sialic acids into assembling 
glycans. As a consequence, CMP-sialic acids accumulate in the cell and disable 
UDP-N-Acetylglucosamine 2-epimerase/N-Acetylmannosamine kinase 
(GNE/MNK), a key enzyme upstream in the de novo synthesis pathway of sialic 
acids.25,26 In a two-step reaction, GNE/MNK catalyzes intracellular sialic acid 
precursors (UDP-N-Acetylglucosamine) to N-Acetylmannosamine (ManNAc) and 
ManNAc-6-phosphate (ManNAc-6P) which is finally converted into CMP-Neu5Ac.27 
This reaction is tightly regulated as CMP-Neu5Ac can inhibit GNE/MNK activity to 
prevent excessive sialylation.  
Together, blocking sialyltransferases directly as well as blocking the synthesis of 
sialic acids indirectly makes P-3Fax-Neu5Ac a global inhibitor of sialylation that 
could be of high value for glycobiological research and moreover could be used to 
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therapeutically restore aberrant sialylation of cancer cells. Therefore we have 
assessed for the first time the effects and kinetics of P-3Fax-Neu5Ac on aberrant 
tumor cell sialylation as well its ability to modulate adhesion, migration and in vivo 
growth of murine cancer cells. 
 
Materials and Methods 
Mice 
Female C57BL/6J mice, 6 to 8 weeks old at the beginning of the experiment, were 
obtained from Harlan Laboratories (Livermore, CA). Mice were housed in the 
Central Animal Laboratory, Radboud University Nijmegen, The Netherlands under 
specific pathogen-free conditions. All experiments were authorized by the local 
animal ethics committee, Nijmegen, The Netherlands and carried out in 
accordance with their guidelines. 
 
Reagents 
Biotinylated lectins SNA-I (Sambucus nigra), PNA (Arachis hypogaea) and WGA 
(Triticum vulgaris) were purchased from EY Laboratories Inc., MALII (Maackia 
amurensis), GSL-I (Griffonia simplicifolia), AAL (Aleuria aurantia) and carbo-free 
blocking solution from Vector Laboratories, Inc., conjugated streptavidin-
phycoerythrin from BD Pharmingen, 7-AAD viability dye from eBioscience, 
NeutrAvidin-Texas Red and DAPI nucleic acid stain from Molecular Probes, Mowiol 
4-88 mounting medium from Merck, carboxyfluorescein succinimidyl ester (CFSE) 
from CellTrace, PureCol (bovine collagen type I) from Nutacon BV. Poly-L-lysine, 
purified Neu5Ac and ManNAc were purchased from Sigma-Aldrich and Clostridium 
perfringens sialidase and fibronectin from Roche. P-Neu5Ac and the fluorinated P-
3Fax-Neu5Ac were synthesized as previously described by others.22,28 
 
Cell lines  
B16F10 melanoma cells were obtained from and authenticated by American Type 
Culture Collection (ATCC; CRL-6475) and cultured in minimum essential medium 
(MEM) (Gibco, Invitrogen, Carlsbad, CA) containing 5 % fetal bovine serum (FBS) 
(Greiner Bio-one), 1 % MEM non-essential amino acids (Gibco), 0.15 % sodium 
bicarbonate (Gibco), 1 mM sodium pyruvate (Gibco), 1.5 % MEM vitamins (Gibco), 
0.5 % antibiotic-antimycotic solution (50 U/ml penicillin, 50 µg/ml streptomycin and 
125 ng/ml amphotericin B; PAA). The 9464D neuroblastoma cell line (kindly 
provided by R. Orentas, Department of Pediatrics, Medical College of Wisconsin, 
WI) was cultured in Dulbecco's modified Eagle's medium (Glutamax, Gibco) with 
10 % FBS, 1 % non-essential amino acids, 20 µM 2-mercaptoethanol (Sigma-
Aldrich) and 1 % antibiotic-antimycotic solution. GL261 glioblastoma cells (kindly 
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provided by U. Herrlinger Department of Neurology, University of Bonn, Bonn, 
Germany) were cultured in Iscove's modified Dulbecco's medium (Gibco) 
supplemented with 10 % FBS, 20 µM 2-mercaptoethanol and 0.5 % antibiotic-
antimycotic solution. Cells were incubated in a humidified CO2 incubator at 37 °C in 
5 % CO2. All cell lines were initially grown and multiple aliquots were cryopreserved 
and used within 6 months after resuscitation and tested for mycoplasma using a 
mycoplasma detection kit (Lonza). 
 
Lectin staining and flow cytometry 
After harvesting, cells were washed with carbo-free blocking solution to remove 
free glycoproteins and incubated for 45 minutes with 5 µg/ml of the respective 
biotinylated lectin. α2,3-linked sialic acids were detected using MALII, α2,6-linked 
sialic acids by SNA-I, exposure of terminal β-galactose/T antigen by PNA, 
exposure of terminal (α-)galactose and (α-)GalNAc by GSL-I, (poly)GlcNAc 
(chitobiose) by WGA and (α-)fucose by AAL.29-31 Free lectin was removed by 
washing the cells in carbo-free blocking solution and cell-bound biotinylated lectin 
was conjugated with 2 µg/ml streptavidin-phycoerythrin for 15 minutes.32 Cell 
viability was assessed by staining the cells with 7-AAD viability dye. For flow 
cytometry, cells were washed and resuspended in FACS-buffer (1x PBS containing 
1 % FBS and 0.02 % sodium azide). Data were acquired using a CyAn ADP flow 
cytometer (Beckman Coulter) and analyzed utilizing FlowJo software (Tree Star). 
Cells stained with only streptavidin-phycoerythrin served as background control. 
The percentage glycosylation or lectin binding was calculated by normalizing the 
fluorescence values from the bound lectins to the respective control.  
 
Inhibitor titration and long-term culture 
To determine the effective dose, B16F10 cells were incubated with 0-512 µM of P-
3Fax-Neu5Ac and as a control Neu5Ac or P-Neu5Ac. Cells were harvested after 3 
days of culture and the glycosylation status was assessed using different 
biotinylated lectins. In the long-term culture experiment, B16F10 cells were cultured 
in the presence or absence of 64 µM inhibitor for 28 days. Every third day, 
condition medium was renewed and sialylation was measured at several time 
points using the lectins MALII and SNA-I. Viability was assessed during long-term 
culture with flow cytometry after staining cells with 7-AAD viability dye. To quantify 
proliferation of treated and untreated B16F10 cells, cell numbers were counted 
every time before passaging and equal amounts of cells were reseeded. The 
numbers of treated and untreated cells before passaging were compared to each 
other. 
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Confocal microscopy 
For confocal microscopy, cells were incubated for 3 days in the presence or 
absence of 64 µM P-3Fax-Neu5Ac, harvested and reseeded on glass slides. Cells 
were allowed to adhere for 1 hour before they were washed with 1x PBS and fixed 
10 minutes with 1 % paraformaldehyde. Next, cells were blocked 30 minutes in 1x 
PBS containing 1 % goat serum, washed and incubated for 1 hour with 2.5 µg/ml 
biotinylated lectin. After washing, cells were incubated with 5 µg/ml NeutrAvidin-
Texas Red for 30 min, washed and stained with DAPI for 10 minutes. Samples 
were mounted with Mowiol and images were acquired using an Olympus FV1000 
confocal laser scanning microscope (Olympus). 
 
Recovery of sialylation and sialyltransferase substrate competition assay 
To determine the time of recovery of sialylation, B16F10 cells were treated 3 days 
with or without P-3Fax-Neu5Ac or for 1 hour with 250 mU/ml Clostridium 
perfringens sialidase in serum-free medium. After extensive washing, cells were 
reseeded and cultured for 4 days. Cell surface sialylation was assessed every day 
using the conjugated lectins MALII and SNA-I. B16F10 cells were cultured for 3 
days in medium in the presence or absence of 64 µM P-3Fax-Neu5Ac together with 
increasing amounts of a competitive sugar (0-1000 µM). P-Neu5Ac was used as 
non-inhibiting competitor for P-3Fax-Neu5Ac and ManNAc was used to increase the 
intracellular Neu5Ac production, respectively.33 Cells were collected and stained 
with MALII to detect α2,3-linked sialic acids, SNA-I for α2,6-linked sialic acids and 
furthermore with 7-AAD to confirm viability of the cells. Cells were acquired with 
flow cytometry and the fluorescence intensities of bound lectins were quantified.  
 
Adhesion assay 
Flat-bottom 96-well plates (Maxisorb) were coated with 20 µg/ml type I collagen, 20 
µg/ml fibronectin or 100 µg/ml poly-L-lysine for 1 hour, washed with PBS-T (1x 
PBS, 0.05 % Tween-20) and blocked for 1 hour with PBS-T containing 1 % bovine 
serum albumin. B16F10, GL261 or 9464D cells were treated with 64 µM P-3Fax-
Neu5Ac for 3 days and labeled with 3 μM CFSE according to the manufacturer´s 
instructions and resuspended in serum-free medium. 4 x 104 cells were added to 
the differentially coated wells and allowed to adhere for 45 minutes at 37 °C. Non-
attached cells were removed by washing the plates carefully three times with pre-
warmed PBS-T. Subsequently, adherent cells were lysed in lysis buffer (50 mM 
TRIS-HCL pH 7.5, 0.1 % SDS) and the fluorescence intensity was measured with a 
Cytofluor II fluorescence multiwell plate reader (PerSeptive Biosystems). 
Additionally, samples were kept in washing buffer and images of adherent cells 
were acquired using a Leica DMIL microscope (Leica).  
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Migration assay 
Cell-free gaps were generated using culture inserts (Ibidi GmbH). B16F10 cells, 
incubated for 3 days with or without 64 µM P-3Fax-Neu5Ac, 265 µM P-3Fax-Neu5Ac 
or P-Neu5Ac, were harvested and 4 x 104 cells were added per culture insert 
chamber, in the presence or absence of the respective sialic acid analogue. After 
12h, culture-inserts were removed; leaving a cell-free gap of approximately 500 µm 
width and gap closure was followed by microscopy. Images were acquired every 6 
hours using a Leica DC300 camera and analyzed using ImageJ (NIH).  
 
Tumor mouse model 
B16F10 cells were incubated for 3 days in medium containing PBS, 64 µM P-
Neu5Ac, 64 µM P-3Fax-Neu5Ac or for 1 hour with 250 mU/ml Clostridium 
perfringens sialidase in serum-free medium. Cells were washed thoroughly and 
resuspended in PBS. 0.5 × 105 cells in a total volume of 50 μl were injected s.c. at 
the right femur. Tumor growth was followed in time and mice were sacrificed when 
tumor volume exceeded 1800 mm3. 
 
Statistical analysis 
Statistical significance between two groups was determined using the Student’s t-
test, multiple comparisons were performed by one-way analysis of variance 
(ANOVA) followed by Bonferroni’s correction and Kaplan–Meier survival curves 
were analyzed with a Log-rank test using Prism 5.03 (GraphPad Software) and p-
values <0.05 were considered significant (p<0.05 *, p<0.01 **, p<0.001 ***). 
 
Results 
P-3Fax-Neu5Ac selectively inhibits sialylation in murine melanoma cells 
To show functionality and to determine the effective dosage of P-3Fax-Neu5Ac in a 
murine setting, B16F10 melanoma cells were chosen as a model because of their 
high expression of sialic acids and metastatic potential.34-36 The cells were 
incubated for 3 days with increasing concentrations of Neu5Ac, P-Neu5Ac or the 
inhibitor P-3Fax-Neu5Ac (Figure 1a), and sialylation was assessed using specific 
carbohydrate-binding lectins. In line with the findings in human leukemia cells 
reported by Rillahan et al, 64 µM P-3Fax-Neu5Ac was sufficient to reduce α2,3-
sialylation and α2,6-sialylation by more than 90 %, as detected by staining with the 
lectins MALII and SNA-I, respectively (Figure 1b). Dose-effect experiments 
revealed that P-3Fax-Neu5Ac could significantly reduce expression of α2,3-linked 
sialic acids and α2,6-linked sialic acids already at 32 µM, whereas higher 
concentrations almost completely depleted the cells from surface sialic acids 
(Figure 1c, d). 
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Figure 1 P-3Fax-Neu5Ac selectively blocks sialylation in B16F10 cells. 
a, Structures of Neu5Ac, P-Neu5Ac and P-3Fax-Neu5Ac. b, Representative histograms showing 
reduced binding of the α2,3 sialic acid-recognizing lectin MALII (left) and the α2,6 sialic acid-recognizing 
lectin SNA-I (right) to B16F10 cells treated with PBS or 64 µM P-3Fax-Neu5Ac for 3 days. c-h, B16F10 
cells were cultured for 3 days in the presence of 0-512 µM Neu5Ac, P-Neu5Ac or P-3Fax-Neu5Ac and 
cell surface sialylation, glucosaminylation and fucosylation were assessed by flow cytometry using → 
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biotinylated lectins conjugated to streptavidin-PE. Presence of α2,3-sialylated structures was 
determined with MALII (c), α2,6-sialylation by SNA-I (d), exposure of terminal β-galactose/T antigen by 
PNA (e), exposure of terminal (α-)galactose and (α-)GalNAc by GSL-I (f), (poly)GlcNAc (chitobiose) and 
sialic acids (partially) by WGA (g) and (α-)fucose by AAL (h). Fluorescence intensities of the lectins 
were normalized to the respective untreated cell controls and calculated as mean percentage ± SEM 
sialylation, lectin binding, glucosaminylation or fucosylation (n=3).  
 
Clearly, the blocking effects of P-3Fax-Neu5Ac can be ascribed to the attached 
fluoride and not to other characteristics of the inhibitor as sialylation was not 
affected in cells treated with either Neu5Ac or the peracetylated form. Despite 
blockage of sialylation with P-3Fax-Neu5Ac was very efficient, complete loss of 
α2,3-linked sialic acids or α2,6-linked sialic acids could not be achieved. At the 
highest used concentrations of P-3Fax-Neu5Ac, a sialoglycan fraction of about 10 
% remained on the cells. This fraction might represent stable sialoglycans with a 
slow turnover, sialoglycans that are salvaged from the culture medium, or products 
of sialyltransferases that are (partially) resistant to the fluorinated sialic acid 
analogue. Consistent with decreased sialic acid expression, exposure of terminal 
galactose residues like the T antigen (Galβ1,3GalNAcαSer/Thr) and terminal N-
acetylgalactosamines (GalNAc) increased as reflected by enhanced binding of the 
lectins PNA and GSL-I (Figure 1e, f). Almost no binding of PNA or GSL-I was 
observed to cells cultured with Neu5Ac or P-Neu5Ac. Expression of N-
Acetylglucosamines (GlcNAc) and fucose did not vary significantly upon incubation 
with P-3Fax-Neu5Ac, Neu5Ac or P-Neu5Ac confirming the specificity of P-3Fax-
Neu5Ac to inhibit sialyltransferases (Figure 1g, h). We noted a slight reduction in 
the binding of WGA to inhibitor-treated cells. This can be explained by the cross-
reactivity of lectin to sialic acids rather than by alterations in the expression of 
GlcNAc.37,38 Noteworthy, even at the highest concentrations used, tumor cell 
viability was unaffected by the inhibitor (data not shown).  
Next confocal microscopy was used to study the presence of sialic acids on the 
membrane of inhibitor-treated B16F10 cells. While the α2,3 sialic acid-binding 
lectin MALII strongly stained the cell membrane of untreated cells, loss of binding 
could be observed in cells incubated with P-3Fax-Neu5Ac (Figure 2a, g). Similar 
results were found for α2,6-linked sialic acids detected with SNA-I (Figure 2b, h). 
Detection of terminal galactose or GalNAc by PNA or GSL-I was hindered by sialic 
acids in control B16F10 cells, but was enabled in cells treated with P-3Fax-Neu5Ac 
(Figure 2c, d, i, j). Again, presence of GlcNAc and fucose residues on the cell 
membrane remained unchanged after blocking sialylation (Figure 2e, f, k, l). 
Similar results were obtained in other murine and human cancer cell lines (data not 
shown). These data reveal P-3Fax-Neu5Ac as a potent and specific inhibitor of 
sialylation in mouse B16F10 melanoma cells.  
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Figure 2 Loss of cell surface sialic acids and exposure of underlying sugar residues.  
a-l, B16F10 cells were cultured for 3 days in the presence or absence of 64 µM P-3Fax-Neu5Ac, stained 
with biotinylated lectins and NeutrAvidin-Texas Red (green) followed by nuclear DAPI staining (red). 
Images of membrane-bound lectins were acquired by confocal microscopy. Representative images 
show binding of the lectins MALII (a, g), SNA-I (b, h), PNA (c, i), GSL-I (d, j), WGA (w, k) and AAL (f, l) 
to treated and untreated cells. Cell contours are indicated (white stepped lines). 
 
P-3Fax-Neu5Ac rapidly affects cell surface sialylation and can be applied for a 
prolonged time period  
Having confirmed the specific and efficient blocking of sialylation in melanoma cells 
cultured for 3 days with P-3Fax-Neu5Ac, we next investigated the kinetics of 
sialylation blockage. Hereto, B16F10 cells were pulsed with 64 µM or 256 µM P-
3Fax-Neu5Ac and changes in sialylation were measured with MALII and SNA-I in 
time. At the lower concentration, reduction in α2,3- and α2,6-sialylation could be 
detected after 6 to 8 hours incubation (Figure 3a, b). Strikingly, sialylation was 
reduced significantly after only 0.5 to 1 hour of incubation and more than halved 
after 4 hours with the high concentration. Cells kept at 4 °C during treatment with a 
high dose of the inhibitor showed no decrease in sialylation. Furthermore, we 
investigated whether P-3Fax-Neu5Ac is suitable to deplete sialic acids permanently 
in cultured cells. B16F10 cells cultured for 28 days in the presence of 64 µM P-
3Fax-Neu5Ac featured permanent loss of cell surface sialic acids as measured with 
the lectins MALII and SNA-I (Figure 3C, D). However, even after 28 days of culture 
complete loss of sialylation could not be achieved. As mentioned above, a stable 
fraction of about 5 % α2,3 linked sialic acids and 20 % α2,6 linked sialic acids 
remained expressed on the cell surface throughout the long-term culture. The 
continuous incubation with P-3Fax-Neu5Ac had no apparent effect on cell viability 
or proliferation of the cells (Figure 3e, f). These data indicate that P-3Fax-Neu5Ac 
can block sialylation in a dose-dependent manner after only a few hours of 
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incubation and can be applied over prolonged time periods to block sialylation in 
culture without causing cellular toxicity. 
 
P-3Fax-Neu5Ac causes sustained blockage of sialylation and outcompetes natural 
sialyltransferase substrates  
To assess longevity of the P-3Fax-Neu5Ac-mediated block of sialylation, cells were 
incubated for 3 days with P-Neu5Ac or P-3Fax-Neu5Ac, extensively washed and 
reappearance of cell surface sialylation was determined in time. As a control 
experiment to determine the normal sialoglycan turnover rate in B16F10 cells 
recovery of cell surface sialic acids was measured after enzymatic removal using 
sialidase from C. perfringens.39 Efficient loss of α2,3-linked and α2,6-linked sialic 
acids at the beginning of the experiment (day 0) was confirmed in cells treated with 
P-3Fax-Neu5Ac or sialidase. The results showed that within 1 day after enzymatic 
removal with sialidase, sialic acid expression was fully restored (Figure 4a, b). For 
inhibitor treated cells 4 days were required for α2,3-linked sialic acids and 2 days 
for α2,6-linked sialic acids to recover. These data indicate that P-3Fax-Neu5Ac 
efficiently inhibits sialylation for prolonged time periods. There is evidence that not 
only overexpression of sialyltransferase leads to aberrant sialylation, but also tumor 
cells can exhibit increased metabolic flux rates of the sialic acid synthesis pathway. 
Here, increased intracellular sialic acid (precursor) levels lead to hypersialylation of 
sialoglycoproteins that are involved in cell adhesion and metastasis.40 Therefore 
we investigated whether increased amounts of natural sialyltransferase substrates 
can neutralize the blocking effect of P-3Fax-Neu5Ac. To this end, B16F10 cells 
were cultured in the absence or presence of 64 µM P-3Fax-Neu5Ac together with 
increasing amounts of either P-Neu5Ac or ManNAc. P-Neu5Ac will increase sialic 
acid levels via the sialic acid salvage pathway and ManNAc can enhance 
intracellular synthesis of Neu5Ac.41 After 3 days of co-incubation, sialylation of the 
cells was analyzed. Addition of either P-Neu5Ac or ManNAc to B16F10 cells 
slightly increased sialylation as expected (Figure 4c, d). Cancer cells treated with 
P-3Fax-Neu5Ac had lost expression of sialic acids and increasing amounts of P-
Neu5Ac could not prevent the loss of α2,3-linked sialic acids even at 1000 (Figure 
4c). Addition of 1000 µM P-Neu5Ac could only partially prevent the loss of α2,6-
linked sialic acids (Figure 4d). Similar results were obtained using ManNAc 
supplementation. Here, 1000 µM ManNAc could not counteract P-3Fax-Neu5Ac-
mediated loss of α2,3-linked or α2,6-linked cell surface sialic acids. Similar results 
were obtained in cells cultured under the same conditions for 1, 2 or 4 days (data 
not shown). Altogether, these data show that P-3Fax-Neu5Ac efficiently disrupts 
sialylation in melanoma cells for a sustained period of time even in the presence of 
large amounts of competing sialyltransferase substrates.  
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Figure 3 Fast effect of P-3Fax-Neu5Ac and long-term depletion of sialic acids. 
a, b, In a pulse-chase experiment, B16F10 cells were incubated at 37 °C with 64 µM or 256 µM P-3Fax-
Neu5Ac or at 4 °C with 512 µM for different time periods and sialylation was quantified 24 hours after 
starting the pulse by flow cytometry with MALII (a) and SNA-I (b). Data of minimal three independent 
experiments are displayed as average values ± SEM normalized to control. c, d, Long-term culture of 
B16F10 cells for 28 days in the presence or absence of 64 µM inhibitor. Sialylation was measured using 
the lectins MALII (c) and SNA-I (d) and is presented as percentage sialylation of untreated cells. e, f, 
Viability and proliferation of B16F10 cells in long-term culture were assessed. Results of six 
independent experiments are presented as percentage viability and percentage proliferation compared 
to untreated cells. 
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Figure 4 P-3Fax-Neu5Ac induces sustained blockage of sialylation and outcompetes natural substrates 
for sialyltransferases. a, b, Restoration of cell surface sialic acids was determined by removing sialic 
acids in B16F10 cells with P-3Fax-Neu5Ac or with C. perfringens sialidase and recovery of cell surface 
sialylation was followed in time. MALII (a), SNA-I (b) were used to detect α2,3- or α2,6-linked sialic 
acids, respectively. c, d, B16F10 cells were incubated for 3 days with or without 64 µM P-3Fax-Neu5Ac 
in the presence of 0-1000 µM P-Neu5Ac or ManNAc which are intracellularly catalyzed to substrates for 
sialyltransferases and compete with P-3Fax-Neu5Ac. Sialylation of B16F10 cells was assessed using the 
biotinylated lectins MALII (c) and SNA-I (d). The percentage sialylation was calculated and average 
values ± SEM of three independent experiments are presented. The percentage sialylation of P-3Fax-
Neu5Ac-treated cells was found to be significantly different from PBS-treated cells (p<0.001). 
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P-3Fax-Neu5Ac impairs binding to ECM components and migratory capacities  
Hypersialylation of adhesion molecules such as integrins has been described to 
enhance binding of tumor cells to the extracellular matrix (ECM) and to increase 
their invasive potential.20,42,43 Given the high efficacy of P-3Fax-Neu5Ac to block 
sialylation, we investigated the ability of treated and untreated murine cancer cells 
to bind ECM components. To this aim 3 cancer cell lines, B16F10, GL261 
(glioblastoma) and 9464D (neuroblastoma) were incubated with or without 64 µM 
P-3Fax-Neu5Ac for 3 days and their ability to adhere to uncoated wells or wells 
coated with poly-L-lysine, type I collagen or fibronectin was tested. While blocking 
sialylation did not change the capacity of these cells to adhere to uncoated wells, a 
significant decrease in binding to poly-L-lysine-coated wells was observed (Figure 
5a). Moreover, desialylated cells showed a remarkable impairment in adhesion to 
type I collagen (Figure 5a, b). Reduced adhesion to fibronectin-coated plates was 
detected in GL261 and 9464D cells, but not in B16F10 cells. 
Aberrant sialylation is correlated with increased motility of cancer cells and 
promotes metastasis.6,18,21 This prompted us to evaluate the potential of P-3Fax-
Neu5Ac to alter the migratory capacity of B16F10 cells. Hereto, B16F10 cells 
treated with or without 64 µM inhibitor were subjected to a gap closure assay. 
Already after 6 hours of culture, a significant reduction in migration could be 
detected comparing treated versus untreated cells (Figure 5c, d). In the course of 
the experiment, the reduced migratory capacity became even more pronounced as 
desialylated cells failed to efficiently invade the cell free area. Even after 18 hours 
of culture, inhibitor treated cells were incapable of closing the gap. Collectively, 
these findings indicate that P-3Fax-Neu5Ac can be used to impair cell adhesion to 
ECM components and cancer cell migration.  
 
Blocking aberrant sialylation in melanoma cells impedes growth in vivo  
The interaction with the ECM is essential for tumor cell survival and progression.44 
Regarding the potential of P-3Fax-Neu5Ac to impair adhesion ECM components in 
vitro, we assessed the ability of inhibitor-treated B16F10 cells to grow in vivo. To 
this aim, B16F10 cells were treated for 3 days with PBS, P-Neu5Ac, P-3Fax-
Neu5Ac or 1 hour with sialidase and inoculated subcutaneously into the flank of 
C57BL/6J mice. Growth of the differentially-treated tumor cells and survival of the 
mice was followed in time. B16F10 cells, treated with the control peracetylated 
sialic acid analogue showed similar growth behavior as the PBS-treated cells 
(Figure 6a). Cells that were incubated with sialidase showed a slight decrease in 
growth, whereas the P-3Fax-Neu5Ac-treated cells exhibited significantly delayed 
growth. The differences in tumor growth were reflected in the survival of the mice 
(Figure 6b). While mice that were injected with PBS or P-Neu5Ac-treated cells 
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showed similar median survival times (PBS; 24 days, P-Neu5Ac; 22 days), the 
median survival time in mice receiving P-3Fax-Neu5Ac-treated cells was almost 
doubled (40 days). Mice injected with sialidase-treated B16F10 cells showed a 
slightly increased median survival time (28 days). Noteworthy, metastases to the 
lungs or livers of the mice could not be detected in any of the treatment groups. 
Altogether, these data indicate that blocking aberrant sialylation with P-3Fax-
Neu5Ac impairs the ability of tumor cells to grow in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Blocked sialylation impairs binding to ECM components and impairs migration. →  
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a, P-3Fax-Neu5Ac-treated B16F10, GL261 or 9464D cells were labeled with CFSE and allowed to 
adhere for 45 minutes to uncoated wells or wells coated with poly-L-Lysine, collagen type I or 
fibronectin. Nonattached cells were removed by washing the wells and remnant adhesive cells were 
lysed and fluorescence signal was measured using a cytofluometer. Representative images of 
untreated or P-3Fax-Neu5Ac-treated cells attached to type I collagen-coated wells are shown (b). c, d, 
PBS or P-3Fax-Neu5Ac-treated B16F10 cells were subjected to a gap closure assay using cell culture 
inserts to generate standardized cell-free areas of 500 µm width. Gap closure was followed in time and 
images were acquired by microscopy. Representative images are shown for untreated cells (upper 
panel) and treated cells (lower panel) (c). Cell-free areas (mm2) for each time point were quantified and 
average values ± SEM of minimal six independent experiments are presented (d).  
 
Discussion 
Considering the detrimental effects of excessive tumor cells sialylation for patients 
with cancer, strategies to reduce deranged sialic acid expression are actively 
explored. In this study, we show that a recently developed fluorinated sialic acid 
analogue, P-3Fax-Neu5Ac, efficiently inhibits sialylation, adhesion and migration of 
murine melanoma cells. While leaving general expression of glycans intact, P-3Fax-
Neu5Ac almost completely depleted cell surface sialic acid residues from B16F10 
cells for several days. Long-term culture with the inhibitor continuously blocked 
sialylation without signs of cellular toxicity. Furthermore, our results suggest that P-
3Fax-Neu5Ac is a highly specific inhibitor for sialyltransferases that outcompetes 
endogenous substrates very efficiently. The resulting loss of sialoglycans impaired 
adhesion of tumor cells to poly-L lysine, type I collagen and fibronectin and their 
migratory capacity. Moreover, here we show for the first time that P-3Fax-Neu5Ac is 
a potent inhibitor of tumor growth in vivo.  
Rillahan and colleagues have described the synthesis of several sialic acid 
analogues among which P-3Fax-Neu5Ac alone was able to inhibit sialylation in 
human cancer cell lines at concentrations around 64 µM. In line with their findings, 
P-3Fax-Neu5Ac blocked α2,3- and α2,6-sialylation efficiently in B16F10 cells at the 
same concentration. Noteworthy, the effect of this fluorinated sialic acid analogue 
on α2,8-linked sialic acid expression has not been studied, yet. Synthesis of α2,8-
linked sialic acids via α2,8-sialyltransferases relies on α2,3 sialic acid substrates.13 
Since P-3Fax-Neu5Ac efficiently blocks α2,3-linked sialic acids, α2,8-linked sialic 
acids expression levels should also be affected. Indeed, we observed reduced 
expression of the α2,8-sialic acid-containing disialoganglioside GD2 in 
neuroblastoma cells upon treatment with P-3Fax-Neu5Ac (data not shown). So far 
the effectivity of P-3Fax-Neu5Ac has been shown only after several days of culture. 
Our data show that P-3Fax-Neu5Ac affects melanoma cell sialylation in a dose-
dependent manner already after 1 hour of incubation. Long-term culture for 28 
days in the presence of the inhibitor permanently reduced sialylation without 
affecting cellular viability or proliferation. These data rule out that P-3Fax-Neu5Ac 
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(e.g. acetylation or fluorination) causes cellular toxicity or that tumor cells develop 
resistance toward the inhibitor. These findings are in line with the observation in 
sialic acid-deficient CHO-Lec2 cells showing that sialylation is not necessary for 
cell survival in vitro.45 
 
Figure 6 Blocking aberrant sialylation reduces tumor growth in vivo.  
a, b, B16F10 cells were treated in vitro for 3 days with PBS, 64 µM P-Neu5Ac, 64 µM P-3Fax-Neu5Ac or 
1 hour with 250 m U/ml C. perfringens sialidase. 0.5 x 105 cells were injected s.c. into the right flank of 
the mice and tumor growth was followed in time. Two independent experiments were performed (total 
n=12) and tumor growth is presented as mean tumor volume ± SEM. Significant differences between 
the PBS group and P-3Fax-Neu5Ac group are indicated (a). Kaplan–Meyer curves represent percentage 
survival of the different treatment groups. Log-rank was used to determine statistically significant 
differences between the groups (b).  
 
Up to now, only sialidases have been described to yield cells lacking sialic acids as 
efficient as P-3Fax-Neu5Ac. Nevertheless, the fast recovery of sialoglycans after 
enzymatic cleavage and their specificity for certain sialic acid linkages limits the 
application of sialidases. In this regard, blocking de novo synthesis using P-3Fax-
Neu5Ac results in sustained depletion of sialic acids, thus providing a powerful tool 
to study sialic acids in many biologic processes in human and mouse systems. The 
sustained blockage of sialylation is potentially due to the accumulation of CMP-P-
3Fax-Neu5Ac in the cell, which needs to be cleared before de novo synthesis of 
sialoglycans can restart. In our experiments, expression of α2,3-linked sialic acids 
was reduced for almost 4 days after P-3Fax-Neu5Ac was removed from the culture 
medium whereas α2,6-sialylation fully recovered after 2 days. Considering that 
both α2,3- and α2,6-linked sialic acids recovered within 1 day after enzymatic 
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removal, the discrepancy in speed of recovery is unlikely to be explained solely by 
different turnover rates of the respective sialoglycans. Although direct evidence is 
lacking, its effect on sialylation is most likely explained by inhibition of 
sialyltransferase activity. Possibly, P-3Fax-Neu5Ac blocks α2,3-sialyltransferases 
more effectively than α2,6-sialyltransferases.  
Next to the overexpression of sialyltransferases, tumor cells can enhance 
sialylation by upregulating the synthesis of sialyltransferase substrates. Recently, 
Almaraz and colleagues suggested that an increased metabolic flux through the 
sialic acid pathway can increase sialylation in pancreatic cancer cells.40 Therefore 
we investigated whether increasing intracellular sialic acid (precursor) levels via 
ManNAc or P-Neu5Ac supplementation could counteract the P-3Fax-Neu5Ac 
effects. Our results clearly show, that P-3Fax-Neu5Ac inhibits sialylation even in the 
presence of a large excess (>15 fold) of P-Neu5Ac or ManNAc. Noteworthy, 
blockade of α2,3-sialylation was hardly affected by the competitors, whereas the 
blockage of α2,6-sialylation could only be partially prevented by high levels of 
competitor. Again, these findings support the idea that P-3Fax-Neu5Ac inhibits 
α2,3-sialyltransferases more efficiently than α2,6-sialyltransferases. 
Overexpression of sialyltransferases and the subsequent increase in sialoglycans 
has been shown to enhance binding to ECM components and migration of cancer 
cells. Our data now show that P-3Fax-Neu5Ac treatment can be used to block 
adhesion of cancer cells to collagen type I or fibronectin and to impair their 
migratory capacity. This effect might be ascribed to α1β1 integrins, as loss of 
sialylation of these adhesion receptors has previously been shown to reduce 
binding to type I collagen.20 In contradiction to studies reporting that hyposialylation 
of α5β1integrins enhances binding to fibronectin, we detected reduced binding to 
this ECM component after P-3Fax-Neu5Ac treatment.46,47 Possibly, other 
sialoglycoproteins that are affected by blocking global sialylation with P-3Fax-
Neu5Ac are involved in binding to fibronectin, too.  
Regarding the vital role of hypersialylated structures in cancer progression and 
migration, blocking sialyltransferases and subsequently sialylation might be of 
therapeutic benefit.18 We observed that melanoma cells treated with P-3Fax-
Neu5Ac before injection into mice feature delayed growth resulting in increased 
survival time of the mice. A similar, but less pronounced effect was observed in 
mice that received sialidase-treated cells. This difference between the P-3Fax-
Neu5Ac and the sialidase group can presumably be explained by the different 
recovery times of sialoglycan expression that we have observed in vitro. While P-
3Fax-Neu5Ac blocked sialylation for 2 to 4 days in vitro, sialoglycan expression was 
restored within 1 day after sialidase treatment. Most likely, tumor cells recover full 
sialylation after inoculation in vivo within these periods, too. Therefore, the delayed 
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outgrowth of the melanomas and the prolonged survival of mice that we observed 
can potentially be ascribed to early events in tumor engraftment that are affected 
by blocked sialylation. On the basis of our in vitro data, the impairment of 
hyposialylated adhesion receptors such as integrins to interact with the ECM could 
contribute to the reduced tumor outgrowth. Although the underlying mechanisms 
remain elusive, the observed impact of temporarily blocked sialylation on tumor 
growth and survival suggests that permanent administration of P-3Fax-Neu5Ac to 
the tumor could lead to therapeutic effects. 
In conclusion, our data show that P-3Fax-Neu5Ac is a highly efficient inhibitor of 
aberrant cancer sialylation. The sustained inhibition of sialylation, its potency in the 
presence of an excess of endogenous competitors and the functional impact on 
cell adhesion, migration and in vivo growth make this novel glycomimetic an 
attractive tool for anticancer therapy. 
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Abstract 
Sialoglycans play a vital role in physiology and aberrant sialoglycan expression is 
associated with a broad spectrum of diseases. Since biosynthesis of sialoglycans 
is only partially regulated at the genetic level, chemical tools are crucial to study 
their function. Here we report the development of propargyloxycarbonyl sialic acid 
(Ac5NeuNPoc) as a powerful tool for sialic acid glycoengineering. Ac5NeuNPoc 
showed strongly increased labeling efficiency and exhibited less toxicity compared 
to those of widely used mannosamine analogues in vitro and was also more 
efficiently incorporated into sialoglycans in vivo. Unlike mannosamine analogues, 
Ac5NeuNPoc was exclusively utilized in the sialoglycan biosynthesis pathway 
allowing a genetic defect in sialic acid biosynthesis to be specifically detected. 
Furthermore, Ac5NeuNPoc-based sialic acid glycoengineering enabled the on-cell 
synthesis of high affinity Siglec-7 ligands and the identification of a novel Siglec-2 
ligand. Thus, Ac5NeuNPoc glycoengineering is a highly efficient, nontoxic and 
selective approach to study and modulate sialoglycan interactions on living cells. 
 
Introduction 
Sialic acids are a diverse family of sugars that terminate the glycan chains of cell 
surface glycolipids and glycoproteins.1 Almost every vertebrate cell can synthesize 
sialic acids via an endogenous enzymatic pathway using mannosamine sugars as 
the biosynthetic precursor. Sialic acids can also be recycled from glycan 
degradation in the lysosome or taken up from exogenous (dietary) sources.1 To 
date, more than 50 derivatives of sialic acid have been identified, with the most 
common being N-acetylneuraminic acid (Neu5Ac), bearing an acetyl group on the 
5-amino substituent and the hydroxylated N-glycolylneuraminic acid (Neu5Gc).1 
Next to the diversity within the sialic acid family itself, sialic acids are enzymatically 
attached to underlying glycan structures (sialoglycans) via different linkages (α2,3, 
α2,6, α2,8), giving rise to a tremendously diverse collection of sialoglycan 
structures on the cell membrane called the ‘sialome’.2 The structural diversity of 
sialoglycans is matched by their diverse role in biology, and we are just beginning 
to understand the meaning of the sialome in physiology and pathology.3 Sialic 
acids contribute to processes ranging from fertilization to blood vessel formation 
and from pathogen recognition to cancer growth and progression.4-7 The biological 
effects of sialic acid often are mediated by sialic acid-recognizing receptors such as 
selectins or Siglecs.8 
Compared to studying the structure and function of DNA or proteins, studying the 
highly complex and diverse structures of (sialo)glycans is more challenging, 
because glycosylation is a highly dynamic, non-template driven process and 
therefore inherently more variable. (Sialo)glycan biosynthesis heavily depends on 
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the availability of different glycosides, the activity of the enzymes involved in 
sialoglycan biosynthesis and the rate of glycosylation reactions.9 In recent years, 
bioorthogonal metabolic glycoengineering or sialic acid glycoengineering has 
emerged as a simple and powerful method to study sialoglycan expression.10,11 
Sialic acid glycoengineering is based on the introduction of sialic acids or 
precursors carrying an unnatural functional group into the cellular sialylation 
pathway, which are than incorporated into sialoglycans to allow for instance 
sialoglycans to be fluorescent labeled or sialoglycan function to be modulated.12,13 
For sialic acid glycoengineering, unnatural sialic acid precursors have been 
developed that allow sialoglycans to be tracked or labeled. Early studies by Reutter 
et al. showed that modified derivatives of N-acetylmannosamine (ManNAc), were 
readily converted and incorporated into sialoglycans.14 Bertozzi and co-workers 
subsequently showed the metabolic incorporation of ManNAc derivatives carrying a 
small, unique reactive functional group that could be chemoselectively ligated 
under physiological conditions.15 This led to the development of a number of 
chemical reporter groups such as ketones15, azides16, alkynes17 and 
cyclopropenes18 as well as complementary bioorthogonal ligation chemistry.11,13,19-
22 
The two main factors that determine the efficiency and selectivity of sialic acid 
glycoengineering are the type of biosynthetic precursor and the type of chemical 
reporter group. The most commonly used biosynthetic precursors for sialic acid 
glycoengineering are mannosamine analogues. Mannosamine analogues are 
enzymatically converted into sialic acids analogues inside the cell and incorporated 
into sialoglycans. The use of mannosamine analogues therefore heavily depends 
on the expression and activity of enzymes like GNE (UDP-N-acetylglucosamine 2-
epimerase/N-acetylmannosamine kinase) or NANS (sialic acid synthase) which are 
involved in the conversion to sialic acids.23,24 Some mannosamine analogues might 
not be recognized by these enzymes and furthermore several mannosamine 
analogues have been reported to be cytotoxic.25,26 Sialic acid glycoengineering 
could become more efficient using unnatural sialic acids that can be directly 
incorporated into sialoglycans without extensive enzymatic conversion. So far, only 
a few unnatural sialic acid analogues have been developed, and data comparing 
the performance of these analogues with the corresponding mannosamine 
analogues in vitro and in vivo are scarce.27-32 
Second, the chemical reporter group also influences the incorporation of unnatural 
sialic acids into cell surface glycans. Chang et al. reported that alkyne-tagged 
mannosamine (Ac4ManNAl) allows more potent sialic acid glycoengineering than 
azide-tagged mannosamine (Ac4ManNAz).33 Notably, cellular uptake of exogenous 
mannosamine or sialic acid is low, but uptake of unnatural glycosides can be 
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greatly enhanced for instance by capping the polar hydroxyl groups with acetyl (Ac) 
groups.34 On the basis of these findings, we hypothesized that a peracetylated 
sialic acid analogue carrying an alkynyl group would be the optimal combination of 
metabolic precursor and chemical reporter for sialic acid glycoengineering both in 
terms of labeling efficiency, toxicity and selectivity. 
Here we report the development of a novel, peracetylated propargyloxycarbonyl-
tagged sialic acid analogue (Ac5NeuNPoc) for efficient and highly specific sialic 
acid glycoengineering in vitro and in vivo that enabled the unequivocal detection of 
a genetic defect in sialic acid biosynthesis and on-cell synthesis and identification 
of Siglec ligands. 
 
Materials and Methods 
Animals 
Female C57BL/6J mice were obtained from Harlan Laboratories and housed in the 
Central Animal Laboratory, Radboud University Nijmegen, The Netherlands, under 
specific pathogen-free conditions and with ad libitum access to food and water. 
Mice were 6 to 8 weeks old at the beginning of each experiment. All experiments 
were authorized by the local animal ethics committee, Nijmegen, The Netherlands, 
and carried out in accordance with their guidelines. 
 
Reagents 
The synthesis of the used glycotools is described in the supporting information. 
Azide-PEG3-biotin and alkyne-PEG4-biotin conjugates, sodium L-ascorbate, L-
histidine, copper(II) sulfate pentahydrate and Ponceau S solution were purchased 
from Sigma-Aldrich. Biotinylated lectins MALII (Maackia amurensis), and SNA-I 
(Sambucus nigra) and carbo-free blocking solution were purchased from Vector 
Laboratories, Inc. 7-AAD viability dye was purchased from eBioscience, 
streptavidin-phycoerythrin (PE) from BD Pharmingen, NeutrAvidin-Texas Red and 
DAPI nucleic acid stain from Molecular Probes, and Neutravidin DyLight 800 from 
Pierce Biotechnology. Recombinant Siglec-2, -4, and -7 Fc chimeras were 
purchased from R&D Systems and Alexa Fluor 647-conjugated goat anti-human 
IgG (H+L) antibody from Life Technologies. 
 
Cell culture 
Jurkat cells (TIB-152, ATCC), THP-1 cells (TIB-202, ATCC) and HL-60 cells (CCL-
240, ATCC) were cultured in RRMI-1640 medium (Life Technologies) 
supplemented with 10 % heat-inactivated fetal bovine serum (FBS) (Greiner Bio-
one), 2 mM glutamine (Lonza) and 1 x antibiotic-antimycotic solution (100 units/mL 
of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL Fungizone) (Life 
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Technologies). HEK293 cells (CRL-1573, ATCC) were cultured in DMEM (Life 
Technologies) supplemented with 10 % FBS, 2 mM Glutamine, 1 % nonessential 
amino acids (Life Technologies) and 1% antibiotic-antimycotic solution. IHH cells 
were cultured in Williams Medium E (Life Technologies) supplied with 10% FBS 
(PAA), Non-essential amino acids (NEAA) (Life Technologies), 100 U/mL 
penicillin/streptomycin (Life Technologies), 0.05 µM dexamethasone (Sigma), 2 
mM glutamine (Life Technologies), and 20 U/mL insulin (Roche) on gelatin coated 
6 well plates as described.35 HAP1 cells were cultured in IMDM (Life Technologies) 
supplemented with 10 % FBS, 200 µM L-glutamine (Life Technologies) and 1 % 
antibiotic-antimycotic solution.36,37 SLC35A1 knockout HAP1 cells were a kind gift 
of Thijn R. Brummelkamp, Netherlands Cancer Institute, Amsterdam, The 
Netherlands and were complemented with full-length wild type SLC35A1 mRNAs a 
described before.38,39 All cells were cultured in a humidified CO2 incubator at 37°C.  
 
Detection of surface sialoglycans by flow cytometry 
To label azide or poc-containing surface glycoconjugates, cells were washed in 1 x 
PBS and incubated with 100 µl CuAAC reaction buffer (1 x PBS containing 250 µM 
CuSO4, 250 µM L-Histidine, 500 µM sodium ascorbate and either 100 µM azide-
PEG3-biotin or 100 µM alkyne-PEG4-biotin) at RT for 30 min.40 For detection of 
surface glycoconjugates, cells were incubated 1 h with the biotinylated lectins 
MALII (5 µg/ml), SNA-I (1 µg/ml), PNA (5 µg/ml) or WGA (5 µg/ml) in carbo-free 
blocking solution containing 1 mM CaCl2+ and 1 mM MgCl2+ at 4 °C. MALII was 
used to detect α2,3-linked sialic acids, SNA-I for α2,6-linked sialic acids, PNA for 
terminal β-galactose and WGA for detection of (poly)GlcNAc (chitobiose). Cells 
were washed in FACS buffer (1 x PBS containing 1 % FBS and 0.02 % sodium 
azide) and biotinylated glycoconjugates or cell-bound biotinylated lectins were 
conjugated for 10 min at 4 °C with 2 µg/ml streptavidin-phycoerythrin. Additionally, 
cells were stained with 7-AAD viability dye. Fluorescence was measured using a 
CyAn ADP flow cytometer (BD Biosciences) and quantified utilizing FlowJo 
software (Tree Star Inc.). Untreated cells or cells stained solely with streptavidin 
served as background control. The percentage labeling or lectin binding was 
calculated by normalizing the MFI values to the respective control. 
 
Titration of azide and Poc sugars and inhibition of sialoglycan and 
glycosaminoglycan synthesis 
To compare the incorporation efficiency of azide-/Poc-mannosamines or sialic 
acids into cell surface glycoconjugates, Jurkat or THP-1 cells were incubated for 3 
days with increasing concentrations of Ac4ManNAz, Ac4ManNPoc, Ac5NeuNAz or 
Ac5NeuNPoc and subjected to CuAAc and flow cytometry analysis. Ac4ManNAc 
4 
Part I Sialic Acid Mimetics to Remodel the Sialome 
84 
and Ac5NeuNAc were used as non-labeling controls. To determine the optimal 
incubation time for bioorthogonal metabolic glycoengineering with Ac4ManNPoc or 
Ac5NeuNPoc, Jurkat and THP-1 cells were incubated for 0-4 days with 100 µM 
sugar analogues, labeled and analyzed by flow cytometry. Additionally, Jurkat, 
THP-1, HL-60 or HEK293 cells were incubated 3 days with 100 µM Ac4ManNPoc 
or Ac5NeuNPoc to compare their labeling efficiencies. To inhibit sialoglycan or 
glycosaminoglycan synthesis, Jurkat or THP-1 cells were incubated with 200 µM 
Ac53Fax-Neu5Ac or 200µM Ac34-deoxy-GlcNAc for 3 days prior to the addition of 
100 µM Ac4ManNPoc or Ac5NeuNPoc for three more days. Efficacy of both 
metabolic inhibitors was confirmed by flow cytometry using MAL-II, SNA-I and 
WGA stainings, respectively. To test incorporation of Ac4ManNPoc or Ac5NeuNPoc 
in SLC35A1 knockout HAP-1 cells, cells were incubated 3 days with 100 µM of the 
sugar analogues, labeled via CuAAC. The presence of modified glycoconjugates 
as well as MALII, SNA-I and PNA lectin binding was determined by flow cytometry. 
 
Confocal microscopy 
THP-1 cells were seeded on glass slides and incubated for 3 days in medium 
containing PBS, 100 µM Ac4ManNPoc or Ac5NeuNPoc. Ten hours before CuAAC 
PMA (0.1 µM) and IL-4 (500 U/ml) were added to the medium to induce 
differentiation and adherence to the glass slides. Cells were washed with 1x PBS 
and incubated for 30 min at RT in CuAAC reaction buffer. Next, cells were washed 
with 1x PBS, fixed for 10 min with 2% paraformaldehyde on ice, blocked 30 min 
with carbo-free blocking solution and incubated for 20 min at 4 °C with 5 µg/ml 
NeutrAvidin-Texas Red. Nuclei were stained for 10 min with DAPI and images 
were acquired using an confocal laser scanning microscope (Olympus FV1000). 
 
Transferrin purification 
Confluent 6 well plates with IHH cells were further grown in the presence of 200 
µM of Ac5NeuNAc, Ac4ManNPoc or Ac5NeuNPoc for additional 48 hours. 1.5 ml of 
medium was collected and further used for immune affinity purification of secreted 
transferrin. The remaining cells were washed 3-4 times with PBS and collected by 
scraping, lysed and used for western blot analysis as described below. Transferrin 
purification was done from 1.5 mL of medium incubated with a 40 µL of a 50 % 
slurry of rabbit anti-human transferrin antibody (DAKO) coupled to NHS-activated 
Sepharose 4 Fast Flow beads (GE Healthcare). After 1 hour incubation at RT, 
beads were washed three times with 10 mM Tris-HCl buffer pH 7.0 and bound 
transferrin was eluted in 50 µL 100 mM glycine-HCl buffer pH 2.7. The solution was 
neutralized with 1 to 2 µL of 1 M Tris-HCl buffer pH 9.0 and purified transferrin was 
subjected to western blot analysis. 
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Western blot analysis 
THP-1 cells with or without pre-incubation with Ac53Fax-Neu5Ac were incubated 3 
days with 100 µM Ac4ManNPoc or Ac5NeuNPoc. Following reaction of Poc-
containing surface glycans with azide-PEG3-biotin, cells were washed in 1 x PBS 
and lysed 1 hour on ice in lysis buffer (150 mM NaCl, 50 mM TRIS-HCl pH 7.5, 5 
mM EDTA, 0.1 % SDS, 1 % Triton X-100 and 1 x protease inhibitor cocktail). Cell 
lysates were resolved on 10% SDS-PAGE gels and blotted to PVDF membranes. 
Membranes were blocked for 1 hour at RT with blocking buffer (1 x PBS, 2 % 
nonfat dry milk, 1 % BSA) and incubated with 0.1 µg/ml Neutravidin DyLight 800 in 
1:4 blocking buffer for 1 hour at RT. After extensive washing with PBS-T (1x PBS, 
0.1% Tween-20), membranes were scanned with an Odyssey infrared imaging 
system (LI-COR). Loading of equal amounts of protein was confirmed by Ponceau 
S staining of the membranes. For visualization of Poc groups in glycans of whole 
IHH cell lysates or purified transferrin, proteins were resolved on 10% SDS gels, 
transferred to PVDF membranes and membranes were incubated 1 h at 37 °C with 
reaction buffer (1x PBS, 500 µM CuSO4, 50 µM azide-PEG3-biotin, 500 µM sodium 
ascorbate) followed by incubation with Neutravidin DyLight 800. 
 
In vivo bioorthogonal metabolic glycoengineering 
To introduce Poc sugars into cell surface glycans in vivo, mice were injected 
intraperitoneally for six consecutive days with Ac4ManNPoc (700 µmol, 300 mg/kg), 
an equimolar dose of Ac5NeuNPoc (700 µmol, 400 mg/kg) both dissolved in 60 % 
DMSO or vehicle control. On day 7, organs were harvested, mechanically 
dissociated and treated with 1 mg/ml collagenase Type III (Worthington 
Biochemical Corporation) and 30 μg/ml DNAse type I (Roche) for 30 min at 37 °C. 
Single cell suspensions were prepared using 100 µm nylon cell strainers (BD 
Biosciences). Cells were washed with 1 x PBS, incubated 30 min at RT in CuAAC 
reaction buffer and incubated for 10 min at 4 °C with 2 µg/ml with streptavidin-PE. 
Fluorescent signal was quantified by flow cytometry, and data were normalized to 
the background fluorescence of corresponding control single-cell suspensions. 
 
On-cell synthesis and detection of Siglec ligands 
THP-1 or Jurkat cells were incubated 3 days with PBS, 100 µM Ac4ManNPoc or 
Ac5NeuNPoc and conjugated with azide 1-3 in 1x PBS containing 500 µM CuSO4, 
100 µM azide1-3, and 500 µM sodium ascorbate for 30 min at RT. Cells were 
washed and incubated for 40 min with 0.4 µg/ml recombinant Siglec-2, -4, or -7 Fc 
chimeras pre-conjugated with Alexa Fluor 647 goat anti-human IgG antibodies in 
carbo-free blocking solution containing 1 mM CaCl2+ and 1 mM MgCl2+ at 4 °C. 
Alternatively, cells were incubated for 40 min at 4°C with plant-derived biotinylated 
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lectins MALII, SNA-I or PNA to occupy α2,3-linked sialic acid, α2,3-linked sialic 
acid or β-galactose before staining with recombinant Siglec-2. Fluorescence was 
measured by flow cytometry and quantified utilizing FlowJo software. 
 
Statistical analysis 
Statistical significance between two groups was determined by an unpaired t-test. 
For multiple comparisons one-way analysis of variance (ANOVA) with Bonferroni’s 
correction was performed using Prism 5.03 (GraphPad Software, Inc.). P-values 
<0.05 were considered to be significant (p<0.05 *, p<0.01 **, p<0.001 ***). 
 
Results and Discussion 
The effect of the biosynthetic precursor and the chemical reporter on sialic acid 
glycoengineering 
To explore the labeling efficiency of distinct metabolic precursor and chemical 
reporter combinations, four glycoprobes were synthesized. Two azide-carrying 
probes, N-azidoacetyl mannosamine (Ac4ManNAz)16 and N-azidoacetyl sialic acid 
(Ac5NeuNAz) and two probes carrying a propargyloxycarbonyl (Poc) group, N-Poc 
mannosamine (Ac4ManNPoc)41 and the N-Poc sialic acid (Ac5NeuNPoc), were 
prepared by chemical synthesis (Figure 1a, b). These analogues carry a Poc or 
azide group on C-2 (Ac4ManNPoc and Ac4ManNAz) or C-5 (Ac5NeuNPoc and 
Ac5NeuNAz), respectively, and are peracetylated to increase cellular uptake. The 
robust chemical synthesis of Ac5NeuNPoc was readily scalable and allowed for the 
preparation of sufficient, highly pure material for in vitro and in vivo sialic acid 
glycoengineering experiments. After metabolic incorporation, the Poc or azide 
group can be reacted selectively with azides or alkynes, respectively, using copper-
catalyzed azide alkyne cycloaddition (CuAAC).16,42 The cytotoxicity of the copper 
complex could be negated by the addition of L-Histidine, hence allowing 
bioorthogonal metabolic glycoengineering experiments to be performed on living 
cells.40 First, we assessed the efficiency of Ac4ManNPoc, Ac4ManNAz, 
Ac5NeuNPoc and Ac5NeuNAz utilization by cells for the synthesis of cell surface 
glycoconjugates. Human THP-1 or Jurkat cells were incubated for 3 days with 
increasing concentrations of the sugar analogues or control Ac4ManNAc or 
Ac5NeuNAc, conjugated to azide- or alkyne-biotin using CuAAC, and stained with 
streptavidin-PE. Fluorescent intensities were quantified by flow cytometry. In both 
cell lines, there was a dose-dependent increase in labeling with a maximum around 
100 µM (Figure 2a, b, Figure S1a, b). Labeling with Ac5NeuNPoc, however, 
resulted in a significantly higher signal compared to that with Ac4ManNPoc. At 100 
µM the labeling signal with Ac5NeuNPoc was almost 3 times higher as compared to 
that with Ac4ManNPoc.  
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Figure 1 Structural representation of mannosamine and sialic acid analogues used for 
glycoengineering. a) ManNAc series containing peracetylated Ac4ManNAc, azide-tagged Ac4ManNAz 
and propargyloxycarbonyl-tagged Ac4ManNPoc. Reporter groups are attached to the nitrogen of 
ManNAc at C2. b) NeuNAc series containing peracetylated Ac5NeuNAc, azide-tagged Ac5NeuNAz and 
propargyloxycarbonyl-tagged Ac5NeuNPoc. Reporters are attached to the nitrogen at C5 of NeuNAc. 
 
Comparing the labeling intensities between Ac4ManNAz and Ac5NeuNAz confirmed 
that sialic acid analogues are incorporated more efficiently into cell surface glycans 
than mannosamine analogues (Figure 2a, b). Furthermore, sialic acids with the 
Poc reporter group yielded higher labeling efficiencies compared to those with the 
azide analogue. Importantly, concentrations above 100µM of the tested ManNAc 
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analogues, but not NeuNAc analogues, decreased cell viability (Figure 2c, d, S1c, 
d). These findings are in line with previous work by others showing cellular toxicity 
of mannosamine analogues.25,26 Focusing on the Poc derivatives, we next 
confirmed that Ac5NeuNPoc was incorporated more efficiently into cell surface 
glycans than was Ac4ManNPoc by confocal microscopy and western blot analysis 
(Figure 2e, f, Figure S2) and in two additional human cell lines HL-60 and 
HEK293 (Figure 3a-d). To show that the increased labeling holds true on the 
single protein level, we assessed the presence of Poc groups in the N-glycans of 
purified transferrin isolated from human hepatocytes cultured with either 
Ac4ManNPoc or Ac5NeuNPoc. Transferrin has two N-glycosylation sites (Asn413, 
Asn611) and commonly carries two bi-antennary N-glycans terminated by sialic 
acids.43 Western blot analysis of whole human hepatocyte protein showed again 
that Ac5NeuNPoc allows significantly more labeling than Poc mannosamine 
(Figure 3e). Analysis of purified transferrin revealed presence of Poc groups in the 
N-glycans in cells treated with Poc sialic acid, but not with Poc mannosamine 
(Figure 3f). Collectively, these data demonstrate that compared to mannosamine 
analogues, Ac5NeuNPoc is an effective and nontoxic tool for sialic acid 
glycoengineering. 
 
Poc sialic acid allows efficient sialic acid glycoengineering in vivo 
Next, we tested the ability of both Poc sugars to be incorporated into surface 
sialoglycans in vivo. Mice were intraperitoneally injected with vehicle control, 
Ac4ManNPoc (700 µmol, 300 mg/kg) or an equimolar dose of Ac5NeuNPoc (700 
µmol, 400 mg/kg) for six consecutive days. For both Poc sugars, signs of toxicity 
were observed neither locally at the injection site nor systemically. On day 7, single 
cell suspensions from 13 different tissues were prepared and Poc-containing 
glycans were labeled with azide-biotin and subsequently streptavidin-PE and 
quantified by flow cytometry (Figure 3g). Except for the brain and blood cells, 
labeling could be found in all organs tested. The labeling efficiency for most organs 
was significantly higher with Ac5NeuNPoc compared to that with Ac4ManNPoc. 
High labeling with Ac5NeuNPoc was found in particular in the mesenteric lymph 
node, lymph nodes, liver and spleen. Altogether, these data indicate that relative to 
Ac4ManNPoc, Ac5NeuNPoc allows more efficient sialic acid glycoengineering in 
vivo. To our knowledge, this is the first time that unnatural sialic acids have been 
used for sialic acid glycoengineering in vivo. Further research should explore 
different doses, treatment schedules, and biodistribution of Ac5NeuNPoc to 
optimize in vivo application of this unnatural sialic acid for the study and 
manipulation of sialic acid-related processes for instance in cancer, infection and 
inflammation.  
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Figure 2 Incorporation of Poc sugars into cell surface glycans. 
a, b) Incorporation of Azide and Poc-modified sugars into surface glycoconjugates of THP-1 (a) and 
Jurkat (b) cells. Cells were cultured with increasing concentrations of Ac4ManNAz, Ac4ManNPoc, 
Ac5NeuNAz, Ac5NeuNPoc or control Ac4ManNAc or Ac5NeuNAc, conjugated with alkyne- or azide-biotin 
and labeled with streptavidin-PE for flow cytometry analysis. c, d) 7-AAD dead cell staining for THP-1 
(c) or Jurkat (d) cells incubated for 3 days with the different ManNAc and NeuNAc derivates. Data of → 
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three independent experiments are presented as mean percentage viable cells ± SEM. e) Confocal 
images show Poc-containing surface glycans introduced with Ac4ManNPoc or Ac5NeuNPoc and 
visualized with alkyne-biotin and NeutrAvidin-Texas Red (green). Bright field images show the cell 
outlines and DAPI staining shows the nuclei (blue). f) Detection of membrane Poc glycoconjugates 
introduced with Ac4ManNPoc or Ac5NeuNPoc by western blot analysis. 
 
Different utilization of Ac4ManNPoc and Ac5NeuNPoc for sialoglycan synthesis 
To determine the reason for the improved labeling efficiency in vitro and in vivo, we 
explored the utilization of Poc sialic acid and mannosamine in different glycoside 
synthesis pathways. First, the utilization of Ac4ManNPoc and Ac5NeuNPoc in the 
sialoglycan synthesis pathway was assessed. Hereto, THP-1 cells were incubated 
for 3 days in the presence of the sialyltransferase inhibitor Ac53Fax-Neu5Ac to block 
sialoglycan synthesis, and were then cultured for another 3 days with Ac4ManNPoc 
or Ac5NeuNPoc.44-46 Blocked sialoglycan synthesis was confirmed by staining with 
the sialic acid-recognizing lectins MALII (Figure 4a) and SNA-I (Figure 4b). 
Assessment of the Poc-carrying surface glycans by flow cytometry analysis 
showed that blocking sialoglycan synthesis almost completely prevented 
incorporation of Ac5NeuNPoc (90% reduction) (Figure 4c). These data show that 
the labeling that was detected is specifically derived from the biosynthetic 
incorporation of Poc sialic acids into surface sialoglycans. Surprisingly, 
incorporation of Ac4ManNPoc was only partially reduced (40%). These findings 
were confirmed by western blot analysis and confocal microscopy analysis (Figure 
4d, Figure S3, S4a, b) and similar results were obtained when repeating these 
studies in Jurkat cells (Figure S4c, d). Our results suggest that Ac5NeuNPoc is 
used for sialoglycan synthesis only, whereas Ac4ManNPoc can be utilized for the 
synthesis of glycosides other than sialic acids. 
It has been reported that next to sialic acid, mannosamines can be converted into 
N-acetylglucosamine (GlcNAc).47 Therefore, we next measured the incorporation of 
Ac4ManNPoc and Ac5NeuNPoc into cell surface glycoconjugates upon 
pharmacological inhibition of sialyltransferases with Ac53Fax-Neu5Ac and inhibition 
of the UDP-GlcNAc synthesis pathway with 4-deoxy-GlcNAc.48 Simultaneous 
interference with sialic acid and GlcNAc glycoconjugate synthesis abrogated 
metabolic labeling with either Ac4ManNPoc or Ac5NeuNPoc (Figure 4e, Figure 
S5). These results indicate that Ac4ManNPoc can be utilized in the sialic acid and 
GlcNAc biosynthesis pathways as has been described by others.47 Therefore, the 
higher incorporation efficiency observed with Ac5NeuNPoc compared to that for 
Ac4ManNPoc can be ascribed to its specific utilization in the sialoglycan synthesis 
pathway. While sialic acids can be directly used for sialoglycan synthesis, the 
cellular fate of ManNAc is determined by expression levels GNE, the key enzyme 
in ManNAc conversion to sialic acid.49  
4 
Sialic Acid Glycoengineering with Unnatural Sialic Acids 
91 
 
Figure 3 Ac5NeuNPoc for efficient sialic acid glycoengineering in vitro and in vivo. 
a-d) Ac5NeuNPoc shows high incorporation efficiency compared to Ac4ManNPoc in THP-1 (a), Jurkat 
(b), HL-60 (c), and HEK293 (d) cells. Data of three independent experiments are presented as MFI 
values ± SEM. e, f) Introduction of Poc groups into hepatocyte glycoproteins and secreted transferrin. e) 
Hepatocytes were treated with Ac4ManNPoc, Ac5NeuNPoc or control Ac5NeuNAc and subjected to 
western blot analysis. Poc-containing cell surface glycans (left) and total protein (right) are shown. f) 
Poc groups in the glycans of purified transferrin (left) secreted from hepatocytes total transferrin (right) 
were visualized by western blot analysis. g) Incorporation of Ac4ManNPoc and Ac5NeuNPoc in surface 
glycans of mice. Data are presented as mean fluorescence values ± SEM compared to control (n=3). 
0
1000
2000
3000
4000
5000
Fl
uo
re
sc
en
ce
 [%
 C
on
tr
ol
]
Jurkat
**
0
1000
2000
3000
4000
5000
Fl
uo
re
sc
en
ce
 [%
 C
on
tr
ol
]
THP-1
**
  
Br
ain
He
art
Lu
ng
Ki
dn
ey
Int
es
tin
e
mL
N LN
Bo
ne
 M
arr
ow
Sp
lee
n
Liv
er
Th
ym
us
Mu
sc
le
Bl
oo
d
0
500
1000
1500
2000
Fl
uo
re
sc
en
ce
 [%
 C
on
tr
ol
]
Metabolic Labeling in vivo
** *
**
**
**
*
**
***
*
Ac5NeuNPoc
Ac4ManNPoc
g
a
Ac5NeuNPocAc4ManNPoc
b
0
500
1000
1500
Fl
uo
re
sc
en
ce
 [%
 C
on
tr
ol
]
HL-60
**
c
0
500
1000
1500
Fl
uo
re
sc
en
ce
 [%
 C
on
tr
ol
]
HEK293
*
d
e
250
150
100
50
37
20
75
25
Loading Control
f
Labeling
Loading ControlLabeling
250
150
100
50
75
*
4 
Part I Sialic Acid Mimetics to Remodel the Sialome 
92 
 
Figure 4 Ac5NeuNPoc is specifically utilized in the sialoglycan synthesis pathway. 
a-b) Sialic acid blockade in THP-1 cells. Cells were treated with or without the sialyltransferase inhibitor 
Ac53Fax-Neu5Ac and expression of surface α2,3-linked sialic acids (a) and α2,6-linked sialic acids (b) 
was determined by flow cytometry analysis using the lectins MALII and SNA-I. Mean percentages lectin 
binding ± SEM of three independent experiments are shown. c) Incorporation of Ac4ManNPoc or 
Ac5NeuNPoc into cell surface glycoconjugates upon sialoglycan synthesis inhibition. THP-1 cells were 
treated with or without Ac53Fax-Neu5Ac prior to metabolic labeling with Ac4ManNPoc or Ac5NeuNPoc. 
Mean labeling percentages ± SEM of three independent experiments are presented. d) Western blot → 
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detection of Poc-containing surface glycoconjugates introduced with Ac4ManNPoc or Ac5NeuNPoc into 
THP-1 cells with or without sialic acid blockage. e) Incorporation of Poc sugars upon interference with 
sialoglycan and/or glycosaminoglycan synthesis in THP-1 cells. Cells were treated with Ac53Fax-
Neu5Ac, Ac34-deoxy-GlcNAc or both and metabolically labeled with Ac4ManNPoc or Ac5NeuNPoc. 
Mean labeling percentages ± SEM of three independent experiments are presented. f, g) Expression of 
sialoglycoconjugates in SLC35A1 knockout HAP1 cells. Wild type, SLC35A1 knockout HAP1 cells or 
knockout cells complemented with wild type SLC35A1 (rescue) were stained with fluorescent lectins 
MALII (f) or SNA-I (g). h) Wild type, SLC35A1 knockout or wild type-complement SLC35A1 knockout 
HAP1 cells were treated with Ac4ManNPoc or Ac5NeuNPoc and conjugated to alkyne-biotin and 
streptavidin-PE. Mean fluorescent intensities ± SEM of three independent experiments are presented. 
 
The enzymatic activity of GNE is tightly regulated by a negative feedback loop that 
is triggered by high levels of endogenous CMP-sialic acid.50-53 Boosting the sialic 
acid metabolic flux with exogenous ManNAc analogues is therefore self-limiting. In 
contrast, exogenous NeuNAc analogues that enter cells via a salvage pathway are 
not subjected to this feedback regulation, but they might even trigger feedback 
inhibition of GNE and inhibit synthesis of competing natural sialic acids from 
ManNAc. This difference in cellular utilization could account for the dramatically 
higher labeling efficiency of Ac5NeuNPoc compared to that of Ac4ManNPoc.  
 
Ac5NeuNPoc as a specific tool to detect a genetic defect in the sialic acid pathway 
On the basis of our findings that Ac5NeuNPoc enables more potent and highly 
specific labeling of sialoglycans compared to that with Ac4ManNPoc, we exploited 
its use for the detection of genetic defects in the sialoglycan synthesis pathway. As 
a model system we selected a CMP-sialic acid transporter (SLC35A1) knockout 
HAP1 cell line that fails to transport sialic acids from the cytoplasm to the Golgi 
system. Indeed, SLC35A1 cells expressed low levels of α2,3- and α2,6-
sialoglycans compared to that of their wild type counterpart or knockout cells 
complemented with wild type SLC35A1 (Figure 4f, g). In line with our previous 
findings in other cell lines, introduction of Poc-sialic acids into surface glycans was 
about 2 times more efficient using Ac5NeuNPoc compared to that using of 
Ac4ManNPoc in wild type HAP1 cells (Figure 4h). In the SLC35A1 knockout cells, 
incorporation of Ac5NeuNPoc into surface sialoglycans was completely prevented, 
whereas Ac4ManNPoc treatment resulted in detectable levels of Poc 
glycoconjugates. Complementing the knockout cells with wild type SLC35A1 
rescued the incorporation of Poc groups into surface glycans using Ac5NeuNPoc. 
These findings indicate that mannosamine analogues are suboptimal for the 
specific detection of defects in the sialylation pathway as ManNPoc is also 
converted into other sugar metabolic pathways. Instead, the Ac5NeuNPoc sialic 
acid derivative allows highly specific imaging of sialic acid biosynthesis and its 
genetic defects. 
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Figure 5 Rendering cell surface sialoglycans reactive to Siglec-7 and Siglec-2. a) Schematic 
representation of the approach. b-e) THP-1 cells treated with PBS, Ac4ManNPoc or Ac5NeuNPoc were 
reacted to different azides using CuAAC. Cells were stained with recombinant Siglec-7, -4, or -2 Fc 
chimeras and anti-human Fc-AF647 Abs and analyzed by flow cytometry. Histograms show average 
MFI ± SEM of three independent experiments for binding of Siglec-7 (b), Siglec-4 (c) and Siglec-2 (d). 
e) To determine linkage specificity of Siglec-2 for the Azide 2-modified cell surface sialoglycans, α2,3-
/α2,6-sialic acids were blocked using MALII or SNA-I, respectively prior to incubation with recombinant 
Siglec-2. β-galactose-binding PNA was used as control. Histograms show fold change binding of 
recombinant Siglec-2 to THP-1 or Jurkat cells pre-treated with MALII, SNA-I or PNA (n=3). 
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Sialic acid glycoengineering using Ac5NeuNPoc enables on-cell synthesis of high 
affinity Siglec Ligands 
Having shown that Ac5NeuNPoc is a powerful tool to specifically introduce Poc-
modified sialic acids into sialoglycans of living cells, we next aimed to functionally 
modulate these surface sialoglycans to enhance their binding to Siglecs. In an on-
chip glycan array screen, Rillahan et al. have found that clicking distinct azide 
groups to sialic acids can strongly enhance their binding affinity to Siglec-7.54 From 
this on-chip screen, we have selected three azides derivatives (azide1-3) that 
either strongly enhance Siglec-7 binding (azide 1), led to an intermediate increase 
in Siglec-7 binding (azide 2) or did not enhance Siglec-7 binding (azide 3) (Figure 
5a).54 THP-1 or Jurkat cells were treated with Ac4ManNPoc or Ac5NeuNPoc and 
the three different azides were clicked to the Poc-modified glycans using CuAAC. 
Binding of recombinant Siglec-7 Fc chimeras to the modified cells was quantified 
by flow cytometry. Siglec-7 showed minor binding to untreated cells and 
Ac4ManNPoc-treated cells and incubation with Ac5NeuNPoc slightly increased 
binding (Figure 5b, Figure S6a, b). Clicking azide 1 to Ac4ManNPoc-treated cells 
enhanced binding of Siglec-7 (MFIControl 221; MFIAc4ManNPoc 704), but binding of 
Siglec-7 to Ac5NeuNPoc-treated cells clicked with azide 1 was greatly enhanced 
(MFIAc5NeuNPoc 1353). Clicking azide 2 to Ac4ManNPoc-treated cells did not enhance 
Siglec-7 binding significantly, whereas an intermediate increase was found for 
Ac5NeuNPoc-treated cells (MFIControl 209; MFIAc5NeuNPoc 594). 
In line with the findings from the on-chip screen, Siglec-7 binding was not 
enhanced to cells clicked with azide 3. As controls, binding of Siglec-4 and Siglec-2 
Fc-chimeras to the modified cells was assessed. As expected, no significant 
changes in Siglec-4 binding were observed (Figure 5c, Figure S6c). Surprisingly, 
we found that Siglec-2 can bind strongly to azide 2-modified cells (Figure 5d, 
Figure S6d), whereas no binding of Siglec-2 to control cells could be detected. 
Binding of Siglec-2 to Ac5NeuNPoc-treated cells clicked with azide 2 (MFIAc5NeuNPoc 
241) was much stronger than for Ac4ManNPoc-treated cells (MFIAc4ManNPoc 91). 
Importantly, treatment with Ac4ManNPoc or Ac5NeuNPoc had no remarkable effect 
on Siglec binding compared to control cells, indicating that Poc-modified sialic 
acids are recognized by recombinant Siglecs with a similar efficiency as the native 
sugars. Moreover, the increased Siglec binding was dependent on the copper(I)-
catalyzed azide alkyne cycloaddition as absences of CuSO4 during the click 
reaction prevented reaction of Poc glycans to the azides and a subsequent 
increase in Siglec binding (Figure S7a-d). 
Using our approach, all sialoglycans are probably modified, regardless of their 
linkage type to penultimate sugars. To further characterize the nature of the newly 
identified on-cell Siglec-2 ligand, the plant derived lectins MALII, SNA-I and PNA 
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were used to occupy α2,3-linked, α2,6-linked sialic acids or as a control β-
galactose, respectively, on Ac5NeuNPoc-treated azide 2-clicked cells prior to 
Siglec-2 binding (Figure S8a, b). While pre-incubation with MALII and PNA had no 
significant effect on Siglec-2 binding, SNA-I abrogated the binding of Siglec-2 to 
azide 2 engineered cells (Figure 5e). This finding is in line with literature reporting 
that Siglec-2 preferentially binds to α2,6-linked sialic acids.8 Altogether, these data 
demonstrate the feasibility of our bioorthogonal metabolic glycoengineering 
approach to functionally modify cell surface sialoglycans on living cells to create 
high affinity Siglec ligand-expressing cells (HASLECs). Most applications of sialic 
acid glycoengineering to date have focused on tracking sialylation by means of 
clicking fluorescent labels to modified sialic acids. We now show for the first time 
that Ac5NeuNPoc-based sialic acid glycoengineering can be used to functionally 
modify cell surface sialoglycans on living cells. To make this on-cell 
glycoengineering approach possible we found that it is crucial to use Ac5NeuNPoc, 
not Ac4ManNPoc, as a sialic acid precursor to ensure high labeling efficiency and 
selectivity. With this approach it is now possible to chemically program the cell 
glycocalyx and modulate its interaction with sialic acid binding receptors like 
Siglecs in a natural context. 
In conclusion, our data show that Ac5NeuNPoc is a powerful tool for sialic acid 
glycoengineering in vitro and in vivo. The so far unprecedented high labeling 
efficiency, high specificity and lack of toxicity of the sialic acid analogue 
Ac5NeuNPoc compared to those of mannosamine analogues, make this novel 
unnatural sialic acid a potent tool to functionally modulate cell surface sialoglycans 
for instance for the targeting of Siglecs. This modulation can be exploited not only 
to study sialic acid/Siglec interactions, but also for the development of therapeutic 
glycoproteins, or to study sialic acid-related processes in health and disease. 
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Figure S1 Incorporation of Poc sugars into cell surface glycans. 
a, b) Incorporation of Poc sugars into surface glycoconjugates of THP-1 cells (a) and Jurkat cells (b) 
using Poc-tagged ManNAc and NeuNAc. Cells were cultured for 3 days with Ac4ManNPoc or 
Ac5NeuNPoc, conjugated with alkyne- or azide-biotin, respectively and labeled with streptavidin-
phycoerythrin for flow cytometry analysis. Data are presented as MFI ± SEM of three independent 
experiments. c, d) 7-AAD dead cell staining for THP-1 (c) or Jurkat (d) cells incubated for 3 days with 
Ac4ManNPoc or Ac5NeuNPoc. Data of three independent experiments are presented as mean 
percentage viable cells ± SEM.  
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Supplementary Figure 2 Loading control for western blot. 
THP-1 cells were incubated 3 days with vehicle control, 100µM Ac4ManNPoc or Ac5NeuNPoc, 
conjugated with azide-biotin using CuAAC, lysed and resolved on a SDS-PAGE gel followed by western 
blotting. Membrane was stained with Ponceau S solution to confirm equal loading of cell lysates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3 Loading control for western blot. 
THP-1 cells were incubated 3 days with or without 200µM Ac53Fax-Neu5Ac and another 3 days with 
vehicle control, 100µM Ac4ManNPoc or Ac5NeuNPoc, conjugated with azide-biotin using CuAAC, lysed 
and resolved on a SDS-PAGE gel followed by western blotting. Membrane was stained with Ponceau S 
solution to confirm equal loading of cell lysates. 
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Supplementary Figure 4 Metabolic labeling upon sialic acid blockade. 
a, b) Representative confocal images showing outlines (bright field), nuclei (blue) and labeled Poc-
containing surface glycoconjugates (green) in control THP-1 cells (a) or cells with blocked sialoglycan 
synthesis (b) upon three days culture with 100µM Ac4ManPoc or Ac5NeuNPoc. c) Jurkat cells were 
incubated for 3 days with or without 200µM Ac53Fax-Neu5Ac and α2,3-linked sialic acids were detected 
with MALII by flow cytometry. Mean percentage lectin binding ± SEM of control and Ac53Fax-Neu5Ac-
treated cells is presented of three independent experiments. d) Mean percentage labeling ± SEM of 
three independent experiments of Jurkat cells with Ac4ManNPoc or Ac5NeuNPoc treated with or without 
200µM Ac53Fax-Neu5Ac before labeling. 
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Supplementary Figure 5 ManNAc analogs can be utilized for GlcNAc biosynthesis. 
a, b) Interference with GlcNAc glycoconjugates synthesis affects sialylation. THP-1 (a) and Jurkat (b) 
cells were incubated 3 days in the presence of 200µM Ac34-deoxy-GlcNAc and stained with lectins 
WGA, MALII and SNA-I to detect (poly)GlcNAc, α2,3- or α2,6-linked sialic acids, respectively. Lectin 
binding was quantified by flow cytometry and fluorescence was normalized to wild type cells. Data of 
three independent experiments are presented as average percentage lectin binding ± SEM. c) 
Incorporation of Poc sugars upon interference with sialoglycan or glycosaminoglycan synthesis. Jurkat 
cells were incubated with for 3 days with 200µM Ac53Fax-Neu5Ac or Ac34-deoxy-GlcNAc or both and 
metabolically labeled for 3 days with 100µM Ac4ManPoc or Ac5NeuNPoc. Poc-glycans were conjugated 
to alkyne-biotin and streptavidin-phycoerythrin and fluorescence was quantified by flow cytometry. Mean 
labeling percentages ± SEM of three independent experiments are presented. 
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Supplementary Figure 6 On-cell synthesis of Siglec-7 and Siglec-2 ligands. 
a) THP-1 or Jurkat cells were incubated for 3 days with 100µM Ac4ManNPoc or Ac5NeuNPoc and 
clicked to biotin-azide. Biotin-azide-conjugated cell surface glycans were probed with streptavidin-PE 
and quantified by flow cytometry. Average mean fluorescence intensities ± SEM of three independent 
experiments are presented. b-d) Jurkat cells were conjugated to azide ligand 1-3 using CuAAC and 
binding of recombinant Siglec-7, -4 and -2 conjugated to AF647 was assessed by flow cytometry. 
Histograms show average fold change binding ± SEM of Siglec-7 (b), Siglec-4 (c) and Siglec-2 (d) 
compared to control treated cells. 
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Supplementary Figure 7 CuSO4 is essential for the Poc-glycan to azide reaction. 
a) THP-1 cells were treated for 3 days with 100µM Ac5NeuNPoc and incubated with biotin-azide and 
click-reaction buffer with or without CuSO4. Biotin-azide-conjugated cell surface glycans were probed 
with streptavidin-PE and quantified by flow cytometry. b-d) Copper-dependent reaction of Poc-
sialoglycans with azide1-3. THP-1 cells were incubated for 3 days with 100µM Ac5NeuNPoc and 
reacted with azide1-3 in the presence or absence of CuSO4. Binding of recombinant Siglec-7 (b), -4 (c) 
and -2 (d) to the cells was quantified by flow cytometry. Average mean fluorescence intensities ± SEM 
of three independent experiments are presented. 
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Supplementary Figure 8 Plant lectin binding to Azide 2 glycoengineerd cells. 
a, b) THP-1 or Jurkat cells were incubated for 3 days with 100µM Ac4ManNPoc or Ac5NeuNPoc and 
clicked to Azide 2. Binding of PE-conjugated lectins MALII (α2,3-NeuNAc), SNA-I (α2,6-NeuNAc) or 
PNA (β-galactose) to the Azide-2-modified cells was assessed by flow cytometry. Average mean 
fluorescence intensities ± SEM of three independent experiments are presented for THP-1 cells (a) and 
Jurkat cells (b). 
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Abstract 
Sialic acid sugars that terminate cell surface glycans form the ligands for the sialic 
acid-binding immuno-globulin-like lectin (Siglec) family, immunomodulatory 
receptors preferentially expressed by immune cells. Sialic acid-Siglec interactions 
regulate the immune system, and aberrations herein contribute to pathologies like 
autoimmunity and cancer. Many biological functions of sialic acid-Siglec 
interactions, however, are yet to be uncovered. Here we report on a 
glycoengineering approach to remodel the surface sialic acids of living cells and 
their binding to Siglecs. Using bioorthogonal chemistry, a library of cells with more 
than sixty different sialic acid modifications was generated that showed 
dramatically increased binding and selectivity toward the different Siglec family 
members. Functional analysis showed that glycoengineered cells carrying sialic 
acid ligands for Siglec-3 dampened the activation of Siglec-3+ monocytic cells via 
the NF-κB and IRF pathways. The here described glycoengineering approach 
could advance the study of sialic acid-Siglec interactions and provide fundamental 
insights into their role in health and disease. 
 
Introduction 
The immune system is comprised of many types of immune cells and defends the 
host from pathogens and cancer. Therefore, the immune system must discriminate 
between self and non-self to avoid damage to healthy tissue. An important 
differentiator in this respect is the presence or absence of sialic acid sugars on the 
cell surface.1-3 Sialic acids are a family of negatively charged nine-carbon sugars 
that frequently terminate the glycans of surface glycoproteins and glycolipids of 
mammalian cells.4,5 Next to their involvement in many different biological 
processes at the cell surface, sialic acids can regulate the immune system by 
interacting with the sialic acid-binding immunoglobulin-like lectin (Siglec) family.6,7 
In humans, 14 Siglecs (Siglec-1 to -11 and Siglec-14 to -16) are functionally 
expressed. All Siglecs consist of an extracellular sialic acid-binding V-set domain 
followed by 2-17 C2-set Ig domains (Scheme 1).8 The intracellular domain of most 
Siglecs contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that 
transmits inhibitory signals upon ligand binding via the recruitment of SHP-1/2 
phosphatases. Alternatively, Siglec 14-16 do not have an ITIM, but carry a 
positively-charged amino acid in their transmembrane region that can bind the 
immunoreceptor tyrosine-based activation motif (ITAM) containing adapter protein 
DAP12. Siglecs can bind to sialic acids present on the same cell (cis-binding) or 
sialic acids present on an adjacent cell (trans-binding).8,9  
In general, the interaction of sialic acids with Siglecs either in cis or trans dampens 
immune cell activation and function.7,10-12 Aberrations in sialic acid and Siglec 
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expression have been associated with autoimmunity, inflammatory diseases, 
neurodegeneration and cancer.9,13-20 Indeed, cancer cells and multiple pathogens 
are often hypersialylated and interact with inhibitory Siglecs to escape from the 
immune system.19,21-26 Although recent scientific advances demonstrate the 
importance of sialic acid-Siglec interactions in immune regulation and beyond, the 
role of many sialic acid interactions with the Siglec family members in physiological 
and pathological processes is barely understood.9 Therefore, chemically modified 
sialic acids that bind to Siglecs with high affinity have been developed as tool to 
study and manipulate sialic acid-Siglec interactions.11,27-29 Sialic acids bind to 
Siglecs in a monovalent manner with relatively low affinity (0.1-3 mM).7 Chemical 
modifications of sialic acids can augment the binding affinity and selectivity towards 
a Siglec by interacting with residues neighboring the shallow sialic acid binding 
domain.11,29 Recently, Rillahan et al. have shown that the copper-catalyzed alkyne-
azide cycloaddition (CuAAC), a so-called “click reaction”, can be used to modify 
sialic acids on glass-based microarray slides to create sialic acid mimetics with 
increased binding affinities to Siglecs.30-32 This approach enables high-throughput 
synthesis and identification of novel sialic acid mimetics for high affinity Siglec 
binding. However, glycan arrays cannot be used to study the putative cellular 
consequences derived from interactions of these sialic acid mimetic with Siglecs. 
To be biologically active, sialic acid mimetics need to be presented to Siglecs in a 
multivalent manner. In nature, multivalency is created by presenting multiple sialic 
acids on the cell surface on glycoproteins and glycolipids.11 Glycan arrays lack the 
natural glycan context as it is found on the cell surface.33 Therefore, we 
investigated the possibility of using click chemistry to modify sialic acids on living 
cells to enhance their binding to Siglecs while maintaining their natural multivalent 
and flexible presentation on the cell surface. 
In this study, C-5 alkyne or C-5 azide modified sialic acids were metabolically 
introduced into the glycans of living cells and reacted with a number of different 
azides or alkynes using CuAAC.34,35 The obtained library of glycoengineered cells, 
each carrying a unique sialic acid modification, was screened for binding to the 
human Siglec family. Using this approach, we identified sialic acid modifications 
resulting in a dramatic increase in Siglec binding to the cells as well as sialic acid 
ligands for orphan Siglecs (-6, -8 and -11). Using structure-guided design, sialic 
acid modifications highly selective for Siglec-5/-14 were developed that showed no 
binding to other Siglecs. Moreover, functional analysis showed that 
glycoengineered cells carrying a newly identified sialic acid ligand for Siglec-3 
dampened the activation of Siglec-3+ monocytic cells via the NF-κB and interferon 
regulatory factor pathways. Altogether, the described glycoengineering approach 
could be highly useful for the reprogramming of cellular sialic acid-Siglec 
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interactions to study the biological role of the human Siglec family in the immune 
system and to modulate Siglec signaling in diseases such as autoimmunity or 
cancer.  
 
Scheme 1 Sialic acid glycoengineering on living cells to modulate Siglec-mediated immune responses. 
Scheme illustrating the used sialic acid glycoengineering approach to generate cells that express 
chemically modified sialic acids on their surface that act as high affinity ligands for the Siglec family. To 
generate the high affinity Siglec ligand expressing cells (HASLECs), clickable sialic acids are introduced 
into the cellular sialylation pathway and incorporated into cell surface sialoglycans (1). The clickable 
sialoglycans on the cell surface can then be reacted with clickable azides and alkynes (2) and their 
impact on binding to Siglecs can be assessed (3). The sialic acid glycoengineered cells can interact with 
Siglec expressing immune cells to modulate immune activation for instance mediated via Toll-like 
receptor stimulation (4). 
 
Materials and Methods 
Reagents and antibodies 
Ac5NeuNAc, Ac5NeuNPoc and Ac5NeuNAz were prepared as previously described 
by us.34 Azide-PEG3-biotin and alkyne-PEG4-biotin, sodium L-ascorbate, L-
histidine and copper(II) sulfate pentahydrate, lipopolysaccharide (LPS) and mouse 
anti-human Siglec-2- phycoerythrin (PE) antibody (MEM-01) were purchased from 
Sigma-Aldrich (St. Louis, MO). Recombinant human Siglec Fc chimeras, mouse 
anti-human Siglec-6-PE antibody (767329), mouse-anti Siglec-8-APC antibody 
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(837535) and PE-conjugated mouse anti-human Siglec-9 antibody (191240) were 
purchased from R&D Systems (Minneapolis, MN) and Alexa Fluor 647-conjugated 
goat anti-human IgG (H+L) secondary antibody and Hank's balanced salt solution 
(HBSS) from Life Technologies (Burlington, Ontario, Canada). Biotin-MALII, Biotin-
SNA-I, Biotin-PNA and carbo-free blocking solution were purchased from Vector 
Laboratories, Inc. (Burlingame, CA). 7-AAD viability dye was purchased from 
eBioscience (San Diego, CA) and streptavidin-PE from BD Pharmingen (Franklin 
Lakes, NJ). Mouse anti-human Siglec-3-PE antibody (WM53), mouse anti-human 
Siglec-5/14-PE antibody (1A5), mouse anti-human Siglec-7-PE antibody (6-434), 
mouse anti-human Siglec-10-PE antibody (5G6) and PE-conjugated mouse IgG 
isotype antibodies were purchased from Biolegend (San Diego, CA). Pam3CSK4, 
blasticidin, zeocin and alkaline phosphatase detection medium (QUANTI-Blue) was 
obtained from Invivogen (San Diego, CA). Rabbit anti-human Siglec-3 polyclonal 
antibody was purchased from Proteintech (Chicago, IL), goat anti-rabbit IgG 
antibody from Jackson ImmunoResearch (Baltimore, PA). SHP-1/-2 phosphatase 
inhibitor NSC-87877 (CAS 56932-43-5) was obtained from Merck Millipore 
(Billerica, MA). 
 
Cell culture 
Jurkat cells (TIB-152, ATCC) and THP1-DUAL cells (Invivogen) were cultured in 
RRMI-1640 medium (Life Technologies) supplemented with 10 % heat-inactivated 
fetal bovine serum (FBS) (Greiner Bio-one, Frickenhausen, Germany), 2 mM 
glutamine (Lonza, Walkersville, MD) and 1x antibiotic-antimycotic solution (100 
units/mL of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL Fungizone) (Life 
Technologies). To maintain selection pressure in the THP1-DUAL reporter cells, 
medium was supplemented with zeocin (100 μg/mL) and blasticidin (10 μg/mL). 
HEK293 cells (CRL-1573, ATCC) were cultured in DMEM (Life Technologies) 
supplemented with 10% FBS, 2 mM glutamine, 1 % non-essential amino acids (Life 
Technologies) and 1% antibiotic-antimycotic solution. All cells were cultured in a 
humidified CO2 incubator at 37 °C.  
 
On-cell synthesis of sialic acid-based Siglec ligands 
Cells were incubated for 3 days with PBS, 150 µM Ac5NeuNAc, 150 µM 
Ac5NeuNPoc or 200 µM Ac5NeuNAz to achieve equal incorporation efficiencies 
and washed with 1x PBS prior to the click reaction. To react surface alkyne or 
azide sialic acids with biotin-azide, biotin-alkyne or L1-64, respectively, cells were 
incubated for 20 minutes at 37 °C with click buffer (1x PBS, 250 µM CuSO4, 200 
µM L-histidine, 500 µM sodium ascorbate) containing 100 µM of an azide or 
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alkyne. Cells incubated with click buffer without any reactive molecule were used 
as control.  
 
Click reaction efficiency  
To determine the efficiency of the click reaction between alkyne and azide surface 
sialic acids and L1-64 Jurkat cells were incubated for three days with 150 µM 
Ac5NeuNPoc or 200 µM Ac5NeuNAz and reacted for 20 minutes at 37 °C to L1-49 
and L50-64, respectively. Cells incubated with click buffer without azides or alkynes 
were used as control. After the first click reaction, cells were clicked a second time 
for 20 minutes at 37 °C with azide- or alkyne-biotin and incubated with 
Streptavidin-PE. Streptavidin-PE signal was measured with flow cytometry. Using 
the MFI of control cells that were not conjugated with an azide or alkyne in the first 
click reaction as maximum labeling, the percentage labeling of cells reacted to L1-
49 and L50-64 during the first click reaction was calculated. 
 
Lectin and antibody staining and flow cytometry 
To detect expression of Siglec ligands on the cell surface, cells were washed with 
1x HBSS and incubated for 45 minutes at 4 °C with 0.4 µg/ml recombinant human 
Siglec Fc chimeras, pre-conjugated with Alexa Fluor 647 goat anti-human IgG 
antibodies in HBSS. Cells were washed with 1x PBS containing 1 % bovine serum 
albumin (BSA) and resuspended for flow cytometry analysis. To detect α2,3-linked 
sialic acids, α2,6-linked sialic acids or non-sialylated β-galactose cells were 
incubated for 45 minutes at 4 °C with biotinylated MALII, SNA-I or PNA, washed 
and incubated 10 minutes at 4 °C with streptavidin-PE. Cells were washed and 
resuspended in PBA (1x PBS, 1 % bovine serum albumin, 0.02 % sodium azide) 
prior to flow cytometry analysis. To detect expression of Siglecs, cells were 
incubated for 20 minutes 4 °C with isotype control antibodies or fluorescent anti-
human Siglec antibodies, washed and resuspended in PBA. Lectin or antibody 
binding was quantified using a CyAn ADP flow cytometer (BD Biosciences, San 
Jose, CA). Data were analyzed with FlowJo software (Tree Star Inc., Ashland, OR) 
to obtain the mean fluorescence intensity (MFI). Fold change Siglec binding was 
calculated by normalizing the MFI to control cells treated with control click buffer. 
 
Sequence alignment and Siglec-5/-14 docking model 
Sequence alignment of Siglec-5 (UniProt O15389), -7 (UniProt Q9Y286) and -9 
(UniProt Q9Y336) was performed using Clustal Omega on the EMBL-EBI 
webserver and Jalview software.36,37 For the docking, the X-ray structure of Siglec-
5 was obtained from the Protein Data Bank (PDB) (entry: 2ZG138) and L24-26 were 
built using Molecular Operating Environment (MOE) 2015.10 ed. 1010 from 
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Chemical Computing Group Inc. (Montreal, QC, Canada). Docking of L24-26 was 
performed using MOE. The Siglec-5 structure was prepared for docking by 
protonation at pH=7.2. All dockings were performed using the MMFF94x force field 
and the induced fit protocol, implemented in the MOE 2013.08 docking tool. Full 
flexibility was allowed for the side chain atoms in pocket residues. The binding 
pocket for sialic acid is very solvent exposed, therefore the docking was guided by 
a pharmacophore model (Figure S9) to ensure similar placement of the sugar 
moiety as observed in the X-ray structure of Siglec-5 with sialic acid (6'-
sialyllactose). Poses were scored using the London dG and GBVI/WSA dG 
methodology, which both estimate the free energy of binding of the ligand from a 
given pose after placement or refinement respectively. In both the placement and 
the refinement step, the best scoring poses (at most 50) were retained as output in 
a MOE database for each compound and visually inspected. 
 
Toll-like receptor (TLR) stimulation reporter cell assay  
Jurkat cells were incubated for 3 days with PBS, 150 µM Ac5NeuNPoc or 200 µM 
Ac5NeuNAz and reacted with L4, L39, L40 or L57 as described above. 3x105 
Jurkat cells were co-cultured for 4 hours with 1x105 THP1-DUAL reporter cells that 
secrete alkaline phosphatase upon activation of the NF-κB pathway and luciferase 
upon IRF induction.39,40 Before co-culture, THP-1 cells were incubated with or 
without 50µM NSC-87877 for 3 hours and alternatively with 10 µg/ml isotype 
antibody or anti-CD33 antibody for 20 minutes followed by the addition of 20 µg/ml 
corresponding cross-linking antibody. Cells were stimulated for 24 hours with 
medium, 10 ng/ml LPS or 50 ng/ml Pam3CSK4. Alkaline phosphatase activity and 
luciferase activity in the medium was determined using a QUANTI-Blue colorimetric 
enzyme or a QUANTI-Luc assay following the manufacturer’s protocol (Invivogen). 
Briefly, to detect alkaline phosphatase activity 20 µl culture supernatants were 
incubated with 180 µl QUANTI-Blue detection reagent for 30 minutes at 37 °C and 
analyzed with a spectrophotometer at 620 nm. To measure luciferase activity, 10 µl 
supernatant was incubated for 4 seconds with 50 µl QUANTI-Luc solution and 
analyzed using a Victor luminometer (Perkin Elmer, Waltham, MA) with a 0.1 
seconds reading time. 
 
Statistical analysis 
Statistical significance was calculated using Prism 5.03 (GraphPad Software, Inc., 
La Jolla, CA). For comparisons between groups one-way ANOVA with Bonferroni 
post-hoc test was used. P-values <0.05 were considered significant (p<0.05 *, 
p<0.01 **, p<0.001 ***). 
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Results 
Generation of a glycoengineered cell library using bioorthogonal chemistry  
To metabolically introduce clickable sialic acids into surface glycans of living cells, 
Jurkat cells were cultured for three days with Ac5NeuNPoc or Ac5NeuNAz sialic 
acid (Figure 1a). These sialic analogs enter the cellular sialylation pathway with 
high specificity, resulting in the expression of alkyne and azide sialoglycans on the 
cell surface.34 Jurkat cells were selected, because this human T cell line does not 
express Siglec receptors on the cell surface circumventing binding in cis to the 
modified sialoglycans (Figure S1). To confirm efficient incorporation of alkyne and 
azide sialic acids into cell surface glycans, the cells were reacted with azide-biotin 
or alkyne-biotin using CuAAC. Toxicity of Cu(I) could largely be prevented by the 
addition of Histidine as reported by Kennedy et al.41 Biotin-tagged surface glycans 
were conjugated with streptavidin-PE and detected by flow cytometry. High 
fluorescence (MFI > 8000) showed efficient incorporation of Ac5NeuNPoc and 
Ac5NeuNAz into the glycocalyx of Jurkat cells, and no fluorescence was detected 
for control sialic acid (Ac5Neu5Ac) (Figure 1b). Noteworthy, Jurkat cells expressed 
both α2,3- and α2,6-linked sialic acids. Treatment of the cells with the clickable 
sialic acids slightly increased sialylation (Figure S2).  
 
Figure 1 Incorporation of poc and azide sialic acids into cell surface glycans. 
a) Structural presentation of control Ac5Neu5Ac or clickable Ac5NeuNPoc and Ac5NeuNAz. b) Detection 
of poc and azide sialic acids on the surface of Jurkat cells incubated for 3 days with Ac5NeuNPoc, 
Ac5NeuNAz or control Ac5Neu5Ac. Cells were reacted with azide or alkyne biotin, respectively, stained 
with streptavidin-PE and analyzed by flow cytometry. Bar diagram shows MFI ± SEM (n=3). 
 
Next, cells carrying azide or alkyne modified sialoglycans were reacted with 64 
different alkynes (L1-49) or azides (L50-64), respectively (Figure 2, S3, S4). To 
determine the reaction efficiency of L1-64 in the first click reaction, a second click 
reaction was performed with biotin-azide/alkyne followed by staining with 
Streptavidin-PE and flow cytometry analysis. All azides and alkynes tested showed 
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reaction efficiencies above 80 % indicating that L1-64 can be reacted to surface 
sialic acids with high efficiency (Figure 2). Noteworthy, reaction of surface alkyne 
sialic acid with L5, a fluorogenic azidofluorescein, could be shown directly, because 
L5 underwent fluorescence enhancement after reaction to alkyne sialic acids 
(Figure S5).42 L1-64 were selected on the basis of known potent structures and in 
silico docking experiments (vide infra). Previous research by other groups showed 
that adding hydrophobic, aromatic substituents (aryl and benzyl azides/alkynes) to 
the sialic acid backbone improved Siglec binding.30,43,44 Our in silico experiments 
indicated the presence of charged amino acids in some Siglec family members and 
hence we included amine and carboxylic acid derivatives for their potential to 
interact with these charged residues. We also assessed the effect of the linkage 
type of the azide/alkyne group to the aromatic portion of the sialic acid binding site 
by the inclusion of an amide or carbamate linkage which can engage in hydrogen 
bonding (Figure S3, S4).31 Altogether, by reacting L1-64 to the sialic acids of 
Jurkat cell, we generated a cell library with 64 different sialic acid modifications. 
 
Figure 2 Generation of a sialic acid-modified cell library using click chemistry. 
Structures of representative azides and alkynes used to modify surface poc or azide sialic acids are 
depicted. Click reaction efficiency of L1-64 to surface alkyne or azide sialic acids, are shown (n=3). Click 
efficiencies were determined by flow cytometry using two click reactions, first with control or L-1-64, 
second with biotin-azide or alkyne-biotin followed by streptavidin-PE labeling and flow cytometry 
analysis. The reduction in streptavidin-PE labeling of cells clicked with L1-64 was used to calculate 
reaction efficiencies. 
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Screening of the glycoengineered cell library for binding to the human Siglec family 
Having shown that L1-64 reacted efficiently with the clickable surface sialic acids, 
the binding of all available recombinant human Siglecs (11 of the 14) to the 
modified cells was assessed. To detect binding, the recombinant Siglec Fc 
chimeras were complexed with AF647 conjugated anti-human Fc antibodies. The 
AF647 conjugated anti-human Fc antibodies alone showed no binding to L1-64 
modified Jurkat cells, but significant changes in binding of the Siglec Fc chimera to 
the glycoengineered cell library were observed (Figure 3, Supplementary Table 
1). Noteworthy, the addition of L1-64 to alkyne and azide sialic acid-treated cells in 
the absence of CuSO4 had no effect on Siglec binding, demonstrating that the click 
reaction with surface sialic acids is required to affect Siglec binding (Figure S6). 
Based on the binding patterns, the members of the Siglec family could be divided 
into two main groups. The first group includes Siglec-2, -3, -6, -8 -10 and -11 
reacted only to a few (1 to 6) of the sialic acid modifications presented by the cells. 
For instance, Siglec-3 showed an almost hundred-fold increase in binding to L4 
and L39-modified cells and also binding to L57 was enhanced almost fifty times. 
The second group including Siglec-5/-14, -7, -9 reacted to many (11 to 49) 
glycoengineered cells. Siglec-5 and Siglec-14, that share the same V-set domain, 
showed a highly increased binding in response to several modifications with azides 
and alkynes. No change in binding of Siglec-4 to any of the modified cells was 
found. Reaction of the azides to Ac5NeuNPoc-treated adherent HEK293 kidney 
cells confirmed that the sialic modifications specifically enhance Siglec binding 
(Figure S7). These findings demonstrate that modifications of sialic acids with L1-
64 and their multivalent presentation on the surface of different types of living cells 
strongly enhance their interaction with Siglecs. Except for Siglec-4, 
glycoengineered cells were identified for each Siglec family member tested, 
including the orphan Siglecs -6, -8 and -11. 
 
Structure-guided design to glycoengineer cells for selective Siglec-5/-14 binding 
Several of the modified sialic acids like L4 showed affinity to multiple Siglecs. While 
these modifications could proof useful for the targeting of different Siglecs at the 
same time, selective targeting is required to study or manipulate an individual 
Siglec family member. Especially Siglec-5/-14, -7 and -9 showed similar binding 
preferences for the same benzyl-derivative modified sialic acids in the Siglec 
binding screening (Figure 3). By modeling the benzyl-derivatives into the crystal 
structure of Siglec-5, we noticed an aspartic acid residue (D130) in relative 
proximity to the sialic acid binding site. This aspartic acid located in the F-G turn is 
specific for Siglec-5/-14. Sequence alignment of Siglec-7 and -9 showed that 
neither of them shares a negatively charged amino acid at this position in the F-G 
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turn (Figure S8). We reasoned that positively charged modifications that could 
form a salt bridge with D130 might allow for the selective binding of Siglec-5/-14. 
We therefore designed L24-26 which all contained an amine group. L24-26-
modified sialic acids were docked into the available crystal structure of Siglec-5 to 
receive better insights into possible interactions of L24-26 and Siglec-5 (Figure 4a, 
Figure S9).38 The docking supported the idea that L24-26 could interact with D130 
in the sialic acid binding site of Siglec-5/-14. As predicted the presence of these 
positively charged groups on the surface of Jurkat cells strongly enhanced binding 
to Siglec-5 and its homolog Siglec-14. Importantly, no binding to Siglec-7 and -9 
nor to any other Siglec family member was experimentally detected for L24-26 
(Figure 4b).  
These data exemplify that depending on the structure of the V-set domain, 
clickable molecules can be produced that alter sialic acids selectivity for a 
particular Siglec member. 
 
Figure 3 Screening of the sialic acid-modified cell library for binding to the human Siglec family. 
Jurkat cells incubated with control, Ac5NeuAc, Ac5NeuNPoc or Ac5NeuNAz were reacted to nothing or 
L1-49 or L50-64, respectively using CuAAC. Cells were stained with recombinant Siglec Fc chimera 
pre-complexed with AF647-conjugated anti-human Fc antibodies. Siglec binding was quantified by flow 
cytometry and normalized to control, non-reacted cells. Data are presented as mean fold change Siglec 
binding (n=4-8). Structures of selected azides and alkynes that increase Siglec binding are depicted.  
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Glycoengineered cells reactive to Siglec-3 dampen immune activation via Siglec-3 
Siglec-3, more commonly known as CD33, is expressed on myeloid cells, 
monocytes, myeloid leukemia cells and more recently has also been identified on 
microglia cells in the brain.9,11 In the glycoengineered cell library, we identified 
three sialic acid modifications that enhance Siglec-3 binding between fifty and 
hundred times. This finding is remarkable, because so far, only a few natural sialic 
acid ligands for Siglec-3 have been identified on living cells, which limits the 
possibilities to study sialic acid-Siglec-3 interactions between host cells and 
immune cells.9,11,45 To address this issue, we investigated the effect of the 
interaction between glycoengineered Jurkat T cells that showed high binding to 
Siglec-3 and Siglec-3 expressing monocytic THP1-DUAL cells. THP1-DUAL cells 
express high Siglec-3 levels, while being negative for the other Siglec family 
members (Figure S10). Moreover, THP1-DUAL cells produce and secrete alkaline 
phosphatase (AP) in response to activation via the NF-κB pathway and luciferase 
(Luc) in response to signaling via the IRF pathway.39,40  
 
Figure 4 Structure-guided design to obtain selective sialic acid ligands for Siglec-5/14.  
a) Docking pose of L24-L26 to the V-set domain of Siglec-5. Best scored docking poses for sialic acid 
conjugated with L24-L26 (from left to right) on the Siglec-5 X-ray structure 2ZG1 are shown. The 
modified sialic acids are presented in grey sticks and hydrogen bonds are shown as yellow dotted lines. 
Amino acid residues important for sialic acid interactions are indicated. b) Binding of recombinant Siglec 
Fc chimera to Jurkat cells modified with L24-L26. Data are presented as fold change Siglec binding. 
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Both pathways are important in immune cell activation and can be triggered by TLR 
ligands.46 To target Siglec-3 on the THP1-DUAL cells, Jurkat cells treated with 
Ac5SiaNPoc or Ac5SiaNAz were reacted to L4, L39 or L57, respectively that 
showed high Siglec-3 binding. Jurkat cells modified with L40, which showed no 
Siglec-3 binding and unconjugated Jurkat cells were used as non-binding control 
(Figure 3). THP1-DUAL cells alone were activated by LPS and Pam3CSK4 (APLPS: 
0.65 AU; LucLPS: 11888 cps) (Figure 5a, b). Co-culture with Ac5SiaNPoc or 
Ac5SiaNAz-treated cells or cells reacted with L40 had no significant effects, 
whereas cross-linking of Siglec-3 with antibodies reduced both alkaline 
phosphatase and luciferase secretion (APLPS: 0.3 AU; LucLPS: 4149 cps). 
Intriguingly, co-culture with L4, L39 or L57-modifed Jurkat cells was as effective as 
cross-linking Siglec-3 in reducing NF-κB and IRF pathway activation in THP1-
DUAL cells. To further show that the dampening effect of the glycoengineered cells 
was mediated via Siglec signaling, the reporter cells were pre-treated with the 
SHP-1/-2 inhibitor NSC-87877. SHP-1/2 inhibition abrogated the inhibiting effects 
of anti-Siglec-3 antibodies and the L4, L39 and L57-modifed Jurkat cells on THP1-
DUAL cell activation by both LPS or Pam3CSK4 (Figure S11). These findings 
indicate that the interaction of sialic acid glycoengineered cells with Siglec-3 
potently suppresses TLR-mediated immune cell activation via the NF-κB and IRF 
pathways. Moreover, these findings show that the described glycoengineering 
approach allows the effects of sialic acid-Siglec interactions to be studied on the 
cellular level. 
 
Figure 5 Glycoengineered cells dampen immune activation via Siglec-3. a, b) Effect of glycoengineered 
cells on Siglec-3+ THP1-DUAL reporter cell activation by TLR ligands. Jurkat cells incubated with 
Ac5NeuNPoc or Ac5NeuNAz were reacted to nothing, L4, L39, L40 or L57 and co-cultured with Siglec-3+ 
monocytic THP1-DUAL reporter cells. THP1-DUAL cells alone or together with anti-Siglec-3 cross-
linking antibodies were used as control. The reporter cells were treated with PBS, LPS or Pam3CSK4 
and AP and Luc activity in the culture supernatant was determined as a measure for cell activation via 
the NF-κB or IRF pathway, respectively. Bar diagrams show mean AP reporter activity ± SEM (a) or 
mean Luc reporter activity ± SEM (b) of three independent experiments. 
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Discussion  
Sialic acid-Siglec interactions play an important role in immune regulation and have 
been suggested to be involved in the onset and development of multiple 
pathologies including autoimmunity, infectious diseases, and cancer.9,11 To 
elucidate the function of sialic acid-Siglec interactions in immunology and beyond, 
specific tools are needed to resemble and modulate these interactions. Such tools 
could also drive the development of targeted therapies for pathologies involving 
sialic acids and Siglecs. Here we describe a glycoengineering approach to render 
the surface sialic acids of living cells highly reactive to the human Siglec family. 
With this approach i) the sialic acids of various types of living cells can be modified 
to obtain increased and selective Siglec binding, ii) a great number of different 
modifications can be made to cell surface sialic acids and readily be screened for 
Siglec binding, iii) the modified sialic acids are presented on the cell surface in a 
multivalent manner and therefore allow to study the functional consequences of 
particular sialic acid-Siglec interactions between living cells.  
So far, mainly glycan microarrays have been used to identify high affinity Siglec 
ligands and glycan-based Siglec targeting has been achieved using sialic acid 
mimetic-decorated nanocarriers (e.g. liposomes or polymers).11,29,47 These 
approaches have the advantage that the type of sialoglycan is well defined, 
however, they lack the context of a cell membrane where many different types of 
glycans on proteins and lipids collectively form the glycocalyx of a cell. Therefore, 
their use to study sialic acid-Siglec interactions like they occur between two cells in 
trans or on one cell in cis is limited.33 To address this issue, Bertozzi and co-
workers have recently developed sialoglycan-decorated polymers that can be 
integrated into the cell surface and allow to mimic the biological effects of sialic 
acid-Siglec interactions that occur for instance between cancer cells and immune 
cells.48 The chemo-enzymatic synthesis of sialoglycans and carrier formulation and 
conjugation is labor-intensive, thereby limiting the diversity of sialoglycans and 
carrier combinations that can be tested for Siglec binding. In this study, we 
describe a glycoengineering approach to alter surface sialic acids on living cells to 
increase their binding to Siglecs, yielding high affinity Siglec ligand-expressing cells 
(HASLECs). As the so modified surface sialic acids are in their natural ‘glycan 
environment’ on a cell this approach makes it possible to study the effects of cis 
and trans sialic acids binding to Siglecs in a natural context.  
The glycoengineering approach to obtain HASLECs is simple, fast and can be 
expanded by altering the type of clickable sialic acid and azide or alkyne molecule. 
Since the cell synthesizes the complex sialoglycans, it obviates the need for 
chemical or (chemo)enzymatic sialoglycan synthesis. Siglec binding can be readily 
assessed using flow cytometry which makes intermediate throughput screening for 
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Siglec binding feasible. The screening performed in this study already yielded 
several sialic acid modifications with increased Siglec binding of over hundred fold. 
Although the precise sialoglycan structures responsible for increased Siglec 
binding are hard to define, their linkage type and density may be studied further by 
varying the used cell type or altering glycosyltransferase or glycosidase 
expression.  
Next to affinity, selectivity of binding towards the various members of the Siglec 
family is of crucial importance. Our screening revealed considerable cross-
reactivity between the Siglecs -5/-14, -7 and -9. Using sequence alignment and 
molecular modeling of sialic acid mimetics into the sialic acid binding pocket of 
Siglec-5 based on the available crystal structure, we identified a difference in the F-
G loop between these Siglecs. Siglec-5/14 contains a unique aspartic acid residue 
at position 130. Hence we designed and docked sialic acid mimetics modified with 
amine groups to interact with this residue and to attain selective Siglec-5/14 
binding. Modeling of how sialic acids could bind to the different Siglecs may result 
in the development of further sialic acid modifications with highly selective binding 
to individual Siglec family members.  
The members of the Siglec family are broadly expressed throughout the immune 
system. Sialic acids are expressed on the surface of virtually every human cell.9,11 
Therefore, it is likely that cis and trans sialic acid-Siglec interactions occur very 
frequently in the body. Even so, the functional consequences hereof for immune 
cells and other cell types are hardly understood. We could demonstrate that cells 
whose sialic acids were modified with L4, L39 and L57 were able to functionally 
interact with Siglec-3+ monocytic cells. These trans sialic acid-Siglec-3 interactions 
clearly dampened immune activation induced by toll-like receptor stimulation. More 
specifically, sialic acid-Siglec-3 interactions lowered activation of the NF-κB and 
IRF pathways. Pharmacological inhibition of SHP-1/-2 abrogated the dampening 
effect, advocating that the observed immune inhibition was Siglec-3 dependent. 
These findings are in line with research from Liu and co-workers that provided 
evidence that murine Siglecs suppress the NF-κB and IRF signaling pathways.49,50 
Therefore, the described sialic acid glycoengineering approach could become a 
useful tool to study the effects of individual sialic acid-Siglec interactions on the 
cellular level. Furthermore, the general principle of using bioorthogonal chemistry 
to edit the glycocalyx and to alter its interaction with lectins may be extended to 
other classes of sialic acid binding lectins (e.g. selectins, hemagglutinin), or other 
classes of glycan-lectin interactions. 
In conclusion, we have developed a glycoengineering approach to readily modify 
the surface sialic acids of living cells with respect to Siglec binding. Next to being 
applied as a type of “glycan array” the glycoengineered cells can be used to study 
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sialic acid-Siglec interactions between living cells. The described sialic acid 
glycoengineering approach therefore is broadly applicable to answer fundamental 
research questions regarding the biological effects of cis/trans sialic acid 
interactions with the Siglec family in the immune system and beyond. 
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Supplementary Information 
Supporting methods and NMR spectra are available on the Angewandte Chemie, 
International Edition website. 
 
Supplementary Table 1 Mean fold change binding data from the Siglec binding screen.   
Modification Sugar Control Siglec-2 Siglec-3 Siglec-4 Siglec-5 Siglec-6 Siglec-7 Siglec-8 Siglec-9 Siglec-10 Siglec-11 Siglec-14
- Ac5NeuNAc 1,1 1,0 1,0 1,2 3,4 0,7 1,0 1,3 1,3 0,8 0,9 2,0
- Ac5NeuNPoc 1,1 1,8 1,1 1,0 6,2 1,2 1,2 1,3 1,2 0,9 1,2 1,0
- Ac5NeuNAz 1,3 1,3 1,2 0,6 1,0 1,1 2,2 1,1 5,4 4,0 0,9 5,2 
L1
Ac5NeuNPoc
2.2 1.8 2.2 0.7 40.8 1.8 5.3 1.2 9.2 2.5 1.5 17.4
L2 1.5 1.3 1.3 1.2 14.8 1.3 2.3 1.2 6.3 1.3 1.2 11.0
L3 2.1 1.8 2.5 1.2 24.7 1.0 3.9 1.5 6.7 3.8 1.2 5.3
L4 1.9 1.7 92.7 1.6 90.3 1.8 6.8 6.0 11.3 2.4 2.0 28.6
L5 1.4 1.1 3.5 1.6 84.9 15.6 11.2 1.4 8.9 1.2 1.8 74.7
L6 2.0 1.2 1.8 1.1 48.3 1.3 6.3 1.9 12.3 2.6 1.5 10.7
L7 0.6 0.6 1.1 4.7 166.9 3.5 1.7 2.5 4.9 1.7 4.1 77.0
L8 0.4 0.6 1.0 1.2 42.3 1.6 1.2 0.7 4.5 1.7 1.1 31.2
L9 0.5 0.8 1.0 1.2 59.6 1.0 1.0 0.3 2.8 0.8 0.9 20.2
L10 0.5 0.8 1.4 0.3 52.7 1.1 1.2 4.5 7.8 3.9 1.9 35.6
L11 1.9 1.4 1.5 1.1 10.2 0.9 1.5 1.7 2.8 1.1 1.1 4.5
L12 0.5 0.6 1.0 2.2 75.5 1.0 1.5 3.0 3.1 10.4 1.1 44.0
L13 0.6 0.5 1.0 1.9 42.3 2.1 1.1 1.3 3.0 1.2 0.9 21.2
L14 0.8 0.6 1.0 1.4 98.9 4.5 1.3 0.9 3.6 2.4 1.6 49.5
L15 0.8 0.7 1.0 1.9 87.2 1.0 1.3 1.4 3.7 1.3 2.5 53.7
L16 0.7 1.0 0.9 3.7 80.7 1.4 1.9 3.4 5.7 1.5 1.2 41.6
L17 0.5 0.5 2.1 2.3 101.4 5.6 1.3 3.4 3.8 0.8 2.7 48.8
L18 1.2 0.6 1.0 3.8 90.7 1.3 1.8 1.1 5.3 2.1 2.8 45.1
L19 2.0 15.0 3.3 1.0 64.6 1.9 5.5 2.0 12.8 3.6 1.6 21.1
L20 0.8 0.7 1.1 0.8 45.2 1.6 0.8 2.3 6.0 3.3 1.6 75.4
L21 1.8 2.6 2.4 1.3 43.4 13.0 4.3 13.5 9.5 3.2 3.0 13.6
L22 2.3 1.9 5.3 1.1 66.6 2.2 9.3 2.6 12.7 2.9 2.4 26.4
L23 1.5 1.2 2.5 1.1 50.8 3.2 6.4 2.5 9.2 1.4 1.3 32.0
L24 1.5 1.2 1.3 1.1 27.2 0.8 1.5 3.6 2.2 1.0 1.2 17.4
L25 1.5 1.1 1.2 1.1 33.0 0.8 1.5 3.0 2.3 0.9 1.3 18.7
L26 1.2 1.2 1.3 1.4 36.7 1.1 1.0 1.5 2.4 0.9 1.2 19.8
L27 1.4 1.6 1.4 0.9 19.5 1.4 1.8 3.7 8.6 1.9 1.2 4.9
L28 1.3 1.0 1.4 1.0 36.9 0.8 5.1 1.3 2.5 0.8 1.1 37.1
L29 1.1 1.3 1.6 1.1 22.6 0.9 3.0 1.2 2.3 0.9 1.2 17.6
L30 1.6 1.2 1.9 0.9 9.7 1.1 1.9 1.3 3.5 1.3 1.0 5.9
L31 1.9 1.5 5.6 1.2 113.0 4.6 9.3 8.3 12.3 2.9 1.3 46.7
L32 1.2 1.3 1.1 1.1 1.9 1.0 1.2 1.7 3.9 1.4 1.0 1.3
L33 0.8 1.1 1.1 0.7 1.6 2.6 1.3 2.9 4.3 2.2 1.3 1.3
L34 0.9 1.2 1.3 0.7 3.5 1.3 1.0 2.2 4.2 1.4 1.2 1.3
L35 1.2 3.9 2.8 1.0 17.1 4.4 1.4 6.2 5.0 2.1 1.7 6.1
L36 0.8 0.5 1.0 0.5 59.9 0.5 1.1 2.2 3.2 1.2 1.2 35.8
L37 0.6 0.6 1.0 0.9 36.9 1.1 1.0 0.8 2.6 4.4 0.9 17.2
L38 0.8 0.7 1.0 2.5 38.6 2.2 1.2 1.2 5.6 2.7 1.5 53.3
L39 1.8 1.2 113.6 1.4 92.4 1.1 5.8 4.1 8.6 2.2 1.2 41.5
L40 2.3 1.1 1.7 1.2 9.7 0.8 1.6 1.3 3.8 1.2 1.4 8.8
L41 2.2 1.2 1.9 1.1 39.9 1.1 5.6 2.0 7.1 2.4 1.3 20.9
L42 0.8 0.6 1.0 0.5 3.4 0.7 0.9 1.0 2.1 1.2 1.1 2.1
L43 0.8 0.5 1.0 0.6 3.6 0.7 0.8 1.4 2.0 0.9 1.2 1.8
L44 0.9 0.6 1.0 0.6 3.3 0.9 0.9 1.2 2.0 1.3 1.2 1.8
L45 1.1 1.0 8.0 0.9 38.9 2.3 1.6 3.6 5.0 1.7 2.8 12.3
L46 1.3 0.7 1.6 0.7 2.0 1.1 1.2 2.2 2.3 1.8 1.4 1.3
L47 1.0 0.7 2.0 0.8 53.7 1.6 1.7 1.4 2.9 0.8 2.3 8.9
L48 0.8 0.7 1.8 0.8 18.8 1.2 1.3 2.2 3.4 1.5 1.8 8.3
L49 0.9 0.7 2.1 0.8 2.6 1.1 1.3 1.9 2.5 0.7 1.0 1.5
L50
Ac5NeuNAz
1.2 1.9 1.1 0.8 1.6 1.0 1.3 1.1 1.8 1.0 1.3 1.3
L51 1.3 1.7 1.1 0.8 1.0 1.0 1.1 1.0 2.0 0.9 1.4 1.0
L52 1.1 1.6 1.2 0.8 1.8 1.0 1.3 0.9 2.1 1.1 1.7 1.2
L53 1.4 1.8 1.3 0.8 1.3 1.1 1.2 0.8 1.9 1.0 1.6 0.9
L54 1.9 9.0 2.5 1.0 31.5 1.8 4.8 8.0 5.4 1.4 8.7 12.2
L55 0.8 0.7 2.0 0.6 2.4 1.0 0.7 0.8 1.6 2.4 0.8 1.3
L56 0.8 0.6 2.9 0.7 3.0 1.0 0.9 1.2 2.2 2.2 1.0 1.6
L57 1.8 1.1 46.5 1.9 155.4 4.2 3.3 3.7 4.6 1.4 9.1 54.8
L58 0.8 0.8 7.2 0.7 25.9 1.4 1.4 1.6 3.6 1.5 1.6 7.8
L59 1.3 0.7 2.4 0.6 6.3 1.0 1.1 1.5 1.8 0.8 0.8 1.9 Fold 
L60 1.3 0.6 1.3 0.8 22.6 1.3 1.4 1.8 3.0 1.0 1.2 6.2 Binding 
L61 0.8 0.6 0.9 0.7 4.7 0.9 0.9 1.5 1.9 1.4 1.0 2.3 >5
L62 0.8 0.6 0.9 0.5 1.6 0.9 0.9 0.9 1.1 0.9 1.0 0.9 >10
L63 1.2 1.8 1.1 0.7 1.0 1.2 1.2 1.2 1.6 0.9 1.4 0.8 >25
L64 1.8 45.8 3.8 1.5 12.2 23.5 2.8 16.5 7.3 1.6 6.4 11.5 >50
5 
Steering Sialic Acid-Siglec Interactions of Living Cells 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1 Expression of Siglecs on Jurkat cells. 
Jurkat cells were stained with fluorescently labeled antibodies directed against human Siglecs or isotype 
control antibody and analyzed with flow cytometry. Representative histogram shows expression of 
Siglecs on Jurkat cells.  
 
 
 
 
 
Supplementary Figure 2 Sialic acid expression on Jurkat cells. 
Jurkat cells treated with PBS, Ac5NeuNPoc or Ac5NeuNAz were stained with fluorescent MALII, SNA-I 
or PNA that recognize α2,3-linked sialic acids, α2,6-linked sialic acids or uncapped galactose residues, 
respectively. Lectin binding was assessed by flow cytometry and representative histograms are 
presented. 
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Supplementary Figure 3 Clickable azides for the modification of alkyne sialic acids. 
Structural presentation of the azides L1-49 used in this study. 
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Supplementary Figure 4 Clickable alkynes for the modification of azide sialic acids. 
Structural presentation of the alkynes L50-64 used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5 Click-induced fluorescence enhancement of L5. 
a) Structural presentation of L5 solely or reacted to poc sialic acid. b, c) Jurkat cells incubated with 
PBS, Ac5NeuNAc or Ac5NeuNPoc were reacted with L5 and fluorescence of this azidofluorescein was 
quantified by flow cytometry. b) Representative histogram showing L5-derived fluorescence. c) Average 
mean fluorescence intensity (MFI) ± SEM of three independent experiments. 
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Supplementary Figure 6 Siglec binding to glycoengineered HEK293 cells. 
a-h) HEK293 cells were incubated with Ac5NeuNPoc and reacted to nothing or L2, 4, 5, 19, 31 or 39 in 
the presence or absence of CuSO4. Cells were stained with recombinant Siglec Fc chimera pre-
complexed with AF647-conjugated anti-human Fc antibodies. Siglec binding was quantified by flow 
cytometry and normalized to control, non-reacted cells. Bar diagrams show mean fold change Siglec 
binding ± SEM (n=3). 
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Supplementary Figure 7 Dependency of the click reaction on CuSO4.    
a-c) In the absence of CuSO4 from the click reaction selected ligands fail to react with Ac5NeuNPoc or 
Ac5NeuNAz treated Jurkat cells. Representative bar diagrams show fold change binding of Siglec-5 (a), 
Siglec-7 (b) or Siglec-9  (c) to the cells. 
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Supplementary Figure 8 Sequence alignment of Siglec-5, -7 and -9. 
Alignment of the amino acid sequences of the V-set domains of human Siglec-5, -7 and -9 is shown. 
The conserved arginine essential for sialic acid binding (red) and D130 (rectangle) in Siglec-5 are 
highlighted.    
 
 
 
Supplementary Figure 9 Pharmacophore-restricted docking of sialic acid. 
When pharmacophore features are added (F3, H-bond donor & H-bond acceptor feature; F4, H-bond 
acceptor feature; F5, H-bond donor feature; all radii are R=1.0 Å) the docking poses are more restricted 
and the sialic acid core does align with the orientation as it was determined with crystallography. 
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Supplementary Figure 10 Siglec expression on THP1-DUAL reporter cells. 
THP1-DUAL reporter cells were stimulated for 24 hours with LPS or Pam3CSK4 and Siglec expression 
was analyzed by flow cytometry using fluorescent anti-Siglec antibodies. Siglec expression is presented 
as mean fluorescent intensity.  
 
 
 
 
 
 
 
Supplementary Figure 11 NSC-87877 inhibits immune suppression via Siglec-3.  
a, b) Jurkat cells incubated with Ac5NeuNPoc or Ac5NeuNAz were reacted to nothing, L4, L39, L40 or 
L57 and co-cultured with Siglec-3+ monocytic THP1-DUAL reporter cells that were treated with the SHP-
1/-2 inhibitor NSC-87877 prior to the co-culture. THP1-DUAL cells alone or together with anti-Siglec-3 
cross-linking antibodies were used as control. The reporter cells were treated with PBS or the toll-like 
receptor ligands LPS or Pam3CSK4 and alkaline phosphatase and luciferase activity in the culture 
supernatant was determined as a measure for cell activation via the NF-κB or IRF pathway, 
respectively. Bar diagrams show mean alkaline phosphatase reporter activity ± SEM (a) or mean 
luciferase reporter activity ± SEM (b) of three independent experiments. 
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Abstract  
Sialic acid sugars are overexpressed by cancer cells and contribute to the 
metastatic cascade at multiple levels. Therapeutic interference of sialic acids, 
however, has been difficult to pursue because of the absence of dedicated tools. 
Here we show that a rationally designed sialic acid-blocking glycomimetic (P-3Fax-
Neu5Ac) successfully prevents cancer metastasis. Formulation of P-3Fax-Neu5Ac 
into poly(lactic-co-glycolic acid) nanoparticles coated with anti-tyrosinase-related 
protein-1 antibodies allowed targeted delivery of P-3Fax-Neu5Ac into melanoma 
cells, slow release, and long-term sialic acid blockade. Most importantly, 
intravenous injections of melanoma-targeting P-3Fax-Neu5Ac nanoparticles 
prevented metastasis formation in a murine lung metastasis model. These findings 
stress the importance of sialoglycans in cancer metastasis and advocate that sialic 
acid blockade using rationally designed glycomimetics targeted to cancer cells can 
effectively prevent cancer metastases. This targeting strategy to interfere with sialic 
acid-dependent processes is broadly applicable not only for different types of 
cancer but also in infection and inflammation. 
 
Introduction 
Evidence is accumulating that aberrant glycosylation and in particular 
overexpression of sialic acid sugars by cancer cells are involved in, and possibly 
drive distinct processes during cancer metastasis.1-7 Dissemination of cancer cells 
from primary tumors and metastases formation in distant organs is the major cause 
of cancer-associated mortality.8,9 Therefore, preventing dissemination of tumor 
cells and their growth at secondary sites are key to effective cancer therapy. 
Following successful detachment from the primary tumor, cancer cells can invade 
the surrounding tissue, enter the circulation via blood vessels or lymphatic vessels, 
form immune protective thromboemboli, extravasate from the circulation, proliferate 
and form metastases,10-12 Each of these steps during metastatic spread requires 
multiple biochemical interactions between different cell types as well as the 
extracellular matrix (ECM) involving both proteins and carbohydrates.13 Especially 
sialic acids that are aberrantly expressed on cancer cells appear to facilitate 
several steps of the metastatic cascade.14,15 Sialic acids (Neu5Ac) comprise a 
diverse family of sugar molecules that terminate glycans (sialoglycans) of cell 
surface glycoproteins and glycolipids in virtually all vertebrate cells. Sialoglycans 
are formed in the Golgi system by a family of 20 sialyltransferases. 
Sialyltransferases specifically conjugate sialic acids to other sugar molecules in 
glycans via distinct glycosidic linkages yielding α2,3-, α2,6- or α2,8-linked sialic 
acids.16 Upon malignant transformation, cancer cells upregulate sialyltransferase 
expression resulting in the accumulation of sialoglycans on their surface.17,18 
Aberrantly high sialic acid expression favors cancer metastasis by i) facilitating 
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cancer cell detachment and protection from detachment-induced apoptosis 
(anoikis); ii) enhancing migration and tissue invasion by increasing integrin 
interactions with the ECM; iii) preventing immune recognition and eradication and 
iv) enabling interactions with endothelial cells to extravasate from the blood stream 
and form metastases.14,15,19-22 
Interference with sialic acid expression in cancer cells could thus be of crucial 
importance in preventing cancer metastasis as multiple steps of the metastatic 
cascade could be targeted at the same time. Accordingly, desialylation of cancer 
cells by overexpressing human sialidases or treatment with bacterial sialidases 
have been reported to inhibit metastases formation in murine metastasis models.23-
27 However, gene therapy is challenging and bacterial sialidases are difficult to 
obtain in clinical grade quality. Therefore synthetic small molecules that inhibit 
sialic acid expression in cancer cells could be of high therapeutic value. We have 
recently explored the therapeutic potential of a global sialyltransferase inhibitor P-
3Fax-Neu5Ac that has been developed by Rillahan et al.28 P-3Fax-Neu5Ac is a 
peracetylated analogue of natural occurring Neu5Ac that due to attachment of a 
fluorine atom to the sialic acid backbone can inhibit sialyltransferase function and 
hence sialylation. We previously demonstrated that treatment of murine melanoma 
cells with this glycomimetic strongly impaired their binding to ECM components and 
migratory capacity in vitro, and delayed tumor growth in vivo.29 Here, we report for 
the first time that pretreatment of mouse melanoma cells with P-3Fax-Neu5Ac to 
block sialylation prevented lung metastases in vivo. Moreover, encapsulation of P-
3Fax-Neu5Ac in biodegradable poly(lactic-co-glycolic acid) (PLGA)-based 
nanoparticles (NPs) targeting the melanoma antigen (TRP-1) allowed specific and 
prolonged blockade of sialic acid expression in vitro and precluded metastatic 
spread in vivo. 
 
Material and Methods 
Mice 
Female C57BL/6J mice were obtained from Harlan Laboratories and housed in the 
Central Animal Laboratory, Radboud University, Nijmegen, The Netherlands, under 
specific pathogen-free conditions and ad libitum access to food and water. Mice 
were 6 to 8 weeks old at the beginning of each experiment. All experiments were 
authorized by the local animal ethics committee, Nijmegen, The Netherlands, and 
carried out in accordance with their guidelines. 
 
Reagents and antibodies 
P-3Fax-Neu5Ac was synthesized as described before.28,29 PLGA (RG 502 H, 
Poly(D,L-lactide-co-glycolide) 50:50) was purchased from Evonik Industries AG 
(Essen, Germany), ATTO 647-COOH from ATTO-TEC (Siegen, Germany), DSPE-
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PEG(2000) Succinyl (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[succinyl(polyethylene glycol)-2000] (ammonium salt)) and 14:0 PEG2000 PE 
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (ammonium salt) from Avanti Polar Lipids, Inc. (Alabaster, AL), 
Biotinylated lectins MALII (Maackia amurensis), SNA-I (Sambucus nigra) and 
carbo-free blocking solution from Vector Laboratories, Inc. (Burlingame, CA). 
Biotinylated PNA (Arachis hypogaea) and WGA (Triticum vulgaris) was purchased 
from EY Laboratories Inc. (San Mateo, CA), 7-AAD viability dye and purified 
isotype IgG2a κ antibody from eBioscience (San Diego, CA), streptavidin-
phycoerythrin and phycoerythrin conjugated goat anti-mouse IgG from BD 
Pharmingen (Franklin Lakes, NJ), NeutrAvidin-Texas Red, DAPI nucleic acid stain, 
Alexa Fluor 647 conjugated goat anti-mouse IgG (H+L) antibody and double-
quenched green bovine serum albumin (DQ-BSA) from Molecular Probes, Inc. 
(Eugene, OR) and Mowiol 4-88 mounting medium from Merck (Frankfurt, 
Germany). Mouse anti-TRP-1 antibody (clone TA99, IgG2a κ) was purified from 
hybridoma cell line HB-8704 (ATCC, Manassas, VA) as previously described.30 
 
Nanoparticle synthesis and antibody conjugation 
PLGA nanoparticles with entrapped P-3Fax-Neu5Ac alone or in combination with 
ATTO 647-COOH were prepared using an o/w emulsion and solvent evaporation–
extraction method as was described before.31 Briefly, 25 mg of PLGA in 750 µl of 
dichloromethane containing P-3Fax-Neu5Ac (200 mg in 200 µL DMSO) and ATTO 
647-COOH (0.25 mg in 12.5 µL DMSO) was added dropwise to 6.25 ml of aqueous 
2 % polyvinyl alcohol and emulsified for 120 seconds using a digital sonicator from 
Branson Ultrasonics (Danbury, CT). The solvent was evaporated overnight at 4 °C 
and nanoparticles were collected by centrifugation at 14.000 rpm for 20 min, 
washed six times with distilled water and lyophilized. Nanoparticles were coated 
with DSPE-PEG(2000) succinyl and 14:0 PEG2000 PE in a 1:1 ratio and 
conjugated with mouse anti-TRP-1 or isotype control IgG2a κ antibodies as 
described previously.31 Presence of anti-TRP-1 or isotype control antibodies on the 
particle surface was confirmed by staining nanoparticles with phycoerythrin-
conjugated goat anti-mouse IgG antibodies. Fluorescence was measured using a 
CyAn ADP flow cytometer (Beckman Coulter, Brea, CA) and quantified utilizing 
FlowJo software (Tree Star, Ashland, OR) 
 
Nanoparticle characterization 
Size, polydispersity index and zeta potential of the nanoparticles was analyzed by 
dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments Ltd, 
Malvern, UK) as described before.31 P-3Fax-Neu5Ac concentrations in 
nanoparticles was determined with a high-performance liquid chromatography 
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(HPLC) system (Shimadzu, Kyoto, Japan) equipped with a Supelcosil lC-18-T 
column (150 mm × 4.6 mm) with a constant flow rate of 1 ml/min and ultraviolet 
detection at a wavelength of 230 nm. By dissolving 1mg nanoparticles in 100 μl 
DMSO followed by centrifugation at 14.000 rpm for 10 min, P-3Fax-Neu5Ac was 
extracted from nanoparticles. 25 µL supernatant or standard was assayed with 
HPLC and the concentration P-3Fax-Neu5Ac and loading efficiency was calculated 
as percentage of loaded amount of P-3Fax-Neu5Ac relative to the total amount of 
nanoparticles. The loading efficiency of all prepared batches was ca. 1 %.  
 
Cell culture 
Mouse B16-F10 melanoma cells (CRL-6475, ATCC) were cultured in minimum 
essential medium (MEM) (Gibco, Invitrogen, Carlsbad, CA) containing 5 % fetal 
bovine serum (FBS) (Greiner Bio-one, Frickenhausen, Germany), 1 % MEM non-
essential amino acids (Gibco), 0.15 % sodium bicarbonate (Gibco), 1 mM sodium 
pyruvate (Gibco), 1.5 % MEM vitamins (Gibco) and 0.5 % antibiotic-antimycotic 
solution (50 U/ml penicillin, 50 µg/ml streptomycin and 125 ng/ml amphotericin B) 
(PAA, Pasching, Austria) in a humidified CO2 incubator at 37 °C. 9464D 
neuroblastoma cells (provided by R. Orentas, Department of Pediatrics, Medical 
College of Wisconsin, WI, USA) were cultured in Dulbecco's modified Eagle's 
medium (Glutamax, Gibco) containing 10 % FBS, 1 % non-essential amino acids, 
20 µM 2-mercaptoethanol (Sigma-Aldrich) and 1 % antibiotic-antimycotic solution.32 
 
Extracellular staining and flow cytometry 
B16-F10 cells were incubated in suspension for 1 h with biotinylated MALII (5 
µg/ml), SNA-I (1 µg/ml), PNA (5 µg/ml) or WGA (5 µg/ml) in carbo-free blocking 
solution containing 1 mM CaCl2+ and 1 mM MgCl2+ at 4 °C. MALII was used to 
detect α2,3-linked sialic acids, SNA-I for α2,6-linked sialic acids, PNA for terminal 
(β-)galactose/T antigen and WGA for detection of (poly)GlcNAc (chitobiose). Cells 
were washed in FACS buffer (1 x PBS containing 1 % FBS and 0.02 % sodium 
azide) and cell-bound biotinylated lectins were conjugated for 10 min at 4 °C with 2 
µg/ml streptavidin-phycoerythrin. Cells stained solely with streptavidin-
phycoerythrin were used as background control. The percentage lectin binding was 
calculated by normalizing the fluorescence values from the bound lectins to the 
respective control. For detection of TRP-1 expression, B16-F10 or 9464D cells 
were stained with anti-TRP-1 or isotype control antibody for 15 min at 4 °C, 
washed and incubated 15 min with phycoerythrin conjugated goat anti-mouse IgG 
antibody. Cells were washed with FACS buffer, stained with 7-AAD viability dye 
and resuspended in FACS buffer. Fluorescence was measured using a CyAn ADP 
flow cytometer or FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) 
and quantified utilizing FlowJo software.  
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Nanoparticle titration, cellular uptake and binding 
To determine the effective dose, B16-F10 cells were cultured for 3 days in medium 
containing 0-1 mg/ml P-3Fax-Neu5Ac-loaded, P-3Fax-Neu5Ac/A647-loaded or 0-2 
mg/ml empty PLGA nanoparticles and stained with biotinylated lectins to assess 
the sialylation status. Lectin binding to empty PLGA nanoparticles-treated cells was 
used to normalize mean fluorescence intensities. To quantify cellular uptake of 
unmodified and antibody-conjugated P-3Fax-Neu5Ac/A647- or DQ-BSA-loaded 
PLGA nanoparticles, B16-F10 cells or 9464D cells were cultured for 0-72 hours in 
the presence of 1 mg/ml nanoparticles at 37 °C or 4 °C. Alternatively, B16-F10 
cells were co-incubated 20 min with 10 µg/ml anti-TRP-1 or isotype control 
antibody (which remained also present during the uptake experiment) or for 3 days 
with 23.1 µg/ml free P-3Fax-Neu5Ac prior to the uptake experiment. Cells were 
thoroughly washed and fluorescent signal of ATTO 647 was measured directly by 
flow cytometry and quantified with FlowJo software. After washing, cells treated 
with DQ-BSA loaded PLGA nanoparticles were incubated 16 hours before 
measurement to allow degradation of nanoparticles and DQ-BSA. To determine 
extracellular binding of antibody conjugated P-3Fax-Neu5Ac/A647 nanoparticles, 
B16-F10 cells were incubated for 15 min at 4 °C, thoroughly washed and analyzed 
by flow cytometry. 
 
Confocal microscopy 
To determine uptake or binding of unmodified or antibody-conjugated P-3Fax-
Neu5Ac/A647-loaded PLGA nanoparticles, B16-F10 cells were seeded on glass 
slides and allowed to attach for 1 hour followed by incubation with 0.5 mg/ml 
nanoparticles for 1, 2 or 24 hours at 37 °C. Next, cells were washed extensively 
with 1x PBS to remove free nanoparticles, fixated for 10 min with 2 % 
paraformaldehyde on ice and blocked 30 min with carbo-free blocking solution. 
Additionally, cell membranes were stained by incubating the fixated cells 45 min 
with 10 µg/ml biotinylated WGA in carbo-free blocking solution at 4 °C followed by 
20 min incubation with 5µg/ml NeutrAvidin-Texas Red. Nuclei were stained by 
incubating the cells 10 min with DAPI. Samples were washed, mounted with 
Mowiol and images were acquired using an Olympus FV1000 confocal laser 
scanning microscope (Olympus, Tokyo, Japan). Images were processed and 
orthogonal projections were generated using ImageJ (NIH, Bethesda, MD). 
 
Nanoparticle kinetics and stability 
To compare the efficacy of nanoparticle encapsulated P-3Fax-Neu5Ac versus 
soluble P-3Fax-Neu5Ac, B16-F10 cells were cultured for 10 days in medium 
containing 1 mg/ml P-3Fax-Neu5Ac nanoparticles or equal amounts of soluble 
inhibitor (23.1 µg/ml). Empty PLGA nanoparticles were used as control and 
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medium was not replenished during the experiment. At various time points, cells 
were collected and stained with biotinylated MALII, SNA-I and PNA to assess cell 
surface expression of sialic acids with flow cytometry. Recovery speed of sialic acid 
expression was determined after incubating B16-F10 cells 3 days with 1 mg/ml 
antibody-conjugated P-3Fax-Neu5Ac nanoparticles, the same amount of soluble 
inhibitor (23.1 µg/ml) or empty PLGA nanoparticles. After extensive washing, cells 
were kept in culture for 6 days and sialylation was measured every day by flow 
cytometry using MALII, SNA-I and PNA lectins.  
To determine stability of unmodified or PEGylated P-3Fax-Neu5Ac nanoparticles, 1 
mg/ml nanoparticles or an equal amount of soluble P-3Fax-Neu5Ac (23.1 µg/ml) 
were incubated for 0-10 days at 37 °C. At several time points, supernatant and 
nanoparticle fractions were collected by centrifugation 14.000 rpm for 10 min. B16-
F10 cells were cultured for 3 days with the collected fractions and 0-17.6 µg/ml 
fresh P-3Fax-Neu5Ac. Expression of α2,3-linked sialic acids was measured by flow 
cytometry using MALII lectin. 
 
Pulmonary metastasis model and histology 
B16-F10 cells were treated 3 days with PBS, 23.1 µg/ml P-3Fax-Neu5Ac or for 45 
min with 150 mU. Cells were thoroughly washed and collected in 1 x PBS. 200µl 
PBS containing either 0.2 x 106 or 0.5 x 106 pre-treated B16-10 cells were injected 
into the tail vein of mice. For in vivo targeting, 20 mg/kg (0.4 mg in 50 µl PBS) anti-
TRP-1 or isotype antibody-conjugated P-3Fax-Neu5Ac nanoparticles were injected 
intravenously and 1 hour later, 0.5 x 106 B16-10 cells were injected intravenously. 
16 hours following injection with B16-F10 cells a second dose 20 mg/kg (0.4 mg in 
50 µl PBS) anti-TRP-1 or isotype antibody-conjugated P-3Fax-Neu5Ac 
nanoparticles was injected intravenously. 14 days post injection, mice were 
euthanized and lungs were collected. The treatment schedule is depicted in Figure 
6a. The lungs were rinsed with PBS and fixed overnight in 1 x Fekete’s solution 
(distilled water containing 70 % absolute ethanol, 10 % 37 % formaldehyde 
solution and 4.5 % glacial acetic acid) at room temperature. Pulmonary lesions, 
melanotic (black) and amelanotic (gray/white), were counted using a stereo 
microscope and representative images were taken. For histology, lungs were fixed 
in 4 % phosphate-buffered formaldehyde, embedded in paraffin, sectioned and 
stained with haematoxylin and eosin. 
 
Statistical analysis 
Statistical significance between two groups was determined by an unpaired t-test. 
For multiple comparisons, ANOVA analysis followed by Bonferroni’s correction was 
performed using Prism 5.03 (GraphPad Software, Inc., La Jolla, CA). P-values 
<0.05 were considered significant (p<0.05 *, p<0.01 **, p<0.001 ***). 
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Results 
P-3Fax-Neu5Ac inhibits B16-F10 lung metastases formation 
Sialoglycans have been indicated to facilitate multiple steps during cancer 
metastasis. Previously, we showed that a rationally designed glycomimetic, P-3Fax-
Neu5Ac, efficiently blocked sialic acid expression in tumor cells and reduced their 
adhesive and migratory capacity.29 Therefore, we evaluated the potential of P-3Fax-
Neu5Ac to inhibit cancer metastasis in an experimental pulmonary metastasis 
model. Hereto, B16-F10 cells were cultured 3 days in the presence or absence of 
P-3Fax-Neu5Ac (23.1 µg/ml) and expression of cell surface sialic acids was 
determined by flow cytometry using biotinylated lectins conjugated to streptavidin-
phycoerythrin. Expression of α2,3-linked sialic acids was reduced by 90 % (Figure 
1a), and α2,6-linked sialic acids by 80 % (Figure 1b) as detected with the lectins 
MALII and SNA-I, respectively. Accordingly, binding of the β-galactose-recognizing 
lectin PNA strongly increased (Figure 1c). Cell viability was not affected by 
treatment with the glycomimetic (Figure S1a). Having confirmed blocked 
sialylation, treated and untreated B16-F10 tumor cells were extensively washed 
and injected into the tail vein of mice. Fourteen days post injection, mice were 
sacrificed, lungs were isolated and pulmonary lesions enumerated. Untreated cells 
on average formed ± 50 metastatic nodules in the lung. Treatment with P-3Fax-
Neu5Ac reduced the number of pulmonary lesions to an average of about 10 
nodules (80 % reduction) (Figure 1d, e). Treatment with C. perfringens sialidase 
decreased sialic acid levels and metastatic lesions in the lung to a similar extent 
confirming that the effects are due to removal of sialic acids (Figure S1b, c). Apart 
from the lung, metastatic lesions were not detected in other organs. These data 
suggest that sialoglycans are a prerequisite for effective metastasis formation and 
that P-3Fax-Neu5Ac is a potent inhibitor of experimental metastases and therefore 
interesting to explore in anti-cancer therapy. 
 
Encapsulation of P-3Fax-Neu5Ac into PLGA nanoparticles  
The potent effects of P-3Fax-Neu5Ac pre-treatment on tumor growth and 
metastasis prompted us to develop sialic acid blockade for in vivo applications. As 
sialic acids play a vital role in physiology and systemic administration of the 
glycomimetic could lead to adverse effects,16 we developed a therapeutic strategy 
for the specific delivery of this sialic acid-blocking glycomimetic to tumor cells in 
vivo. To this end, we encapsulated P-3Fax-Neu5Ac only or in combination with 
fluorescent ATTO 647 dye into biodegradable, FDA-approved poly(lactic-co-
glycolic acid) (PLGA)-based nanoparticles that have previously been described by 
others and our own group.31,33,34 The formulated NPs had an average size of about 
200 nm (polydispersity index: 0.118 ± 0.063; Zeta potential: -30.4 mV) and 
contained 23.1 µg P-3Fax-Neu5Ac per milligram NP as determined with HPLC. P-
6 
Sialic Acid-Blocking Glycomimetic Inhibits Metastasis 
145 
3Fax-Neu5Ac incorporation efficiency was similar when combined with ATTO 647 
(Supplementary Table 1).  
 
 
Figure 1  Blocking sialic acid expression using P-3Fax-Neu5Ac impairs B16-F10 metastases formation. 
a-c) P-3Fax-Neu5Ac efficiently blocks sialylation. B16-F10 cells were cultured for 3 days with or without 
23.1 µg/ml P-3Fax-Neu5Ac and expression of α2,3-linked sialic acids, α2,6-linked sialic acids, and 
terminal β-galactose was quantified by flow cytometry using biotinylated lectins MALII (a), SNA-I (b) or 
PNA (c) conjugated to streptavidin-PE. Fluorescence values were normalized to untreated control cells 
and data of three independent experiments are presented as average percentage lectin binding ± SEM. 
d, e) Metastases formation of B16-F10 cells incubated 3 days with or without 23.1 µg/ml P-3Fax-
Neu5Ac. Prior to injection, cells were washed extensively and 0.5 x 106 cells were injected into the tail 
vein of mice (n = 6). 14 days later, mice were sacrificed and lungs were collected and fixed overnight in 
Fekete’s solution. Representative images of pulmonary lesions are shown (d) and nodules were 
enumerated and presented in a scatter plot (e). 
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Figure 2  P-3Fax-Neu5Ac NPs block sialylation and are readily taken up and degraded by B16-F10 
cells. a-c) B16-F10 cells were cultured for 3 days with 0-1 mg/ml P-3Fax-Neu5Ac NPs and expression of 
α2,3-linked sialic acids, α2,6-linked sialic acids, and terminal β-galactose was quantified by flow 
cytometry using biotinylated lectins MALII (a), SNA-I (b) or PNA (c) conjugated to streptavidin-PE. 
Fluorescence values were normalized to untreated control cells presented as average percentage lectin 
binding ± SEM. d-h) B16-F10 cells were cultured on glass slides in the presence of 1 mg/ml P-3Fax-
Neu5Ac/A647 NPs. Representative confocal images show cell outlines (bright), nuclei (blue) and ATTO 
647 fluorescence (green) following 1 hour or 24 hours culture (d). Following 2 hours incubation with P-
3Fax-Neu5Ac/A647 NPs, B16-F10 cells were stained with DAPI (blue) and biotinylated WGA-
NeutrAvidin-Texas Red conjugates (red) to visualize the cell membrane. A representative overview → 
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image (e), magnification of a selected cell (stepped lines) (f) and reconstructed orthogonal projections 
as viewed in the xz-plane (g) and yz-plane (h) show intracellular localization of P-3Fax-Neu5Ac/A647 
NPs (green). (i) Uptake of P-3Fax-Neu5Ac/A647 NPs in B16-F10 cells cultured 0-72 hours at 4 °C or 37 
°C was quantified using flow cytometry. Mean fluorescence intensity values of three independent 
experiments ± SEM are presented. j) B16-F10 cells were incubated for 0-24 hours at 4 °C or 37 °C with 
1 mg/ml nanoparticles containing double-quenched bovine serum albumin (DQ-BSA). 16 hours after 
removal of the NPs from medium, degradation of NPs and DQ-BSA was measured by flow cytometry. 
Percentage fluorescence normalized to control of three independent experiments ± SEM is shown. 
 
To determine the effective dose of P-3Fax-Neu5Ac-loaded NPs, B16-F10 cells were 
cultured for 3 days in medium containing increasing amounts of nanoparticles. 
Sialic acid expression was reduced in a dose-dependent manner (Figure 2a-c). At 
a 1 mg/ml dose, the NPs were effective in reducing expression of α2,3-linked sialic 
acids and α2,6-linked sialic acids to the same extend as 23.1 µg/ml soluble P-3Fax-
Neu5Ac (Figure 2a, b, Figure S2a-e). Accordingly, increased exposure of terminal 
β-galactose residues upon incubation with P-3Fax-Neu5Ac NPs was detected with 
PNA lectin (Figure 2c, Figure S2f). Noteworthy, neither P-3Fax-Neu5Ac-loaded nor 
control PLGA NPs affected cell viability and even a concentration of 2 mg/ml empty 
PLGA nanoparticles did not influence overall cell surface glycosylation (Figure S3). 
A comparable sialic acid blockade was observed for P-3Fax-Neu5Ac NPs co-loaded 
with the fluorescent ATTO 647 (P-3Fax-Neu5Ac/A647 NPs) (Figure S4). Using 
these fluorescent P-3Fax-Neu5Ac/A647 NPs, cellular uptake was readily observed 
in B16-F10 cells (Figure 2d). Orthogonal projections confirmed that these 
fluorescent P-3Fax-Neu5Ac/A647 NPs were readily taken up into the cytoplasm, 
most likely the endosomal compartment, of B16-F10 cells (Figure 2d-h).35,36 Flow 
cytometry analysis of the P-3Fax-Neu5Ac/A647 NPs uptake kinetics showed that 
already after 1 hour a fluorescent signal could be measured in all cells. Signal 
intensity increased over time reaching a maximum between 8h and 24h incubation 
(Figure 2i, Figure S5). Incubation at 4 °C prevented cellular uptake indicating that 
the NPs are actively taken up and do not adhere to the cell membrane.  
To demonstrate intracellular degradation, NPs were co-loaded with double-
quenched (DQ)-BSA that emits fluorescence upon protease cleavage. Following 
0.5 to 24 hours incubation, increasing fluorescence from cells cultured with DQ-
BSA-loaded NPs was detected by flow cytometry (Figure 2j). Furthermore, while 
incubation with soluble P-3Fax-Neu5Ac reduced sialic acid expression upon one 
day of incubation, NP-encapsulated P-3Fax-Neu5Ac reduced sialic acid expression 
after two to three days incubation (Figure S6). These data indicate that PLGA NPs 
form neutral carriers that can be effectively loaded with the P-3Fax-Neu5Ac 
glycomimetic to induce sialic acid blockade in tumor cells. 
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Figure 3  Anti-TRP-1 antibody conjugation allows targeting of P-3Fax-Neu5Ac NPs to B16-F10 cells. 
a) Representative histograms show expression of TRP-1 on B16-F10 cells stained with anti-TRP-1 
antibody. b) Representation of TRP-1-targeting P-3Fax-Neu5Ac NPs. The glycomimetic was 
encapsulated in PLGA-based NPs with a diameter of 200 nm. The NPs were PEGylated to reduce 
nonspecific uptake and coated with mAbs directed against the melanoma antigen TRP-1. c) Detection 
of isotype or anti-TRP-1 antibody on the surface of P-3Fax-Neu5Ac/A647 NPs stained with PE-
conjugated anti-mouse IgG antibody by flow cytometry. d-f) Binding of anti-TRP-1 P-3Fax-Neu5Ac NPs 
to B16-F10 cells. Confocal images show binding of isotype (left) or anti-TRP-1 (right) P-3Fax-
Neu5Ac/A647 NPs (green) to B16-F10 cells following 15 min incubation at 4 °C (d). Cell membrane was 
stained with WGA-NeutrAvidin-Texas Red (red) and nuclei with DAPI (blue). Representative histogram 
shows isotype control or anti-TRP-1 P-3Fax-Neu5Ac/A647 NP binding to the surface of B16-F10 cells 
(e). MFI ± SEM of cell surface-bound isotype or anti-TRP-1 P-3Fax-Neu5Ac/A647 NPs (n=3) (f). 
 
Targeted delivery of P-3Fax-Neu5Ac-containing nanoparticles to B16-F10 cells 
B16-F10 cells express the melanoma associated antigen tyrosinase-related 
protein-1 (TRP-1), that is involved in melanin synthesis on their surface (Figure 3a, 
Figure S7a).37 TRP-1 has been shown to rapidly internalize at the surface,38 and 
was therefore chosen to deliver P-3Fax-Neu5Ac NPs specifically to B16-F10 cells. 
To this aim, P-3Fax-Neu5Ac or P-3Fax-Neu5Ac/A647 NPs were coated with a lipid 
PEG layer and monoclonal anti-TRP-1 or isotype control (IgG2a κ) antibodies 
(Figure 3b). Flow cytometry analysis confirmed efficient and equal coupling of anti-
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TRP-1 or isotype control antibodies to NPs as well as equal fluorescence 
intensities of P-3Fax-Neu5Ac/A647 NPs (Figure 3c, Figure S7b). Confocal 
microscopy analysis of the binding of the antibody-conjugated nanoparticles to 
B16-F10 cells demonstrated that almost no fluorescent signal could be detected at 
the surface of cells incubated with isotype control antibody-coated P-3Fax-
Neu5Ac/A647 NPs (Figure 3d). In contrast, TRP-1-targeting NPs were found to 
bind effectively to the membrane of B16-F10 cells. Analysis of the cells with flow 
cytometry confirmed binding of anti-TRP-1 P-3Fax-Neu5Ac/A647 NPs to B16-F10 
cells, whereas isotype control NPs could not bind (Figure 3e, f).  
Having confirmed the binding of TRP-1-targeting P-3Fax-Neu5Ac NPs to B16-F10 
cells, we next assessed uptake and degradation characteristics of these tumor-
targeting NPs. Isotype control NPs showed low uptake levels similar to PEGylated 
control NPs. In contrast, anti-TRP-1 NPs were taken up efficiently by B16-F10 cells 
(Figure 4a, b). The difference in uptake of isotype and anti-TRP-1 NPs was 
confirmed by confocal microscopy (Figure 4c). Intracellular uptake and 
degradation of TRP-1 antibody-coated NPs, was assessed by co-encapsulating 
DQ-BSA into the NPs. At 1 and 24 hour of incubation, fluorescence was markedly 
higher in B16-F10 cells incubated with anti-TRP-1 DQ-BSA NPs compared to 
isotype NPs (Figure 4d). These data indicate that anti-TRP-1 NPs, but not non-
targeting isotype NPs are readily taken up and degraded by B16-F10 cells. Uptake 
specificity of the anti-TRP-1 NPs was further confirmed by the ability of TRP-1 
antibody, but not by isotype control antibody, to block uptake of TRP-1-targeting 
NPs (Figure 4e, f). In line with these findings, 9464D cells, which do not express 
TRP-1, showed similar uptake levels for isotype and anti-TRP-1 NPs (Figure S7c, 
d). These data indicate that anti-TRP-1 NPs effectively and specifically are taken 
up by B16-F10 cells allowing targeted intracellular delivery of P-3Fax-Neu5Ac. 
 
Targeted delivery of P-3Fax-Neu5Ac to B16-F10 and sustained sialic acid blockade  
Having shown specific binding and uptake of anti-TRP-1-targeting NPs, we next 
investigated the release kinetics of anti-TRP-1-targeting NPs containing P-3Fax-
Neu5Ac. Therefore, B16-F10 cells were incubated for 3 days in the presence of P-
3Fax-Neu5Ac-loaded control NPs or anti-TRP-1 NPs or with an equal amount of 
soluble glycomimetic and cell surface sialylation was assessed by lectin binding. 
Soluble P-3Fax-Neu5Ac blocked expression of cell surface sialoglycans potently 
(Figure 5a-c). In line with the findings that anti-TRP-1 NPs were taken up at high 
levels compared to isotype NPs, only anti-TRP-1 P-3Fax-Neu5Ac NPs strongly 
blocked sialylation (80 % α2,3-Neu5Ac; 60 % α2,6-Neu5Ac) while isotype P-3Fax-
Neu5Ac NPs only mildly reduced sialic acid expression (40 % α2,3-Neu5Ac; 20 % 
α2,6-Neu5Ac). Noteworthy, sialic acid blockade by NP-entrapped P-3Fax-Neu5Ac 
was not due to leakage of the glycomimetic from the NPs, as the NPs remained 
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highly stable in medium for more than 10 days (Figure S8). Following removal of 
soluble glycomimetic or NPs from culture, recovery of sialic acid expression was 
followed in time by flow cytometry using fluorescent lectins. Comparable to 
unmodified P-3Fax-Neu5Ac NPs, anti-TRP-1 P-3Fax-Neu5Ac NPs blocked 
sialylation significantly longer than equal amounts of soluble glycomimetic. α2,3-
sialylation was reduced for 6 days, α2,6-sialylation and exposure of terminal β-
galactose for 5 days (Figure 5d-f). The mild reduction in sialylation following 
incubation with isotype P-3Fax-Neu5Ac NPs was restored within 24 hours. These 
findings indicate that anti-TRP-1 NPs specifically deliver P-3Fax-Neu5Ac to B16-
F10 cells and block sialylation for a prolonged period of time due to slow release. 
 
Figure 4  TRP-1-dependent uptake of anti-TRP-1 P-3Fax-Neu5Ac NPs in B16-F10 cells. 
a-c) Uptake of PEGylated, isotype control antibody- or anti-TRP-1 antibody-coated P-3Fax-
Neu5Ac/A647 NPs (1 mg/ml) in B16-F10 cells following 16 hours incubation at 37 °C. Representative 
histogram (a) and mean fluorescence intensities ± SEM of three independent experiments (b) showing 
nanoparticle uptake as determined by flow cytometry. Confocal images of B16-F10 cells after 16 h 
incubation with isotype control antibody- or anti-TRP-1 antibody-coated P-3Fax-Neu5Ac/A647 NPs → 
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(green) (c). d) Uptake and degradation of isotype or anti-TRP-1 antibody-coated NPs containing DQ-
BSA. B16-F10 cells were incubated with 1 mg/ml NPs for 1 hour or 24 hours and another 16 hours later, 
fluorescence of DQ-BSA was quantified by flow cytometry. Percentage fluorescence normalized to 
control of three independent experiments ± SEM is shown. e, f) TRP-1-dependent uptake of anti-TRP-1 
antibody-coated P-3Fax-Neu5Ac/A647 NPs. B16-F10 cells were pre-incubated with 10 µg/ml free isotype 
or anti-TRP-1 antibody for 20 min, followed by 1 mg/ml isotype antibody- or anti-TRP-1 antibody-coated 
P-3Fax-Neu5Ac/A647 NPs for 16 h. Representative histogram shows uptake of anti-TRP-1 NPs upon 
blockade with anti-TRP-1 antibody (e) and MFI ± SEM of three independent experiments (f).  
 
Figure 5  Targeted delivery of P-3Fax-Neu5Ac to melanoma and sustained sialic acid blockade. 
(a-c) B16-F10 cells were cultured for 3 days in the presence of 1 mg/ml isotype control antibody- or anti-
TRP-1 antibody-coated P-3Fax-Neu5Ac NPs or an equal amount of soluble P-3Fax-Neu5Ac (23.1 µg/ml). 
Expression of α2,3-linked sialic acids, α2,6-linked sialic acids, and terminal β-galactose was quantified 
by flow cytometry using biotinylated lectins MALII (a), SNA-I (b) or PNA (c) conjugated to streptavidin-
PE. d-f) Recovery of sialylation in time following treatment of B16-F10 cells for 3 days with 1 mg/ml 
isotype control antibody- or anti-TRP-1 antibody-coated P-3Fax-Neu5Ac NPs or an equal amount of 
soluble P-3Fax-Neu5Ac (23.1 µg/ml). Sialic acid expression was measured at several time points by flow 
cytometry using streptavidin-PE conjugated MALII (d), SNA-I (e) or PNA (f). All fluorescence values 
were normalized to untreated control cells and data of three independent experiments are presented as 
average percentage lectin binding ± SEM. 
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Targeted delivery of P-3Fax-Neu5Ac using anti-TRP-1 NPs precludes metastatic 
spread in vivo 
TRP-1-targeting NPs allowed specific delivery of P-3Fax-Neu5Ac to B16-F10 cells 
and prolonged blockade of sialylation. As in vitro pre-treatment with the 
glycomimetic effectively prevented the formation of pulmonary metastases (Figure 
1d, e), we now assessed if in vivo administration of anti-TRP-1 P-3Fax-Neu5Ac 
NPs could affect metastatic spread in vivo (Figure 6a) Following a schedule 
resembling adjuvant therapy,39 mice were injected twice intravenously (i.v.) with 20 
mg/kg (0.4 mg/mouse) PBS, empty anti-TRP-1 coated NPs, isotype control P-3Fax-
Neu5Ac NPs or anti-TRP-1 P-3Fax-Neu5Ac NPs. One hour after the first injection, 
0.5 x 106 B16-F10 cells were injected i.v. followed by a second injection with NPs 
or controls sixteen hours after start of the experiment. After 14 days following 
injection, lungs were isolated and metastatic lesions were enumerated. PBS 
treated mice showed an average of about ± 80 nodules/lung, and administration of 
empty anti-TRP-1 NPs or P-3Fax-Neu5Ac-containing isotype control NPs had no 
significant impact on the number of nodules (Figure 6b, c). Strikingly, treatment 
with P-3Fax-Neu5Ac-loaded anti-TRP-1 NPs strongly reduced the metastatic load 
to ± 20 nodules/lung (75 % reduction). 
TRP-1 is involved in melanogenesis and B16-F10 cells are known to form both 
melanin-containing melanotic (black) and amelanotic (gray/white) nodules with low 
amounts of melanin.40 Histological analysis of the lungs of the mice treated with 
anti-TRP-1 P-3Fax-Neu5Ac NPs revealed that the detectable metastases 
essentially lacked melanin (Figure 6d). Additional analysis showed that the 
number of amelanotic nodules was similar among all treatment groups, but the 
number of melanotic nodules was decreased by 95 % in mice treated with anti-
TRP-1 P-3Fax-Neu5Ac NPs (Figure 6e). Altogether, these findings demonstrate 
that sialic acid blockade using targeted delivery of P-3Fax-Neu5Ac to B16-F10 cells 
in the blood stream using anti-TRP-1 NPs largely prevents outgrowth of melanoma 
cells at distant sites.  
 
Discussion 
In this study, we have explored for the first time the possibility to prevent 
metastases formation by blocking sialic acid expression in cancer cells using a 
rationally designed glycomimetic encapsulated into tumor-targeting nanoparticles. 
In particular we demonstrated that 1) the overexpression of sialic acids may play a 
role in melanoma cell metastasis, 2) TRP-1 mAb targeted delivery of the sialic acid-
blocking glycomimetic P-3Fax-Neu5Ac using PLGA nanoparticles allows for long-
lasting sialic acid blockade in melanoma cells in vitro, 3) therapy with anti-TRP-1 P-
3Fax-Neu5Ac NPs can prevent metastatic spread of melanoma cells in vivo.  
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Figure 6  Targeted delivery 
of P-3Fax-Neu5Ac precludes 
metastatic spread. 
a) Treatment schedule. 20 
mg/kg isotype antibody- or 
anti-TRP-1 antibody-coated 
P-3Fax-Neu5Ac NPs or empty 
anti-TRP-1 antibody-coated 
NPs were injected i.v. into 
the tail vein of mice. 1 hour 
later, 0.5 x 106 B16-F10 cells 
were injected into the tail vein 
of mice (n = 6). 16 hours 
following injection with B16-
F10 cells, another dose of 20 
mg/kg NPs was administered 
i.v. and 14 days later, mice 
were sacrificed and lungs 
were collected and fixed 
overnight in Fekete’s 
solution. b) Representative 
images show formation of 
nodules in the lung. c) 
Nodules were enumerated 
and are presented in a dot 
plot. d) Hematoxylin and 
eosin staining of lung 
sections from control or anti-
TRP-1 P-3Fax-Neu5Ac NP-
treated mice. Magnification 
(squares) shows presence of 
melanin (arrow) in the 
metastases of control mice, 
but not anti-TRP-1 P-3Fax-
Neu5Ac NPs treated mice. e) 
Distribution of melanotic 
(black) and amelanotic 
(grey/white) nodules between 
the treatment groups.  
 
Over four decades ago specific tumor characteristics were ascribed to the 
increased expression of sialic acid sugars on the surface of cancer cells, including 
effects on tumor growth, escape from apoptosis, metastasis formation and 
resistance to therapy. Strategies to target aberrant sialylation in cancer, however, 
have been lacking for a long time. We have recently reported that sialic acid 
blockade with the broad sialic acid inhibitor P-3Fax-Neu5Ac developed by Rillahan 
and colleagues impaired tumor cell binding to ECM components, migration and 
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tumor cell engraftment.28,29 Elevated high expression of sialyltransferases and 
consequently of many different sialoglycans such as the sialyl Lewis x antigen 
(sLex) or α2,6-sialylated integrins have been reported to correlate with 
aggressiveness of tumors and their ability to form metastases.1,2,5,14 We now show 
that pre-treatment of B16-F10 cells with soluble glycomimetic remarkably reduced 
formation of pulmonary metastasis. We have previously reported that P-3Fax-
Neu5Ac is not toxic for B16-F10 cells nor does affect their proliferation in vitro even 
upon thirty days of culture in the permanent presence of the glycomimetic.29 Also 
pretreatment with sialidase reduced the metastatic load to a similar extent. These 
findings advocate that the reduced metastatic spread is directly related to the 
blocked sialic acid expression rather than indirect effects of P-3Fax-Neu5Ac. The 
observed potency of sialic acid blockade to prevent cancer metastasis is most 
likely related to the involvement of sialic acids in many different steps of the 
metastatic cascade. In our experimental metastasis model, tumor cells possibly are 
trapped in the blood stream, because they lack expression of the selectin ligands 
sLex and other sialoglycans that are essential to adhere to selectins on endothelial 
cells and leave the blood stream. 4,41 In addition, tumor cells might be cleared from 
the blood by the immune system because they fail to form immunoprotective 
thromboemboli with platelets and leukocytes.6 Furthermore, sialic acid blockade is 
likely to prevent settlement and growth of the cancer cells in the lung tissue. 
Indeed, it has been reported that for instance sialoglycans on integrins enable 
binding to ECM components, provide survival and growth signals, and prevent 
galectin-induced apoptosis.42,43 It will be intriguing to unravel how sialic acid 
blockade exactly prevents metastases formation and which of the steps in the 
metastasis process depend most on sialic acids.  
The potent effects of P-3Fax-Neu5Ac pre-treatment on tumor growth and 
metastasis led us to design a therapeutic strategy to deliver this sialic acid-blocking 
glycomimetic specifically to tumor cells in vivo while limiting exposure to normal 
cells. Non-targeted sialic acid blockade could cause adverse effects as it has been 
described for mice with defective sialic acid synthesis.44,45 Therefore, the 
melanoma specific antigen TRP-1 was selected for the targeting of P-3Fax-Neu5Ac 
loaded PLGA NPs to melanoma tumor cells in vivo. Our data showed that TRP-1 
mAb targeted delivery of the sialic acid-blocking glycomimetic P-3Fax-Neu5Ac 
using PLGA nanoparticles allowed efficient sialic acid blockade in melanoma cells 
in vitro. TRP-1 itself is a glycoprotein containing complex N-glycans including sialic 
acids.46 Sialic acids can influence stability and membrane trafficking and turnover 
of proteins.16,47 Interestingly, sialic acid blockade slightly increased expression of 
TRP-1 and NP uptake, suggesting that delivery of P-3Fax-Neu5Ac to B16-F10 cells 
favors further uptake of anti-TRP-1-coated PLGA NPs (Figure S9). Furthermore, 
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other nanoparticle formulations (e.g. liposomes or micelles) might allow for potent 
delivery of this sialic acid-blocking glycomimetic to cancer cells. 
Disseminated cancer cells circulate in the blood stream and can form metastases 
at distant sites.8,48,49 In several conditions related to the treatment of the primary 
tumors, like surgery, the number of circulating tumor cells may be enhanced.50-53 
Targeting circulating cancer cells in such conditions may prevent their outgrowth at 
distant sites and significantly improve the outcome of cancer therapy.54,55 Using the 
B16-F10 metastasis model, we now show that anti-TRP-1 NP-mediated targeting 
of P-3Fax-Neu5Ac to these melanoma cells in the circulation prevents their 
metastatic spread. We are aware that the used anti-TRP-1 antibody alone has anti-
metastatic effects and is effective for the usage in cancer therapy.30,56,57 However, 
the Fc part of the TRP-1 antibodies conjugated to the PEG lipid layer on NPs might 
not be available for binding to Fc receptors thereby avoiding antibody-mediated 
anti-tumor effects. Indeed, injection of empty anti-TRP-1 conjugated nanoparticles 
did not significantly affect metastases formation. In contrast, the formation of 
melanotic nodules was strongly reduced upon injections with anti-TRP-1 NP 
containing P-3Fax-Neu5Ac. The presence of TRP-1 however, is essential as 
isotype mAb conjugated NPs containing P-3Fax-Neu5Ac had no effect. The finding 
that melanotic but not amelanotic metastases that are known to downregulate the 
TRP-1 antigen were reduced, provides further evidence that targeting TRP-1 on 
tumor cells is indeed essential for the observed effects.58 These data further 
indicate that targeting multiple different tumor antigens with P-3Fax-Neu5Ac-loaded 
NPs may be important to counteract antigen escape variants. Finally, no adverse 
effects or abnormalities at the organ level were found in mice following the injection 
of two doses of P-3Fax-Neu5Ac-loaded NPs, ascribing the treatment a good safety 
profile. The precise biodistribution and uptake of anti-TRP-1 P-3Fax-Neu5Ac NPs in 
vivo as well as alternative treatment schedules and their effect on primary tumor 
growth remain to be investigated.59 A small percentage of the anti-TRP-1 P-3Fax-
Neu5Ac NPs might be taken up by other cell types in vivo, as it has been shown for 
other antibody-nanoparticle conjugates.60,61 Nevertheless, the striking effects 
observed in vivo provide first evidence that anti-TRP-1 P-3Fax-Neu5Ac NPs 
eventually enrich in melanoma cells. 
In conclusion, our data stress that sialoglycans are essential for cancer metastasis 
and that rationally designed sialic acid blocking glycomimetics encapsulated in 
nanoparticles allow specific and safe targeting to tumor cells to prevent metastatic 
spread. This combined glycobiological and nanotechnological strategy to block 
sialoglycan expression in specific target cells in blood will be broadly applicable to 
interfere with sialic acid-dependent processes in cancer, infection and 
inflammation. 
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Supplementary Information 
 
 
Supplementary Figure 1 Desialylation abrogates metastases formation. 
a) Viability of B16-F10 cells treated 3 days with or without 23.1 µg/ml P-3Fax-Neu5Ac determined by 7-
AAD using flow cytometry presented as average percentage viable cells ± SEM (n=3). b) B16-F10 cells 
were incubated 3 days with PBS, 23.1 µg/ml P-3Fax-Neu5Ac or for 45 min with 150 mU/ml C. 
perfringens sialidase. Histogram shows cell surface expression of α2,3-linked sialic acids, α2,6-linked 
sialic acids and terminal β-galactose as detected with flow cytometry using the biotinylated lectins 
MALII, SNA-I or PNA, respectively. Data of three independent experiments are presented as average 
percentage lectin binding ± SEM. c) 2 x 105 control (n=5), P-3Fax-Neu5Ac (n=5) or sialidase-treated 
(n=4) B16-F10 cells were thoroughly washed and injected into the tail vein of mice and 14 days later 
lung metastases were enumerated and presented as dot plot . 
 
 
 
 
Supplementary Table 1 Characteristics of P-3Fax-Neu5Ac and P-3Fax-Neu5Ac/A647 nanoparticles. 
P-3Fax-Neu5Ac solely or in combination with ATTO 647 was encapsulated into PLGA nanoparticles. 
Drug loading was determined with HPLC and dynamic light scattering was used to determine size, size 
distribution and zeta potential of the nanoparticle preparations.  
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Supplementary Figure 2 Blockage of sialylation with P-3Fax-Neu5Ac and P-3Fax-Neu5Ac NPs. 
a-c) B16-F10 cells were incubated 3 days with 0-23.1 µg/ml P-3Fax-Neu5Ac NPs and the effect on 
sialylation was determined with flow cytometry by staining cell surface α2,3-linked sialic acids with 
MALII  (a), α2,6-linked sialic acids with SNA-I (b) and terminal β-galactose with PNA (c). Data of three 
independent experiments are presented as average percentage lectin binding ± SEM. d-f) B16-F10 
cells were incubated 3 days with 1 mg/ml empty NPs, 1mg/ml P-3Fax-Neu5Ac NPs or equal amounts of 
soluble P-3Fax-Neu5Ac (23.1 µg/ml). Representative histograms show cell surface expression of α2,3-
linked sialic acids (d) α2,6-linked sialic acids (e) terminal β-galactose (f) as detected with flow cytometry 
using the biotinylated lectins MALII, SNA-I or PNA, respectively. 
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Supplementary Figure 3 (P-3Fax-Neu5Ac) PLGA NPs are non-toxic and do not affect cellular 
glycosylation. a, b) B16-F10 cells were cultured for 3 days with 0-1 mg/ml P-3Fax-Neu5Ac NPs or 0-2 
mg/ml empty PLGA NPs, stained with 7-AAD viability dye and the percentage viable cells was 
quantified with flow cytometry. (c) B16-F10 cells were cultured 3 days in the presence of 0-2mg/ml 
empty PLGA NPs and the effect on cell surface glycosylation was assessed. Binding of biotinylated 
MALII (α2,3-sialic acids), SNA-I (α2,6-sialic acids), PNA (β-galactose) and WGA ((poly)GlcNAc) was 
quantified with flow cytometry and fluorescence values were normalized to untreated control cells. Data 
of three independent experiments are presented as average percentage lectin binding ± SEM. 
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Supplementary Figure 4 Co-delivery of P-3Fax-Neu5Ac and ATTO 647 to B16-F10 cells using NPs. 
a-c) B16-F10 cells were cultured 3 days in the presence of 0-1 mg/ml NPs containing P-3Fax-Neu5Ac 
and ATTO 647. Effect on sialylation was determined with flow cytometry by staining cell surface α2,3-
linked sialic acids with MALII (a), α2,6-linked sialic acids with SNA-I (b) and terminal β-galactose with 
PNA (c). Data of three independent experiments are presented as average percentage lectin binding ± 
SEM. (d) Presence of ATTO 647 in B16-F10 cells that were cultured 3 days with 0-1 mg/ml P-3Fax-
Neu5Ac/A647 NPs was detected using flow cytometry and mean fluorescence intensity values ± SEM 
are presented. 
 
 
 
 
 
 
 
Supplementary Figure 5 Uptake of P-3Fax-
Neu5Ac/A647 NPs in B16-F10 cells. 
B16-F10 cells were incubated at 4 °C or 37 °C in 
the presence of 1 mg/ml P-3Fax-Neu5Ac/A647 NPs 
and uptake of NPs was measured by flow 
cytometry. Histograms show representative dot 
plots following 0 or 1 hour uptake and the 
percentages of ATTO 647 positive cells. 
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Supplementary Figure 6 Blockage kinetics of P-3Fax-Neu5Ac NPs versus soluble P-3Fax-Neu5Ac. 
a-c) 10 day culture of B16-F10 cells in the presence of 1 mg/ml empty NPs, 1 mg/ml P-3Fax-Neu5Ac 
NPs or equal amounts of soluble P-3Fax-Neu5Ac (23.1 µg/ml). During the culture, medium was not 
renewed. At several time points, surface sialic acid expression was determined by flow cytometry with 
biotinylated lectins MALII (a), SNA-I (b) or PNA (c). Sialylation is presented as average percentage 
lectin binding ± SEM of three independent experiments.  
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Supplementary Figure 7 Expression of TRP-1 on B16-F10 cells and 9464 cells and uptake of αTRP-1-
targeting P-3FaxNeu5Ac/A647 NPs. a) Confocal image of B16-F10 cells stained with anti-TRP1 antibody 
(TA99) and DAPI. b) Histogram showing direct fluorescence of anti-TRP1 antibody- (TA99) or control 
IgG2a isotype antibody-conjugated P-3FaxNeu5Ac/A647 NP as measured with flow cytometry. c) Dot 
plots showing binding of IgG2a isotype (upper panel) or anti-TRP1 antibody (TA99) (lower panel) to 
9464D cells as determined by flow cytometry. d) Uptake of isotype- or anti-TRP1-conjugated P-
3FaxNeu5Ac/A647 NPs in 9464D cells following 24 hours incubation. Fluorescence of the NPs was 
determined by flow cytometry and mean fluorescence intensities of three independent experiments are 
presented ± SEM. 
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Supplementary Figure 8 Stability of unmodified or PEGylated P-3FaxNeu5Ac NPs. 
1 mg/ml unmodified or PEGylated P-3FaxNeu5Ac NPs or an equal dose of free P-3FaxNeu5Ac (23.1 
µg/ml) were incubated 0-10 days in complete B16-F10 culture medium. On different time points 
supernatant (Sup.) or nanoparticle (NPs) fraction was collected and added to B16-F10 cells. After 3 
days, expression of α2,3-linked sialic acids was determined by flow cytometry using MALII lectin (right 
panel). As a control, B16-F10 cells were cultured 3 days in the presence of 0-17.6 µg/ml fresh P-
3FaxNeu5Ac (left panel). Data are presented as percentage lectin binding ± SEM of two independent 
experiments. 
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Supplementary Figure 9 Expression of TRP-1 and α-TRP-1 NPs uptake following P-3FaxNeu5Ac 
treatment. a, b) B16-F10 cells were cultured 3 days with 17.6 µg P-3FaxNeu5Ac and expression of TRP-
1 was determined by flow cytometry using PE-conjugated anti-TRP-1 antibody (TA99). Representative 
histogram showing TRP-1 expression (a) or expression values of three independent experiments 
normalized to control are presented ± SEM (b). c, d) Uptake of isotype or α-TRP-1 P-3FaxNeu5Ac/A647 
NPs in B16-F10 cells after 3 days of culture with 64 µM P-3FaxNeu5Ac. Histogram (c) or bar diagram (d) 
showing uptake of α-TRP-1 P-3FaxNeu5Ac/A647 NPs or uptake levels of isotype or α-TRP-1 P-
3FaxNeu5Ac/A647 NPs of three independent experiments normalized to control ± SEM. 
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Abstract 
Myeloid derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid 
cell population that is increased under various pathological conditions, including 
cancer. In humans, these cells are defined by the expression of the myeloid 
markers Siglec-3 (CD33) and/or CD11b, and the absence or low expression of 
MHC II. Siglec-3 is a member of the of the sialic acid-binding immunoglobulin-like 
lectin (Siglec) family and has been suggested to promote MDSC expansion. So far 
it is unknown if, next to Siglec-3, MDSCs express other members of the Siglec 
family. Therefore we assessed Siglec expression in two MDSCs subsets, 
monocytic-MDSCs (M-MDSCs) and polymorphonuclear-MDSCs (PMN-MDSCs) 
isolated from blood and tumor material of glioma patients. Besides Siglec-3, Siglec-
5, -7 and -9 were detected in both MDSC subsets and further comparison showed 
that M-MDSCs expressed higher levels of Siglec-3, -7 and -9 whereas higher levels 
of Siglec-5 were found on PMN-MDSCs. Siglec expression levels on MDSCs 
isolated from glioma patients were comparable to the expression found on MDSCs 
isolated from healthy controls. Furthermore we found that PMN-MDSCs within 
glioma tissue display a Siglec expression profile comparable to their blood-derived 
counterparts. Strikingly, freshly isolated glioma cells predominantly expressed sialic 
acid ligands for Siglec-7 and -9 and to a lower extent ligands for Siglec-3 and -5. 
Altogether, our data show that MDSCs feature a distinct Siglec expression profile 
and propose possible sialic acid-Siglec interactions between glioma cells and 
MDSCs in the tumor microenvironment. 
 
Introduction 
Gliomas are the most frequently occurring primary brain tumors in adults arising 
from glial progenitor cells.1 Patients with a glioblastoma, the most malignant form of 
astrocytoma, have a dismissal prognosis of only 14-16 months.2 Since these 
tumors grow diffusively within healthy brain tissue, they can rapidly reoccur after 
surgical resection. Patients are therefore subsequently treated with radio- and 
chemotherapy to destroy residual tumor cells. Despite these measures, gliomas 
often develop therapy resistance leading to rapid reoccurrence of the disease.2,3 At 
the moment, there are no effective FDA-approved treatment options available for 
radio- and chemotherapy-resistant gliomas. For that reason, cancer 
immunotherapy where the patient’s own immune system is activated to eradicate 
tumor cells is a promising approach to specifically destroy glioma cells. Several 
clinical trials have explored immunotherapy for the treatment of glioma showing the 
induction of a cytotoxic T cell response to autologous tumor cells and a prolonged 
long term survival in a fraction of patients.4,5 However, gliomas can acquire multiple 
mechanisms to counteract anti-tumor immune responses, e.g. by the production of 
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immune inhibitory soluble factors, enzymes and/or cell surface molecules.6 
Additionally, various immunosuppressive cells are recruited to the tumor site 
resulting in the formation of an immunosuppressive tumor microenvironment.7 
We and others have previously reported an increase of myeloid derived suppressor 
cells (MDSCs), but not of regulatory T cells (Tregs), in the blood of glioma 
patients.8-11 MDSCs lack markers of mature myeloid cells (MHC II molecules HLA-
DR,DP,DQ), but express the myeloid lineage markers Siglec-3 (CD33) and CD11b. 
There are two distinct MDSC populations, a monocytic (M-) and a poly-
morphonuclear (PMN-) MDSC population which are defined by the expression of 
CD14 or CD15, respectively. Both populations are elevated in the blood of glioma 
patients, with PMN-MDSCs being the main population detected in the tumor 
tissue.10,12 We have previously shown that PMN-MDSCs from glioma patients are 
potent inhibitors of T cell function that possibly contribute to the immune-
suppressive microenvironment.13 To interfere with their immunosuppressive 
function, a better understanding of the induction of MDSCs and their suppressive 
phenotype is necessary. One of the cell surface markers used to discriminate 
MDSCs is Siglec-3, a member of the Sialic acid-binding immunoglobulin-like lectin 
(Siglec) family.14  
The human Siglec family is comprised of more than 14 members and can be 
divided into two groups; the conserved Siglecs and the CD33-related Siglecs. 
Conserved Siglecs (-1, -2, -4, -15) show a high sequence similarity across 
mammals whereas CD33-related Siglecs (-3, -5/-11, -14/-16) display high 
sequence variability across species.15 CD33-related Siglecs are broadly expressed 
throughout the immune system, but which Siglecs are expressed by MDSCs apart 
from Siglec-3 is largely unknown. CD33-related Siglecs are type I transmembrane 
proteins with an N-terminal sialic-acid binding domain and a C-terminal, 
cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM). Their ligands 
are sialic acid sugars which usually are present in the glycans of membrane 
glycoproteins and glycolipids of all vertebrate cells. Sialic acids play an important 
physiological role at the molecular level (e.g. regulation of glycoprotein and 
glycolipid stability and function) and cellular level (e.g. cell-cell interactions).16,17 
In general, the interaction between a Siglec with a sialic acid ligand initiates a 
suppressive signal in the immune cell that is mediated via the ITIMs.18 Thereby, 
Siglecs can dampen immune cell activation and possibly contribute to immune 
homeostasis.19 Recent examples demonstrate the strong immunosuppressive 
function of Siglecs. For instance, binding of Siglec-2 to its sialic acid ligand has 
been shown to suppress B cell activation and enforces B cell tolerance to 
membrane antigens.20,21 Similarly, sialic acid binding to Siglec-7 has been reported 
to dampen NK cell activation and function.22,23 Strikingly, it was shown that Siglec-3 
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signaling in MDSCs induced the secretion of the immunosuppressive cytokines 
TGF-β and IL-10, thereby promoting MDSC expansion.24  
Tumor cells express aberrantly high levels of sialic acids on their surface that can 
be recognized as ligands by the Siglec family. The interaction between tumor sialic 
acids and Siglecs has been shown to modulate immune cell function and to 
facilitate tumor immune evasion.25,26 Therefore, we assessed the expression of 
Siglec family members on MDSCs from glioma patients and healthy controls. In 
addition, the expression of putative cis and trans sialic acid ligands on MDSCs and 
glioma cells, respectively was analyzed. Here we report that both M-MDSCs and 
PMN-MDSCs isolated from blood of healthy controls and glioma patients express 
multiple members of the Siglec family. The Siglec expression profile found in blood 
PMN-MDSCs could be confirmed in glioma infiltrating PMN-MDSCs. Moreover, 
using recombinant Siglec receptors we identified expression of putative trans 
Siglec ligands on glioma cell lines as well as freshly isolated glioma cells. 
Altogether, these data suggest possible sialic acid-Siglec interactions between 
PMN-MDSCs and glioma cells in the tumor microenvironment which may 
contribute to the immunosuppressive role of MDSCs in glioma patients. 
  
Materials and Methods 
Blood and tumor sample 
Peripheral blood samples were collected from 9 healthy individuals and from 14 
glioma patients undergoing neurosurgical resection or biopsy for intracranial 
tumors at the Radboud University Medical Center (Radboudumc). All patients had 
histologically proven brain tumors determined by neuropathologists of the 
Radboudumc according to the WHO 2007 Classification of tumors of the Central 
Nervous System.27 The brain tumors consisted of 2 WHO grade II tumors (1 oligo-
astrocytoma and 1 oligodendroglioma), 4 WHO grade III tumors (all anaplastic 
oligodendroglioma) and 8 WHO grade IV (glioblastoma n=5, gliosarcoma n=2, 
oligodendroglioma n=1). Tumor tissue samples were obtained from 5 patients by 
sonic aspiration. 8 patients had started a 3x 5mg dexamethasone regime on the 
day before surgery, while 6 patients received dexamethasone at an earlier time 
point to reduce edema. All donors signed an informed consent and the study was 
approved by our Institutional Review Board. Immediately after the blood and fresh 
tumor tissue samples were obtained, processing of these samples was started. 
Flow cytometry measurements were performed within 24 hours. 
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Tissue handling 
Fresh brain tumor material was obtained by excision and by ultrasonic aspiration. 
Aspirates were collected in a closed system. Tumor cell suspensions were pre-
pared as described previously.8 Briefly, tumor fragments were filtered and washed 
to discard blood and suction fluid. Tumor fragments were incubated with 
collagenase type-IA (50 µg/ml) (Sigma-Aldrich), DNAse type-I (10 μg/ml) (Roche) 
and trypsin inhibitor (1 μg/ml) (Sigma-Aldrich) in Hank’s Balanced Salt Solution 
(HBSS) (Gibco) at 37 oC followed by mechanical disruption by pipetting. Tumor cell 
suspensions were placed on a Ficoll gradient (Lucron Bioproducts) to remove 
granulocytes, including potential mature granule rich neutrophils. Similarly, a Ficoll 
gradient was used to obtain peripheral blood mononuclear cells (PBMCs) from 
freshly obtained blood. 
 
FACS analysis and sorting 
FACS stainings were performed as described elsewhere.10,23 For lectin staining, 
cells were stained with biotinylated lectins MALII (Maackia amurensis lectin II), 
SNA-I (Sambucus nigra agglutinin) and PNA (Peanut agglutinin) in carbo-free 
blocking buffer (Vector Laboratories) for 40 minutes, washed and incubated with 
PE-conjugated Streptavidin (BD). For Siglec ligand staining, recombinant human 
Siglec-Fc chimera (R&D systems) were mixed with Alexa Fluor 647-conjugated 
goat anti-human IgG (H+L) antibody (Life Technologies). Cells were washed and 
incubated for 40 minutes with 0.4 µg/ml recombinant Siglec Fc chimeras pre-
conjugated with Alexa Fluor 647 goat anti-human IgG antibodies in carbo-free 
blocking solution containing 1 mM CaCl2+ and 1 mM MgCl2+ at 4 °C. Cells 
incubated with Alexa Fluor 647 goat anti-human IgG antibody only served as con-
trol. Subsequently, PBMCs, glioma cell lines or single cell tumor tissue suspen-
sions were stained with fixable viability dye eFluor 780 (eBioscience). After 
washing, cells were stained with directly conjugated monoclonal antibodies (mAbs) 
for 20 minutes on ice. Directly fluorescent conjugated mAbs were obtained from BD 
(CD33-APC, HLA-DR/DP/DQ-FITC, CD14-PerCP), Pelicluster (CD14-PE), IO-Test 
(CD11b-PE), Biolegend (CD15-PE-Cy7, CD45-PerCP, Siglec-5-PE, Siglec-7-PE, 
Siglec-10-PE), Sigma (Siglec-2-PE) and R&D Systems (Siglec-9-PE). Isotype 
controls were obtained from BD (IgG1-APC, IgG1-PE-Cy7, IgG2a-PE, IgG2a-FITC, 
and IgG1-PE) and Biolegend (IgG2a-PerCP). Cells were resuspended in PBA (1x 
PBS, 1 % BSA, and 0.02 % sodium azide) and measured on a CyAn (Beckman 
Coulter) or Gallios (Beckman Coulter) flow cytometer. Data was analyzed using 
FlowJo 9.2 where events were gated on single viable cells for further analysis. For 
sorting, cells were stained with HLA-DR,DP,DQ-FITC, CD33-APC, CD14-PE and 
CD15-PE-Cy7 and sorted on a FACS Aria (BD) 
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Quantitative PCR (qPCR) 
PBMCs, FACS-sorted cells or cells of single cells tumor tissue suspension were 
pelleted and resuspended in RNA lysis buffer (Zymo Research (R1055)) and 
stored at -80oC till further use. RNA isolations were performed using the ZR RNA 
isolation kit (Zymo Research) according to manufacturer’s instructions. Remaining 
DNA was removed using DNAse I (amplification grade; Invitrogen). cDNA was 
synthesized as described elsewhere28 Briefly, cDNA synthesis from RNA was 
performed by reverse transcriptase by using random hexamers and Moloney 
murine leukemia virus reverse transcriptase (Invitrogen). To exclude genomic DNA 
contamination we included a “-RT” control in which the reverse transcriptase was 
replaced with RNase-free water. cDNA was stored at -20°C until further use. cDNA 
amplification of genes of interest was measured by SYBR Green (Applied 
Biosystems) using a Biorad CFX apparatus. Primer (Sigma) sequences were 
derived from the Harvard Primer Bank database and can be found in 
Supplementary Table 1.29 Siglec expression was normalized against GAPDH.  
 
Glioma cell culture 
Human glioma cell lines U87, T98G and U251 (ATCC) were grown in Dulbecco’s 
Modified Eagle’s Medium (Gibco), 10 % heat-inactivated fetal bovine serum 
(Greiner Bio-one), 2 mM glutamine (Lonza), 1 mM sodium pyruvate (Gibco), 1x 
antibiotic-antimycotic solution (Life Technologies) to confluency and passaged 
using trypsin. Cells were harvested for flow cytometry analyses by washing with 
PBS and subsequently adding cold PBS for five minutes.  
 
Results 
Blood MDSCs express several Siglec family members 
Myeloid cells express several members of the Siglec family, but MDSCs have so 
far only been shown to express Siglec-3. Therefore, we investigated whether, apart 
from Siglec-3, MDSCs express other Siglecs. To this end, M-MDSCs (CD33+ MHC 
IIlow/- CD14+) and PMN-MDSCs CD33+ MHC IIlow/- CD15+) were purified from blood 
derived PBMCs of glioma patients using FACS-sorting and analyzed for Siglec 
expression (Figure 1a). As expected, Siglec-3 mRNA was readily detected in both 
M- and PMN-MDSCs (Figure 1b, c). Additionally, M-MDSCs expressed mRNAs of 
Siglecs-5, -7, -9, -10, -11, -14, and -16 with Siglec-9 being expressed the highest. 
PMN-MDSCs showed a similar expression profile, but also expressed Siglec-6, 
and -8. Additionally, expression of Siglec-5 was more than 4 times higher in PMN-
MDSCs compared to M-MDSCs. Next we examined the Siglec protein expression 
on the cell surface of the two MDSC subpopulations (Figure 1d) using available 
Siglec antibodies.  
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Figure 1 Siglec expression on MDSCs from glioma patients.  
a) Gating strategy for MDSCs. b, c) qPCR analysis of Siglec expression in M-MDSCs (b) and PMN-
MDSCs (c). Bar diagrams show mean relative Siglec expression normalized to GAPDH ± SEM. d-h) 
Cell surface expression of Siglecs on MDSC subsets measured by flow cytometry. Representative 
histograms showing cell surface Siglec expression on M-MDSCs (left panel) and PMN-MDSCs (right 
panel) (d). Bar diagrams show mean fluorescence intensity (MFI) of cell surface Siglec expression ± 
SEM of M-MDSCs (e) and PMN-MDSCs (f) derived from blood of glioma patients as well as from 
healthy controls (g, h). Data from nine individual experiments are presented. 
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The phenotypic marker Siglec-3 could be detected on the cell surface of both 
subpopulations, with a higher expression on M-MDSCs (Figure 1e, f). As 
expected, Siglec-2, a conserved Siglec known to be B-cell specific, was not 
detected on either M- or PMN-MDSCs. Siglec-5, -7 and -9 were detected on both 
M- and PMN-MDSCs, but in contrast to the qPCR data, there was little or no 
expression of Siglec-10 detectable. Partially in line with the qPCR data, M-MDSCs 
showed higher Siglec-3, -7 and -9 expression whereas Siglec-5 was higher 
expressed on PMN-MDSCs. 
Previously, we described that MDSCs from glioma patients are in a more activated 
state than those of healthy individuals, indicated by an increase in intracellular 
expression of S100A8/9.13 To determine whether this increased activation is 
accompanied by altered expression of cell surface Siglecs, we compared Siglec 
expression on MDSCs between glioma patients and healthy donors. MDSCs from 
healthy donors showed comparable Siglec expression, with slightly lower Siglec-3 
expression on M-MDSCs, indicating that the increased activation does not 
influence Siglec expression (Figure 1g, h). 
 
Figure 2 Siglec expression on tumor infiltrating PMN-MDSCs.  
a-c) Expression of Siglecs on the surface of PMN-MDSCs and myeloid cells in glioma tissue. Gating 
strategy shows CD45+ MHCII+ CD11b+ myeloid cells and CD45+ MHCII- CD11b+ CD15+ PMN-MDSCs 
(a, left panels). Representative histograms show Siglec expression on myeloid cells (a, upper panel) 
and PMN-MDSCs (a, lower panel). Bar diagrams show mean Siglec expression ± SEM on glioma-
infiltrating PMN-MDSCs (b) and myeloid cells (c) of three independent experiments. 
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
10
0
10
1
10
2
10
3
10
4
c
Isotype 2 5 7 9 10
0
50
100
150
Siglec
M
FI
 [A
U
]
CD45+ MHC II+ within Tumor Tissue
M
H
C
 II
CD45+
SSC
C
D
45
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
10 0 10 1 10 2 10 3 10 4
0
20
40
60
80
100
CD15
%
 o
f m
ax
Siglec
%
 o
f m
ax
Viable Siglec-10Siglec-9Siglec-7Siglec-5Siglec-2a
CD11b
Isotype 2 5 7 9 10
0
50
100
150
200
Siglec
M
FI
 [A
U
]
b
PMN-MDSCs within Tumor Tissue
7 
Profiling of the Sialic Acid-Siglec Axis in Glioma 
177 
Glioma-infiltrating PMN-MDSCs express Siglec-3, -5, -7, and -9   
We previously described the presence of MDSCs within glioma tissue, which 
consisted almost exclusively of PMN-MDSCs.10,13 Therefore, Siglec expression on 
glioma infiltrating PMN-MDSCs was analyzed. Single cell suspensions derived 
from tumor tissue were stained for PMN-MDSC markers and Siglecs. Single, viable 
cells were gated on CD45 expression (Figure 2a, left panel) and further separated 
by their CD11b MHC II as well as CD15 expression (Figure 2a, right panels). As 
described previously, PMN-MDSCs in glioma tissue were defined as CD11b+ MHC 
II- CD15+, as no clear Siglec-3 signal above background can be detected on these 
tumor infiltrating MDSCs.10 Siglec expression on tumor infiltrating PMN-MDSCs 
was similar to PMN-MDSCs in the blood, albeit with a lower mean fluorescent 
intensity (MFI) for Siglec-5 (Figure 2a, b). Besides PMN-MDSCs, other myeloid 
cells are present within glioma tissue. These cells express CD45, CD11b and MHC 
II and resemble tumor infiltrating monocytes, tumor-associated macrophages 
and/or microglia. They expressed Siglec-7 and -9 to a similar extent as monocytes 
derived from blood, but displayed lower levels of Siglec-5 (Figure 2a, c, Figure 
S1). Altogether, these data show that glioma-infiltrating PMN-MDSCs display a 
similar Siglec expression profile compared to their blood counterparts. 
 
 
Expression of cis Siglec ligands on MDSCs 
Having determined the expression of Siglec receptors, we next investigated the 
expression of sialic acids on MDSCs using the biotinylated lectins MAL-II, SNA-I 
and PNA that recognize α2,3-linked, α2,6-linked sialic acids or glycans without 
sialic acids, respectively. PMN-MDSCs and M-MDSCs were gated as shown in 
Figure 1a and analyzed for lectin binding. M-MDSCs expressed higher levels of 
sialic acid-carrying glycans on their cell surface relative to PMN-MDSCs (Figure 
3a, b). Interestingly, also PNA binding to M-MDSCs, but not to PMN-MDSCs could 
be observed, indicating the presence of uncapped glycans on these cells. These 
data indicate that both cells express sialic acids that can potentially interact in cis 
with Siglec receptors on the surface of MDSCs. In order to determine which Siglecs 
could potentially form cis interactions with sialic acids, PBMCs from healthy donors 
were stained with recombinant human Siglec-Fc chimeras complexed with AF647-
conjugated anti-human IgG antibodies and analyzed by flow cytometry. Binding of 
Siglec-7 and Siglec-9 to M-MDSCs and PMN-MDSCs of healthy controls could be 
detected (Figure 3c, d). On both cell types, more ligands for Siglec-9 were found 
than for Siglec-7 and in line with the plant-derived lectin staining, M-MDSCs 
showed generally higher binding of Siglec-7 and -9 compared to PMN-MDSCs. 
Similarly to the healthy controls, PMN-MDSCs derived from blood of glioma 
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patients expressed ligands for Siglec-7 and -9, but the higher expression of Siglec-
9 ligands compared to Siglec-7 ligands was not detected (Figure 3e, f). 
Additionally, Siglec-5 binding to a sub-population of PMN-MDSCs was detectable 
(Figure 3f), however additional research is necessary to identify which cells are 
responsible for this staining. No signal for Siglec-2 and Siglec-3 binding was found, 
yet putative Siglec-3 ligands could be masked by endogenously expressed Siglec-
3. Since no expression of Siglec-2 on the RNA and protein level was detected, we 
can exclude such a masking effect for Siglec 2. Altogether, our data show that 
PMN-MDSCs express ligands for Siglec-5, -7 and -9 that may form cis interactions 
with the corresponding Siglecs which are also present on these cells.  
 
 
Figure 3 Expression of sialic acids on MDSCs.  
a, b) Binding of sialic acid-binding lectins MALII and SNA-I and galactose-binding lectin PNA to MDSCs 
isolated from blood of healthy donors. Representative histograms show lectin binding to M-MDSCs (a, 
upper panel) and PMN-MDSCs (a, lower panel) as determined by flow cytometry. Bar diagram shows 
mean fluorescent intensity (MFI) ± SEM of lectin binding to both MDSC subsets of three independent 
experiment (b). c, d) Binding of recombinant Siglec Fc chimera to MDSCs from healthy donors. Bar → 
M-MDSC
PM
N
-M
D
SC
s
M
-M
D
SC
s
%
 o
f m
ax
Lectin
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
a
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
MALII
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
SNA-I
10
0
10
1
10
2
10
3
10
4
0
20
40
60
80
100
PNA
b
Lectin Binding
 
MALII SNA-I PNA
0
200
400
600
800
1000
M
FI
 [A
U
]
PMN-MDSC
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
%
 o
f m
ax
Siglec Fc
f
Siglec-2 Siglec-3 Siglec-5 Siglec-7 Siglec-9 Siglec-10
Ctrl 2 3 5 7 9 10
0
500
1000
1500
2000
Siglec Fc
M
FI
 [A
U
]
Ctrl 2 3 5 7 9 10
0
500
1000
1500
Siglec Fc
M
FI
 [A
U
]
Ctrl 2 3 5 7 9 10
0
1000
2000
3000
4000
5000
Siglec Fc
M
FI
 [A
U
]
c HC M-MDSCs HC PMN-MDSCs PMN-MDSCsd e
7 
Profiling of the Sialic Acid-Siglec Axis in Glioma 
179 
diagrams show mean fluorescent intensity (MFI) ± SEM of Siglec Fc binding to M-MDSCs (c) and PMN-
MDSCs (d) (n = 4). e, f) Siglec ligand expression on PMN-MDSCs obtained from glioma patients. Bar 
diagram shows Siglec Fc binding as mean fluorescence intensity ± SEM (e) and histograms show 
representative Siglec Fc binding (f). 
 
Glioma-derived cell lines and freshly obtained glioma cells express trans Siglec 
ligands 
Various tumors show aberrantly high expression of sialic acid-carrying glycans, that 
possibly interact with Siglecs expressed on MDSCs and other infiltrating immune 
cells. To investigate if glioma cells express sialic acids that can serve as ligands for 
Siglecs, three different human glioma cell lines (U87, T98G and U251) were 
stained with recombinant human Siglec-Fc chimeras complexed with AF647-
conjugated anti-human IgG antibodies and analyzed by flow cytometry. While no 
staining of ligands for Siglec-2, -3, and -10 was observed, low Siglec-5 ligand 
expression was detected on U87 and T98G cells and high expression was found 
on U251 cells (Figure 4a). Ligands for Siglec-7 were detected on all three cell lines 
and Siglec-9 ligands could be detected only on U87 and T98G cells. Noteworthy, 
expression of Siglec receptors themselves on the cell surface of glioma cells was 
not detected (data not shown).  
Next we investigated if the glioma cell lines resemble the Siglec ligand expression 
as it occurs on glioma cells in situ. Therefore, single cell suspensions were 
prepared from freshly isolated glioma tissue and stained with anti-CD45 antibody 
and recombinant human Siglec-Fc chimeras complexed with AF647-conjugated 
anti-human IgG antibodies and measured by flow cytometry. Glioma cells were 
identified as single, viable cells lacking CD45 expression, the marker for infiltrating 
immune cells. On the glioma cells, high expression of ligands for Siglec-7 and -9 
and low expression of ligands for Siglec-3 and -5 was detected (Figure 4b, c). 
These data show that sialic acid ligands for Siglec-7 and -9 are expressed by 
glioma cell lines and freshly isolated glioma cells. Interestingly, Siglec-7 and -9 
were the Siglecs predominantly expressed by M-MDSCs and PMN-MDSCs, 
suggesting possible interactions between glioma cells and MDSCs in the tumor. 
 
Discussion 
MDSCs are increased in the blood of patients with glioma and infiltrate the glioma 
tissue.10,13 Siglec-3 is a widely used surface marker for MDSCs and has been 
suggested to promote MDSC expansion as well as their suppressive 
phenotype.14,18,24 Expression of Siglec-3 on MDSCs was already well established, 
but expression of other Siglec family members on MDSCs has not been described 
so far. Here, we report on the expression of Siglec-5, -7 and -9 on the cell surface 
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of M-MDSCs and PMN-MDSCs isolated from the blood of glioma patients. M-
MDSCs expressed higher Siglec-3, -7 and -9 levels compared to PMN-MDSCs, 
whereas Siglec-5 was higher expressed on PMN-MDSCs. No significant difference 
in Siglec expression between MDSCs from healthy controls versus glioma patients 
was observed. PMN-MDSCs derived from tumor tissue displayed a similar Siglec 
expression profile compared to their blood counterparts. Additionally, we showed 
that glioma cells express high levels of ligands for Siglec-7 and -9. These data 
imply that Siglec-sialic acid interactions between glioma cells and PMN-MDSCs in 
the tumor microenvironment can occur that could influence MDSC function. 
MDSCs are immature myeloid cells which are prematurely released from the bone 
marrow in pathological conditions, such as cancer.14 We compared Siglec 
expression on MDSCs derived from the blood of glioma patients with MDSCs from 
the blood of healthy controls. M-MDSCs and PMN-MDSCs from glioma patients 
expressed higher levels of Siglec-3, but there was no significant difference in the 
expression of other Siglec family members. 
 
 
Figure 4 Glioma cell lines and freshly resected glioma cells express trans ligands for Siglecs.  
a) Three glioma cell lines were stained with recombinant Siglec Fc chimera and analyzed by flow 
cytometry. Representative histograms show binding of Siglec Fc chimera to U87, T98G and U251 cells. 
b, c) Expression of Siglec ligands on primary glioma cells. Representative histograms show binding of 
Siglec Fc chimera to CD45- cells isolated from glioma material (b). Bar graphs show mean fluorescent 
intensity ± SEM of Siglec Fc binding from four individual experiments. 
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In general, M-MDSCs expressed higher levels of Siglec-3, -7 and -9 compared to 
PMN-MDSCs, whereas Siglec-5 was higher expressed on PMN-MDSCs. 
Noteworthy, the antibody against Siglec-5 is cross-reactive to Siglec-14, but the 
higher expression of Siglec-5 in PMN-MDSCs was also confirmed on mRNA level. 
The biological relevance of the different expression pattern of Siglec-3, -5, -7 and -
9 between both MDSC subsets remains to be determined.  
For Siglec-3, -5, -7 and -9, we found RNA transcripts as well as cell surface protein 
expression on both M-MDSCs and PMN-MDSCs. In addition, expression of Siglec-
6, -8, -11, -14 and -16 was found on the mRNA level, but their expression on the 
cell surface is not yet confirmed. Surprisingly, mRNA transcripts for Siglec-10 were 
detected in both M-MDSC and PMN-MDSCs, but no protein expression was 
measured with flow cytometry. There are many mechanisms involved in regulating 
translation and protein trafficking, which may explain the difference found in mRNA 
levels and cell surface expression. Additionally, cell surface proteins interacting 
with their cis ligands can be shielded from recognition by antibodies. This shielding 
effect has been described for Siglecs that bind to sialic acids in cis. Sialidase 
treatment removes sialic acids from glycoproteins and glycolipids and can increase 
antibody binding to cell surface Siglecs, including Siglec-3 and -9.30,31 The actual 
Siglec expression on MDSCs might therefore slightly differ from the expression 
measured by flow cytometry using antibodies. Furthermore, we have previously 
shown that S100A9 is expressed by PMN-MDSCs in both blood and glioma 
tissue.13 This myeloid cell-related protein can from a functional ligand-receptor pair 
with Siglec-3.24 Future research should address whether binding of S100A9 to 
Siglec blocks binding of the anti-Siglec-3 antibody and whether ligands of Siglec-3 
other than S100A9 have similar results on MDSC signaling and suppressive 
capacity. 
In general, Siglecs have one or more ITIM motif allowing them to modulate immune 
cell activation and function. In MDSCs, Siglec-3 signaling can induce secretion of 
suppressive cytokines after forming a functional ligand-receptor pair, for example 
with S100A9.24 We have previously shown that serum from glioma patients 
contains increased levels of S100A8/9 compared to healthy individuals, suggesting 
that MDSCs in glioma patients could gain a more suppressive phenotype due to 
enhanced Siglec-3-S100A9 interactions.13 We could only detect low levels of 
ligands for Siglec-3 on fresh glioma cells, but high levels of ligands for Siglec-7 and 
-9 were observed. These findings suggest that glioma cells could interact with 
MDSCs via the sialic acid-Siglec-7/-9 axis. It has been shown for other immune cell 
types that sialic acid-Siglec-7/-9 interactions can dampen immune cell activation or 
effector function thereby shaping the immunosuppressive tumor 
microenvironment.19,22,23,25,32-34 Whether glioma sialic acids directly interact with 
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Siglec-7 and Siglec-9 on MSDCs in the tumor microenvironment and what the 
functional consequences are remains to be elucidated.  
In summary, we showed that next to Siglec-3, also Siglec-5, -7 and -9 are 
expressed on MDSCs from glioma patients. Freshly isolated glioma cells display 
ligands for Siglec-7 and Siglec-9, indicating a possible interaction between glioma 
cells and MDSCs in the tumor microenvironment. It could be highly rewarding to 
further elucidate whether this interaction occurs in the tumor microenvironment and 
if sialic acid-Siglec interaction influence the suppressive function of MDSCs. Such 
studies may provide new opportunities to interfere with MDSC function and thus 
may potentiate anti-glioma immunity. 
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Supplementary Information 
 
Supplementary Table 1 qPCR primers for the human SIGLEC family  
 
 
 
 
 
 
 
 
 
 
 
 
 
SIGLEC FW Primer RV Primer
SIGLEC1 CCTCGGGGAGGAACATCCTT AGGCGTACCCCATCCTTGA
SIGLEC2 GCACCCTGAAACCCTCTACG ATCAAACTTCGAGGTGTTCTTGT
SIGLEC3 GCCCCAGGACTACTCACTC CCAGCGAACTTCACCTGACA
SIGLEC5 TTCAGGAACGGCATAGCCCTA TACTCGACGAAGCTCCAAGAT
SIGLEC6 AGCCTCGTACTATGGTTATGGC CACTTCTTCGTCTGGGTCGTT
SIGLEC7 CGGAAGGATTACTCGCTGACG CCAGCTTATATCATTCCCTGCC
SIGLEC8 CAATATGGGGATGGTTACTTGCT GGAGCGTCTTGGTATGGTCTG
SIGLEC9 CCACATACCAAGAATTGCACCC ACAGAGAGCCGGTGATGTTTAT
SIGLEC10 AAGGGACTCATCTCAACGGC CCGTCTCTTCGGTAGAATCTTCA
SIGLEC11 CTACTGCTGCTTATGGCTACTG CGAAAGAAGTACCATGCCTCATC
SIGLEC14 CACTGACTACCCCTCTTTTC CGAAAGTACATTCCCTTCAC
SIGLEC15 CGCGGATCGTCAACATCTC GTTCGGCGGTCACTAGGTG
SIGLEC16 GGCTAATCAGAAACTCCAAA AGGGAGACTTGAGACATGAG
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Supplementary Figure 1 Siglec expression on CD33+ MHC II+ PBMCs. 
PBMCs freshly isolated from blood were stained as described and single, viable cells were gated based 
on CD33 and MHC II expression as shown in Figure 1a. CD33+ MHC II+ cells were further analyzed for 
Siglec expression. Bar diagram shows cell surface Siglec expression as mean fluorescence intensity ± 
SEM from 9 individual experiments.  
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Abstract 
Sialic acid sugars cover the surface of dendritic cells (DCs) and have been 
suggested to impact several aspects of DC biology. Research into the role of sialic 
acids in DCs, however, is complicated by the limited number of tools available to 
modulate sialic acid expression. Here, we report on a synthetic, fluorinated sialic 
acid mimetic, Ac53FaxNeu5Ac, which potently blocks sialic acid expression in 
human monocyte-derived DCs (moDCs). Sialic acid blockade enhanced the 
responsiveness of moDCs to Toll-like receptor (TLR) stimulation as measured by 
increased maturation marker expression and cytokine production. Consequently, 
the T cell activation capacity of Ac53FaxNeu5Ac-treated moDCs was strongly 
increased. In addition to sialic acids, moDCs also expressed the sialic acid-binding 
immunoglobulin-like lectins (Siglecs) -3, -5, -7, -9 and -10, immune inhibitory 
receptors recognizing these sialic acids. Treatment with Ac53FaxNeu5Ac abrogated 
putative cis and trans interactions between sialic acids and Siglec-7/-9. These data 
indicate that sialic acids limit the activation of moDCs via the TLR pathway, 
possibly by interacting with Siglec-7 or Siglec-9. Metabolic sialic acid blockade with 
Ac53FaxNeu5Ac could therefore potentially be used to generate more potent DC-
based vaccines for induction of robust anti-viral or anti-tumor immune responses.  
 
Introduction 
Sialic acids are a family of sugar molecules that terminate the glycans of surface 
glycoproteins and glycolipids.1 Amongst many other physiological functions, sialic 
acids are involved in a multitude of processes in the immune system.2 For 
instance, sialic acid-carrying glycans (sialoglycans) can mediate leukocyte 
trafficking and extravasation, prevent complement activation on sialylated host 
cells, and regulate immune cell activation by interacting with immunoregulatory 
Siglec receptors.2-6 Interestingly, it has been suggested that sialoglycans regulate 
multiple functions of DCs, the key regulators of the immune system.7 Several 
groups have reported that removal of surface sialic acids with bacterial sialidases 
enhanced the response of DCs to LPS. In addition to enhanced maturation and 
cytokine production upon LPS stimulation, DCs treated with sialidase were also 
more potent T cell activators.8-14 These data evidence that sialic acids limit the 
response of DCs to stimulation via the TLR pathway. 
There are only a limited number of tools available to modulate sialoglycan 
expression in DCs or other cells in general. So far, mainly bacterial sialidases, 
which cleave sialic acids from glycans have been used. Bacterial sialidases are a 
useful tool for sialic acid research, but several issues limit their application in 
immunological research. First, the sialidase effect is short-lived due to the fast 
turnover rate of sialoglycans.15,16 Second, bacterial sialidases are hard to obtain in 
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endotoxin-free grade, because they are often produced in bacteria. To exclude 
endotoxin-mediated effects, heat-inactivated sialidase has to be included as a 
control in immunological experiments.8,10 Third, there is evidence that bacterial 
sialidases remain bound to the cell surface following sialic acid cleavage. Surface 
bound sialidases could be recognized as antigens or interfere with the recognition 
of other surface molecules thereby influencing the outcome of immunological 
experiments.17,18 
We have previously shown that a fluorinated sialic acid mimetic, Ac53FaxNeu5Ac, 
blocks sialic acid expression in human and mouse tumor cell lines with high 
efficiency and specificity.15,19-21 Most notably, this inhibitor caused a prolonged 
inhibition of the sialic acid biosynthesis (about 48 h to recover 50% sialylation) and 
is chemically pure and free from endotoxins. This makes it possible to study the 
effect of (de)sialylation on immune responses without the aforementioned concerns 
when using bacterial sialidases. In this study, we investigated the consequences of 
Ac53FaxNeu5Ac-mediated sialic acid blockade on TLR-induced maturation of 
freshly generated human moDCs, their cytokine production and T cell activation 
capacity. We found that Ac53FaxNeu5Ac efficiently blocks sialic acid expression in 
moDCs, leading to increased responsiveness of moDCs to TLR stimulation as 
reflected by their enhanced maturation and cytokine production. Consequently, 
Ac53FaxNeu5Ac-treated moDCs were potent activators of allogeneic T cells. 
Furthermore, we found that sialic acids on moDCs can serve as ligands for 
immunosuppressive Siglec receptors and treatment with Ac53FaxNeu5Ac abrogated 
these sialic acid-Siglec interactions.  
 
Materials and Methods 
Reagents and antibodies 
Ac53FaxNeu5Ac was synthesized as described earlier.20,21 Carbo-free blocking 
solution and the biotinylated lectins MALII, SNA-I and PNA were obtained from 
Vector Laboratories, Inc. (Burlingame, CA). Streptavidin-PE from BD Pharmingen 
(Franklin Lakes, NJ), eFluor 780 viability dye from eBioscience, Inc. (San Diego, 
CA), Lymphoprep from ELITech Group (Puteaux, France), IL-4 and GM-CSF from 
Cellgenix (Freiburg, Germany), methyl-3H-thymidine (2 Ci/mM) from MP 
Biomedicals (Costa Mesa, CA). Poly(I:C) (polyinosinic-polycytidylic acid) was 
obtained from Enzo Life Sciences (Farmingdale, NY) and LPS (lipopolysaccharide) 
from Sigma-Aldrich (St. Louis, MO). Mouse anti-human CD80-PE-Cy7 (L307.4), 
anti-CD86-PE-Cy7 (2331), anti-CD274-PE (MIH1) and goat anti-mouse Ig-PE were 
purchased from BD Bioscience (Franklin Lakes, NJ), anti-Siglec-2-PE (MEM-01) 
from Sigma-Aldrich, anti-Siglec-3-PE (WM53), anti-Siglec-5-PE (1A5), anti-Siglec-
7-PE (6-434) and anti- Siglec-10-PE (5G6) from Biolegend (San Diego, CA), anti-
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Siglec-9-PE (191240) and recombinant human Siglec-His and Siglec-Fc chimera 
were purchased from R&D Systems (Minneapolis, MN) and Alexa Fluor 647-
conjugated goat anti-human IgG and mouse anti-His (HIS.H8) antibody from 
Thermo Scientific (Waltham, MA).  
 
Generation of monocyte-derived dendritic cells  
The moDCs were generated from peripheral blood mononuclear cells (PBMCs) as 
described previously.28 PBMCs were isolated from buffy coats, obtained from 
healthy donors after informed consent and according to institutional guidelines 
(Sanquin, Nijmegen, the Netherlands) using Lymphoprep density gradient 
centrifugation. Plastic-adherent monocytes were cultured for a total of 6 days in X-
VIVO 15 medium (Lonza, Walkersville, MD) supplemented with 2 % human serum 
(Sanquin), IL-4 (300 U/ml) and GM-CSF (450 U/ml). Cells were cultured in a 
humidified CO2 incubator at 37° C and the cytokines were renewed on day 4. 
 
Sialic acid blockade, sialidase treatment and TLR stimulation 
During the 6 day differentiation phase of moDCs, PBS or Ac53FaxNeu5Ac was 
added on day 1 and refreshed together with the cytokines on day 4. For the dose-
response experiment 0-512 µM Ac53FaxNeu5Ac was used, and 250 µM was used 
for all other experiments. To compare the efficiency between sialidase treatment 
and metabolic sialic acid blockade, day 6 moDCs treated with 250 µM 
Ac53FaxNeu5Ac were thoroughly washed to remove the mimetic from the culture 
and reseeded in medium containing IL-4 and GM-CSF. Control day 6 moDCs were 
incubated for 1 h with 150 mU/ml Clostridium perfringens sialidase (Sigma-Aldrich) 
at 37 °C, thoroughly washed and reseeded. On different time points, sialylation 
was quantified by flow cytometry using the lectins MALII, SNA-I and PNA. For TLR 
stimulation, day 6 moDCs were washed, collected in cold PBS and seeded on 24-
well culture plates in culture medium (Costar, Corning, NY). Cells were stimulated 
for 24 h with poly(I:C) (20 µg/ml, 2 µg/ml, 0.2 µg/ml) or LPS (1 µg/ml, 0.1 µg/ml, 
0.01 µg/ml). 24 h post-stimulation, cells were harvested for flow cytometry analysis 
and supernatants were collected for cytokine measurements using ELISA.  
 
Flow cytometry analysis 
Prior to lectin or antibody staining, moDCs were stained with eFluor 780 viability 
dye according to the manufacturer’s protocol. For staining with biotinylated lectins, 
moDCs were washed with 1 x carbo-free blocking solution and incubated for 45 
min at 4° C with MAL-II (5µg/ml), SNA-I (1µg/ml), or PNA (5µg/ml). Next, moDCs 
were washed in PBA (1x PBS, 1 % bovine serum albumin, 0.02 % sodium azide) 
and incubated for 15 min with Streptavidin-PE. For staining with Siglec-1, 0.4 µg/ml 
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Siglec-1 His chimera was complexed with mouse anti-His antibody for 20 min at 4° 
C in HBSS. Cells were incubated with this complex for 40 min at 4° C, washed and 
stained for 20 min with goat anti-mouse Ig-PE at 4° C. For staining with 
recombinant Siglec-Fc chimera, 0.4 µg/ml Siglec-Fc was pre-incubated for 20 min 
with Alexa Fluor 647-conjugated goat anti-human IgG at 4° C in HBSS (Gibco, 
Carlsbad, CA) and subsequently added to the moDCs for 40 min at 4° C. For 
antibody staining, Fc receptors were blocked for 10 min with PBA containing 2 % 
human serum and 2% goat serum at 4° C and cells were incubated for 20 min with 
fluorescent antibodies at 4° C. Cells were washed three times with PBA and 
measured with a CyAn ADP flow cytometer (Beckman Coulter, Fullerton, CA) 
followed by analysis using FlowJo software (Tree Star, Ashland, OR). 
 
Mixed lymphocyte reaction 
PBS or Ac53FaxNeu5Ac-treated moDCs were washed and stimulated with TLR 
ligands as described above for 24 h in 96-well round bottom plates (Costar). 
Following stimulation, allogeneic, non-adherent peripheral blood lymphocytes 
(PBLs) isolated from PBMCs of healthy donors were added in a 1:10 moDC:PBL 
ratio. Cells were cultured in X-VIVO 15 medium containing 2 % human serum. After 
2 days of co-culture supernatant was collected for IFNγ measurement and after 4 
days of co-culture cells were pulsed with 1 μCi 3H-thymidine for 8 h. 3H-thymidine 
incorporation was measured using a beta-counter. 
 
Endotoxin detection and ELISA 
PBS and Ac53FaxNeu5Ac batches were analyzed for endotoxin contamination 
using an endpoint chromogenic limulus amebocyte lysate assay (Lonza) following 
the manufacturer’s instructions. Cytokine levels in the supernatants were quantified 
using sandwich ELISAs for IL-6, IL-10 (eBioscience, San Diego, CA), IL-12p70 
(Thermo Scientific) and IFN-γ (eBioscience) according to the manufacturer’s 
instructions.  
 
Statistical analysis 
Statistical significance was calculated using a t-test or one-way analysis of 
variance (ANOVA) followed by Bonferroni’s correction using Prism 5 software 
(GraphPad, Inc., La Jolla, CA). P-values <0.05 were considered significant (p<0.05 
*, p<0.01 **, p<0.001 ***).  
 
 
 
 
8 
Part II Sialic Acids and Siglecs as Targets for Cancer Immunotherapy  
194 
 
Figure 1 Ac53FaxNeu5Ac blocks sialic acid expression in moDCs. 
a) Schematic representation of metabolic sialic acid blockade. Ac53FaxNeu5Ac can enter the cell and is 
deacetylated by cytosolic esterases. The deacetylated 3FaxNeu5Ac can enter the Golgi apparatus → 
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where it directly inhibits sialyltransferases, enzymes that incorporate sialic acids into glycans. This 
inhibition also leads to the accumulation of sialic acids in the cell. Sialic acid accumulation stops the 
synthesis of natural sialic acids via a negative feedback inhibition pathway, resulting in sialic acid 
blockade. b) Ac53FaxNeu5Ac is endotoxin free. Possible endotoxin contamination in the synthesized 
sialic acid mimetic or vehicle PBS was assessed using a LAL assay. c-e) Dose-dependent inhibition of 
sialic acid expression with Ac53FaxNeu5Ac. Expression of α2,3- and α2,6-linked sialic acids or uncapped 
galactose on moDCs was detected with the lectins MALII (c), SNA-I (d) and PNA (e). Bar diagrams 
show mean values ± SEM lectin binding to moDCs from four different donors treated with increasing 
concentrations of sialic acid mimetic. Lectin binding intensity was normalized to control untreated cells. 
f) Mean percentage viable cells ± SEM in moDC cultures treated with 0-512µM Ac53FaxNeu5Ac (n=4). 
eFluor780 viability dye negative cells in moDC cultures were quantified by flow cytometry. g-i) Metabolic 
sialic acid blockade in moDCs from eight different donors. Dot plots showing average MALII (g), SNA-I 
(h) or PNA (i) binding ± SEM to moDCs treated with 250 µM Ac5Neu5Ac normalized to control, PBS-
treated cells. j-l) Recovery of sialylation after sialidase and Ac53FaxNeu5Ac treatment. moDCs were 
treated with sialidase or Ac53FaxNeu5Ac and recovery of surface sialic acid expression was measured in 
time using the lectins MALII (j), SNA-I (k) and PNA (l). Data from independent experiments are 
presented as mean values ± SEM lectin binding normalized to untreated control moDCs. 
 
Results and Discussion 
Ac53FaxNeu5Ac blocks sialic acid expression in moDCs and potentiates TLR-
induced maturation. 
Ac53FaxNeu5Ac was developed by Rillahan et al. as metabolic inhibitor for 
sialyltransferases, enzymes in the Golgi system that transfer sialic acids to 
glycans.21 As a result, sialic acids are not longer coupled to glycans and 
accumulate in the cell. Accumulating sialic acids trigger a negative feedback 
inhibition pathway that stops de novo sialic acid synthesis in the cell. Together, the 
direct inhibition of sialyltransferases and the indirect inhibition of sialic acid 
synthesis result in metabolic sialic acid blockade in the cell (Figure 1a). Previously, 
we have reported that Ac53FaxNeu5Ac blocks sialic acid incorporation into surface 
glycans of the monocytic THP-1 cell line.19 Here, we assessed if the sialic acid 
mimetic blocks sialoglycan expression in freshly generated moDCs. 
Ac53FaxNeu5Ac was synthesized with high purity and tested negative for endotoxin 
contamination (Figure 1b). Increasing concentrations of Ac53FaxNeu5Ac were 
added during moDC differentiation and on day 6 of culture, the expression of sialic 
acids and uncapped β-galactose was measured by flow cytometry using the lectins 
MALII (α2,3-linked sialic acid), SNA-I (α2,6-linked sialic acid) and PNA (β-
galactose). Sialic acid expression on moDCs was reduced in a dose-dependent 
manner without affecting cell viability (Figure 1c-f). Sialic acid blockade was most 
effective at concentrations around 250 µM, where a reduction of about 70-80 % in 
sialylation was found for all donors tested (Figure 1g-i). Importantly, based on 
phenotypical analysis of the immature moDC by flow cytometry the sialic acid 
mimetic had no detectable impact on moDC differentiation (Figure 2a, top panel).  
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Figure 2 Sialic acid blockade enhances TLR-induced maturation of moDCs. 
a) Representative histograms showing upregulation of CD80 in response to 0-20µg/ml poly(I:C) on the 
surface of moDCs differentiated in the presence of PBS or Ac53FaxNeu5Ac. Cells were stained with 
fluorescent anti-CD80 antibodies and binding was quantified using flow cytometry. b-d) Expression of 
maturation markers on moDCs. Bar diagrams show CD80 (b), CD86 (c) or PD-L1 (d) expression on 
control or Ac53FaxNeu5Ac-treated moDCs stimulated with increasing concentrations of poly(I:C) or LPS. 
Cells were stained with fluorescent antibodies and analyzed by flow cytometry. Data from 6-8 donors 
are presented as mean fluorescence intensity (MFI). 
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To compare the potency of Ac53FaxNeu5Ac to deplete cell surface sialic acids with 
a bacterial sialidase, moDCs were treated with the sialic acid mimetic or C. 
perfringens sialidase and recovery of surface sialylation was followed in time. Sialic 
acid expression after sialidase treatment was completely recovered after 2 days, 
whereas Ac53FaxNeu5Ac treatment blocked sialylation for > 4 days (Figure 1j-l). 
Next, we investigated if sialic acid blockade influenced moDC maturation with TLR 
agonists. MoDCs treated with PBS or Ac53FaxNeu5Ac were stimulated for 24 h with 
different concentrations of poly(I:C) (TLR3 agonist) or LPS (TLR4 agonist) and the 
expression of co-stimulatory/co-inhibitory molecules was measured by flow 
cytometry. Sialic acid blockade resulted in significantly higher CD80 expression in 
response to TLR activation (Figure 2a, b). Notably, already a low concentration of 
poly(I:C) (0.2 µg/ml) induced a stronger upregulation of CD80 in moDCs with 
blocked sialic acid expression (MFI 79.9) compared with control moDCs (MFI 40.0) 
(Figure 2a, b). A similar, but not significant trend was found for CD86 expression 
(Figure 2c), and PD-L1 expression was significantly higher in Ac53FaxNeu5Ac-
treated moDCs (Figure 2d). These data imply that metabolic interference with the 
sialylation pathway is well-tolerated by moDCs and leads to prolonged sialic acid 
removal from the cell surface relative to sialidase. Ac53FaxNeu5Ac is therefore a 
powerful tool to study the versatile role of sialic acids in DC biology. Moreover, in 
line with previous studies involving bacterial sialidase, we found that metabolic 
sialic acid blockade enhanced the responsiveness of moDCs for TLR agonists.  
 
Sialic acid blockade enhances cytokine production and T cell activation by moDCs. 
Next, we investigated the effect of sialic acid blockade on the production of 
cytokines by moDCs stimulated with increasing concentrations of poly(I:C) or LPS 
for 24 h. Following stimulation with 20, 2 or 0.2 µg/ml poly(I:C), IL-6 production was 
4-5 times higher in moDCs with blocked sialic acid expression compared with 
control (Figure 3a). Also in response to LPS, Ac53FaxNeu5Ac-treated moDCs 
produced 2-3 times more IL-6 than control moDCs. Similar results were obtained 
for TLR-induced IL-10 production (Figure 3b). IL-12 was mainly produced in 
response to poly(I:C), and were 4-6 times higher in Ac53FaxNeu5Ac-treated moDCs 
compared with control moDCs (Figure 3c). Notably, Ac53FaxNeu5Ac alone had no 
effect on moDC maturation or cytokine production. These results demonstrate that 
sialic acid blockade augments TLR-induced maturation and cytokine production of 
moDCs. Based on these findings, we investigated if sialic acid blockade influenced 
T cell activation by moDCs. PBS- or Ac53FaxNeu5Ac-treated moDCs were 
stimulated for 24 h with TLR ligands and subjected to a mixed lymphocyte reaction. 
Sialic acid blockade in TLR ligand-treated moDCs significantly enhanced the 
proliferative response in the mixed lymphocyte reaction as measured by IFNγ 
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secretion and 3H-thymidine incorporation (Figure 3d, e). Altogether, these data 
indicate that sialic acid blockade potentiates TLR-induced maturation and cytokine 
production of moDCs, thereby enhancing their T cell activation capacity.  
 
 
Figure 3 Ac53FaxNeu5Ac increases TLR-mediated cytokine production and T cell activation by moDCs. 
a-c) Cytokine production of moDCs in response to TLR agonists. Bar diagrams show average fold 
change ± SEM in IL-6 (a), IL-10 (b) and IL-12 (c) production by moDCs from 6-8 different donors 
differentiated in the presence of PBS or Ac53FaxNeu5Ac and stimulated for 24 h with increasing 
amounts of poly(I:C) or LPS. Cytokine production was measured using ELISA and data were 
normalized to PBS-treated moDCs stimulated with the different TLR ligands. d, e) T cell activation by 
Ac53FaxNeu5Ac-treated moDCs in a mixed lymphocyte reaction. MoDCs from 6-8 different donors were 
differentiated in the presence of PBS or Ac53FaxNeu5Ac, stimulated for 24 h with TLR ligands and co-
cultured with allogeneic PBLs. d) Bar diagram shows fold change ± SEM IFN-γ production in the mixed 
lymphocyte reaction. e) 3H-Thymidine incorporation in mixed lymphocyte reactions with PBS or 
Ac53FaxNeu5Ac-treated moDCs stimulated with different concentrations TLR ligands was measured with 
a beta-counter. Bar diagram shows average 3H-Thymidine incorporation ± SEM. 
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Ac53FaxNeu5Ac depletes sialic acid ligands for immunosuppressive Siglecs on 
moDCs. 
In part, the biological function of sialic acids is mediated by their interaction with 
immunosuppressive Siglecs on immune cells. It has been suggested that cis and 
trans sialic acid-Siglec interactions dampen immune cell activation and function.4,22-
24 Sialic acid blockade could abrogate these immunosuppressive interactions, 
thereby allowing enhanced stimulation of moDCs by TLR agonists. To identify 
possible sialic acid-Siglec interactions on moDCs and their disruption by sialic acid 
blockade, the expression of Siglecs and their sialic acid ligands on moDCs cultured 
with PBS or Ac53FaxNeu5Ac was determined by flow cytometry. Siglec-3, -5, -7, -9 
and -10 were expressed by immature moDCs, but not Siglec-1 (CD169) which is, 
however, expressed on mature DCs and the B cell marker Siglec-2 (CD22) (Figure 
4a, b).4,25,26 Noteworthy, sialic acid blockade increased the expression or detection 
of Siglec-9. These data imply that Siglec-9 could interact with sialic acids in cis on 
the moDCs surface, thereby being masked from recognition by the anti-Siglec-9 
antibody. Staining of moDCs with recombinant Siglec-Fc chimera revealed that 
moDCs express sialic acid ligands for Siglec-7 and Siglec-9 (Figure 4c, d). 
Treatment of moDCs with Ac53FaxNeu5Ac highly downregulated their expression. 
 
These findings provide evidence that sialic acids and Siglecs, especially Siglec-7 
and -9, could interact on the surface of moDCs and that these interactions can be 
disrupted by sialic acid blockade. In addition, it has been suggested that Siglecs 
can directly interact with TLRs and that this interaction negatively regulates 
cytokine production by dendritic cells following stimulation with TLR ligands.27 
Future research is needed to unravel the molecular mechanism behind the 
enhanced responsiveness of desialylated DCs to TLR activation and to further 
establish the contribution of immune suppressive Siglec receptors herein.  
In conclusion, we have shown that Ac53FaxNeu5Ac is a new tool to metabolically 
block sialic acid expression in human moDCs. Together, the potent blocking effect 
and the endotoxin-free synthesis make this sialic acid mimetic an interesting 
alternative to bacterial sialidases to study the versatile role of sialic acids in DC 
biology. Sialic acid blockade potentiated the responsiveness of moDCs to TLR 
stimulation and their capacity to activate T cells. Therefore, sialic acid blockade 
could help to improve the development of ex vivo generated DC-based vaccines to 
elicit strong anti-viral or anti-tumor immunity in vivo.  
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Figure 4 Ac53FaxNeu5Ac abrogates sialic acid-Siglec interactions on moDCs. 
a, b) Expression of Siglecs on moDCs treated with PBS or Ac53FaxNeu5Ac. MoDCs were stained with 
fluorescent isotype antibody or anti-Siglec antibodies and analyzed by flow cytometry. Representative 
histograms show anti-Siglec antibody binding to moDCs (a). Bar diagram showing average MFI ± SEM 
from 4-8 donors (b). c, d) Expression of Siglec ligands on the surface of moDCs treated with PBS or 
Ac53FaxNeu5Ac. Representative histograms show binding of fluorescent recombinant Siglecs to moDCs 
(c). Bar diagram show average MFI ± SEM of Siglec binding to moDCs from 4-8 donors (d).  
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Abstract 
The surface of tumor cells is covered with a dense layer of sialic acid sugar-
carrying glycans (sialoglycans). Tumor sialoglycans emerge as potent immune 
modulators that contribute to the formation of an immunosuppressive 
microenvironment and tumor immune evasion. Therapeutic strategies directed 
against tumor sialoglycans are, however, limited and barely exploited in the 
preclinical setting. Here we report that intratumoral injections of an inhibitory sialic 
acid mimetic, Ac53FaxNeu5Ac, blocked tumor sialoglycan expression in vivo and 
limited tumor growth in three different mouse tumor models. Strikingly, in a B16-
F10OVA melanoma model, several mice successfully eradicated their tumor 
following sialic acid blockade therapy. These mice were largely protected against a 
subsequent tumor rechallenge, indicating the establishment of immunological 
memory. Further analysis showed that Ac53FaxNeu5Ac injections had a major 
impact on the immune cell composition of the tumor, enhancing tumor-infiltrating 
natural killer (NK) cells and CD8+ T cell numbers, while reducing regulatory T cells 
and myeloid cells. In search for a mechanism, we found that CD8+ T cells, not 
CD4+ T cells or NK cells, mediated the anti-tumor effects of Ac53FaxNeu5Ac in vivo 
and showed that sialic acid blockade rendered tumor cells highly vulnerable to 
eradication by cytotoxic CD8+ T cells. Moreover, sialic acid blockade enhanced 
CpG-mediated activation of dendritic cells in vivo thereby promoting CD8+ T cell 
responses and growth inhibition of poorly immunogenic B16-F10WT tumors. 
Collectively, these data emphasize that sialic acids are critical mediators of tumor 
immune evasion and identify Ac53FaxNeu5Ac as potent therapeutic that blocks 
aberrant sialylation in tumors and boosts CD8+ T cell-mediated tumor immunity, 
alone or in combination with CpG immunotherapy. 
 
Introduction 
Altered glycosylation is a hallmark of tumor cells, and several aspects of tumor 
growth and progression are mediated by tumor-associated glycans.1 One of the 
most remarkable changes in tumor glycosylation is the aberrantly high expression 
of sialic acid-carrying glycans.2 Sialic acids are a family of negatively charged, 
nine-carbon sugar molecules that often terminate the glycans of cell surface 
glycoproteins and glycolipids. Virtually all vertebrate cells possess an intracellular 
sialic acid synthesis machinery for the de novo synthesis of sialic acids from the 
precursor sugar N-Acetylmannosamine (ManNAc). In addition, exogenous, dietary 
sialic acids can be utilized by cells for sialoglycan synthesis.3,4 Intracellular 
enzymes modify the nine-carbon backbone of sialic acid, thereby producing 
different sialic acid family members such as N-acetylneuraminic acid (Neu5Ac) or 
N-glycolylneuraminic acid (Neu5Gc).5 These sialic acids are activated with cytidine 
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monophosphate (CMP) and transported via the CMP-sialic acid transporter 
(SLC35A1) into the Golgi system. There, twenty different sialyltransferases link 
sialic acids to the glycans of glycoproteins and glycolipids. The sialyltransferase 
family members can couple sialic acids via their second carbon (C2) to different 
carbons of underlying sugars, generating α2,3-, α2,6- or α2,8-linkages. The 
transfer of a sialic acid, the sialylation reaction, usually terminates the glycan chain 
and the sialylated glycoproteins or glycolipids can traffic to the cell membrane.6-8  
Already decades ago, it has been noticed that tumor cells are highly sialylated and 
that they express unique sialoglycans on their surface (e.g. SLea/x, STn, GM2/3, 
GD2/3 or SSEA-4) that can potentially be used as targets for the development of 
cancer vaccines.9-11 Next to facilitating tumor cell migration and metastasis, tumor 
sialoglycans emerge as immune modulators that promote tumor immune 
evasion.2,12-14 Due to their negative charge, sialic acids can mask cell surface 
antigens or bind to factor H in order to avoid complement system activation.5,13,15 
Sialic acids act also as ligands for the immune modulatory sialic acid-binding 
immunoglobulin-like lectin (Siglec) family that are expressed on most immune cells. 
Sialic acid-Siglec interactions have been shown to dampen immune cell function 
and hinder eradication of tumor cells by natural NK cells.13,16,17 Moreover, recent 
studies suggest that tumor sialoglycans promote the formation of an immune 
suppressive tumor microenvironment that prevents effective anti-tumor immune 
responses and therefore limits the outcome of cancer immunotherapy.13 Tumor 
sialic acid-Siglec-9 interactions were found to reprogram myeloid cells and 
macrophages in the tumor microenvironment to produce immune inhibitory factors 
that suppress anti-tumor immunity and favor tumor growth.18,19 Targeting aberrant 
sialylation of tumor cells could therefore promote their recognition and destruction 
by the immune system.  
Approaches to interfere with sialoglycan expression in tumor cells are limited and 
barely tested in preclinical tumor models. Our group has previously reported that a 
fluorinated sialic acid mimetic, Ac53FaxNeu5Ac, originally developed by Rillahan et 
al., potently blocked sialic acid expression in various murine and human cancer cell 
lines.20-23 The blocking effects of Ac53FaxNeu5Ac were mediated directly by 
inhibition of sialyltransferases and indirectly by accumulating CMP-sialic acid in the 
cell that triggers a feedback inhibition mechanism stopping the conversion of 
ManNAc into sialic acid.20 We found that blocking sialylation with Ac53FaxNeu5Ac 
impaired cancer cell adhesion and migration in vitro and largely prevented 
metastasis formation in vivo.22,23  
Here we report that intratumoral injections of Ac53FaxNeu5Ac blocked sialylation of 
tumor cells in vivo and suppressed tumor growth in different murine tumor models. 
Sialic acid blockade even induced complete remission in several mice bearing an 
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immunogenic B16-F10OVA tumor and protected them from rechallenge. Injections 
with fluorinated sialic acid mimetic dramatically changed the immune cell 
composition of the tumors, increasing effector immune cells while reducing immune 
suppressive cell types. Mechanistic studies revealed that the anti-tumor effect of 
Ac53FaxNeu5Ac was mediated by CD8+ T cells which potently eradicated sialic 
acid-deficient tumor cells in vitro and in vivo. In addition, sialic acid blockade 
augmented the maturation of dendritic cells in the tumor microenvironment with the 
toll-like receptor (TLR) ligand CpG and boosted the induction of a CD8+ T cell 
immune response. Accordingly, combining sialic acid blockade with adoptive CD8+ 
T cell transfer or CD8+ T cell-promoting CpG immunotherapy resulted in strong 
tumor growth reduction. These data demonstrate that sialic acid blockade using the 
recently developed sialic acid mimetic Ac53FaxNeu5Ac induces an immune 
permissive tumor microenvironment and sensitizes tumor cells towards CD8+ T 
cell-mediated killing. Sialic acid blockade could therefore help to overcome the 
immunosuppressive tumor microenvironment and improve the outcome of cancer 
immunotherapy. 
 
Material and Methods 
Mice 
Female C57BL/6JRccHsd WT mice, obtained from Harlan Laboratories, were 
housed at the Central Animal Laboratory, Radboud University Medical Centre, 
Nijmegen, The Netherlands. Mice were allowed to acclimatize for at least one week 
before starting an experiment. Mice were 8 to 10 weeks old at the beginning of the 
experiments. OT-I mice that produce CD90.1+ CD8+ T cells with a transgenic T cell 
receptor specific for the chicken ovalbumin (OVA) epitope SIINFEKL (OVA257-264) 
presented on MHC I H-2kb were bred in the Central Animal Laboratory. Animals 
were housed under specific pathogen-free conditions and ad libitum access to food 
and water. All experiments were authorized by the local animal ethics committee, 
Nijmegen, The Netherlands, and carried out in accordance with their guidelines. 
 
Reagents and Antibodies 
Ac53FaxNeu5Ac and Ac5Neu5Ac were synthesized as described before.20,21,23 
Carbo-free blocking solution, biotinylated lectins MALII (Maackia amurensis lectin 
II), SNA-I (Sambucus nigra agglutinin) and PNA (Peanut agglutinin) were 
purchased from Vector Laboratories Inc. (Burlingame, CA). Streptavidin-PE was 
obtained from BD Pharmingen (Franklin Lakes, NJ), eFluor 780 fixable viability dye 
from eBioscience, Inc. (San Diego, CA). CD8 (2.43), CD4 (GK1.5) and NK1.1 
(PK136) depleting monoclonal antibodies (mAbs) were provided by EPIRUS 
Biopharmaceuticals (Utrecht, The Netherlands). OVA257-264 (SIINFEKL) was 
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purchased from AnaSpec Inc. (San Jose, CA) and CpG ODN 1826 from InvivoGen 
(San Diego, CA). Carboxyfluorescein succinimidyl ester (CFSE) was obtained from 
Life Technologies (Invitrogen, Carlsbad, CA). Purified anti-CD16/CD32 (2.42G), 
anti-CD45.2-biotin (104) and anti-CD161/NK1.1-PE (PK136) were purchased from 
BD Pharmingen. Anti-CD8α-AF700 (53-6.7) was purchased from EXBIO (Vestec, 
Czech Republic) and anti-CD4-PerCP (RM4-5), anti-CD11c-APC (N418), anti-
CD11b-AF700 (M1/70), anti-CD45R/B220-PerCp (RA3-6B2) and anti-H-2Kb/H-2Db-
PE (28-8-6) from BioLegend (San Diego, CA). Anti-CD25-APC (PC61.5), anti-
FoxP3-PE-Cy7 (FJK-16s), anti-Mult-1-PE (5D10) and anti-CD274/PD-L1-PE 
(MIH5) were obtained from eBioscience (San Diego, CA). Anti-Rae-1-APC 
(FAB17582A) was obtained from R&D Systems (Minneapolis, MN).  
 
Cell culture and titration of Ac53FaxNeu5Ac 
B16-F10WT melanoma cells (ATCC CRL-6475) were cultured in minimum essential 
medium (MEM) (Gibco, Invitrogen, Carlsbad, CA) containing 5 % fetal bovine 
serum (FBS) (Greiner Bio-one, Frickenhausen, Germany), 1 % MEM non-essential 
amino acids (Gibco), 0.15 % sodium bicarbonate (Gibco), 1 mM sodium pyruvate 
(Gibco), 1.5 % MEM vitamins (Gibco), 1 % antibiotic-antimycotic solution (50 U/ml 
penicillin, 50 µg/ml streptomycin and 125 ng/ml amphotericin B) (PAA, Pasching, 
Austria). B16-F10OVA cells (clone MO5) were kindly provided by Dr. Kenneth Rock 
and cultured in B16-F10WT medium supplemented with 200 µg/ml geneticin (G418) 
(Gibco) and Hygromycin B (Calbiochem, Merck, Billerica, MA, USA).24 The 9464D 
neuroblastoma cell line (kindly provided by R. Orentas, Department of Pediatrics, 
Medical College of Wisconsin, WI, USA) was cultured in Dulbecco's modified 
Eagle's medium (Glutamax, Gibco) with 10 % FBS, 1 % non-essential amino acids, 
20 µM 2-mercaptoethanol (Sigma-Aldrich) and 1 % antibiotic-antimycotic 
solution.25,26 To compare the effect of Ac53FaxNeu5Ac on sialic acid expression 
between B16-F10WT and B16-F10OVA cells, both cell lines were incubated for 3 
days with 100 µM Ac53FaxNeu5Ac. To determine the effective dose of 
Ac53FaxNeu5Ac in the 9464D cell line, cells were incubated for 3 days with 0-500 
µM sialic acid mimetic. Sialylation was quantified by flow cytometry using lectins as 
described below. All cells were incubated in a humidified CO2 incubator at 37 °C. 
 
In vivo tumor experiments 
Following reconstitution from liquid nitrogen, tumor cell lines were cultured in T75 
flasks (Corning, Corning, NY), passaged two times and grown to 60-70 % 
confluency. Cells were detached, extensively washed and collected in 1x PBS at a 
concentration of 0.5x106 cells/ml (B16-F10WT), 1x106 cells/ml (B16-F10OVA) or 
10x106 cells/ml (9464D). The injection site around the right femur was shaved, the 
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mice were anesthetized using isoflurane inhalation and 100 μl of the cell 
suspension was injected subcutaneously into the right femur of the mice. Tumor 
size was examined every 2-3 days using a caliper and tumor volumes were 
calculated with the formula ((A × B2) × 0.4), in which A is the largest and B is the 
shortest tumor dimension. Mice were sacrificed when the tumor volume exceeded 
1800 mm3. For intratumoral injections, Ac53FaxNeu5Ac and Ac5Neu5Ac were 
dissolved in 1x PBS, and on day 10 when a palpable tumor mass was formed 50 µl 
of 1x PBS containing 10, 20 or 30 mg/kg sialic acid mimetic were injected three 
times per week into the tumor mass. Optional, CpG was injected into the tumor 
mass on day 14 and 21 following tumor inoculation. Naïve mice without tumor were 
injected subcutaneously three times per week with sialic acid mimetic for two 
weeks. PBS only injections were used as control. For rechallenge experiments in 
the B16-F10OVA model, 30.000 B16-F10OVA cells were injected subcutaneously into 
the left femur of mice with remission after the initial tumor challenge or naïve, age-
matched control mice and tumor growth was monitored in time. For the depletion of 
CD4+, CD8+ or NK1.1+ cells in vivo 300 μg depleting mAbs or isotype control 
antibodies were injected intraperitoneally either on day -2 and 6 or day 8 and 20 
following tumor inoculation.  
 
Preparation of single cell suspensions  
On indicated days, mice were sacrificed by cervical dislocation and the tumor, 
spleen, draining and non-draining lymph nodes (superficial inguinal) were isolated. 
Tumor and spleens were mashed through a 100 µm nylon cell strainer (Corning) 
and collected in 1x PBS and red blood cells were lysed by incubating the 
suspension for 1 minute in ice-cold ACK lysis buffer (150 mM NH4Cl, 10 mM 
KHCO3 and 0.1 mM Na2-EDTA, pH 7.2). Lymph nodes (brachial, axillary, inguinal) 
were comminuted using glass slides and single cells were harvested in 1x PBS.  
 
Intra-/extracellular cell staining and flow cytometry analysis 
For extracellular staining with biotinylated lectins cells were washed with 1x carbo-
free blocking solution and incubated for 45 minutes with MALII (5 µg/ml), SNA-I (1 
µg/ml) and PNA (5 µg/ml) in 1x carbo-free blocking solution containing 1 mM 
CaCl2+ and 1 mM MgCl2+ at 4 °C. Next, cells were washed with 1x carbo-free 
blocking solution, incubated for 20 minutes at 4 °C with Streptavidin-PE conjugate, 
washed again and resuspended in PBA (1x PBS, 1 % BSA, and 0.02 % sodium 
azide) for flow cytometry analysis. For extracellular antibody staining, cells were 
first incubated 10 minutes at 4 °C with PBA containing Fc receptor blocking 
antibody (2.42G), then washed with PBA and incubated for 20 minutes at 4 °C with 
fluorescent antibodies direct against surface molecules. After extensive washing, 
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cells were resuspended in PBA for flow cytometry analysis or further used for 
intracellular staining. For intracellular stainings, a cell fixation and permeabilization 
kit (BD, Franklin Lakes, NJ) was used following the manufacturer’s instructions. 
Briefly, cells were incubated for 20 minutes with 1x fix/perm solution 4 °C and 
washed twice with perm/wash buffer. Next, cells were incubated overnight with 
fluorescent antibody in perm/wash buffer at 4 °C, washed with perm/wash buffer 
and resuspended in PBA for flow cytometry analysis. Cells were measured using a 
CyAn ADP flow cytometer (Beckman Coulter, Fullerton, CA) and data were 
analyzed using FlowJo software (Tree Star Inc., Ashland, OR). 
 
Urine and blood collection and determination of albuminuria and serum ureum 
Naïve mice were subcutaneously injected three times a week for two weeks with 
PBS, 10, 20 or 30 mg/kg Ac53FaxNeu5Ac. At several time points, urine of the mice 
was collected pooled per time point and treatment group. Blood was collected from 
the mice at several time points via the tail vein. Mice were placed in a temperature-
controlled chamber at 38 °C for 10 minutes and a small incision perpendicular to 
the tail vein was made using a razor blade to collect approximately 200 µl of blood 
into MiniCollect tubes (Greiner Bio-one). To obtain serum, the tubes were 
centrifuged for 10 minutes, 12.000 rpm, at room temperature. Albumin 
concentration was measured by radial immunodiffusion (Mancini) and urinary 
creatinine and serum ureum levels were determined as described before.27 
 
Immunofluorescence staining of renal tissue 
Naïve mice received subcutaneous injections with PBS, 10, 20 or 30 mg/kg 
Ac53FaxNeu5Ac three times per week for two weeks. Two or four weeks after 
starting the treatment kidneys were collected and snap frozen in liquid nitrogen and 
immunohistochemical analysis was performed as described previously.28 Briefly, 
frozen renal sections (2 µm) were fixed in ice-cold acetone for 10 minutes and 
incubated with the biotinylated lectins SNA-I or PNA diluted in PBS containing 1 % 
BSA and 0.05 % sodium azide for 45-60 minutes. Biotinylated lectins were 
detected with Alexa Fluor 488 Streptavidin (Life Technologies). Images were 
acquired with a Zeiss Axio Imager M1 fluorescence microscope. Fluorescent 
intensity was evaluated semi-quantitatively from 0 (no staining) to 10 (100% 
maximum intensity) on blinded sections.  
 
In vitro OT-I activation, adoptive transfer and killing assay 
Single cell suspensions prepared from OT-I spleens were cultured for 5 days in the 
presence of 0.75 µg/ml OVA257-264 peptide in RPMI-1640 medium (Life 
Technologies) supplemented with 10 % FBS (Greiner Bio-one), 2 mM glutamine 
9 
Part II Sialic Acids and Siglecs as Targets for Cancer Immunotherapy 
212 
(Lonza, Walkersville, MD) and 1x antibiotic-antimycotic solution (100 units/mL of 
penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL Fungizone) (Life 
Technologies). On day 3, 5 ng/ml recombinant mouse IL-2 was added to the 
culture. Following activation, CD8+ OT-I cells were purified using a CD8a+ T Cell 
isolation kit according to the manufacturer’s protocol (Miltenyi Biotec, Bergisch-
Gladbach, Germany). For in vitro killing assays, B16-F10WT or B16-F10OVA cells 
were cultured for three days with PBS, 100 µM Ac5Neu5Ac or 100 µM 
Ac53FaxNeu5Ac, extensively washed with 1x PBS and 30.000 cells were seeded 
into 96-wells flat bottom wells (Costar). Cells were allowed to adhere for two hours 
before purified, activated OT-I CD8+ T cells were added in different effector-to-
target ratios (0.1:1, 0.25:1, 0.5:1, 0.75:1, 1:1). After 16 hours of co-culture, images 
were taken and numbers of B16-F10 cells and CD8+ CD90.1+ OT-I T cells were 
quantified using flow cytometry. For adoptive transfer experiments, 10x106 purified 
OT-I cells were injected intraperitoneally on day 15 following inoculation. Tumor 
growth was monitored or tumors were isolated two days after adoptive transfer to 
assess OT-I CD8+ T cell infiltration and activation marker expression by flow 
cytometry. For the latter experiment, OT-I CD8+ T cells were labeled with CFSE 
prior to adoptive transfer following the manufacturer’s instructions. 
 
Statistical analysis  
Significance between groups was calculated using a student’s t-test. Comparisons 
between multiple groups were made using one-way analysis of variance (ANOVA) 
followed by Bonferroni’s correction. Kaplan-Meier survival curves were analyzed 
with a log-rank test using Prism 5 software (GraphPad, Inc., La Jolla, CA) and p-
values <0.05 were considered significant (p<0.05 *, p<0.01 **, p<0.001 ***).  
 
Results 
Intratumoral Ac53FaxNeu5Ac injections suppress tumor growth 
The sialic acid mimetic Ac53FaxNeu5Ac specifically blocks sialic acid expression in 
different mouse and human cell lines in vitro.21,23 In vitro pre-treatment of mouse 
B16-F10WT melanoma cells with this sialic acid mimetic delayed their outgrowth in 
vivo following subcutaneous injection, and moreover prevented metastatic 
spread.22,23 These data prompted us to investigate the effect of intratumoral 
administration of Ac53FaxNeu5Ac on B16-F10WT growth in vivo. Mice bearing 
palpable, subcutaneous B16-F10WT tumors were injected with 10 or 30 mg/kg 
Ac53FaxNeu5Ac directly into the tumor mass three times a week for a period of four 
weeks (Figure 1a). This treatment schedule was selected based on our previous 
observation that the blocking effect of Ac53FaxNeu5Ac lasted 2 days (α2,6-linked 
sialic acid acids) to 4 days (α2,3-linked sialic acid acids) in B16-F10WT cells after 
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removal from the cell culture.23 Injections with 1x PBS and 10 or 30 mg/kg 
peracetylated non-blocking sialic acid (Ac5Neu5Ac) were used as control. B16-
F10WT tumors injected with PBS grew rapidly, resulting in a median survival time of 
24 days (Figure 1b, c). While injections with 10 or 30 mg/kg Ac5Neu5Ac control 
sialic acid had no effect on tumor growth, Ac53FaxNeu5Ac injections suppressed 
tumor growth significantly in this stringent tumor model. In a dose-dependent 
manner, treatment with the sialic acid-blocking mimetic increased median survival 
times to 36 days (10 mg/kg) and 47 days (30 mg/kg), respectively (Figure 1b, c). 
 
Next, we investigated whether intratumoral injections with Ac53FaxNeu5Ac 
influenced tumor growth in the related, more immunogenic ovalbumin-expressing 
B16-F10OVA model and an unrelated 9464D neuroblastoma model. In vitro, B16-
F10OVA cells showed the same sensitivity to 100 µM Ac53FaxNeu5Ac as B16-F10WT 
cells, whereas a higher dose sialic acid mimetic (> 250 µM) was required to block 
sialic acid expression in 9464D cells (Figure S1). In line with these findings, 
injections with 10 mg/kg had little effect on 9464D growth, but 20 mg/kg injections 
significantly increased the median survival from 40 days to 58 days (Figure 1d). 
Noteworthy, in the B16-F10WT model 20 mg/kg injections showed the same efficacy 
as 10 mg/ml injections (Figure S2). In the B16-F10OVA model, already 10 mg/kg 
Ac53FaxNeu5Ac injections strongly reduced tumor growth and in about half of the 
mice even complete remission of the tumors was observed (Figure 1e, f). These 
mice remained tumor-free for over 120 days post-inoculation. Moreover, when 
rechallenged with B16-F10OVA cells, 70 % of the mice were protected from tumor 
outgrowth (Figure 1g). These data show that intratumoral administration of 
Ac53FaxNeu5Ac suppress tumor growth in poorly immunogenic melanoma as well 
as neuroblastoma models and even results in tumor remission in the more 
immunogenic B16-F10OVA model.  
In the tumor growth experiments described above, no adverse effects were 
observed as a result of the repeated intratumoral injections with the 10 mg/kg dose. 
Even several weeks of intratumoral injections were tolerated and no adverse 
effects or changes in weight were noticed. In mice that received repeated injections 
with 20 and 30 mg/kg Ac53FaxNeu5Ac, we detected abdominal fluid accumulation, 
an increase in weight and reduced kidney function around two weeks after starting 
the treatment (Figure S3). Previously, Macauley et al. have reported that a single 
intravenous injection with a ten times higher dose Ac53FaxNeu5Ac (300 mg/kg), 
reduced systemic sialylation in mice and induced kidney damage and failure to 
thrive.29 No effect on kidney function was observed in mice after injections with 10 
mg/kg Ac53FaxNeu5Ac (Figure S3), therefore this dose was used for all 
subsequent experiments. 
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Figure 1 Intratumoral Ac53FaxNeu5Ac injections suppress tumor growth. 
a) Schematic representation of the experiment. b, c) Tumors were injected with PBS, 10 mg/kg or 30 
mg/kg Ac5Neu5Ac or Ac53FaxNeu5Ac (n=9-12). Average tumor volumes ± SEM are shown (b). Kaplan-
Meier curves show percentage survival (c). d) Kaplan-Meier curves show survival percentage of mice 
inoculated with 9464D neuroblastoma cells receiving PBS, 10 mg/kg or 20 mg/kg Ac53FaxNeu5Ac 
injections. e, f) Effect of intratumoral sialic acid mimetic injections on B16-F10OVA tumor growth (n=9-
12). Average B16-F10OVA tumor growth ± SEM in time (e) and corresponding Kaplan-Meier curves are 
shown (f). g) Rechallenge of mice with B16-F10OVA cells after Ac53FaxNeu5Ac-induced remission of the 
initial tumor. Kaplan-Meier curves show tumor take in naïve control, age-matched mice (n=7) or 
rechallenged mice after Ac53FaxNeu5Ac therapy (n=9). 
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Ac53FaxNeu5Ac blocks sialic acid expression in the tumor mass  
Next, we assessed the effect of intratumoral injections with 10 mg/kg 
Ac53FaxNeu5Ac on the level of sialic acid expression in tumor cells as well as 
tumor-infiltrating lymphocytes. After two weeks of injections with PBS, 10 mg/kg 
Ac5Neu5Ac or 10 mg/kg Ac53FaxNeu5Ac B16-F10WT tumors were isolated and 
single cell suspensions were prepared. Cell suspensions from tumors treated with 
PBS or Ac5Neu5Ac contained around 25 % viable cells. Ac53FaxNeu5Ac treatment 
reduced the number of viable cells to 10.3 % (Figure 2a, Figure S4). Within the 
viable cell population, tumor cells were defined as leukocyte marker CD45.2 
negative cells and immune cells as CD45.2 positive cells (Figure S4). 
Ac53FaxNeu5Ac injections reduced α2,3-linked sialic acid expression on tumor cells 
by 60 % and α2,6-linked sialic acid expression by 50 % compared to control 
(Figure 2b-d). In line with the reduced sialylation, exposure of galactose residues 
was detected with the lectin PNA (Figure 2b, e). Interestingly, in tumors injected 
with PBS or Ac5Neu5Ac there were more tumor cells present than immune cells 
(CD45+/CD45- ratio 0.32-0.43), but Ac53FaxNeu5Ac injections significantly 
increased the immune cell to tumor cell ratio (3,1) (Figure 2f, Figure S4).  
Whereas Ac53FaxNeu5Ac treatment strongly reduced sialylation of tumor cells, 
CD45.2+ tumor-infiltrating lymphocytes showed only a mild reduction (20 %) in 
sialic acid expression (Figure 2g-i). Noteworthy, no significant changes in the 
sialylation of cells in the tumor-draining lymph node, non-draining lymph nodes or 
spleen were detected following Ac53FaxNeu5Ac injections (Figure S5). Similar 
findings were obtained in the 9464D neuroblastoma model (data not shown). 
Altogether these data show that intratumoral injections with Ac53FaxNeu5Ac block 
sialic acid expression locally in the tumor mass, particularly in tumor cells and to a 
lesser extent in immune cells. The reduced number of viable cells in the tumor and 
relative increase in infiltrating immune cells indicates that the sialic acid blocking 
mimetic injections lead to tumor cell death.  
 
Sialic acid blockade alters the tumor microenvironment composition 
Sialic acid blockade suppressed tumor growth and even resulted in complete 
remission and protection from rechallenge in the B16-F10OVA model. These 
findings, together with the observed high tumor-infiltrating lymphocyte to tumor cell 
ratio after Ac53FaxNeu5Ac treatment indicate that the loss of tumor sialic acids 
could affect tumor immunity. Therefore, we assessed the immune cell composition 
of B16-F10WT tumors that were treated for two weeks with the sialic acid-blocking 
mimetic. Compared to PBS and Ac5Neu5Ac-treated tumors, Ac53FaxNeu5Ac 
treatment increased the percentage of NK cells, CD8+ T cells and CD4+ T cells 
within the viable, tumor-infiltrating lymphocyte population (Figure 3a-c, 3e-g).  
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Figure 2 Ac53FaxNeu5Ac injections block sialic acid expression and increase immune cell numbers in 
the tumor. 
a-i) Subcutaneous B16-F10WT tumors treated for two weeks with PBS, 10 mg/kg Ac5Neu5Ac or 
Ac53FaxNeu5Ac were isolated to determine sialylation and immune cell infiltration by flow cytometry 
(n=6). a) Bar diagram shows mean percentage viable cells ± SEM in the cell suspensions. b-e) 
Sialylation of CD45- cells in the tumor mass. Representative histograms show binding of the lectins 
MALII, SNA-I and PNA that recognize α2,3-linked sialic acids, α2,6-linked sialic acids or terminal β-
galactose, respectively, to CD45.2- cells in the tumor mass (b). Bar diagrams show average binding 
percentages ± SEM of MALII (b), SNA (c) or PNA (d) to tumor cells. f) Mean percentage ± SEM of 
viable, tumor-infiltrating CD45.2+ immune cells. g-i) Sialylation of CD45+ immune cell in the tumor mass. 
Bar diagrams show average binding percentage ± SEM of the lectins MALII (g), SNA-I (h) and PNA (i) 
to CD45.2+ tumor-infiltrating immune cells. 
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Figure 3 Sialic acid blockade alters the immune cell composition of the tumor. 
a-k) Flow cytometry analysis of subcutaneous B16-F10WT tumors isolated from mice treated with PBS, 
10 mg/kg Ac5Neu5Ac or Ac53FaxNeu5Ac for two weeks (n=6). a-d) Gating strategy of viable, CD45.2+ 
NK cells (CD161+) (a), CD4+ T cells (b), CD8+ T cells (c), and CD25highFoxP3+ regulatory T cells (d). e-
k) Bar diagrams show mean percentages ± SEM of NK cells (e), CD4+ T cells (f), CD8+ T cells (g) 
regulatory T cells (h), CD45R+ B cells (i) CD11c+ dendritic cells (j) and CD11b+ myeloid cells (k) in the 
tumors of the different treatment groups.  
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In addition, the number of regulatory T cells was significantly reduced compared to 
control-injected tumors (Figure 3d, h). Noteworthy, while the percentages of 
tumor-infiltrating B cells and dendritic cells were unaltered between the treatment 
groups, Ac53FaxNeu5Ac injections reduced the percentage of myeloid cells in the 
tumor (Figure 3i-k). Similar results were obtained when performing the same 
experiment in the 9464D model. The immune cell composition in the (non-)draining 
lymph nodes and spleen remained unaltered by Ac53FaxNeu5Ac injections (Figure 
S6, 7). These results demonstrate that Ac53FaxNeu5Ac injections alter the tumor 
microenvironment composition, resulting in increased numbers of effector immune 
cell subsets while lowering regulatory T cell and myeloid cell numbers. 
Furthermore, these results indicate that sialic acid blockade converts the immune 
suppressive tumor microenvironment into a more immune permissive one. 
 
Tumor growth suppression upon sialic acid blockade is mediated by CD8+ T cells 
Intratumoral injections with Ac53FaxNeu5Ac suppressed growth of established 
tumors and resulted in complete remission and protection from tumor rechallenge 
in some mice. The injections furthermore altered the immune cell composition of 
the tumor with higher percentages of effector immune cells and lower percentages 
of myeloid cells. These findings suggest that sialic acid blockade counteracts the 
immune suppressive tumor microenvironment and influences anti-tumor immunity. 
Therefore, we investigated if the growth inhibitory effect of Ac53FaxNeu5Ac 
injections on established tumors was mediated by effector immune cell subsets. 
B16-F10WT tumor bearing mice were depleted from NK cells, CD4+ T cells or CD8+ 
T cells using monoclonal antibodies and treated as described in Figure 4a. 
Successful depletion of NK cells and T cells from the blood of the mice was 
confirmed (Figure 4b-d). In line with the previous experiments, intratumoral 
Ac53FaxNeu5Ac injections hampered tumor growth in mice that received isotype 
control antibodies and increased median survival from 18.5 days to 39.5 days 
(Figure 4e). Depletion of neither NK cells nor CD4+ T cells had a significant effect 
on Ac53FaxNeu5Ac-mediated tumor growth suppression (Figure 4e). Remarkably, 
depletion of CD8+ T cells from mice largely abolished the anti-tumor effect of 
Ac53FaxNeu5Ac resulting in a median survival time of only 25 days (Figure 4f). Of 
note, depletion of NK cells and CD8+ T cells prior to the tumor cell inoculation 
facilitated tumor take and abrogated the anti-tumor effect of Ac53FaxNeu5Ac 
(Figure S8). Altogether, these data suggest that the growth suppressive effects of 
Ac53FaxNeu5Ac on established tumors is largely mediated by CD8+ T cells. 
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Figure 4 Depletion of CD8+ T cells abrogates the suppressive effects of Ac53FaxNeu5Ac on tumor 
growth. 
a) Schematic representation of the experiment. b-d) Representative dot plots showing depletion of 
effector immune cells subsets from blood using depleting monoclonal antibodies. Presence of NK cells 
(b), CD4+ T cells (c) or CD8+ T cells (d) in blood three days following isotype antibody (left) or depleting 
antibody (right) injection is shown. e) Kaplan-Meier curves showing percentage survival of mice with 
B16-F10WT tumors that received intratumoral PBS or 10 mg/kg Ac53FaxNeu5Ac injections as well as 
intraperitoneal injections with isotype antibodies, CD4+ T cell or NK cell depleting antibodies (n=6). f) 
Kaplan-Meier curves showing percent survival of B16-F10WT tumor-bearing mice depleted from CD8+ T 
cells and treated with sialic acid mimetic or control (n=12). 
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Sialic acid blockade promotes tumor eradication by CD8+ T cells 
To further elucidate how CD8+ T cells mediate the anti-tumor effects of 
Ac53FaxNeu5Ac, we assessed the cytotoxic effects of OVA-specific OT-I CD8+ T 
cells on sialic acid competent or deficient B16-F10OVA cells in an in vitro killing 
assay. Sialic acid blockade strongly enhanced the eradication of B16-F10OVA cells 
by activated OT-I CD8+ T cells. Already at low effector to target ratios (0.1 : 1, 0.25 
: 1) efficient killing of B16-F10OVA cells pre-treated with Ac53FaxNeu5Ac was 
observed (Figure 5a, b). B16-F10WT cells not expressing OVA were not sensitive 
to OT-I CD8+ T cell cytotoxicity, irrespective of prior treatment with Ac53FaxNeu5Ac 
(Figure 5b). Treatment of B16-F10OVA cells with the sialic acid-blocking mimetics 
had no effect on MHC I expression or other molecules involved in effector immune 
cell interactions (PD-L1, Rae1, Mult-1) (Figure S9a). Moreover, the concentration 
of Ac53FaxNeu5Ac used to block sialic acid expression in B16-F10 cells had no 
effect on OT-I CD8+ T cell sialylation (Figure S9b). These data indicate that sialic 
acid blockade increases the sensitivity of B16-F10 cells for killing by CD8+ T cells 
in an antigen-specific manner.  
Based on these results we tested if sialic acid blockade could enhance OT-I CD8+ 
T cell-mediated tumor killing in vivo. Purified, activated OT-I CD8+ T cells were 
adoptively transferred into mice bearing subcutaneous B16-F10OVA tumors that 
were treated with PBS or Ac53FaxNeu5Ac (Figure 5c, S9c). Sialic acid blockade 
significantly increased the percentage of OT-I CD8+ T cells in the tumor mass (two 
fold increase) (Figure 5d). OT-I CD8+ T cells in the tumors treated with 
Ac53FaxNeu5Ac compared to control displayed a more cytotoxic phenotype with 
higher expression of the activation markers CD44 and CD69 and the degranulation 
marker CD107a (Figure 5e-g). These results suggest that sialic acid blockade 
renders tumor cells vulnerable to killing by cytotoxic CD8+ T cells. Accordingly, 
Ac53FaxNeu5Ac injections enhanced rejection of established B16-F10OVA tumors by 
adoptively transferred OT-I CD8+ T cells. Without sialic acid blockade therapy, 
adoptive transfer of activated OT-I CD8+ T cells enhanced the median survival time 
from 20 days to 28 days compared to mice without T cell transfer (Figure 5h, i). In 
combination with sialic acid blockade, OT-I CD8+ T cell transfer strongly increased 
the median survival time of the mice and resulted in complete remission in the 
majority of the mice (> 60 %) (Figure 5h, i). Altogether, these data imply that sialic 
acids protect tumor cells from killing by CD8+ effector T cells and that sialic acid 
blockade therefore facilitates T cell-mediated tumor immunity. 
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Figure 5 Sialic acid blockade enhances tumor killing by cytotoxic T cells. 
a, b) Killing of B16-F10WT and B16-10OVA cells with blocked sialic acids expression by OVA-specific OT-I 
CD8+ T cells. a) Representative images show killing of B16-F10OVA cells treated with PBS (upper row) or 
Ac53FaxNeu5Ac (lower row). b) Histogram showing mean killing percentage ± SEM of B16-F10WT and 
B16-10OVA cells by OT-I CD8+ T cells (n=6). c) Scheme of the experiment. d-g) Histograms show 
average percentage ± SEM of tumor-infiltrating OT-I CD8+ T cells two days after adoptive transfer (d) 
and average MFI ± SEM for the activation markers CD44 (e), CD69 (f) and CD107a (g) (n = 3). h, i) 
Combination effect of sialic acid blockade and adoptive OT-I CD8+ T cell transfer on B16-F10OVA growth. 
h) Graph showing average tumor volume ± SEM of the different treatment groups. The arrow indicates 
OT-I CD8+ T cell transfer. i) Corresponding Kaplan-Meier curves are shown (n=12). 
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Sialic acid blockade synergizes with CpG immunotherapy  
Based on our findings that sialic acid blockade facilitates CD8+ T cell-mediated 
tumor immunity we hypothesized that adjuvants able to induce CD8+ T cell 
responses, such as CpG, could potentially strengthen the antitumor effect of sialic 
acid blockade.30 Therefore, Ac53FaxNeu5Ac treatment was combined with CpG 
injections in the poorly immunogenic B16-F10WT model (Figure 6a). CpG injections 
alone had no significant effect on tumors growth, but the combination of CpG with 
Ac53FaxNeu5Ac significantly delayed tumor growth and increased the median 
survival time from 24 days (Ac53FaxNeu5Ac alone) to 35 days (Figure 6b, c).  
 
Figure 6 Combining sialic acid blockade with CpG injections induces strong tumor growth inhibition. 
a) Schematic representation of the experiment. b, c) B16-F10WT tumors were injected with PBS or 
Ac53FaxNeu5Ac three times a week and on day 14 and 21 post-inoculation CpG was injected. Tumor 
growth and survival was followed in time (n=12). Histograms show average tumor volume ± SEM (b) → 
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and corresponding Kaplan-Meier survival curves (c) for the different treatment groups. d-f) Infiltration of 
CD11c+ dendritic cells into the tumor after treatment. Bar diagrams show mean percentage tumor-
infiltrating dendritic cells ± SEM (d) and their expression of CD80 (e) and CD86 (f) as mean 
fluorescence intensity ± SEM (n=6). g-j) Number and activation status of CD8+ effector T cells in the 
tumor after treatment. Mean percentage ± SEM of CD8+ T cells in the tumor is shown (g) as well as their 
expression of CD44 (h), CD69 (i) and CD107a (j) (n=6).  
 
CpG is a TLR9 ligand that has been described to induce dendritic cell maturation in 
the tumor.30,31 In line with these results, we found that CpG injections enhanced 
maturation of CD11c+ dendritic cells in the tumor as shown by the upregulation of 
the costimulatory molecules CD80 and CD86 (Figure 6d-f). Interestingly, 
Ac53FaxNeu5Ac injections alone also increased CD80 and CD86 upregulation, 
although to lesser extent than CpG. Strikingly, combining both compounds strongly 
induced dendritic cell maturation in the tumor. This strong upregulation of CD80 
and CD86 after combination treatment was also observed in dendritic cells in the 
tumor-draining lymph node, but not in the non-draining lymph nodes or the spleen 
(Figure S10). In line with the enhanced dendritic cell maturation in the tumor and 
tumor-draining lymph node, high numbers of activated CD8+ CD107a+ cytotoxic T 
cells were detected in tumors after CpG and Ac53FaxNeu5Ac treatment (Figure 6g-
j, Figure S11). These data indicate that sialic acid blockade together with the CD8+ 
T cell promoting activity of CpG induces highly potent anti-tumor immune 
responses.  
 
Discussion 
Aberrant sialic acid expression has been associated with multiple aspects of tumor 
growth and progression. Yet, there are only few approaches available to interfere 
with aberrant sialylation in tumors and their therapeutic potential is largely 
unexplored. In this study, we have investigated the use of the fluorinated sialic acid 
mimetic Ac53FaxNeu5Ac to block sialic acid expression in an established tumor 
mass in vivo and studied its effects on tumor growth, the tumor microenvironment 
and tumor immunity. In the B16-F10WT melanoma model and the 9464D 
neuroblastoma model survival times were significantly increased upon intratumoral 
Ac53FaxNeu5Ac injections. Moreover, in the more immunogenic ovalbumin-
expressing B16-F10OVA model Ac53FaxNeu5Ac mediated sialic acid blockade 
resulted in remission of the tumors in half of the mice. First mechanistic studies 
showed that sialic acid blockade changed the immune cell composition with higher 
percentages of effector immune cells and decreased percentages of regulatory T 
cells and myeloid cells. The anti-tumor effects of Ac53FaxNeu5Ac were largely 
mediated by CD8+ T cells and loss of sialic acid expression on tumor cells 
rendered them highly vulnerable to killing by cytotoxic T cells. Adoptive transfer of 
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OVA-specific CD8+ T cells in combination with sialic acid blocking mimetic 
injections therefore increased the rejection percentage of established B16-F10OVA 
tumors in mice. Sialic acid blockade in the tumor mass also enhanced maturation 
of dendritic cells with CpG in vivo, resulting in stronger CD8+ T cell responses and 
tumor growth suppression in the poorly immunogenic B16-F10WT model. In vitro, 
both B16-F10 cell lines displayed the same sensitivity for the sialic acid mimetic 
while the effective dose for 9464D neuroblastoma cells was two times higher. 
Accordingly, a higher dose (20 mg/kg) was required to induce an effect on tumor 
growth in the 9464D model, while the B16-F10 tumors responded already to 10 
mg/kg Ac53FaxNeu5Ac. This difference in sensitivity between the two cell types can 
most likely be explained by differences in uptake and handling of the inhibitor, the 
endogenous sialic acid concentrations or sialyltransferase expression level.  
Macauley et al. reported that intravenous administration of a ten times higher dose 
Ac53FaxNeu5Ac than used in our study (300 mg/kg) blocked sialic acid expression 
systemically and caused irreversible kidney damage in mice.29 In our experiments, 
repeated intratumoral injections with 10 mg/kg Ac53FaxNeu5Ac for up to four weeks 
were well tolerated. In contrast, multiple injections with 20 and 30 mg/kg for more 
than two weeks resulted in severe kidney dysfunction and edema formation in the 
abdominal cavity. Possibly, a low dose of Ac53FaxNeu5Ac injected into the tumor is 
partially retained in the tumor tissue, limiting systemic exposure. Accordingly, we 
could not observe reduced sialylation in lymph nodes or the spleen after 
intratumoral injections with 10 mg/kg. Han and co-workers have reported that 
compared to other cell types, cancer cells preferably take up sialic acids.32,33 They 
found that the uptake rate of exogenous sialic acids in subcutaneous tumors in 
mice was much higher than in other tissues. These findings could explain the 
milder adverse effects of Ac53FaxNeu5Ac when injected intratumorally compared to 
subcutaneously in non-tumor bearing mice. Nevertheless, future, safe 
administration would require a delivery system to specifically target the sialic acid 
mimetic to tumor cells. To this aim, our group has recently encapsulated 
Ac53FaxNeu5Ac into tumor-targeting nanoparticles that allowed for the specific 
delivery of the sialic acid mimetic to melanoma cells in the blood stream.22 
 
Pharmacological inhibition of sialic acid expression in tumors in vivo has not been 
feasible so far. Previous studies have used sialidase-treated tumors or transgenic 
tumor cell lines with reduced sialylation to study the role of sialic acids in tumor 
growth and tumor immunology.34,35 In this study, we demonstrate that intratumoral 
injections with Ac53FaxNeu5Ac enable sialic acid blockade in the tumor mass. 
Interestingly, sialic acid blockade was much stronger in tumor cells than in tumor-
infiltrating lymphocytes, supporting the idea that tumor cells have a higher uptake 
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rate of exogenous sialic acid. Furthermore, these data suggest that the effects on 
tumor growth and the tumor microenvironment were primarily caused by the 
blocked expression of tumor-derived sialic acids. Sialic acid blockade had a 
profound effect on the tumor microenvironment as tested in the B16-F10 and the 
9464D model. Compared to control-treated tumors, sialic acid blockade strongly 
enhanced the ratio of immune cells to tumor cells. In particular, there was a strong 
increase in NK cells and CD4+ and CD8+ T cells and reduced percentages of 
regulatory T cells as well as myeloid cells. These findings are in line with previous 
results from Perdicchio et al. that reported enhanced effector immune cell numbers 
and reduced regulatory T cell numbers in the microenvironment of sialic acid-
deficient SLC35A1 knockout B16-F10 tumors.35 We favor the explanation that sialic 
acid blockade renders the tumor microenvironment immune permissive, promoting 
anti-tumor immune responses. As sialic acids are involved in many processes, it is 
likely that the impact of sialic acid blockade on the tumor microenvironment is 
multifactorial. Our first mechanistic studies indicate that sialic acid blockade; i) 
benefits pro-immune effects like enhanced dendritic cell maturation and increased 
numbers and activation state of effector immune cells, especially CD8+ T cells, ii) 
decreases immune suppressive regulatory T cells and myeloid cells in the tumor 
and iii) facilitates tumor cell killing by cytotoxic T cells. These effects were not 
observed upon control PBS or Ac5Neu5Ac injections, indicating that the injections 
with sialic acid blocking mimetic per se were not directly cytotoxic. Also, we have 
previously reported that concentrations higher than 500 µM Ac53FaxNeu5Ac had no 
effect on viability of B16-F10WT cells in vitro and that long-term culture in the 
presence of the sialic acid mimetic did not result in reduced viability or 
proliferation.23 How sialic acid blockade results in these changes in the tumor 
microenvironment at the molecular level remains to be investigated.  
 
Tumor sialic acids have been shown to interact with immune inhibitory Siglecs on 
immune cells. These tumor sialic acid-Siglec interactions were found to suppress 
NK cells and alter myeloid cell and macrophage function, thereby contributing to 
tumor immune evasion.13,16-19 Possibly, the alterations in the tumor 
microenvironment are provoked by the depletion of tumor sialic acids that 
otherwise serve as ligands for immune suppressive Siglec receptors. Furthermore, 
galectin binding to uncapped glycans and disturbed interactions of the tumor cells 
with the extracellular matrix and tissue invasion could be involved as well.2,36,37 
Nevertheless, while sialic acid blockade has a broad impact on tumor cells, our 
data strongly indicate that the increased cell death and growth inhibition and even 
complete remission after Ac53FaxNeu5Ac treatment results from enhanced killing of 
tumor cells by cytotoxic T cells. This hypothesis is supported by several 
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observations. First, depletion of CD8+ T cells from mice largely abrogated the anti-
tumor effects of Ac53FaxNeu5Ac injections. Second, we detected an increased 
number of CD8+ T cells present in tumors with sialic acid blockade. These T cells 
also showed higher expression of the degranulation marker CD107a on their 
membrane. Third, desialylated B16-F10OVA cells showed an increased 
susceptibility to killing by OVA-specific CD8+ T cells compared to control, sialylated 
cells. Moreover, adoptive transfer of activated CD8+ OT-I T cells further increased 
tumor rejection in mice treated with Ac53FaxNeu5Ac. It has been suggested that 
hypersialylation of the Fas receptor in tumor cells protects tumor cells from Fas-
mediated killing by cytotoxic T cells and that tumor-derived sialic acids inhibit the 
release of cytotoxic granules from CD8+ T cells.38,39 Preliminary data by our group 
indicate that neither effects on Fas- nor perforin-mediated killing pathways play a 
dominant effect in sialic blockade. Possibly, removal of negatively charged sialic 
acids could influence the biophysical interaction between tumor cells and T cells for 
instance by affecting MHC I-T cell receptor and CD8 interactions and subsequent 
signaling events.40,41 Further research is needed to unravel the mechanisms 
underlying enhanced susceptibility of sialic acid-depleted tumor cells to killing by 
cytotoxic T cells. 
Stimulation of the immune system using CpG strongly enhanced the effect of sialic 
acid blockade-mediated tumor growth inhibition. Injections of CpG at the tumor site 
mature dendritic cells and induce robust anti-tumor CD8+ T cell responses when 
combined with tumor antigens.30,31,42 Indeed, we observed CpG-induced maturation 
of dendritic cells in the tumor microenvironment and interestingly, sialic acid 
blockade alone also resulted in slightly increased expression of CD80 and CD86 
on dendritic cells. Combined CpG and Ac53FaxNeu5Ac injections even further 
enhanced dendritic cell maturation. Accordingly, co-injections of CpG and sialic 
acid mimetic enhanced the number of CD8+ T cells expressing the degranulation 
marker CD107a in the tumor. We recently showed that blocking sialic acid 
expression in human monocyte-derived dendritic cells lowers the threshold for 
activation by toll-like receptor ligands including CpG and LPS. This effect was 
possibly mediated by the removal of cell surface sialic acids that can serve as 
ligands for immune suppressive Siglec receptors on the dendritic cell surface.43 
Likewise, tumor sialic acids inhibit dendritic cell activation by interacting with 
immune inhibitory Siglecs, and therefore suppress the initiation of anti-tumor 
immune responses.13,44,45 Interestingly, it has been reported that the presentation 
of sialylated antigens by dendritic cells induces regulatory T cells while suppressing 
CD8+ effector T cell formation.46 Possibly, sialic acid blockade results in the release 
and uptake of non-sialylated antigens thereby favoring effector T cell responses. 
These findings could also explain the reduced regulatory T cell numbers.  
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Overall, sialic acid blockade possibly counteracts the suppression of dendritic cells 
in the tumor microenvironment, resulting in the formation of tumor-reactive CD8+ T 
cells. As sialic acid blockade also enhances the vulnerability of tumor cells to 
cytotoxic T cell killing, Ac53FaxNeu5Ac injections could benefit both the initiation 
and effector phase of anti-tumor immunity. Future research should further exploit 
this hypothesis by investigating the influence of tumor sialic acids on immune cell 
function in the tumor microenvironment and the involvement of Siglecs herein. 
We conclude that sialic acid blockade in the tumor mass in vivo is feasible by 
intratumoral injections of the fluorinated sialic acid mimetic Ac53FaxNeu5Ac. Such 
injections significantly reduced melanoma as well as neuroblastoma tumor growth 
and resulted even in remission in the immunogenic B16-F10OVA model. Sialic acid 
blockade increased the numbers of effector immune cells in the tumor 
microenvironment while reducing regulatory T cell and myeloid cell numbers. The 
tumor growth suppression following sialic acid blockade was dependent on CD8+ T 
cells which displayed an enhanced capacity to eradicate desialylated tumor cells. 
These data support the current concept that tumor sialic acids have an immune 
modulatory role and participate in tumor immune evasion. Sialic acid blocking 
glycomimetics such as Ac53FaxNeu5Ac could therefore help to overcome the 
immune suppressive tumor microenvironment to permit strong tumor immune 
responses, alone or in combination with existing immunotherapies. 
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Supplementary Information 
 
Figure S1 Responsiveness of melanoma and neuroblastoma cells to Ac53FaxNeu5Ac. 
a-d) Comparison of the sensitivity of B16-F10WT and B16-F10OVA cells to Ac53FaxNeu5Ac. Both B16-F10 
cell lines were incubated for three days with 100 µM Ac53FaxNeu5Ac and sialylation and viability was 
measured by flow cytometry using the lectins MALII (a), SNA-I (b) and PNA (c) or the viability dye 
eFluor 780 (d), respectively. Graphs show average lectin binding ± SEM normalized to control, PBS-
treated cells or percentage viable cells in culture of three experiments. e-g) Dose-response of 9464D 
cells to increasing concentrations of Ac53FaxNeu5Ac as measured with the lectins MALII (e), SNA-I (f) 
and PNA (g). Graphs show average lectin binding ± SEM of three independent experiments. 
 
 
 
Figure S2 Effect of intratumoral 
injections with 20 mg/kg 
Ac53FaxNeu5Ac on B16-F10WT 
tumor growth. Kaplan-Meier 
curve depicts percentage 
survival of mice with a B16-
F10WT tumor treated with PBS or 
20 mg/kg Ac53FaxNeu5Ac (n=12). 
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Figure S3 10 mg/kg Ac53FaxNeu5Ac injections are well tolerated. 
a-h) Naïve, non-tumor bearing mice were injected s.c. with PBS, 10, 20 or 30 mg/kg Ac53FaxNeu5Ac 
three times per week for two weeks and followed up for another 2 weeks without injections (n=3). a) 
Representative images show mice after two weeks of treatment. b) Body weight of the mice treated with 
Ac53FaxNeu5Ac. c-f) Sialoglycan and asialoglycan expression in kidney sections from Ac53FaxNeu5Ac-
treated mice. Representative images show SNA (c) and PNA (e) binding to glomeruli two weeks after 
starting the treatment with Ac53FaxNeu5Ac. Mean fluorescence intensity ± SEM from the renal sections 
stained with SNA (d) or PNA (f). g, h) Urine and blood was collected at indicated time points and the 
albumin/creatinine ratio (ACR) (g) as well as the blood urea nitrogen (BUN) levels (h) were determined.  
 
 
 
 
 
 
 
 
PBS 10 mg/kg 20 mg/kg 30 mg/kg
a
0 7 14
0
10
20
30
 
 
 
Days
W
ei
gh
t [
g]
b Weight
***
  
0
2
4
6
8
10
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 [A
U
]
0
2
4
6
8
10
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 [A
U
]
10 mg/kg
SNA
dc
PBS
SNA
20 mg/kg 30 mg/kg
**
ns
**
*** ***
***
10 mg/kg
PNA
fe
PBS
PNA
20 mg/kg 30 mg/kg
PBS 10 mg/kg 20 mg/kg 30 mg/kg
0 1 2 3 4 5
0
50
100
150
200
250
 
 
 
Weeks
B
U
N
 [m
g/
dL
]
h
BUN
PBS
10 mg/kg
20 mg/kg
30 mg/kg
0 1 2 3 4 5
0.00
0.25
0.50
5
10
15
 
 
 
Weeks
Al
bu
m
in
/C
re
at
in
in
e 
R
at
io
[m
g/
m
g]
g
ACR
PBS
10 mg/kg
20 mg/kg
30 mg/kg
PBS
10 mg/kg
20 mg/kg
30 mg/kg
9 
Sialic Acid Blockade Enhances Tumor Immunity 
233 
Figure S4 Immune cell infiltration of tumors injected with Ac53FaxNeu5Ac. 
Representative dot plots show flow cytometry analysis of viable cells and immune cells isolated from 
tumors treated with PBS or 10 mg/kg Ac53FaxNeu5Ac. 
 
 
 
 
 
 
 
 
 
 
Figure S5 Effect of intratumoral 
Ac53FaxNeu5Ac injections on 
systemic sialylation. 
a-c) Bar diagrams depict 
average lectin binding ± SEM to 
viable CD45.2+ cells isolated 
from tumor-draining lymph 
nodes (a) systemic lymph 
nodes (b) and spleen (c) after 
two weeks of intratumoral 
injections with PBS, 10 mg/kg 
Ac5Neu5Ac or Ac53FaxNeu5Ac 
(n=6). 
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Figure S6 Effect of intratumoral Ac53FaxNeu5Ac injections on lymphocyte populations in (tumor-
draining) lymph nodes and spleen. a-c) Composition of immune cell populations in lymphoid organs 
following two weeks of intratumoral injections with PBS or 10 mg/kg Ac5Neu5Ac or Ac53FaxNeu5Ac 
(n=6). Histograms show average percentages ± SEM NK cells, CD8+ T cells, CD4+ T cells and 
regulatory T cells in the tumor-draining lymph node (a), systemic lymph nodes (b) and spleen (c).  
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Figure S7 Effect of intratumoral Ac53FaxNeu5Ac injections on immune cell populations in (tumor-
draining) lymph nodes and spleen. a-c) Composition of immune cell populations in lymphoid organs 
following two weeks of intratumoral injections with PBS or 10 mg/kg Ac5Neu5Ac or Ac53FaxNeu5Ac 
(n=6). Average percentages ± SEM CD45R+ B cells, CD11c+ dendritic cells and CD11b+ myeloid cells in 
the tumor-draining lymph node (a), systemic lymph nodes (b) and spleen (c) are presented.  
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Figure S8 Depletion of NK cells and CD8+ T cells prior to tumor injection. 
a) Schematic representation of the experiment. b) Dot plots showing depletion of NK cells and CD8+ T 
cells following injection with depleting antibodies, isotype control antibodies or PBS. c) Kaplan-Meier 
curves depicting percentage survival of mice in the different treatment groups (n=6). 
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Figure S9 B16-F10OVA cell surface molecule expression and purification and sialylation of OT-I CD8+ T 
cells. a) Bar diagram shows the expression of MHC I, Rae1, Mult-1 and PD-L1 on the surface of B16-
F10OVA cells incubated for three days with PBS, Ac5Neu5Ac or Ac53FaxNeu5Ac. Data are presented as 
average MFI ± SEM (n=3). b) Effect of Ac53FaxNeu5Ac on OT-I CD8+ T cells. OT-I CD8+ T cells were 
cultured for three days with PBS or 100 µM Ac53FaxNeu5Ac and surface sialic acid expression was 
detected with lectins. Bar diagram shows average binding of MALII, SNA-I and PNA ± SEM to 
Ac53FaxNeu5Ac-treated OT-I CD8+ T cells (n=3). c) Dot plots show OT-I splenocyte unstimulated (left) 
or stimulated with OVA257-264 peptide before (middle) or after (right) purification of CD8+ cells. Upper row 
shows forward and side scatter of splenocyte cultures gated on the lymphocyte fraction. Lower row 
shows expression of CD8 and Vβ5 T cell receptor subunit molecules on lymphocytes.  
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Figure S10 Systemic effect of sialic acid blockade on CpG-induced dendritic cell maturation. 
a-i) B16-F10WT tumors were injected with PBS or Ac53FaxNeu5Ac three times a week and on day 14 and 
21 post-inoculation CpG was co-injected. Bar diagrams show average percentage ± SEM CD11c+ 
dendritic cells and their expression of CD80 and CD86 presented as mean fluorescence intensity ± 
SEM in the tumor draining lymph node (a-c), non-draining lymph nodes (d-f) and spleen (g-h) (n=6). 
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Figure S11 Systemic effect of sialic acid blockade on CD8+ T cell numbers. 
a-c) B16-F10WT tumors were injected with PBS or Ac53FaxNeu5Ac three times a week and on day 14 
and 21 post-inoculation CpG was co-injected. Bar diagrams show average percentage ± SEM CD8+ T 
cells in the tumor draining lymph node (a), non-draining lymph nodes (b) and spleen (c) (n=6). 
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Abstract  
Sialic acids represent a family of sugar molecules derived from neuraminic acid 
that frequently terminate glycan chains and contribute to many biological 
processes. Already five decades ago, aberrantly high expression of sialic acids has 
been proposed to protect cancer cells from recognition and eradication by the 
immune system. Today, increased understanding at the molecular level 
demonstrates the broad immunomodulatory capacity of tumor-derived sialic acids 
that is, at least in part, mediated through interactions with immunoinhibitory Siglec 
receptors. Here we will summarize and discuss the findings described in this thesis 
as well as current studies from a sialic acid sugar perspective showing that tumor-
derived sialic acids disable major killing mechanisms of effector immune cells, 
trigger production of immune suppressive cytokines and dampen activation of 
antigen-presenting cells and subsequent induction of anti-tumor immune 
responses. Furthermore, the use of sialic acid mimetics to modulate sialic acid 
expression in cancer cells and immune cells to improve cancer immunotherapy will 
be discussed. 
 
Introduction 
Every living cell is surrounded by a dense layer of glycans that are attached to cell 
surface glycoproteins and glycolipids. Glycans are composed of various 
monosaccharides and show an enormous, cell-specific structural diversity 
illustrating their importance in many biological processes at the molecular level.1 
Despite their abundance on the cell membrane, many physiological functions and 
effects of glycans are not yet understood. Nevertheless, it is known for decades 
that glycosylation changes reflect, and are causative for several pathological 
conditions. Upon malignant transformation, tumor cells present a significantly 
different glycosylation pattern relative to their normal counterparts, and several 
cancer-specific glycans have been identified that promote tumor growth and 
progression. Among the glycosylation changes reported in cancer, aberrantly high 
expression of sialic acid sugar-carrying glycans (sialoglycans) is commonly 
found.2,3 
Sialic acids represent a family of about fifty derivates of neuraminic acids that 
share a common nine-carbon (C1-9) backbone. In general, sialic acids terminate 
glycan chains of all vertebrate and many invertebrate cells and contribute to protein 
stability and trafficking as well as cell-cell and cell-extracellular matrix interactions. 
Most cells possess a specific machinery to synthesize the different sialic acids from 
precursor carbohydrates in the cytoplasm. Following transport, Golgi-resident 
sialyltransferases incorporate these sialic acids into the glycans of glycoproteins 
and glycolipids. To date, more than 20 different sialyltransferases have been 
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identified, each attaching sialic acids via different glycosidic linkages (α2,3; α2,6 or 
α2,8) to underlying sugars.4 In cancer cells, overexpression of sialyltransferases 
leads to increased synthesis of sialoglycoconjugates that are deposited on the cell 
surface. Possibly, overexpression of sialyltransferases also leads to the 
neoformation of cancer sialoglycans, however this hypothesis remains to be 
proven.5,6 Prominent cancer-associated sialoglycan structures include the 
sialogangliosides fucosyl-GM1, GD1a, GM2, GD2, GM3 and GD3, the sialyl Lewis 
antigens A and X (SLeA/X), the sialyl Tn (STn) antigen, polysialic acid (PSA) and 
mucins.3,7-9 Due to hypersialylation, cancer cells acquire distinct characteristics 
including resistance to apoptosis and enhanced migratory properties which 
correlate with tumor aggressiveness and a poor prognosis for patients.6,10,11 In 
chapter 1, we have summarized the known molecular mechanisms and functional 
consequences of aberrant sialylation in cancer. 
An increasing amount of evidence advocates tumor sialoglycans as potent immune 
modulators acting at the tumor/immune interface. It becomes more and more 
apparent that hypersialylation provides a selective advantage for tumor cells to 
escape from anti-tumor immunity and is even involved in manipulating immune cell 
function to benefit tumor growth. 
 
In this chapter, we discuss recent findings obtained in this thesis and by others 
emphasizing that tumor cells escape from host anti-tumor immunity through 
aberrant expression of sialic acids. In particular, the effect of tumor-derived 
sialoglycans on the function of different immune cell subsets involved in anti-tumor 
immunity will be discussed as well as the contribution of sialic acid-recognizing 
Siglec receptors herein. An overview of the immunomodulatory events at the tumor 
sialoglycan/immune interface is provided in Figure 1.  
 
Sialic acids in immune regulation  
The dense layer of glycans protruding from the cell surface is one of the first 
structures recognized by immune cells that constantly screen host cell surfaces for 
(malignant) aberrations or presence of pathogens. Indeed, immune cells express 
multiple distinct carbohydrate-binding receptor families that modulate their function 
and that have recently been reviewed elsewhere.12 Among the various 
carbohydrates present in cell surface glycans, the diverse family of sialic acids is of 
particular interest.13 Being vertebrate specific, expression of sialic acids allows 
discrimination of pathogens lacking sialic acid expression from sialylated host cells. 
Interestingly, pathogens have been identified that have evolved strategies to 
express host sialic acids as molecular mimicry to evade the host immune 
system.14,15  
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Figure 1 Sialic acids in tumor immune evasion. 
Aberrant expression of sialic acids on cancer cells prevents complement activation (blue), protects from 
NK cell killing (red), disables major killing mechanisms of cytotoxic T cells (orange), modulates 
macrophage function (green) and dampens dendritic cell activation and function (gray). 
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A growing body of evidence suggests that sialic acids control immune homeostasis 
and dampen inappropriate immune activation in order to avoid or limit damage of 
sialylated host cells. The importance of sialic acids herein became apparent in a 
cohort of patients lacking the expression of 9-O acetylated sialic acids due to a 
defect in the sialic acid acetylesterase (SIAE) gene. These patients developed a 
broad spectrum of autoimmune diseases ranging from rheumatoid arthritis to type I 
diabetes.16 In line with these findings, expression of sialoglycans on colonic 
epithelia cells or neurons has been indicated to prevent immune activation and to 
protect the gut mucosa and nervous system, respectively.17,18 Together, the 
importance of sialic acids in the discrimination of self and non-self and as immune 
inhibitory signals preventing inappropriate immune activation has brought forth the 
idea that sialic acids act as self-associated molecular patterns (SAMPs, Ajit Varki 
2011).19 This implies that there are sialic acid-recognizing receptors that transmit 
inhibitory signals to control immune activation.  
So far, three sialic acid-binding lectins have been identified including Selectins, 
factor H and the family of Sialic acid-binding immunoglobulin-like lectins (Siglecs). 
Selectins (P-, L-and E-Selectin) belong to the family of C-type lectins and are well-
known for their binding to SLex and involvement in leukocyte trafficking, but also 
cancer metastasis. Factor H is a central regulatory protein in the alternative 
complement pathway discussed in more detail below.4 Siglecs comprise a family of 
more than 14 I-type lectins expressed by virtually all immune cells that specifically 
recognize diverse sialoglycans (Box 1). Siglecs are type I transmembrane proteins 
with an N-terminal sialic acid-binding site and most of them possess one or more 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) at their C-terminus.4,20 In 
general, binding of sialic acid ligands to immune inhibitory Siglecs results in 
inhibition of immune cell activation and function. Therefore, the sialic acid/Siglecs 
axis has been proposed to signal self-recognition limiting immune activation and 
destruction of host cells.19 Consequently, faulty synthesis or expression of sialic 
acids and altered expression or mutation of Siglecs contributes to the development 
of immune abnormalities.21 Moreover, pathogens that express sialic acids and 
cancer cells with aberrant sialic acid expression are likely to exploit immune 
suppressive Siglecs to escape from the immune system.  
In chapter 2, we have described the molecular basis of sialic acid binding to 
Siglecs and the role of the sialic acid-Siglec axis in disease. Furthermore we 
explained how sialic acid mimetics with high binding affinity and selectivity for 
Siglecs can be used to modulate immune cell function in disease.  
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Box 1 Siglecs in immune control. 
The importance of sialic acid recognition in the immune system emerged with the 
discovery of sialic acid-containing ligands for lectins receptors. In the early 1990’s, 
CD22 (Siglec-2) on B cells and sialoadhesin (Siglec-1) on macrophages were the first 
receptors shown to bind sialylated glycoproteins.22,23 Their immunoglobulin-like 
domains distinguished them from other C-type or calcium-dependent lectins and 
formed the basis for a new, still growing family of I-type lectin receptors - the Siglecs. 
Next to their Ig-like domain, many Siglecs contain tyrosine-based signaling motifs, 
particularly immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that are often 
implicated in attenuating cell signaling and endocytosis. Siglecs are almost exclusively 
expressed by cells of the immune system, and can be divided into two subsets based 
on their structural relatedness. The main subset mostly comprises ITIM-containing 
Siglecs which are closely related to CD33 (Siglec-3). This group shows important 
differences in repertoire between mammalian species and consists of Siglec-3, -5 to -
12, -14 and -16 in humans and the mouse homologues Siglec-3, E-H. The second 
group contains Siglec-1, -2, -4 (MAG) and -15 that are conserved between humans and 
mice.20,24 Various functions of Siglecs in immune cells have been described. Siglec-1 
has been shown to play a role in the phagocytosis of pathogens covered with sialic 
acids. CD33- related Siglecs were shown to attenuate inflammatory responses by 
binding to ligands on the same cell-surface (cis interactions) or surfaces of other cells 
(trans interactions). Therefore, Siglecs have shown to be important in the attenuation of 
‘self’-inflammatory triggers, called damage-associated molecular patterns (DAMPs). 
Chen et al demonstrated the existence of an inhibitory feedback mechanism that 
suppresses TLR signaling by DAMPs.25,26 In their studies the DAMP high-mobility group 
B1 (HMGB1) released from necrotic cells bound to CD24. This glycoprotein on dendritic 
cells consecutively interacted with the inhibitory Siglec-G on the same cell, which 
together inhibited HMGB1-driven TLR activation. In a more recent report the authors 
demonstrated the importance of this inhibitory mechanism in systemic sepsis.27 Their 
data suggested that bacterial sialidases cause excessive inflammation-related damage 
by cleaving the sialic acids on CD24 required for binding by Siglec-G, or the human 
equivalent Siglec-10. Using various sialidase inhibitors they could attenuate the effects 
of bacterial sialidase, suggesting these compounds can be used to dampen the 
morbidity associated with sepsis. 
Finally, instead of modulating the levels of Siglec ligands, pathogens were also 
reported to modulate Siglec expression itself. Recently, RNA viruses were shown to 
specifically upregulate Siglec-G expression in macrophages by a RIG-I dependent 
mechanism.28 This binding targeted RIG-I for proteasomal degradation, leading to less 
IFN production and resulting in a compromised protection against viral spreading. The 
structure of Siglecs and the role they have in general immune regulation is more 
extensively described in a recent review.20 10 
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Sialic acids in tumor immune evasion 
Already fifty years ago, Barbara H. Sanford and others proposed that aberrantly 
high expression of sialic acids on tumor cells allows immune escape (Box 2). They 
suggested that the dense layer of sialic acids found on tumor cells masks surface 
antigens preventing recognition by the immune system (antigen masking). This 
concept was supported by the observation that removal of sialic acids from tumor 
cells using bacterial sialidases strongly increased their immunogenicity and 
hindered growth in immunocompetent mice.29,30 Subsequently, sialidase-treated 
tumor cells were exploited as preventive and therapeutic vaccine in several animal 
tumor models. These vaccines showed impressive results in animal tumor models 
and culminated in clinical trials in men. However, efficacy of sialidase-treated tumor 
vaccines could not be demonstrated unequivocally in cancer patient cohorts 
between 1970 and 1990.31,32 Nevertheless, these early important studies indicated 
a vital role for sialic acids in tumor immunology and defined them as potential 
target for tumor immunotherapy. 
Today, advances in glycobiology and immunology renewed the interest into tumor 
sialoglycan research and revealed their strong immunomodulatory potential beyond 
the concept of antigen masking. A growing body of evidence indicates that tumor 
sialoglycans affect numerous immune relevant processes and make a major 
contribution to immune evasion. Below, we discuss immunomodulatory processes 
at the tumor sialoglycan-immune cell interface in the context of tumor immune 
escape and describe how sialic acid mimetics can be utilized for cancer 
immunotherapy. 
 
Box 2 Historical overview of sialic acid-focused tumor immunotherapy. 
In 1967, Sanford, Currie and others independently reported that removal of sialic acids 
from tumor cells using sialidase causes loss of transplantability in mice.29,33-35 This 
effect could be linked to altered recognition of the tumor cells by the immune system as 
sialidase-treated mouse and human tumor cells were shown to be more immunogenic 
in mixed lymphocyte reactions and only immunocompetent mice showed resistance to 
sialidase-treated tumors.30,36-39 In addition, Currie reported that injection of sialidase-
treated leukemia cells immunized mice against the non-immunogenic, untreated 
leukemia cells.30 Sanford and others suggested that tumor cells hide surface antigens 
from the immune system by veiling their cell surface with a dense layer of sialoglycans. 
Consequently, the idea that sialidase-treated tumor cells can be used to therapeutically 
vaccinate hosts against tumors emerged. In 1971 Simmons and Rios provided first 
evidence for the feasibility of sialidase-treated tumor vaccines. They reported that 
established methylcholanthrene (MCA)-induced fibrosarcomas were rejected in mice 
injected with living, sialidase-treated tumor cells. After several sialidase-based tumor 
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vaccines showed impressive results in animal tumor models, first non-randomized 
clinical trials in patients were conducted in the 1970s. Seigler and colleagues reported 
complete regression in a small cohort of melanoma patients after treatment with 
autologous, irradiated, sialidase-treated melanoma cells.40 Rosato et al. showed 
beneficial effects using vaccinations with sialidase-treated tumor cells in patients with 
various solid tumors.41,42 Based on these promising results, first randomized clinical 
trials were performed. In 1979 Bekesi and Holland reported significantly increased 
remission times in AML patients receiving vaccinations with irradiated, autologous 
sialidase-treated tumor cells.43 However, findings in the late eighties by Urbanitz and 
colleagues were less encouraging. They reported only mild effects in patients treated 
with desialylated myeloblasts.44 Moreover, Gray and colleagues evaluated the efficacy 
of sialidase-treated tumor cell vaccines in a large cohort of bowel cancer patients. Here, 
no improvement in five-year survival could be found.45 Sedlacek and Seiler summarized 
the issues that might have complicated the use of sialidase-treated tumor cells as 
antitumor vaccine and offered an explanation for the contradictory results.31,32 First, the 
tumor type, size, stage and pretreatment in the patients might be determinative for the 
efficacy. Next, no proper analysis has taken place regarding standardized treatment 
regimens including the number of tumor cells, the route of administration and the 
frequency of injections. These are important variables that need to be thoroughly 
determined in order to achieve successful vaccination against tumors in general, but 
have not been conducted at that time.46 Notably, the molecular mechanisms linking 
removal of sialic acids from the tumor surface to increased immunogenicity were poorly 
understood. Conflicting results reported that sialidase remained bound to the tumor 
cells and eventually could be recognized as antigen.47 The discrepancy between 
preclinical expectations and moderate results from clinical trials together with the lack 
of molecular and mechanistic understanding of the effects of sialidase treatment ended 
a hype that lasted more than 20 years. Nevertheless, these early studies have pointed 
out the detrimental effects of tumor sialic acids and founded the basis for recent 
therapeutic approaches to target sialic acids in cancer.  
 
Sialic acids in complement system evasion 
In vertebrates, sialoglycans were suggested to characterize host cells as self and 
have been reported to prevent activation of the complement system by recruitment 
of the complement control protein factor H to the cell surface.13,19 Factor H has 
several polyanionic binding sites that bind to sialoglycans, glycosaminoglycans and 
other negatively charged molecules on the surface of host cells. Surface-bound 
factor H hinders deposition and amplification of the complement-activating protein 
C3b on the cell surface and downstream activation of the alternative complement 
pathway. This regulatory mechanism has been suggested to prevent inappropriate 
complement activation and killing of sialylated host cells.48 Pathogens that lack 
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sialic acid expression do not recruit factor H and activate the complement 
cascade.49 Some pathogens like as Neisseria meningitides, have been found to 
utilize host sialic acids as molecular mimicry to recruit factor H to their surface and 
avoid lysis by the complement system.50,51 Although the role of the complement 
system in tumorigenesis is not yet understood, it has been suggested that tumor 
cells escape from complement activation by covering their membrane with 
sialoglycans.52,53 Removal of sialic acids from prostate, breast and ovarian 
carcinoma cells using sialidase has been reported to sensitize tumor cells to 
complement-mediated lysis.54 In addition, tumor cells have been reported to 
produce factor H to acquire resistance to complement activation.55,56 In the 
chapters 3, 6 and 9 we observed reduced tumor growth and metastasis formation 
as a consequence of sialic blockade. It could be that the absence of surface sialic 
acids identifies the cancer cells as foreign resulting in C3b deposition on their 
surface and subsequent killing by the complement system. Studies with 
complement system deficient mice could reveal if this mechanism plays a role in 
the reduced tumor growth following treatment with the sialic acid-blocking mimetic. 
Next to complement activation following sialic acid depletion from cancer cells, 
galectin binding to exposed galactose and N-acetyllactosamine residues could be 
responsible for some of the effects we observed in the chapters 3, 6, 8, 9. The 
family of galectins full fills a wide variety of biological functions and galectin binding 
to cancer cells with blocked sialic acid expression could influence their survival, 
migration and interaction with immune cells.57 Therefore, future research into the 
effects of sialic acid blockade on cancer cell characteristics should pay attention to 
the role of galectins.  
 
Sialic acids in natural killer cell evasion 
Natural killer (NK) cells have the ability to recognize and kill tumor cells that lack 
expression of MHC class I molecules (missing self-recognition). Tumor cells can 
escape NK cell-mediated killing by expressing ligands for inhibitory NK cell 
receptors or by downregulating the expression of activating ligands, thereby limiting 
success of current NK cell therapies.58 More recently, two NK cell evasion 
strategies have been identified involving hypersialylation of tumor cells. 
First, the dense layer of sialoglycans surrounding tumor cells has been reported to 
hinder physical interactions with NK cells and to mask activating ligands on the 
tumor cell surface. Cohen et al showed that growth of desialylated fibrosarcoma 
cells was abrogated in immunocompetent mice, but could be restored by depletion 
of NK cells.59 Furthermore, sialylation of tumor cells impaired the formation of 
immunological synapses between tumor cells and NK cells precluding cytotoxicity. 
This effect could be linked to impaired recognition of ligands for the activating NK 
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cell receptor NKG2D on sialylated tumors most likely via charge repulsion due to 
the highly negative charge of sialylated membranes and/or hypersialylation of 
NKG2D ligands itself. Noteworthy, in the same study it was shown that immune 
reactivity selects for the outgrowth of hypersialylated tumor cell variants. 
Fibrosarcoma cells isolated from mice with impaired immunoediting capacity (IL-1α 
-/- or IFNγ-/-) exhibited lower expression of sialoglycans compared to wild type mice. 
Inoculation of these hyposialylated tumor cells into wild type mice showed reduced 
growth, indicating that high expression of sialic acids is beneficial for tumor immune 
evasion. 
Second, several studies advocate that tumor sialoglycans interfere with NK cell 
function by triggering immune inhibitory signaling through Siglec receptors. Most 
human NK cells express Siglec-7 and about 40% of NK cells also express Siglec-
9.60,61 Siglec-7 recognizes α2,8-linked sialic acids that are mainly expressed on NK 
cells themselves, cells of the central nervous system and tumor cells including 
melanoma, glioma or neuroblastoma.7,20,62 Several studies indicate that binding of 
tumor α2,8-linked sialic acids (e.g. GD3) to Siglec-7 dampens NK cell activation 
and function allowing tumor cells to escape NK cell-mediated killing.62-65 By loading 
tumor cell surfaces with synthetic sialic acid glycopolymers that serve as ligand for 
Siglec-7, Hudak et al recently demonstrated their protection from NK cell-mediated 
cytotoxicity.66 Increased Siglec-7 phosphorylation and recruitment of SHP-1 upon 
engagement with their sialic acid ligands on the surface of tumor cells inhibited NK 
cell degranulation and tumor killing. Less is known about the function of Siglec-9 
on NK cells, but there is evidence that binding of α2,3-sialic acid-bearing mucin 16 
(MUC16) to Siglec-9 prevents the formation of immunological synapses between 
tumor cells and NK cells.60,67 In a recent study, Jandus et al demonstrated 
expression of Siglec-7 and Siglec-9 ligands on tumor biopsies and confirmed that 
these ligands protect tumor cells from NK cell killing.61 In line with these findings, 
we noticed increased infiltration of NK cells in melanomas with blocked sialic acid 
expression (chapter 9). Indeed, depletion of NK cells prior to the tumor challenge 
facilitated tumor growth and abrogated the suppressive effects of Ac53FaxNeu5Ac 
injections. Depletion of NK cells after tumor cell injection, however had no 
significant effect on the sialic acid blockade-mediated tumor growth suppression. 
These data indicate, that in the used melanoma model NK cells are important for 
the early tumor settling phase of, but less for the later expansion phase. Future 
studies should consider these two phases when depleting NK cells in tumor growth 
experiments. Moreover, while the expression of Siglec-7 and Siglec-9 and their 
inhibitory effects are established in human NK cells, the expression of Siglecs on 
mouse NK cells has not been described yet. Therefore it remains to be determined 
what the effects of tumor sialic acids on NK cell function in mice are.  
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Next to NK cells, natural killer T (NKT) cells are important mediators in innate 
tumor immunity. While Siglec expression by NKT cells has not yet been 
investigated, it has been reported that the sialic acid-carrying melanoma antigen 
can bind to the NKT cell receptor CD1.68 Binding of GD3 isolated from ovarian 
cancer cells to CD1 suppressed NKT cells and inhibited NKT cell activation with α-
galactosylceramide in vivo.69 These findings indicate that tumor-derived 
sialogangliosides can affect NKT cell function and imply that it may be rewarding to 
further investigate the Sialic acid/Siglec axis in these innate lymphocytes.  
 
Sialic acids in cytotoxic T cell evasion 
In addition to NK cells, also adaptive immune cells are affected by tumor 
sialoglycans. Sialoglycans facilitate tumor immune evasion from cytotoxic T cells 
(CTLs) by inhibiting their activation and disabling their killing mechanisms. CTLs 
feature two powerful ways to eradicate tumor cells, granule- and Fas-mediated 
cytotoxicity, both of which can be affected by aberrant expression of sialoglycans 
on tumor cells. Lee et al reported that tumor-derived sialic acid-containing 
gangliosides (GM1-3, GD1a) inhibit trafficking and exocytosis of lytic granules from 
CTLs.70 They showed that gangliosides do not impair TCR engagement and 
immunological synapse formation, but affect trafficking of lytic granules to the 
immunological synapse and subsequent release of lytic proteins. Despite their 
potency as inhibitors of CTL function, it is still unclear yet how gangliosides affect 
trafficking and exocytosis of lytic granules.  
Next, there is evidence that hypersialylation of the Fas receptor (FasR, CD95) 
desensitizes tumor cells to Fas-mediated cytotoxicity. CTLs express the Fas ligand 
(FasL, CD95L) and are capable of eliminating tumor cells that express FasR. Upon 
engagement of FasL, the death-inducing signaling complex (DISC) assembles at 
the cytoplasmic tail of FasR leading to internalization of the complex and 
downstream activation of caspases that lead to DNA and mitochondria 
disintegration and finally apoptosis.71 Swindall and Bellis reported that upregulation 
of the sialyltransferase ST6Gal I in tumor cells leads to high α2,6-sialylation of 
FasR and reduced assembly and internalization of the DISC complex upon Fas 
ligand encounter.72 Even though the relevance of this mechanism remains to be 
proven in vivo, the data suggest a novel strategy of tumor cells to disable a major 
killing mechanism of CTLs. In line with these studies, we observed in chapter 9 
that sialic acid blockade leads to reduced tumor growth in vivo in a CD8+ T cell-
dependent manner. Tumor cells with blocked sialic acid expression were more 
efficiently destroyed by cytotoxic T cells. These findings support the idea that tumor 
sialic acids inhibit cytotoxic T cell function, but how this effect is mediated is still 
unknown. Do the negatively charged sialic acids mask antigens on the tumor cell 
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surface, act as biophysical shield or could Siglecs mediate T cell suppression upon 
binding to tumor sialic acids? At the moment it is neither clear which Siglecs are 
expressed on human T cells nor if Siglecs are involved in escape from CTL lysis.73 
In a Jurkat T cell overexpression model artificial introduction and stimulation of 
Siglec-7/-9 resulted in dephosphorylation of the ZAP-70 signaling molecule and 
subsequent inhibition of downstream TCR-signaling.74 More recently, Bandala-
Sanchez and colleagues provided evidence for Siglec-mediated regulation of T-cell 
activation in humans.75 They identified a novel CD4+ T-cell subset that expresses 
and releases high levels of the sialoglycoprotein CD52. These CD4+CD52high T 
cells were capable of suppressing activation and function of CD4+CD52low T-cells 
via the interaction with Siglec-10. By suppressing other CD4+ T cells, CD4+CD52high 
T cells were suggested to be involved in immune homeostasis and control of 
autoimmunity as only low levels of this novel suppressive subset were found in 
type I diabetes patients. Noteworthy, CD52 expression has been reported on cells 
in malignant hematologic diseases and levels of circulating CD52 correlate with a 
poor prognosis in leukemia patients.76 Future research is needed to elucidate if this 
recently identified immunosuppressive CD52/Siglec-10 axis is utilized by tumors in 
order to limit T-cell activation and function in the tumor microenvironment or even 
systemically. 
Another outstanding question is whether tumor sialoglycans can affect the function 
of other T cell subsets like Th1, Th2, Th17 or regulatory T (Tregs) cells. It has been 
reported that cis sialic acids can regulate T cell polarization and activation.77,78 In 
chapter 9 we observed that sialic acid blockade reduced Treg numbers in the 
tumor microenvironment. Therefore, it would be interesting to investigate the 
influence of sialoglycans produced and secreted by tumor cells to affect the 
different T cell subsets in trans.  
 
Sialic acids in myeloid cell function modulation 
Myeloid cells have been reported to exhibit pro- and anti-tumorigenic roles 
depending the different factors present in the tumor microenvironment.79 
Interestingly, also sialic acids expressed by tumor cells appear to have dual effects 
on myeloid cell. Tumor sialoglycans allow recognition and uptake by macrophages 
on one hand, but on the other hand tumor sialoglycans can skew macrophages 
towards a more pro-tumorigenic phenotype.20 Macrophages commonly express 
Siglec-1 (sialoadhesin/CD169), a conserved Siglec without C-terminal ITIM motif 
that recognizes α2,3-linked sialic acids.80,81 These Siglec-1 positive macrophages 
have been reported to be beneficial in anti-cancer immunity as they can 
phagocytose dead tumor cells and cross-present antigens to CTLs. Intriguingly, 10 
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blockage of Siglec-1 hinders the activation of CTLs and subsequent antitumor 
immunity in mice.82  
Opposing the anti-tumorigenic effects, recent studies suggest that tumors can 
modulate the activation and secretion of tumor-promoting cytokines by 
macrophages via the interaction with Siglecs. Miyazaki et al demonstrated that 
disialyl Lewisa ligands on normal colonic epithelial cells serve as ligands for Siglec-
7 and -9 on mucosal macrophages and suppress their activation possibly to avoid 
inflammtion and tissue damage. Notably, the authors showed that colon cancer 
cells change their sialic acid signature, expressing more of the selectin ligands 
sialyl Lewisa and sialyl Lewisx instead of disialyl Lewisa. These findings suggest 
that Siglec-7/-9 control of macrophage activation might be abolished in colon 
cancer leading to production of inflammatory factors by macrophages that drive 
tumor progression.17 In the aforementioned example loss of Siglec ligands on 
tumor cells favors activation of macrophages and production of pro-inflammatory 
cytokines. In a different study, Takamiya and colleagues reported that the 
expression of α2,6 sialic acids on lung tumor cells stimulated production of TGF-β 
by monocytes and macrophages in a Siglec-15-dependent manner.83 This more 
recently discovered member of the Siglec family is expressed by tumor-associated 
macrophages in tumor tissue of patients. Binding of α2,6 sialic acid ligands on 
tumor cells induced recruitment of the activating adaptor protein DAP12 to the 
cytoplasmic tail of Siglec-15 and triggered downstream activating signaling via Syk-
kinase resulting in increased production of the immunosuppressive cytokine TGF-
β. In line with these findings, expression of Siglec-9 on macrophages has been 
reported to lower TNF-α production and increase IL-10 production.84 Obviously, the 
varying sialic acid signature on cancer cells of different origin and the expression 
pattern of Siglecs on myeloid cell subsets co-determine the context-dependent 
production of pro- or anti-inflammatory cytokines. This concept was recently 
confirmed by Läubli et al. who showed a dualistic role for Siglecs in myeloid cells. 
Depending on the tumor stage, interactions between tumor sialic acids and Siglec-
9 on myeloid cells was pro- or anti-tumorigenic.85 
Apart from the discussed examples, the extent to which tumor sialoglycans 
influence myeloid cells is largely unknown. Regarding that myeloid cells broadly 
express Siglecs, it is likely that they are highly sensitive to aberrant sialic acid 
expression on tumor cells. Recent evidence showing that Siglec-3 (CD33) drives 
myeloid-derived suppressor cell (MDSC) expansion allows to speculate that tumor 
sialoglycans are involved in the recruitment of these potent immune suppressive 
cells in the tumor microenvironment.86,87 We could extend these studies, by 
showing in chapter 7 that MDSCs isolated from glioma patients not only express 
Siglec-3, but also the immunoinhibitory Siglec family members Siglec-5, -7 and -9. 
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Furthermore, we found that that glioma cells express sialic acid ligands for Siglec-7 
and Siglec-9. The identification of four immunosuppressive Siglec family members 
on the MDSC surface suggest that there is extensive cross-talk between myeloid 
cells/MDSCs with cancer cells in the tumor microenvironment via the sialic acid-
Siglec axis. Interestingly, in chapter 9 we observed reduced numbers of myeloid 
cells and most likely MDSCs in the B16-F10 tumor microenvironment after 
injections with the sialic acid-blocking glycomimetic. Possibly, by interacting with 
Siglecs, tumor sialoglycans help recruiting or expanding myeloid cells and MDSCs 
in the tumor microenvironment. As tumors also secrete sialylated molecules, the 
effects could not only be limited to the tumor microenvironment, but myeloid cell 
differentiation or recruitment could be influenced at a systemic level. Future 
research is needed to understand the effects of tumor sialic acid on Siglec-
expressing myeloid cells. For this purpose, the on cell synthesis approach of high 
affinity Siglec ligands described in chapter 4 and chapter 5 could proof highly 
useful. By synthesizing a sialic acid mimetic on the cell surface that binds to a 
particular Siglec family member, the effect of this sialic acid-Siglec interaction on a 
myeloid cell type could be studied. These studies could provide further rationale for 
therapeutic targeting of aberrant sialylation in cancer. Moreover, as myeloid cells, 
especially MDSCs limit anti-tumor immunity, such studies could improve the 
efficacy of cancer immunotherapy. 
 
Sialic acids in dendritic cell modulation 
Dendritic cells (DCs) are the major antigen-presenting cells of the immune system 
capable of inducing T cell responses against tumor cells. To this aim, matured DCs 
need to present tumor antigens as well as co-stimulatory molecules to naïve T 
cells. Tumor-bound or secreted sialoglycans have been reported to modulate DC 
activation and maturation thereby hindering the initiation of antitumor T cell 
responses. GD1a, a disialoganglioside produced for instance by gastric, pancreatic 
or prostate cancer cells, was shown to counteract DC activation, upregulation of 
costimulatory molecules CD80/86 and IL-12 production. As a consequence, DCs 
pulsed with GD1a failed to induce Th1 effector cell development, but promoted 
differentiation into immunosuppressive Tregs.88 Similarly, other tumor-derived 
gangliosides e.g. GD2 (neuroblastoma) or GM3/GD3 (melanoma) were reported to 
inhibit DC activation, IL-12 production and subsequent effector T cell activation.89,90 
Likewise, melanoma GM3/GD3 was reported to prevent activation and migratory 
function of tissue-residing Langerhans cells and induce to apoptosis.91 How 
precisely tumor sialogangliosides mediate these immune suppressive effects are 
yet to be determined. Possibly, immune inhibitory Siglecs that are widely 
expressed on DCs recognize sialogangliosides and are responsible for the 
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described effects. This assumption is in line with studies demonstrating that highly 
sialylated mucins bind to Siglecs on DCs and dampen their activation. For 
example, α2,6 sialic acid-carrying mucin 2 (MUC2) has been described to bind 
Siglec-3 and to induce apoptosis of monocyte-derived DCs.92 Binding of tumor 
mucins and other sialoglycans to Siglec-9 on DCs was shown to dampen 
production of IL-12 while leaving IL-10 production unaffected.93 Moreover, MUC1 
has been described to attract immature DCs and induce maturation, but these DCs 
are functionally impaired and fail to produce IL-12 and to induce Th1 effector 
cells.94 These data collectively suggest, that tumor sialoglycans dampen activation 
and function of DCs and prevent induction of anti-tumor immune responses.95  
The findings obtained in this thesis support the hypothesis that the sialic acid-
Siglec axis limits DC maturation and function. In chapter 8 we found that human 
monocyte-derived DCs (moDCs) express the Siglecs-3, -5, -7, -9 and -10 as well 
as putative cis sialic acid ligands for Siglec-7 and Siglec-9. Treatment of moDCs 
with Ac53FaxNeu5Ac abrogated these cis sialic acid-Siglec interactions and resulted 
in strongly enhanced maturation and T cell activation capacity after stimulation with 
toll-like receptor (TLR) ligands. Accordingly, in chapter 9 we found that DCs in the 
tumor and tumor-draining lymph nodes of mice showed higher expression of co-
stimulatory molecules after co-injections with the sialic acid-blocking mimetic and 
the TLR adjuvant CpG. Therefore, the increased numbers of CD8+ T cells in the 
tumor microenvironment after Ac53FaxNeu5Ac treatment could not only be the 
result of sialic acid blockade in tumor cells, but also the result of enhanced DC 
maturation. Sialic acid blockade could be thus an effective way to increase the 
potency of DC-based cancer vaccines. It has to be mentioned, however, that sialic 
acids also regulate DC chemokine recognition and migration.96 Future studies are 
required to obtain insights into the effect of individual sialic acid-Siglec interaction 
on DCs function. The on-cell Siglec ligand synthesis approach reported in chapter 
4 and chapter 5 could make this research possible now. Identification of individual 
sialic acid-Siglec interactions that hamper DC activation and are exploited by 
cancer cells could advance the development of more specific approaches than 
global sialic acid blockade.  
 
Sialic acid mimetics for cancer immunotherapy 
Given the strong immunomodulatory capacity of sialic acids, hypersialylation 
appears to protect cancer cells from recognition and eradication by the immune 
system, thereby limiting the outcome of cancer immunotherapy. Therefore, sialic 
acids emerge as targets to enhance cancer immunotherapy (Figure 2). Removing 
cell surface sialic acids from cancer cells with bacterial sialidases increased their 
immunogenicity in mixed lymphocyte reactions and has been explored in the past 
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to induce anti-tumor immune responses in cancer patients (Box 2). More recently, 
sialidase treatment was shown to render cancer cells immunoreactive in a mouse 
model suggesting that interfering with sialic expression could allow eradication of 
cancer cells by the immune system.59 For decades, bacterial sialidases were the 
only way to efficiently remove sialic acids from cells, however, sialic acid 
expression restores quickly following enzymatic removal.97 This issue could be 
solved by sialic acid-blocking sialic acid mimetics, like the fluorinated sialic acid 
analog (Ac53FaxNeu5Ac), developed by Rillahan et al., that inhibits 
sialyltransferases and subsequent incorporation of sialic acids into glycans.98 In 
chapter 3 and 8, we could demonstrate that this sialic acid mimetic efficiently 
blocks sialic acid expression in cancer cells and also DCs for several days.97 
Moreover, in vitro pre-treatment of B16-F10 cells with Ac53FaxNeu5Ac hampered 
their outgrowth in mice. In chapter 9, we revealed that repeated injections with this 
inhibitor suppresses tumor growth in a cytotoxic T cell-dependent manner. 
Interestingly, sialic acid blockade also enhanced DC maturation and reduced the 
numbers of immunosuppressive cells in the tumor microenvironment. These 
findings advocate that the sialic acid blocking mimetic boost tumor immunity at 
multiple levels. Sialic acid blockade could therefore improve the outcome of 
existing cancer immunotherapies. We showed already that combining 
Ac53FaxNeu5Ac injections together with the Th1 response-promoting immune 
adjuvant CpG or antigen-specific cytotoxic T cell transfer resulted in strong tumor 
growth suppression (chapter 9 and WO/2016/071431, A combination for cancer 
therapy, Adema GJ, Büll C, Boltje TJ). Future research should explore the effects 
of sialic acid blockade on other types of immunotherapy (e.g. immune checkpoint 
blockade, DC vaccination). Ultimately such research could lead to the development 
of effective immunocombination therapies for cancer. 
Regarding the importance of sialic acid acids in physiology, changing or blocking 
sialic acid expression systemically could evoke severe adverse effects. Sialic acids 
are crucial for proper development and function of the brain, muscles, kidneys, the 
immune system and other organs. Defects in sialic acid and sialoglycan synthesis 
result in severe intellectual developmental disorders, muscular dystrophy, renal 
failure, autoimmunity and other disorders.16,99-102 Complete failure to synthesize 
sialic acids results is embryonic lethality in mice.103 Accordingly, we observed that 
repeated injections with a high dose Ac53FaxNeu5Ac reduced sialylation of the 
kidney glomeruli and damaged kidney function in mice (chapter 9). In the light of 
these findings, it is remarkable that blocking sialic acid expression in cell lines and 
primary cells used in this thesis in vitro had no effect on cell proliferation or viability. 
Other groups also reported that the stable knockdown of crucial genes involved in 
sialoglycan synthesis is viable in cell lines.104-107  
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Figure 2 Sialic acid mimetics for cancer immunotherapy. 
Sialic acid mimetics block sialylation in cancer cells resulting in the loss of sialic acid expression on cell 
surface glycoproteins and glycolipids (red). Sialic acid mimetics that are recognized as antigen by the 
immune system are introduced into the cellular sialylation pathway leading to their presentation on the 
cell surface (blue). Clickable sialic acid mimetics are metabolically incorporated into cell surface 
sialoglycans and reacted on the cell surface with small molecules that alter sialic acid binding to Siglecs 
(orange). Sialic acid mimetics that resemble tumor-associated carbohydrate antigens (TACA) in 
complex with an immune adjuvant induce the production of tumor-specific anti-TACA antibodies.  
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These findings evidence that sialic acids are not absolutely necessary for the in 
vitro growth of cells, but they are extremely important for the development and 
function of an organism. Therefore, for the safe application of sialic acid blocking 
mimetics in cancer immunotherapy in vivo, they need to be specifically targeted to 
tumor cells and the tumor microenvironment.  
Multiple strategies have been developed to deliver compounds to tumor cells in 
vivo. Biodegradable PLGA (poly(lactic-co-glycolic acid))-based nanoparticles are 
particularly interesting for this purpose because, PLGA has already been approved 
for the safe use in humans.108 We have therefore encapsulated Ac53FaxNeu5Ac 
into PLGA-based nanoparticles that are degraded inside the cell followed by slow 
release of the sialic acid mimetic. To target the nanoparticles specifically to B16-
F10 melanoma cells, they were coated with antibodies that bind to the melanoma 
antigen TRP1 (tyrosinase-related protein 1). This targeted delivery approach 
allowed to block sialic acid expression in melanoma cells specifically and 
remarkably prevented their metastatic spread in vivo (chapter 6). Targeted delivery 
of the blocking sialic acid mimetic to tumor cells could boost anti-tumor immunity 
while keeping systemic exposure and side effects at a minimum. Moreover, in 
future studies this targeted delivery approach could help to dissect the effects of 
sialic acid blockade on the tumor microenvironment. In this thesis, soluble 
Ac53FaxNeu5Ac was injected into the tumor mass and therefore the observed 
effects on tumor growth could be the mixed effect of the inhibitor on tumor cells, 
immune cells or stromal cells in the tumor microenvironment.  
Alternatively, synthetic sialic acids or sialic acid precursors carrying chemical 
modifications can be administered to cancer cells and enter the sialic acid 
biosynthesis pathway to affect anti-tumor immunity (Figure 2).10,109,110 For instance, 
the sialic acid mimetics Ac5NeuNPoc and Ac5NeuNAz characterized in chapter 4 
and 5, could be targeted to cancer cells using nanocarriers such as the melanoma-
targeting PLGA particles developed in chapter 6. Surface poc or azide sialic acids 
could be reacted with clickable molecules that alter Siglec binding to study and 
alter the effects of specific sialic acid-Siglec interactions in cancer cell-immune cell 
cross-talk and the formation of the tumor microenvironment (chapter 2, 7). Next to 
studying the sialic acid-Siglec axis, with this approach tumor sialic acids could be 
reacted with immune activating agents to generate an anti-tumor immune 
response. Likewise, antigenic sialic acid mimetics could be metabolically 
incorporated into the cell surface glycans of cancer cells to induce an anti-tumor 
immune response. Surprisingly, incorporation of non-human, immunogenic sialic 
acids into cell surface sialoglycans of cancer cells can occur ‘naturally’. Research 
led by Ajit Varki has identified expression of a non-human sialic acid, Neu5Gc (N-
glycolylneuraminic acid), in several types of cancer. Neu5Gc cannot be 
10 
Sialic Acid Mimetics for Cancer Immunotherapy 
259 
synthesized by human cells, but is taken up from dietary sources, and introduced 
into cell surface sialoglycans of normal cells and especially cancer cells. Antibodies 
against this non-human sialic can be detected in most individuals and could 
potentially be used in cancer immunotherapy.111,112 Future research is needed to 
explore safety and efficacy of such strategies in preclinical animal tumor models. 
When interpreting these studies it is very important to realize the differences 
between human and non-human, even primate, sialic acids and Siglecs. During 
evolution, humans lost the ability to produce Neu5Gc and also human-specific 
changes in the evolution of the Siglec receptor family occurred (chapter 2). 
Despite these differences, the immunoregulatory role of the sialic acid-Siglec axis 
appears to be functionally conserved between species.85,113 Mouse tumor models 
can therefore be used to evaluate the potential of therapeutic strategies focusing 
on sialic acids and Siglecs for cancer immunotherapy. 
Instead of blocking or introducing synthetic sialic acids in cancer cells, also 
strategies to vaccinate patients against specific tumor sialoglycans are explored.7 
In cancer patients, antibodies against sialoglycans can be detected, suggesting 
that so called tumor-associated carbohydrate antigens (TACA) can be recognized 
as non-self by the immune system and induce an anti-tumor immune response. 
Therefore, sialoglycans that are almost exclusively expressed on cancer cells (e.g. 
fucosyl-GM1, GD1a, GM2, GD2, GM3, GD3, SLeA/X, STn, PSA, mucins) are 
purified or synthesized and combined with immune adjuvant to induce humoral and 
cellular anti-tumor immune responses in preclinical and in clinical studies (Figure 
2).114-118 The past, present and future of (sialo)carbohydrate-based anticancer 
vaccines was recently reviewed by others.119,120 
Next to these vaccines, therapeutic antibodies directed against specific tumor 
sialoglycans can be of high potency in cancer immunotherapy. For example, Lou et 
al. recently identified the α2,3 sialic acid-carrying sialoglycolipid SSEA-4 (stage-
specific embryonic antigen-4) on glioblastoma multifore (GBM) cells as highly 
specific TACA that is not expressed in normal brain tissue. They showed that 
administration of a monoclonal antibody against SSEA-4 potently suppresses 
tumor growth in a GBM mouse model.121 Our group showed that monoclonal 
antibodies recognizing the neuroblastoma-specific TACA GD2 (disialoganglioside), 
induce antibody-dependent cell-mediated cytotoxicity and inhibited tumor 
outgrowth.122,123 Overall, results obtained in preclinical animal models and clinical 
trials are encouraging, stimulating the further development of effective sialic acid-
based anti-cancer vaccines. 
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Concluding Remarks 
Almost five decades ago, the concept that tumor sialic acids allow immune escape 
was founded. At that time attempts were made to translate this concept into the 
clinic and to induce tumor immune responses using sialic acid-depleted tumor cell 
vaccines. The absence of mechanistic insight and the lack of clear pre-clinical and 
clinical results obtained at that time, rebutted the concept that sialic acids facilitate 
tumor immune evasion. Since that time, a significant progress in the field of 
glycobiology and immunology was made and recent studies, including the work 
described in this thesis, breathe new life into the early concept of tumor 
sialoglycan-mediated immune escape. So far, tumor sialoglycans were shown to 
hinder physical interactions with immune receptors and ligands on the tumor cell 
surface including antigens (i), to disguise them as self (ii), to disable major killing 
mechanisms of the immune system (iii) and to modulate immune cell function 
locally and systemically by forming the ligands for immune suppressive Siglec 
receptors (iv). Presumably, additional modes of action of sialic acids exist at the 
tumor-immune interface, not to mention the important role of sialic acids in multiple 
other aspects of tumor growth e.g. metastasis. Future research is required to 
understand the effects of the numerous tumor sialoglycans on immune cell function 
and to elucidate the role of sialic acid-recognizing lectins on immune cell subsets 
and in (tumor)immunology. For this purpose, high-throughput methods to decipher 
the large collection of sialoglycans on tumor cells (the sialome), synthetic 
carbohydrates that resemble tumor sialoglycans or sialic acid mimetics that inhibit 
or alter sialic acid expression are highly desired.124 Clearly, studying the tumor 
sialic acid-immune cell interface requires the close collaboration between 
glycochemistry and glycoimmunology. This cooperation has largely brought forth 
the work described in this thesis. The developed glycoengineering approach to 
render cell surface sialic acids reactive to a particular Siglec family member could 
be of high value to understand the effect of tumor sialic acid-Siglec interactions on 
immune cells. These insights could also provide further rationale for blocking sialic 
acid expression in tumor cells using sialic acid mimetics to boost cancer 
immunotherapy.  
 
Finally, proper translation of strategies to block sialic acid expression in cancer 
cells, to incorporate modifiable or immunogenic sialic acid mimetics into surface 
glycans or to vaccinate against tumor sialoglycans into the clinics could 
successfully follow up the “historical” attempts using sialidase-treated tumor cells 
and pave the way for cancer immunotherapy. 
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Siaalzuur-mimetica voor Immunotherapie 
Suikers zijn belangrijke bouwstenen van het leven 
Ons lichaam is opgebouwd uit biljoenen cellen, microscopisch kleine eenheden die 
ons erfelijk materiaal, het DNA, bevatten. Elke cel heeft een speciale functie en 
draagt hierdoor bij aan het goed functioneren van het lichaam. Huidcellen 
bijvoorbeeld beschermen het lichaam tegen uitdroging en het binnendringen van 
ziekteverwekkers zoals bacteriën en virussen. Mochten er toch ziekteverwekkers 
het lichaam binnen dringen, dan worden deze opgeruimd door witte bloedcellen die 
bij het afweersysteem, ook immuunsysteem genoemd, horen. De cellen in ons 
lichaam zijn allemaal omhuld door een wand, de celmembraan, en bevatten een 
kern waarin het DNA ligt opgeslagen. Verder zijn cellen gevuld met het 
zogenaamde cytoplasma, een soort vloeistof samengesteld uit verschillende 
moleculen zoals eiwitten, vetten en suikers. In principe zijn er 68 verschillende 
moleculen nodig om een levende cel te bouwen. Deze bouwstenen kunnen worden 
onderverdeeld in DNA (8 bouwstenen), eiwitten (20 bouwstenen), vetten (8 
bouwstenen) en suikers (32 bouwstenen). De meeste bouwstenen van een cel zijn 
dus suikermoleculen (koolhydraten). Bij deze 32 suikermoleculen hoort onder 
andere het bekende druivensuiker of glucose, een heel belangrijke leverancier van 
brandstof voor de cel. Het grootste deel van de suikermoleculen dient echter niet 
als brandstof voor de cel, maar vormt een belangrijk onderdeel van de 
celmembraan. De membraan zit vol met verschillende soorten suikermoleculen. 
Deze suikers zijn meestal met elkaar verbonden en vormen suikerketens, 
zogenaamde glycanen. De suikerketens of glycanen op het celoppervlak kunnen 
zeer sterk variëren in samenstelling en structuur en spelen een belangrijke rol bij 
het functioneren van een cel. Ze zijn bijvoorbeeld nodig voor cellen om onderling te 
communiceren of contact te maken om zo een weefsel te kunnen vormen. 
 
Siaalzuur - Een zeer speciaal suikermolecuul  
Een heel belangrijke soort suiker dat op de membraan van elke menselijke cel te 
vinden is, heet siaalzuur. De naam siaalzuur is een beetje misleidend, want het is 
toch een suikermolecuul. Siaalzuur wordt vaak als roze vierkant afgebeeld, zoals in 
Figuur 1. Chemisch is siaalzuur opgebouwd uit negen koolstofatomen die een 
soort ring vormen, waaraan verschillende andere atomen zoals waterstof en 
zuurstof vastzitten. Siaalzuur kan door elke cel in het lichaam worden gemaakt en 
wordt ingebouwd in glycanen op de celmembraan. Het bijzondere van siaalzuur is 
dat het altijd aan het uiteinde van een glycaan wordt ingebouwd, dus de 
suikerketen afsluit. Siaalzuur heeft veel verschillende functies in de cel. Het helpt 
b.v. hersencellen om verbindingen met elkaar te maken en spiercellen om goed te 
kunnen werken. Siaalzuur geeft aan hoe oud rode bloedlichaampjes, die zuurstof 
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transporteren, zijn en zorgen dat deze worden opgeruimd als ze te oud zijn 
geworden. Verder heeft siaalzuur meerdere belangrijke functies in het 
immuunsysteem. De witte bloedcellen gebruiken siaalzuur aan hun oppervlakte om 
bloedvaten te verlaten en zo naar de plek te komen waar bijvoorbeeld een infectie 
is. Verder helpt siaalzuur witte bloedcellen om menselijke cellen te onderscheiden 
van micro-organismen, zoals bacteriën. Dit werkt omdat menselijke cellen en ook 
de meeste dierlijke cellen siaalzuur aan hun oppervlakte tonen, maar bacteriën 
niet. Witte bloedcellen kunnen dus cellen, die niet bij het lichaam horen, herkennen 
aan de afwezigheid van siaalzuur en deze cellen vervolgens opruimen. 
 
Figuur 1 Siaalzuur op het celoppervlak. 
 
Kankercellen gebruiken siaalzuur in hun voordeel 
Elke cel in het lichaam volgt een programma dat bepaalt wat de functie van de cel 
is. Het ‘huidcel programma’ bepaalt bijvoorbeeld dat een huidcel stevig contact 
maakt met andere huidcellen om een beschermlaag, de huid, te vormen. Ook zorgt 
dit programma ervoor dat een huidcel pigment kan produceren dat beschermt 
tegen het UV licht van de zon. Als het programma van een cel wordt verstoord, kan 
een cel veranderen en een kankercel worden. Een huidcel wordt dan bijvoorbeeld 
een melanoomcel, een cel die zelfstandig ongeremd kan delen en zo een tumor 
kan vormen. Dit proces heet maligne (kwaadaardige) transformatie en gaat samen 
met een aantal veranderingen in de cel. Een van de veranderingen die in 
kankercellen optreedt, is dat ze meer siaalzuur op hun oppervlakte krijgen. Beter 
gezegd bedekken kankercellen vaak hun hele oppervlak met een dichte laag van 
siaalzuur (zie Figuur 2). 
 
Figuur 2 Kankercellen brengen veel siaalzuur tot expressie.  
Cel met Siaalzuur
Kern
Membraan
Structuur Siaalzuur
Siaalzuur
Cytoplasma
O
OH
COOH
OH
HN
O
HO
OHHO
Normale Cel Kankercel
Kwaadaardige 
Transformatie
Dutch Summary 
274 
Verschillende onderzoeksgroepen hebben eerder aangetoond dat de verhoogde 
expressie (aanwezigheid) van siaalzuur bepaalde eigenschappen van kankercellen 
beïnvloedt (zie Figuur 3). Ten eerste blijkt de verhoogde siaalzuurexpressie 
kankercellen te beschermen tegen afsterven. Normaal gesproken gaat een cel 
dood als het normale celprogramma is veranderd en de cel daardoor zijn functie 
niet meer goed kan uitoefenen. Kankercellen weten hieraan te ontsnappen en een 
overmaat aan siaalzuur speelt hierbij een rol. Ten tweede helpt verhoogde 
siaalzuurexpressie kankercellen om zich aan bindweefsel-bestanddelen, zoals 
collageen, te binden en door het bindweefsel te bewegen. Zo kunnen ze bij een 
bloedvat terecht komen om via het bloed naar een andere plek, een ander orgaan 
in het lichaam, te migreren. Dit proces wordt metastasering (uitzaaïng) genoemd 
en ook hieraan dragen siaalzuren bij. Ten derde zijn er aanwijzingen dat een dichte 
siaalzuurlaag kankercellen beschermt tegen de werking van chemotherapie en 
bestraling. Deze voorbeelden laten zien dat de verhoogde expressie van siaalzuur 
in het voordeel is van kankercellen. Naast deze voorbeelden is er nog een heel 
belangrijke eigenschap van siaalzuur waar kankercellen gebruik van maken; 
ontsnappen aan het immuunsysteem. 
 
Figuur 3 Verhoogde siaalzuur is voordelig voor kanker cellen. 
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Siaalzuur helpt kankercellen aan het immuunsysteem te ontsnappen 
Het immuunsysteem kan kankercellen herkennen en doden en beschermt zo het 
lichaam tegen het ontstaan van kanker. Helaas kan het gebeuren dat een 
kankercel ontstaat die niet door het immuunsysteem wordt herkend. Zo’n cel kan 
zich vervolgens delen en een tumor vormen, die niet meer door het 
immuunsysteem wordt opgeruimd. Gelukkig is het mogelijk het immuunsysteem 
dusdanig te activeren, dat het kankercellen weer wél kan herkennen en doden. 
Deze vorm van therapie heet immunotherapie en is tegenwoordig een 
veelbelovende behandelmethode van kanker. Op dit moment worden verschillende 
vormen van immunotherapie als standaardbehandeling toegepast (b.v. immune 
checkpoint inhibitors) of in klinische studies getest (b.v. dendritische cel 
vaccinaties) en leveren veelbelovende resultaten op. Met immunotherapie kan het 
immuunsysteem succesvol worden geactiveerd, zodat effector immuuncellen 
(“opruimers”) zoals T cellen ontstaan, die kankercellen kunnen opruimen. Maar 
kankercellen weten op verschillende manieren aan die immuunactiviteiten te 
ontkomen. Een manier is mogelijk het aanmaken van een dichte laag siaalzuur. 
Meerdere onderzoeksgroepen vermoeden dat de verhoogde expressie van 
siaalzuur op kankercellen, een remmend effect heeft op immuuncellen die aan de 
anti-tumor (opruim) reactie meewerken. Deze immuuncellen bevinden zich in de 
tumor en kunnen met de kankercellen communiceren. Hiervoor beschikken 
immuuncellen over receptoren die 
moleculen aan de oppervlakte van 
kankercellen kunnen herkennen. Een 
groep van deze receptoren, die 
specifiek siaalzuur kunnen 
herkennen, zijn de Siglec receptoren 
(Siglecs). In het menselijk lichaam 
worden veertien verschillende 
Siglecs onderkend, die allemaal op 
het oppervlakte van bijna elke 
immuuncel voorkomen. Mogelijk 
kunnen al deze Siglecs zich binden 
aan siaalzuren op het oppervlak van 
kankercellen. De gevolgen van deze siaalzuur-Siglec interacties zijn voor een groot 
deel onduidelijk, maar het lijkt er op dat ze een remmend effect hebben op de 
immuuncellen die zich in de tumor bevinden (zie Figuur 4). Dus door hun 
oppervlakte met siaalzuren te bedekken lijken kankercellen het immuunsysteem en 
dus mogelijk ook immunotherapie negatief te beïnvloeden. Hoe dit precies werkt en 
welke rol Siglecs hierbij spelen is moet nog verder worden onderzocht. 
Immuuncel
Remming Immuuncel Functie
Siglec
Kankercel
Figuur 4 Siaalzuren op kankercellen verzwakken 
immuuncellen door aan Siglec receptoren te binden. 
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Bevindingen van dit proefschrift 
Om de functie van een molecuul in een cel of organisme te bestuderen, wordt in 
het biologisch onderzoek vaak van twee methodes gebruik gemaakt. Het 
doelmolecuul, in dit geval siaalzuur, wordt uitgeschakeld of veranderd tot expressie 
gebracht. Ten tijde van het begin van dit onderzoek bestonden er weinig 
mogelijkheden om siaalzuurexpressie op een cel te remmen of te veranderen. 
Daarom moesten eerst methodes ontwikkeld worden om siaalzuurexpressie op 
een cel te beïnvloeden. Hiervoor is het natuurlijke siaalzuurmolecuul op 
verschillende manieren chemisch veranderd, om stoffen te verkrijgen die op het 
natuurlijke siaalzuurzuur lijken, maar een ander gedrag in de cel vertonen. Deze 
chemisch veranderde siaalzuren worden siaalzuur-analogen of siaalzuur-mimetica 
genoemd. In het eerste deel van dit proefschrift worden twee types siaalzuur-
mimetica beschreven, die het mogelijk maken siaalzuurexpressie op een cel te 
voorkomen of te veranderen.  
 
In hoofdstuk 3 wordt een siaalzuur-mimetica 
beschreven die de expressie van siaalzuur aan het 
oppervlak van een kankercel volledig blokkeert. 
Hiervoor werd door een chemische reactie een fluor 
atoom, afgekort door de letter F, aan het natuurlijke 
siaalzuurmolecuul vastgemaakt (zie Figuur 1). Door 
het toevoegen van een fluor atoom aan de 
siaalzuurstructuur, remt dit suiker de inbouw van 
natuurlijk siaalzuur op de celmembraan (Figuur 5). 
In een aantal experimenten werd aangetoond dat 
een type fluor-siaalzuur, genoemd Ac53FaxNeu5Ac, 
inderdaad siaalzuurexpressie aan het celoppervlak 
van melanoomcellen afkomstig van muizen 
blokkeerde. De remming van siaalzuurexpressie met 
fluor-siaalzuur was veel sterker dan tot nu toe met 
andere methoden mogelijk is geweest, zoals bijvoorbeeld het verwijderen van 
siaalzuur van het celoppervlak met behulp van een enzym genoemd sialidase. Na 
analyse van de blokkerende eigenschappen van dit siaalzuur-mimetica werden de 
effecten van Ac53FaxNeu5Ac op het hechten, migreren en uitzaaien van 
melanoomcellen onderzocht. Kankercellen kunnen zich aan bindweefsel hechten 
en ook via het bindweefsel door organen migreren. Siaalzuur helpt bij dit proces, 
maar de behandeling met fluor-siaalzuur remde de interactie tussen 
melanoomcellen en bindweefsel zoals collageen en verminderde zo de migratie. 
Nog opmerkelijker was dat melanoomcellen die eerst met fluor-siaalzuur werden 
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Figuur 5 Fluor-siaalzuur remt 
siaalzuurexpressie in kankercellen. 
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behandeld en vervolgens onderhuids bij een muis werden ingespoten, veel 
langzamer tot een tumor uitgroeiden dan controle melanoomcellen met natuurlijk 
siaalzuur. Het inbrengen van fluor-siaalzuur is dus een zeer krachtige moleculaire 
methode, die het mogelijk maakt siaalzuurexpressie heel efficiënt uit te schakelen 
om zo de consequenties hiervan voor kankercellen te onderzoeken. 
 
Hoofdstuk 4 beschrijft twee siaalzuur-
mimetica (Ac5SiaNAz en Ac5SiaNPoc) die 
zijn gemodificeerd met een soort 
chemisch handvat waardoor het mogelijk 
wordt andere moleculen met dit siaalzuur 
te verbinden. Dit gebeurt door een 
scheikundige reactie die ‘click’-chemie 
wordt genoemd. Het bijzondere van click-
chemie is, dat hiermee moleculen met een 
chemisch handvat, zoals de siaalzuur-
mimetica, op het oppervlak van een 
levende cel kunnen worden verbonden 
met andere soorten moleculen zonder dat 
de cel hieraan dood gaat. In tegenstelling 
tot fluor-siaalzuur dat siaalzuurexpressie 
door de cel remt, worden deze twee 
siaalzuur-mimetica ingebouwd in de 
glycanen op het oppervlak van een cel 
(Figuur 6). Ze vervangen dus voor een 
groot deel de natuurlijke siaalzuren op het 
celoppervlak. Door middel van het 
handvat is het mogelijk de ingebouwde siaalzuur-mimetica aan het celoppervlak te 
verbinden met bijvoorbeeld een fluorescerende markering. Hierdoor kunnen de 
siaalzuur-analogen op de celmembraan zichtbaar worden gemaakt in een 
microscoop. Deze experimenten werden gedaan met menselijke cellen die op het 
laboratorium kunnen worden gekweekt. Hiernaast werden de siaalzuur-mimetica 
ook in muizen ingespoten, om te onderzoeken of ze ook in de cellen van een 
organisme worden opgenomen en in de glycanen worden ingebouwd. Na injectie 
kon het gemodificeerd siaalzuur duidelijk worden gedetecteerd op het oppervlak 
van cellen die geïsoleerd werden uit verschillende organen zoals de lever en 
lymfeklieren. Dit geeft aan dat deze siaalzuur-mimetica inderdaad op de 
celmembraan terecht komen en dat ze kunnen worden verbonden met andere 
moleculen door middel van click-chemie. Op basis van dit principe wordt in 
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Figuur 6 Inbouw van reactief siaalzuur in de 
celmembraan. 
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hoofdstuk 5 aangetoond dat de siaalzuur-mimetica op de celmembraan met meer 
dan 64 verschillende kleine moleculen kunnen reageren. Zo werden cellen 
gemaakt die allemaal verschillend gemodificeerde siaalzuren aan hun oppervlakte 
tonen. Siaalzuren kunnen aan Siglec receptoren binden en daarom werd 
vervolgens onderzocht of de modificaties de binding met de Siglecs beïnvloeden. 
Opvallend was dat het merendeel van de siaalzuurmodificaties de binding aan 
Siglecs aanzienlijk versterken, voor sommigen meer dan honderdvoudig. 
Bovendien hadden sommige modificaties het effect dat het siaalzuur ineens alleen 
nog maar met één type Siglec reageert en niet meer met de andere types Siglec. 
Dankzij deze methode was het mogelijk te onderzoeken wat het effect van een cel 
met een veranderde siaalzuur expressie is op een immuuncel die een Siglec 
receptor heeft. De geteste siaalzuur-Siglec interactie had een duidelijk remmend 
effect op de werking van de immuuncel. Dit geeft aan dat deze methode kan 
worden gebruikt om het effect van siaalzuur-Siglec interacties tussen twee cellen, 
een kankercel en een immuuncel, te bestuderen.  
 
Deel twee van dit proefschrift beschrijft de rol van siaalzuur in de tumor-
immunologie en onderzoekt de toepassing van fluor-siaalzuur (Ac53FaxNeu5Ac) in 
immunotherapie bij kanker. In hoofdstuk 6 wordt beschreven hoe het blokkerende 
siaalzuur-mimetica Ac53FaxNeu5Ac in nanopartikels, kleine bolletjes, kan worden 
verpakt die specifiek door melanoomcellen worden opgenomen. Aangezien 
siaalzuur heel belangrijk is voor het functioneren van allerlei cellen in het lichaam, 
kan fluor-siaalzuur niet zomaar in de mens worden ingespoten, vanwege mogelijke 
ernstige bijwerkingen. Om deze reden werd Ac53FaxNeu5Ac in nanopartikels 
geladen die slechts 200 nanometer (nm) groot zijn. Een nm is een miljoenste van 
een millimeter en een menselijke cel is 10.000 nm tot 30.000 nm groot. De 
nanopartikels zijn dus circa 50-150 keer kleiner dan een cel. Om deze 
nanopartikels gericht naar een kankercel in het lichaam te sturen, werden ze 
omhuld met antilichamen die specifiek binden aan een eiwit op het oppervlak van 
melanoomcellen. Deze nanopartikels werden hierdoor specifiek door 
melanoomcellen en nauwelijks door andere cellen opgenomen. In de melanoomcel 
worden de nanopartikels afgebroken, zodat het fluor-siaalzuur vrijkomt en de 
natuurlijke siaalzuur inbouw in glycanen blokkeert. Omdat de cel een aantal van 
deze nanopartikels kan opnemen en fluor-siaalzuur alleen maar langzaam vrij 
komt, duurt het remmend effect op siaalzuur expressie veel langer dan het met vrij 
siaalzuur-mimetica mogelijk is. Tot slot wordt beschreven hoe deze nanopartikels 
melanoomcellen in het bloed van muizen kunnen bereiken en de 
siaalzuurexpressie blokkeren. Hierdoor waren de melanoomcellen niet meer in 
staat om vanuit het bloed metastasen (uitzaaïngen) te vormen in de longen of 
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andere organen. Mogelijk kunnen deze nanopartikels het in de toekomst mogelijk 
maken fluor-siaalzuur, zoals Ac53FaxNeu5Ac, gericht naar kankercellen in het 
menselijk lichaam te sturen.  
 
Kankercellen omhullen hun oppervlakte met siaalzuur en kunnen glycanen met 
siaalzuur ook in hun omgeving, het tumor micromilieu, uitscheiden. Immuuncellen 
die zich in het tumor micromilieu bevinden, kunnen siaalzuren afkomstig van 
tumoren herkennen middels hun Siglec receptoren. Deze interactie kan mogelijk de 
functie van immuuncellen lokaal in het micromilieu beïnvloeden. In het tumor 
micromilieu zijn niet alleen maar positieve immuuncellen (o.a. T cellen en natural 
killer cellen) die tumoren kunnen doden, maar ook negatieve immuuncellen die de 
tumor juist kunnen helpen groeien door positieve immuuncellen uit te schakelen. 
Een groep van deze negatieve immuuncellen zijn de myeloïde suppressor cellen. 
Myeloïde suppressor cellen staan erom bekend een bepaald type Siglec, Siglec-3 
of CD33 genoemd, tot expressie te brengen. Dit suggereert dat kankercellen via 
hun siaalzuren met deze myeloïde suppressor cellen kunnen communiceren. Tot 
nu toe is nog niet bekend of dat ook daadwerkelijk gebeurt en of myeloïde 
suppressor cellen nog andere Siglecs tot expressie brengen. Hoofdstuk 7 
beschrijft daarom het onderzoek naar welke overige leden van de Siglec 
receptorfamilie tot expressie komen op myeloïde suppressor cellen. De myeloïde 
suppressor cellen werden geïsoleerd uit patiënten met een glioom, een 
hersentumor. Van de veertien humane Siglec familieleden werden er vier duidelijk 
op het oppervlak van myeloïde suppressor cellen gedetecteerd. Opmerkelijk is dat 
al deze vier gevonden Siglecs (Siglec-3, -5, -7 en -9) de immuunreactie in andere 
immuuncellen sterk onderdrukken. Verder werd onderzocht of glioom cellen 
siaalzuren tot expressie brengen die door deze vier Siglecs kunnen worden 
herkend. Hieruit bleek dat vers geïsoleerde glioomcellen uit patiënten een grote 
hoeveelheid siaalzuren op hun oppervlakte dragen die aan twee (Siglec-7 en -9) 
van de vier Siglecs kunnen binden. Deze bevinding suggereert dat kankercellen 
via hun siaalzuur met myeloïde suppressorcellen kunnen communiceren. Verder 
onderzoek is nodig om te ontdekken wat de effecten van deze siaalzuur-Siglec 
interacties zijn op myeloïde suppressor cellen. 
 
Naast de suppressieve (negatieve) immuuncellen zijn er ook immuuncellen die 
kankercellen kunnen herkennen om dan een anti-tumor reactie op gang te 
brengen. Een type cel dat uitermate belangrijk is om de afweerreactie tegen kanker 
te initiëren is de dendritische cel. Dendritische cellen kunnen herkenningseiwitten 
(antigenen) van kankercellen opnemen en T cellen activeren die dan heel specifiek 
die kankercellen kunnen elimineren. In hoofdstuk 8 wordt beschreven dat 
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menselijke dendritische cellen met een geblokkeerde siaalzuurexpressie beter 
kunnen worden geactiveerd en daardoor effectiever T cellen kunnen aanzetten tot 
opruim-actie. Uit het bloed van gezonde vrijwilligers kunnen voorlopers van 
dendritische cellen worden geïsoleerd die in het laboratorium verder tot 
dendritische cellen kunnen worden gekweekt. Als tijdens dit kweekproces fluor-
siaalzuur wordt toegevoegd, kunnen dendritische cellen worden verkregen met 
heel weinig siaalzuur. Deze dendritische cellen reageerden veel sterker op 
activatiesignalen zoals bacteriële of virale stimuli. Verder konden dendritische 
cellen met weinig siaalzuur veel beter T cellen activeren. Opvallend was dat 
dendritische cellen dezelfde vier Siglecs tot expressie brengen als de myeloïde 
suppressor cellen. Aan het oppervlakte van dendritische cellen werden ook 
siaalzuren gevonden die de eigen Siglecs kunnen binden. Deze resultaten 
suggereren dat de interacties tussen siaalzuur en Siglecs op het oppervlak van 
dendritische cellen de effectiviteit van dit type cel kunnen remmen. Door de 
dendritische cellen met fluor-siaalzuur te behandelen, kon deze rem worden 
opgeheven, waardoor de dendritische cellen veel actiever werden. Mogelijk wordt 
dit mechanisme ook door kankercellen gebruikt om door middel van 
siaalzuurexpressie te voorkomen dat een anti-tumor reactie wordt gestart. 
 
Siaalzuren op het oppervlak van kankercellen blijken dus interacties te kunnen 
hebben met verschillende types immuuncellen, die zelf weer verschillende types 
Siglec receptoren hebben. Al deze verschillende interacties kunnen theoretisch 
gelijktijdig in het tumor micromilieu plaatsvinden en zo mede bepalen of het 
immuunsysteem kankercellen kan opruimen of niet. Om al deze verschillende 
interacties tegelijk na te bootsen in een reageerbuis in het laboratorium is heel 
moeilijk en daarom wordt in het onderzoek vaak gebruik gemaakt van muizen. 
Muizen lijken qua biologie heel sterk op de mens en beschikken over een 
vergelijkbaar immuunsysteem. Verder is het mogelijk tumoren te laten groeien in 
muizen door kankercellen te injecteren op verschillende plekken, bijvoorbeeld 
onder de huid. De tumoren die dan ontstaan zitten, net zoals bij de mens, vol met 
verschillende soorten immuuncellen. In het onderzoek met muizen, beschreven in 
hoofdstuk 9, werd de rol van siaalzuur op tumorgroei, het tumormilieu en 
immunotherapie onderzocht. Hiervoor werden in muizen verschillende types 
tumoren, zoals melanomen of neuroblastomen, onder de huid ingebracht en 
behandeld met fluor-siaalzuur. Opmerkelijk was dat deze behandeling de groei van 
de tumoren aanzienlijk remde. Vergeleken met een controlebehandeling, kon met 
fluor-siaalzuur de overlevingstijd van de muizen worden verdubbeld. Nog 
opvallender was dat van muizen met een melanoom variant die goed herkenbaar is 
voor het immuunsysteem, de helft helemaal kon worden genezen. Op zoek naar de 
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oorzaak van dit indrukwekkende effect werd duidelijk dat de behandeling met fluor-
siaalzuur de siaalzuurexpressie met name op de kankercellen blokkeerde en niet 
op de immuuncellen. Onderzoek naar het tumor micromilieu maakte duidelijk dat 
de immuuncel-infiltratie in de tumoren veranderde en er meer positieve 
immuuncellen zoals T cellen en minder negatieve immuuncellen, zoals myeloïde 
suppressor cellen, werden gevonden. Verder werd duidelijk dat het remmende 
effect van fluor-siaalzuur op kankergroei werd veroorzaakt door T cellen die in 
staat zijn kankercellen te doden. Na het verwijderen van siaalzuur waren T cellen 
veel beter in staat om de kankercellen te doden. Vervolgens werkte 
immunotherapie waarbij anti-tumor T cellen direct in de muis werden ingespoten 
veel beter in combinatie met de fluor-siaalzuur behandeling. Ook immunotherapie 
met CpG, een stof die dendritische cellen stimuleert om T cellen te activeren, 
werkte veel beter in combinatie met siaalzuur-blokkade. Toekomstig onderzoek 
dient verder uit te zoeken hoe het blokkeren van siaalzuur in kankercellen tot een 
betere afweerreactie tegen kanker leidt en hoe deze veelbelovende resultaten 
klinisch toegepast zouden kunnen worden. 
 
Conclusie 
De bevindingen beschreven in dit proefschrift leveren een belangrijke bijdrage aan 
de ontrafeling van de complexe rol van siaalzuur in tumor immunologie. De 
beschreven siaalzuur-mimetica bieden nieuwe moleculaire methoden, die kunnen 
helpen om de biologische functie van siaalzuur-Siglec interacties in de 
immunologie en in het bijzonder in de tumor immunologie te bestuderen. In dit 
proefschrift wordt met behulp van deze siaalzuur-mimetica aangetoond dat 
siaalzuren kankercellen helpen om te metastaseren en aan het immuunsysteem te 
ontsnappen. De overmaat aan siaalzuur op de membraan van de kankercel heeft 
een sterk remmend effect op het immuunsysteem en dit komt waarschijnlijk door 
de interactie tussen het siaalzuur en de Siglecs. Verder kan worden gesteld dat de 
hoge expressie van siaalzuur kankercellen beschermt tegen het gedood worden 
door T cellen en daarom mogelijk de werking van immunotherapie tegenwerkt. 
Siaalzuur-mimetica zijn daarom een belangrijke methode voor het onderzoek naar 
de rol van siaalzuren in kanker en zijn mogelijk in de toekomst toepasbaar voor de 
behandeling van kanker, alleen of in combinatie met andere types 
(immuno)therapie. 
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Sialinsäuren: Zielmoleküle für die Immuntherapie gegen Krebs 
Der menschliche Körper besteht aus Billionen von Zellen, kleine, lebende 
Einheiten die unterschiedliche Funktionen im Körper haben. So beschützen 
Hautzellen den Körper z.B. vor UV Licht oder dem Eindringen von 
Krankheitserregern wie Bakterien oder Viren. Falls doch Krankheitserreger in den 
Organismus gelangen können diese durch die weißen Blutzellen, die zum 
Abwehrsystem (Immunsystem) gehören, unschädlich gemacht werden. Jede Zelle 
ist von einer Membran umgeben, die die Zelloberfläche bildet. Auf der 
Zelloberfläche befinden sich viele unterschiedliche Moleküle so wie Eiweiße, Fette 
und Zucker, die zum Funktionieren einer Zelle beitragen. Zuckermoleküle bilden 
hierbei den größten Anteil, sind aber im Vergleich zu den anderen 
Zelloberflächenmolekülen am wenigsten erforscht. Zuckermoleküle auf der 
Zelloberfläche spielen eine wichtige Rolle bei der Kommunikation von Zellen 
untereinander. Eine bestimmte Gruppe von Zuckern auf der Zelloberfläche sind die 
Sialinsäuren. Sialinsäuren haben viele unterschiedliche Funktionen. Sie tragen z.B. 
dazu bei, dass weiße Blutzellen aus den Blutgefäßen in umliegende Gewebe 
austreten können oder dass Nervenzellen im Gehirn Verbindungen untereinander 
aufbauen können. Obwohl Sialinsäuren sich auf jeder Zelle im Körper befinden, 
können besonders hohe Konzentrationen von diesen Zuckern auf der Oberfläche 
von Krebszellen gefunden werden. Die Bedeutung der erhöhten Konzentration von 
Sialinsäuren auf der Oberfläche von Krebszellen ist noch nicht genau bekannt. 
Einige Studien haben nachgewiesen, dass Sialinsäuren zur Bildung von 
Metastasen beitragen und Krebszellen gegen die Wirkung von Chemo- oder 
Radiotherapie resistent machen.  
Neuere Erkenntnisse zeigen, dass Sialinsäuren Krebszellen auch vor dem 
Immunsystem tarnen können. Normalerweise sind weiße Blutzellen in der Lage, 
Krebszellen frühzeitig zu erkennen und zu zerstören. Krebszellen hingegen können 
Fähigkeiten entwickeln dies zu verhindern. Dadurch können sie sich unerkannt 
vermehren und einen Tumor formen. Das Immunsystem ist dann außerstande, die 
Krebszellen zu zerstören. Allerdings ist es möglich, das Immunsystem mithilfe der 
sogenannten Immuntherapie zu reaktivieren, so dass es die Fähigkeit 
wiedererlangt, Krebszellen zu zerstören. Die Immuntherapie wird heutzutage schon 
vielerorts eingesetzt um Patienten mit Krebs zu behandeln und zeigt 
vielversprechende Therapieerfolge. Die natürliche Abwehr gegen Krebs und der 
Behandlungserfolg von Immuntherapie kann noch weiter gesteigert werden, wenn 
wir die Strategien, die Krebszellen nutzen um das Immunsystem zu 
beeinträchtigen, besser verstehen. Die erhöhte Produktion von Sialinsäuren 
scheint solch eine Strategie zu sein, die von Krebszellen benutzt wird, um das 
Immunsystem zu hemmen. Die Details dieses Prozesses sind weitgehend 
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unbekannt. Möglicherweise werden Sialinsäuren auf der Zellmembran von 
Krebszellen von Rezeptoren auf der Oberfläche der weißen Blutzellen erkannt. 
Diese Rezeptoren werden Siglecs genannt und können die Funktion von weißen 
Blutzellen beeinträchtigen.  
 
Zielsetzung der Arbeit 
Um die Funktion eines Moleküls z.B. Sialinsäuren zu erforschen, werden in der 
Biologie häufig Methoden genutzt, die es entweder ermöglichen, das Zielmolekül in 
der Zelle auszuschalten, oder es verändert zur Expression zu bringen. Für 
Sialinsäuren gibt es jedoch nur wenige Methoden, dies zu erreichen, was die 
Erforschung dieser Zucker erschwert. Ziel dieser Arbeit war es, zum einen 
Methoden bzw. molekulare Werkzeuge zu entwickeln, die es erlauben Sialinsäuren 
von der Oberfläche von Krebszellen zu entfernen, oder ihre Eigenschaften zu 
verändern. Zum anderen sollte mithilfe dieser molekularen Werkzeuge untersucht 
werden, wie Krebszellen Sialinsäuren benutzen um das Immunsystem zu 
beeinflussen.  
 
Ergebnisse 
Als erstes wurden Sialinsäuren chemisch so verändert, dass sie neue 
Eigenschaften erhalten und sich anders in Zellen verhalten. Diese chemisch 
veränderten Sialinsäuren bezeichnet man als Sialinsäure-Mimetika. So konnten 
Sialinsäure-Mimetika entwickelt werden, die über eine Art chemisches 
Verbindungstück verfügen. Diese Sialinsäure-Mimetika wurden durch Krebszellen 
aufgenommen und in die Zelloberfläche eingebaut. Auf der Zelloberfläche war es 
dann möglich, durch eine chemische Reaktion die Sialinsäure-Mimetika mithilfe 
des Verbindungsstückes mit anderen Molekülen zu verbinden. Durch z.B. 
fluoreszierende Moleküle mit den Sialinsäure-Mimetika zu koppeln, konnten 
Sialinsäuren auf der Oberfläche von Krebszellen unter dem Mikroskop sichtbar 
gemacht werden. Darüber hinaus konnten die Sialinsäure-Mimetika mit einer Reihe 
von kleinen Molekülen verbunden werden, um zu erforschen, ob sich dadurch die 
Erkennung von Sialinsäuren durch Siglec Rezeptoren ändert. Erstaunlicherweise 
konnten auf diesem Weg einige Veränderungen identifiziert werden, die die 
Binding an Siglec Rezeptoren sehr stark erhöhten. Dies ermöglichte es, der Frage 
nach zu gehen, was der Effekt von verstärkten Sialinsäure-Siglec Interaktionen auf 
die weißen Blutzellen ist. Die chemisch veränderteren Sialinsäure-Mimetika auf der 
Oberfläche von Krebszellen konnten die Aktivierung von weißen Blutzellen 
verhindern. Diese Ergebnisse unterstützen die Hypothese, dass Krebszellen 
Sialinsäuren benutzen um das Immunsystem zu unterdrücken. 
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In einem weiteren Teil der Arbeit wurde natürliche Sialinsäure mit einem Fluor 
Atom versehen. Dadurch konnte ein Sialinsäure-Mimetika hergestellt werden, das 
in der Lage ist, die Produktion von natürlichen Sialinsäuren in Zellen zu blockieren. 
Diese Fluorsialinsäure konnte die Expression von Sialinsäuren in Krebszellen sehr 
stark reduzieren. Krebszellen, die mit diesem Mimetika behandelt wurden, banden 
nicht mehr an Bestandteile des Bindegewebes z.B. Kollagen und waren kaum 
noch in der Lage, Metastasen in Mäusen zu formen. Erwähnenswert ist, dass 
Fluorsialinsäure für die Experimente zur Metastasen Bildung in Nanopartikel 
eingebaut wurde. Diese Nanopartikel sind hundertmal kleiner als eine Zelle und 
können ihren Inhalt gezielt zu Krebszellen im Körper transportieren. Diese 
Eigenschaft macht Nanopartikel sehr attraktive Boten um Wirkstoffe zielgerichtet 
an ihren Bestimmungsort im Körper zu bringen  
Eine der wichtigsten Ergebnisse dieser Arbeit ist die Entdeckung, dass in Mäusen 
Krebszellen, die mit Fluorsialinsäure behandelt wurden, im Vergleich zu Kontroll-
Krebszellen viel langsamer wuchsen. Durch diese Behandlung konnten Tumore 
teilweise sogar vollständig abgetötet und die Mäuse geheilt werden. Dieser Effekt 
trat nicht in Mäusen auf, denen eine bestimmte Form von weißen Blutzellen, die 
sogenannten T Zellen, fehlt. T Zellen sind in der Lage, Krebszellen im Körper zu 
finden und zu zerstören. Erhöhte Produktion von Sialinsäuren scheint Krebszellen 
dagegen zu schützen. Dementsprechend konnten T Zellen Krebszellen ohne 
Sialinsäure besser erkennen und effizienter abtöten. Heutzutage angewandte 
Formen der Immuntherapie, die zum Ziel haben, T Zellen gegen Krebszellen zu 
mobilisieren, waren daher effektiver in Mäusen deren Tumor zuvor mit 
Fluorsialinsäure behandelt wurde. Außerdem konnte in Mäusen und auch in 
Patienten Material nachgewiesen werden, dass Sialinsäure die Funktion weiterer 
Arten von Immunzellen, die sich in Tumoren befinden, beeinflusst. In diesen 
Experimenten deutet vieles darauf hin, dass Sialinsäuren ihren Einfluss auf 
Immunzellen mittels Siglec Rezeptoren ausüben. 
 
Fazit 
Die Ergebnisse dieser Arbeit unterstützen das Konzept, dass die erhöhte 
Produktion van Sialinsäuren Krebszellen hilft, das Immunsystem zu 
beeinträchtigen und dass Sialinsäure-Siglec Interaktionen wie eine Bremse für 
Immunzellen wirken. Die beschriebenen Sialinsäure-Mimetika ermöglichen es nun, 
diese Vorgänge besser zu erforschen. Darüber hinaus legen die Ergebnisse dieser 
Arbeit nahe, dass Sialinsäure-Mimetika, wie z.B. Fluorsialinsäure, Krebszellen auf 
mehreren Ebenen schaden können. Sie könnten deshalb eingesetzt werden um 
die Bremse vom Immunsystem zu lösen und so die Immuntherapie gegen Krebs in 
Zukunft zu verbessern. 
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